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Magnesium Basics
Magnesium (Mg2+) is an essential ion for health. Within the periodic table of elements, 
Mg has atom number 12 and is classified as an alkaline earth element (group 2). Mg occurs 
in nature in three stable isotopes, 24Mg, 25Mg, and 26Mg. 24Mg is the most common 
isotope (78,99 %) and has a relative atomic mass of 24.305 Da, a melting point of 648.8 °C 
and a boiling point of 1090 °C (97). In the dissolved state, Mg2+ has two hydration shells, 
making its radius ±400 times larger than its dehydrated radius. Consequently, before 
passing through channels and transporters, Mg2+ needs to be dehydrated, which is a 
highly energy consuming process. The radius of hydrated Mg2+ is much bigger than other 
cations like Na+, K+ and even Ca2+ (28). As a result, Mg2+ is a powerful Ca2+-antagonist, 
despite their same charge and similar chemical properties.
 Mg2+ is a co-factor of over 600 enzymes (http://www.metacyc.org, (24)). Among the 
enzymes that require Mg2+ as co-activator, many enzymes are essential for life. For 
instance, Mg2+ is necessary for proper structure and activity of DNA and RNA polymerases 
(15, 139). Knowing that other enzymes using Mg2+ are topisomerases, helicases and 
exonucleases, Mg2+ is an essential component of DNA replication, RNA transcription, 
amino acid synthesis and protein formation. Since kinases, ATP-ases, guanylyl cyclases and 
adenylyl cyclases all depend on Mg-ATP for proper function, Mg2+ plays a role in virtually 
every process within the human cell.
Magnesium in Health and Disease
The first use of Mg2+ in human medicine can be traced back to 1697 when Dr. Nehemiah 
Grew identified magnesium sulfate (MgSO4) as the major ingredient of Epsom salt (51). 
Epsom Salt was extracted from a well in Epsom, England and was used over the years to 
treat abdominal pain, constipation, sprains, muscle strains, hyaline membrane disease, 
and cerebral edema. Subsequently, Mg2+ was recognized as an element (Mg) by Joseph 
Black in 1755 and first isolated by Sir Humphrey Davy from magnesia (Mg3SO4O10(OH)2) 
and mercury (Hg) in 1808 (30). The role of Mg2+ in the human body emerged once Mg2+ 
was described in blood plasma by Willey Glover Denis in 1920 (31). Subsequently, Jehan 
Leroy demonstrated that Mg2+ is essential for life in mice (85). These findings were 
translated to humans, and the first reports of Mg2+ deficiency in man were by Arthur 
Hirschfelder & Victor Haury in 1934 (61). Since then, Mg2+ has been implicated in and used 
for treatment of a variety of diseases, including migraines, cardiovascular diseases and 
diabetes (Figure 1). Although the importance of Mg2+ is widely acknowledged, serum 
Mg2+ values are not generally determined in clinical medicine. Therefore, Mg2+ is often 
referred to as the ‘forgotten’ cation in human health. 
Brain
In brain, intracellular Mg2+ regulates the activity of the N-Methyl-D-aspartic acid (NMDA) 
receptor. During Mg2+ deficiency, NMDA receptors become hyperexcitable, resulting in 
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Figure 1  Magnesium in health and disease
Overview of the major diseases in which Mg2+ disturbances have been reported or in which Mg2+ 
supplementation has been considered as potential treatment.
- Myocardial infarction
- Arrythmias
- Preeclampsia
- Hypertension
- Asthma
- COPD
- Cystic Fibrosis
- Osteoporosis
- Muscle Cramps
- Migraine
- Depression
- Epilepsy
- Stroke
- Traumatic Brain Injury
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severe brain pathologies (92, 103). Patients with migraines, depression, epilepsy and 
traumatic brain injury have lower blood Mg2+ values (6, 32, 115, 137). Therefore, Mg2+ 
 supplementation has been proposed as potential treatment for these disorders. In a 
recent large-scale trial Mg2+ was shown to decrease death and disability after stroke when 
applied within three hours of the onset of the stroke (99). In contrast, Mg2+ was unsuccessful to 
improve outcome after traumatic brain injury (140). Despite the absence of large-scale 
clinical trials, Mg2+ is considered second-line treatment for migraine and epilepsy (62, 131). 
Heart and Vasculature
Mg2+ regulates the activity of ion channels in the cardiac cells, thereby affecting the 
electrical properties of the myocardium (98). Moreover, it determines myocardial contractility 
by influencing the intracellular Ca2+ mobility and Mg2+ has an anti-inflammatory and 
vasodilatory effect. Patients with severe hypomagnesemia may, therefore, suffer from 
arrhythmias and hypertension. Mg2+ is the most important treatment for patients with 
preeclampsia and has been widely advocated by the world health organization (WHO) in 
third world countries to reduce child mortality (59). Additionally, Mg2+ is the first treatment 
option for patients with torsades des pointes type of cardiac arrhythmias (158).
Lung
Given the bronchodilatory and anti-inflammatory effects of Mg2+, the use of Mg2+ has also 
been advocated in lung disease (104). Specifically, Mg2+ is considered second-line 
treatment for acute asthma patients (2). Recently, a large randomized controlled study In 
children with asthma showed the improvement of the asthma severity after inhalation of 
MgSO4 (111). Large-scale studies are necessary to examine the efficacy of Mg2+ in the 
treatment of chronic obstructive pulmonary disorder (COPD) and cystic fibrosis.
Muscle
In muscle, the main effect of Mg2+ is as a Ca2+ antagonist on Ca2+-permeable channels 
and Ca2+-binding proteins (63, 110). Muscle contraction is a highly Ca2+-dependent 
process, since Ca2+ will bind to troponin C and myosin to induce contraction (50). Mg2+ 
competes for the Ca2+-binding sites on these proteins. Consequently, more Ca2+ will bind 
troponin C and myosin in Mg2+ deficiency, resulting in hypercontractibility, which presents 
as muscle cramps and spasms in the clinic. Therefore, Mg2+ supplementation is considered 
second line treatment for muscle cramps (74).
Magnesium Deficiency
The US Food and Nutrition Board recommends a daily intake of 420 mg for men and 320 
mg for women (1). However, recent reports estimate that at least 60 % of the population 
does not meet daily-required Mg2+ intake (76). Part of the problem stems from the soil 
used for agriculture, which is becoming increasingly deficient in essential minerals. Over 
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the last 60 years the Mg2+ content in fruit and vegetables decreased by 20-30 % (151). 
Moreover, the Western diet is containing more refined grains and processed food. 
Estimates are that 80-90 % of Mg2+ is lost during food processing. As a result, a significant 
number of people are Mg2+ deficient, which may comprise up to 60 % of critically ill 
patients (26, 35). Mg2+ deficiency is commonly determined by measuring the total serum 
Mg2+ concentration, which ranges between 0.7 and 1.1 mmol/L in healthy persons (90). 
 Hypomagnesemia is generally defined as serum Mg2+ levels below 0.7 mmol/L (Table 1). 
Patients suffer from non-specific symptoms such as depression, tiredness, muscle spasms 
and muscle weakness and diagnosis therefore may take years (44, 143). Only severe Mg2+ 
depletion (< 0.4 mmol/L) may lead to cardiac arrhythmias, tetany and seizures. Secondary to 
hypomagnesemia, disturbances in K+ and Ca2+ handling are often detected. Hypokalemia 
Table 1   Symptoms of Mg2+ Disturbances  
Hypomagnesemia
Concentration Clinical manifestation
< 0.7 mmol/L Neuromuscular irritability
Hypocalcemia
Hypokalemia
< 0.4 mmol/L Tetany
Seizures
Arrhythmias
Hypermagnesemia
Concentration Clinical manifestation
> 1.1 mmol/L Lethargy
> 2 mmol/L Drowsiness
Flushing
Nausea and vomiting
Diminished deep tendon reflex
> 3 mmol/L Somnolence
Loss of deep tendon reflexes
Hypotension
ECG changes
> 5 mmol/L Complete heart block
Cardiac arrest
Apnea
Paralysis
Coma
Death
Clinical symptoms of disturbed Mg2+ homeostasis.
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can be attributed to increased renal K+ secretion via ROMK in the connecting tubule (CNT) 
and collecting duct (CD) (67). Low intracellular Mg2+ levels release the Mg2+-dependent 
inhibition of renal outer medullary potassium channel (ROMK) channels, resulting in increased 
renal K+ secretion. Hypocalcemia can be explained by low parathyroid hormone (PTH) 
levels due to altered activation of the calcium-sensing receptor (CaSR) (154).
 Hypomagnesemia is generally treated by oral Mg2+ supplementation (± 360 mg/day), 
although oral Mg2+ intake may cause diarrhea at high doses. Intravenous Mg2+ supple-
mentation may be more effective, but this treatment has the disadvantage that it requires 
regular hospital visits (143). When serum Mg2+ levels are extremely low or are associated 
with hypokalemia, Mg2+ supplementation may not be sufficient to restore normal Mg2+ 
levels. In that case, patients are often co-supplemented with K+ or receive amiloride to 
prevent K+ secretion.
 The human body contains approximately 24 g of Mg2+ of which 99 % is stored in 
bone, muscle and other soft tissues (Figure 2). Since serum Mg2+ values reflect only 1 % of 
the body Mg2+ content, serum values may be within the normal range whereas the body 
may be in a severely Mg2+-depleted state. As a result, the clinical impact of Mg2+ deficiency 
may be largely underestimated. 
Magnesium Uptake in Intestine
Given a daily Mg2+ intake of 370 mg, approximately 30-50 % of Mg2+ is absorbed in the 
intestine, resulting in a net uptake of ±100 mg (Figure 2). However, if Mg2+ intake is low, up 
to 80 % of dietary Mg2+ can be absorbed (48). Mg2+ absorption in the gut depends on two 
separate pathways; paracellular transport is responsible for bulk Mg2+ absorption and 
takes place mostly in the small intestine, whereas fine-tuning occurs in the cecum and 
colon via transcellular transport. In spite of this, the intestine seems to have a limited role 
in regulation of the Mg2+ balance. In contrast to other minerals, intestinal Mg2+ absorption 
is poorly regulated and depends mainly on Mg2+ intake (58, 126). Thus, the kidneys 
presumably primarily regulate the maintenance of Mg2+ homeostasis. 
Small Intestine
Mg2+ absorption in the small intestine is hypothesized to be exclusively of a paracellular 
nature (Figure 3), since Mg2+ absorption in this region of the intestine correlates linearly to 
luminal Mg2+ concentrations (73, 112). Moreover, epithelial Mg2+ channel Transient 
receptor potential melastatin type 6 (TRPM6) is not expressed in the small intestine (52). 
Mg2+ is poorly absorbed in the duodenum, where unfavorable electrochemical gradients 
may even result in a limited amount of paracellular Mg2+ excretion (107). In later parts of 
the small intestine, such as late jejunum and ileum, the driving force for passive Mg2+ 
transport is established by the high luminal Mg2+ concentration and the lumen-positive 
transepithelial voltage of ±15 mV (38). The Km for Mg2+ transport in the late small intestine 
has been reported to be in the range of 4-12 mmol/L (95, 126). These results suggest that 
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NaCl and water absorption are prerequisites for Mg2+ uptake, since water absorption 
concentrates luminal Mg2+. Tight junction permeability underlying paracellular Mg2+ 
transport is still poorly understood. The small intestine has been described to be the most 
permeable for ions because of the relatively low expression of ‘tightening’ claudins 1, 3, 4, 
5 and 8 (7, 83). Claudins 16 and 19, which are linked to Mg2+ transport, are not expressed in 
the intestine (7, 65). The exact composition of the tight junction complex facilitating 
intestinal Mg2+ absorption remains to be elucidated.
Figure 2  Magnesium Homeostasis
Panels represent the daily amount of Mg2+ intake and excretion. Daily the intestines absorption 
approximately 120 mg and secrete 20 mg of Mg2+, resulting in a net absorption of 100 mg. In the 
kidney daily about 2,400 mg Mg2+ is filtered by the glomerulus, of which 2,300 mg is reabsorbed 
along the kidney tubule. This results in a net excretion of 100 mg, which matches the intestinal 
absorption. Bone and muscle provide the most important Mg2+ stores.
0.7-1.1 mmol/L
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Large Intestine
Mg2+ absorption in cecum and colon is thought to be transcellular of nature and is on the 
luminal side of the enterocyte mediated by TRPM6 and TRPM7 Mg2+ channels (Figure 3). 
Specifically, the intestinal expression of TRPM6 is located in caecum and colon (52, 82). In 
a study with rat colon epithelium, 37 % of Mg2+ was transported transcellularly (72). This 
suggests the existence of significant paracellular transport of Mg2+ in the colon, which 
would be unlikely given the expression of tight claudins 3, 4 and 8 in this segment (83). In 
contrary to Ca2+, Mg2+ transport in colon is independent of 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3) signaling, nor is TRPM6 expression dependent on 1,25(OH)2D3 (52, 72). It has 
Figure 3  Magnesium Absorption in the Intestine
Bulk Mg2+ is absorbed paracellular by the late part of the small intestine. Fine-tuning of Mg2+ 
absorption takes place transcellular by the colon, where TRPM6 and TRPM7 Mg2+ channels facilitate 
luminal Mg2+ uptake in the enterocyte. CNNM4 provides the basolateral Mg2+ extrusion mechanism.
TRPM6: Transient receptor potential melastatin type 6, TRPM7: Transient receptor potential melastatin type 
7, ENaC: Epithelial Sodium Channel, CNNM4: Cyclin M4.
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been suggested that the basolateral Mg2+ extrusion mechanism of the enterocyte is 
coupled to the Na+ gradient (117). Indeed, a recent study using Cyclin M4 (CNNM4) KO 
mice, suggests that CNNM4 may act as a Na+/Mg2+ exchanger at the basolateral 
membrane of enterocytes (155). CNNM4 knockout mice suffer from hypomagnesemia, 
and functional analysis using Magnesium Green showed that CNNM4 overexpression 
increased Mg2+ efflux in HEK293 cells. However, patients with CNNM4 mutations do not 
suffer from hypomagnesemia (106, 109). 
Magnesium Storage in Bone
Approximately 50-60 % of the total body Mg2+ content is stored in bone (Figure 2). Serum 
Mg2+ concentrations are closely related to bone metabolism; bone surface Mg2+ is 
continuously exchangeable with blood Mg2+ (5). Bone hydroxy-apatite structures mainly 
consist of Pi and Ca2+ and are bound by Mg2+ ions at the surface of the hydroxy-apatite 
crystals. Mg2+ increases the solubility of the minerals and thereby acts on the crystal size 
and formation (120). Crystals in Mg2+-deficient bone are larger and the bones may 
therefore be brittle and more susceptible to fractures (27). Moreover, Mg2+ stimulates 
osteoblast proliferation, suggesting that Mg2+ deficiency results in decreased bone 
formation (88). Mg2+-deficient rats have reduced osteoblast numbers and decreased 
bone mass (118). Moreover, Mg2+ deficiency increases the secretion of pro-inflammatory 
cytokines such as TNFα, IL1β and substance P (118, 148), all of which have been implicated 
in increased osteoclastic bone resorption (75). These effects may be further enhanced by 
reduced PTH and 1,25(OH)2D3 levels, which are often associated with hypomagnesemia (119). 
Magnesium Reabsorption in Kidney
Approximately 2,400 mg of Mg2+ is filtered by the glomeruli on a daily basis. The nephron 
recovers 95-99 % of this; the remaining 100 mg leaves the body via the urine (Figure 2). 
Proximal Tubule
The mechanisms of proximal tubule (PT) Mg2+ reabsorption are poorly understood, but 
early micropuncture studies show that approximately 10-25 % of Mg2+ is reabsorbed by 
the proximal convoluted tubule segment of the nephron (Figure 4) (84, 114). In the 
glomeruli, 70 % of the serum Mg2+ is freely filterable, suggesting that the concentration in 
the glomerular filtrates and thus the start of the PT ranges between 0.5-0.7 mmol/L. The 
transepithelial potential difference ranges from slightly lumen negative (-6 mV) at the 
early parts of the PT to positive (3 mV) in later parts (78). Micropuncture studies have 
shown that a 1.9 ratio between the concentration of Mg2+ in the tubular fluid and the 
interstitial fluid is necessary to initiate Mg2+ transport (84). This finding could be explained 
by the poor tight junction permeability for Mg2+ in PT. As a result, water uptake via 
aquaporin1 (AQP1) precedes Mg2+ reabsorption (113). Consequently, Mg2+ reabsorption 
mainly occurs in the late parts of the PT, where the transepithelial chemical Mg2+ gradient 
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is sufficient to favor Mg2+ transport. Generally, PT Mg2+ reabsorption is considered to be a 
passive paracellular process, but there might be some transcellular Mg2+ transport via a 
poorly characterized amiloride-sensitive mechanism (69). In both cases, sufficient Na+ 
transport is required to drive water transport that is prerequisite for Mg2+ reabsorption. 
Therefore, hormonal effects on Na+ reabsorption in the PT will also affect Mg2+ 
reabsorption in this segment. However, disturbances of proximal tubular Mg2+ 
reabsorption generally do not result in clinical symptoms, since more distal segments will 
compensate for reduced Mg2+ uptake in PT.
Thick Ascending Limb of Henle’s Loop
Whereas most electrolytes are majorly transported in the PT, the Thick Ascending Limb of 
Henle’s Loop (TAL) is the main location for Mg2+ reabsorption. Due to the unique 
properties of this segment, approximately 50-70 % of filtered Mg2+ is reabsorbed here. 
Most of the Mg2+ is reabsorbed by the cortical part of the TAL, since medullary Mg2+ 
reabsorption is negligible (130). Paracellular bulk Mg2+ transport is dependent on the 
lumen-positive transepithelial voltage (+10 mV) that is determined by the activity of the 
Na+-K+-2Cl- co-transporter (NKCC2) and the subsequent secretion of K+ at the apical 
membrane (49). Inhibition of the NKCC2 by furosemide diuretics therefore results in 
decreased TAL Mg2+ reabsorption. Further contributors to the transepithelial membrane 
voltage are K+ secretion via ROMK and paracellular back flux of Na+ ions as a result of 
decreasing luminal Na+ concentrations.
 The reabsorption of Mg2+ in the TAL follow the paracellular pathway and therefore 
depends on the tight junction permeability (Figure 4). Tight junctions form a physical and 
chemical barrier between the epithelial cells. The major components of tight junctions are 
proteins of the claudin family. Currently, 26 claudins have been described in humans (57). 
Tight junction permeability is determined by the individual claudins in each tight junction 
complex. TAL tubules are known to express claudins 3, 10, 11, 14, 16 and 19. Claudin 16 and 
19 are considered to be the main claudins influencing Mg2+ permeability, since mutations 
in these proteins results in renal Mg2+ wasting (80, 135). 
 However, the role of claudin 16 in Mg2+ reabsorption is controversial. Claudin 16 was 
initially considered to act as a paracellular Mg2+ channel, but this hypothesis has not been 
unequivocally confirmed (55, 64). Reports using the claudin 16 knockdown (KD) mouse 
model and the LLC-PK1 cell model suggest that claudin 16 increases Na+ permeability (60, 
64, 129). This would imply that claudin 16 is mainly involved in the regulation of the tran-
sepithelial voltage gradient by controlling the paracellular Na+ back leak. However, in 
MDCK-C7 cells overexpressing claudin 16, Na+ permeability remained stable, whereas 
Mg2+ permeability increased significantly (55). Claudin 16 KD mice demonstrate 2-fold 
lower permeability ratio for Na+ over Cl− without a change in paracellular conductance. 
Consequently, the transepithelial voltage collapsed, reducing the driving force for Mg2+ 
reabsorption in TAL (128).
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Figure 4  Magnesium Reabsorption in the Kidney
Along the nephron 95 % is reabsorbed. 10-25 % of Mg2+ is reabsorbed in the late proximal tubule 
(PT), where Na+ and H2O reabsorption via NHE3 and AQP1 are prerequisites for paracellular Mg2+ 
transport. Bulk Mg2+ reabsorption (50-70 %) takes place in the thick ascending limb of Henle’s Loop 
(TAL). In TAL, Mg2+ reabsorption take place paracellular and depends on the uptake of Na+ and K+ via 
NKCC2. Fine-tuning (10 %) of Mg2+ transport takes place transcellular in the distal convoluted tubule 
(DCT). In DCT, TRPM6 facilitates Mg2+ uptake from the pro-urine, which depends on the voltage-gra-
dient set by back leak of K+ via ROMK and Kv1.1 potassium channels. At the basolateral membrane, 
Mg2+ is extruded via an unknown mechanism, which may be regulated by CNNM2 acting as 
Mg2+-sensor. Mg2+ extrusion depends on the Na+ gradient, set by the Na+-K+-ATPase. The activity of 
the Na+-K+-ATPase is in turn dependent on K+ recycling via Kir4.1. FXYD2 transcription encoding the 
γ-subunit of the Na+-K+-ATPase, is regulated by HNF1β. Upon activation of the EGFR and IR an 
intracellular signaling cascade (PI3K, Akt and Rac1) results in an increased TRPM6 membrane 
expression and channel activity. Additionally, estrogens stimulate TRPM6 mRNA expression.
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 Claudin 19 has been studied less extensively, but claudin 19 has been suggested to 
increase the tight junction barrier function (8). The claudin 19 KD mouse exhibits highly 
increased urinary excretion of K+, Mg2+ and Ca2+, but Mg2+ is the only electrolyte changed 
at serum level (65). The discrepancy between studies with claudin 16 and claudin 19 
isoforms might be explained by their interdependence in forming functional tight 
junction barriers (65, 66). Both in vitro and in vivo studies demonstrated that claudin 16 and 
19 need to interact for proper insertion in the tight junction to be become functionally 
active. Further differences in experimental results may depend on the endogenous 
expression of other claudin isoforms in the specific cell types used in these experiments.
Claudin 14 reduces the cation specificity of tight junction barriers, when co-expressed 
with claudin 16, or with claudin 16 - claudin 19 complexes (46). Consequently, claudin 14 
KO mice exhibit increased serum Mg2+ values and decreased urinary Mg2+ excretion. This 
agrees with previous findings in Madin-Darby canine kidney (MDCK) cells showing that 
claudin 14 acts as a non-specific cation blocker (12, 149). Studies on claudin 14 KO mice 
have mainly focused on Ca2+ homeostasis, since claudin 14 expression is highly Ca2+ 
sensitive (33, 46). The CaSR  regulates claudin 14 expression and Ca2+ reabsorption in the 
TAL by downregulation of two microRNAs, miR-9 and miR-374. Since CaSR is also activated 
by Mg2+, although to a lesser extent than Ca2+, it would be interesting to address the 
effect of elevated serum Mg2+ levels on claudin 14 expression in future studies. 
 Recently, claudin 10 has been identified as an important factor in cation selectivity in 
TAL, as demonstrated in a mouse model where claudin 10 was deleted specifically in this 
segment (16). Claudin 10 TAL-KO mice show hypermagnesemia, nephrocalcinosis and 
impaired paracellular Na+ permeability. In the absence of claudin 10, TAL tight junctions 
become more permeable for Ca2+ and Mg2+ and the transepithelial voltage increases. 
These results are in line with in vitro studies overexpressing claudin 10b, suggesting that 
this splice variant is mainly expressed in TAL (16, 56).
 Over the last decades several mutations have been found that result in disturbed 
Mg2+ reabsorption in the TAL. An overview of TAL-caused genetic Mg2+ disorders is 
presented in Box 1.
PT: Proximal Tubule, TAL: Thick Ascending Limb of Henle’s Loop, DCT: Distal Convoluted Tubule, CNT: 
Connecting Tubule, CD: Collecting Duct, NHE3: Na+-H+-exchanger type 3, AQP1: Aquaporin 1, NKCC2: Na+-
K+-2Cl--cotransporter, ROMK: Renal Outer Medulla K+ channel, ClC-Kb: Chloride channel Kb, Kv1.1: Voltage 
gated K+ channel 1.1,TRPM6: Transient receptor potential melastatin type 6, NCC: Na+-Cl- co-transporter, 
CNNM2: Cyclin M2, FXYD2: FXYD-domain containing 2, HNF1β: Hepatocyte Nuclear Factor 1β, EGF: 
Epidermal Growth Factor, EGFR: Epidermal Growth Factor Receptor, IR: Insulin Receptor, PI3K: Phosphoinos-
itide 3-kinase, Rac1: Ras-related C3 botulinum toxin substrate 1, Cdk5: Cyclin-dependent kinase 5.
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Box 1  Genetic Disorders of TAL Mg2+ Reabsorption
CLDN16 Familial hypomagnesemia with hypercalciuria and nephrocalcinosis Type 1 
(FHHNC Type 1; OMIM: 248250) is caused by mutations in claudin 16 previously 
known as Paracellin-1 (135). Patients suffer from renal Mg2+ wasting, hypo-
magnesemia, renal Ca2+ wasting, renal parenchymal calcification (nephro-
calcinosis) and renal failure. Serum and urinary Na+, K+, Cl- and HCO3- are 
initially normal, but may get indirectly affected after progression of renal 
failure. Sometimes these symptoms are extended to urinary tract infections, 
kidney stones and hyperuricemia. Mg2+ supplementation is not capable in 
restoring normal serum Mg2+ levels or slow down disease progression (150). 
A few dozen different mutations have been reported, all characterized by a 
recessive mode of inheritance (44). All symptoms can be traced to the TAL, the 
main site for paracellular Ca2+ and Mg2+ reabsorption. Claudin 16 is part of the 
tight junction barrier between the cells. The TAL is the main site for paracellular 
Ca2+ and Mg2+ reabsorption, and disruption of these tight junctions result in 
a lack of Ca2+ and Mg2+ absorption in TAL, which can only be partially be 
compensated for in the downstream DCT and CNT segments.
CLDN19 Similar to FHHNC Type 1, patients with FHHNC type 2 (OMIM: 248190) suffer 
from severe hypomagnesemia accompanied with hypercalciuria and nephro-
calcinosis. Additionally, patients have ocular defects consisting of macular 
colobomata, significant myopia, and horizontal nystagmus. FHHNC type 2 is 
caused by mutations in Claudin 19, which is expressed in the TAL segment of 
the kidney. In the initial publication from Konrad and colleagues 12 patients 
from 10 families were genotyped and characterized (80). Remarkably, 9 out 
of 12 patients developed chronic kidney disease or underwent kidney 
 transplantation. Indeed, other studies confirmed that FHHNC type 2 patients 
are more prone to developing CKD and develop the disease at an earlier age 
compared to Type 1 patients (44), Over the years, several treatment regimens 
have been proposed including oral magnesium supplementation, thiazide 
diuretics and indomethacin. However, none of these treatments significantly 
increased serum Mg2+ values (44).
SLC12A1  BSND 
CLCNKB  KCNJ1
Bartter’s syndrome was originally described by Dr. Bartter in 1962 and is 
characterized by salt wasting, hypokalemic alkalosis, elevated renin and 
aldosterone levels and low blood pressure (10). Mutations in SLC12A1, 
encoding NKCC2, Barttin, ClC-Kb, KCNJ1, encoding ROMK and the CaSR form 
the genetic basis of Bartter’s syndrome (13, 132-134). Mild hypomagnesemia is 
sometimes observed in Bartter’s patients, which could be explained by a 
reduced driving force for paracellular Mg2+ reabsorption in the TAL. 
Compensation for reduced TAL Mg2+ reabsorption may take place in the DCT, 
which explains why Bartter’s patients often have normal Mg2+ levels. ClC-Kb 
and Barttin are also expressed in DCT, which justifies why patients with 
mutations in these genes more often show hypomagnesemia (70).
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Distal Convoluted Tubule
The distal convoluted tubule (DCT) determines the final urinary Mg2+ excretion, since no 
reabsorption of Mg2+ take place beyond this segment. Approximately 10 % of the total 
Mg2+ is reabsorbed by tightly regulated transcellular transport mechanisms (Figure 2) (18). 
DCT cells form a high-resistance epithelium with a lumen negative voltage of approximately −5 
mV (49, 152). In DCT, TRPM6 divalent cation channels mediate luminal Mg2+ uptake (Figure 4). 
Within the kidney, TRPM6 is specifically expressed in DCT and its activity is regulated by 
intracellular Mg2+ (144). TRPM6 contains six transmembrane spanning domains with a 
pore region between the fifth and sixth segment and a large kinase domain fused to the 
channel’s intracellular C-terminus. TRPM6 may function in homo- and heteromeric 
tetramers with TRPM7, although there is some controversy about the necessity of TRPM7 
for TRPM6 function (87, 157). 
TRPM6 is regulated by numerous factors at the level of transcription, plasma membrane 
availability and activity (21). Epidermal growth factor (EGF) and insulin act on TRPM6 by a 
PI3K-Akt-Rac1 dependent mechanism, increasing the insertion of TRPM6 in the membrane 
(100, 141). Insulin may directly affect TRPM6 activity through cyclin-dependent kinase 5 
(cdk5)-dependent phosphorylation of the channel. Patients with reduced EGF receptor or 
insulin receptor activity are therefore more susceptible to hypomagnesemia (100, 124). 
Additionally, estrogens increase TRPM6 mRNA expression (52). Over the last decade, 
several important interactors of TRPM6, including guanine nucleotide-binding protein 
subunit beta-2-like 1 (GNB2L1/RACK1) and prohibitin2 (PHB2/REA), have been identified 
(22, 23). Interestingly, GNB2L1 interacts with the α-kinase domain of TRPM6 in the auto-
phosphorylated state thereby reducing channel activity (22). Other modulators of TRPM6 
activity include dietary Mg2+, pH and ATP (142). Interestingly, acidification-induced current 
potentiation is dependent on residues p.Glu1024 and p.Glu1029, which also determine 
the pore selectivity for Mg2+ (86, 101). Moreover, recent findings indicate that TRPM6 is 
inhibited by low concentrations of intracellular ATP (IC50: 29 μmol/L), questioning the 
physiological activity of monomeric TRPM6 channels (157). 
 A chemical gradient for Mg2+ entry in DCT cells is almost absent. The luminal Mg2+ 
concentrations vary between 0.2-0.7 mmol/L and the intracellular Mg2+ levels are typically 
in the range of 0.5-1.0 mmol/L. Therefore, luminal Mg2+ entry is purely dependent on the 
negative membrane potential in the DCT cell. Luminal K+ channels are indispensable for 
maintaining the necessary driving force for Mg2+ uptake. The voltage-gated K+ channel 
Kv1.1 has been suggested to provide efflux K+ currents resulting in hyperpolarization of 
the luminal membrane, although expression levels in the DCT are limited (43). To prevent 
Mg2+ overload and hyperpolarization of the luminal membrane, intracellular Mg2+ blocks 
Kv1.1 (45). Interestingly, recent studies suggest that other K+ channels in the luminal 
membrane of DCT cells may have similar roles. ROMK is prominently expressed in DCT and 
its expression in this segment is regulated by dietary Mg2+ (153). Similar to Kv1.1, intracellular 
Mg2+ blocks ROMK currents, suggesting a regulatory function on Mg2+ homeostasis (156). 
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Moreover, indirect inhibition of ROMK by aldosterone or Epithelial Na+ Channel (ENaC) 
blockers represent the only effective approach to prevent renal Mg2+ wasting in most 
clinical situations (34).
 Several proteins have been suggested to mediate Mg2+ extrusion to the bloodstream, 
but general consensus of the extrusion mechanism has not been reached. Due to the 
absence of a representative DCT cell model, the properties of Mg2+ extrusion have not 
been elucidated. Nevertheless, over the last decade several groups have claimed to 
identify Mg2+ extrusion proteins. Originally described in 2002, Cyclin M2 (CNNM2 
previously known as ACDP2) is exclusively expressed at the basolateral membrane of DCT 
and CNT cells within the kidney (138, 147). Moreover, expression of CNNM2 is sensitive to 
dietary Mg2+ availability (138). CNNM2 was initially depicted as Mg2+ transporter, since 
overexpression in Xenopus laevis oocytes allows uptake of a variety of divalent cations, 
with highest affinity for Mg2+ (47). However, these results could not be confirmed in 
mammalian cell lines (138). Thus, it remains unclear whether CNNM2 mediates Mg2+ 
uptake directly or activates other Mg2+ carriers.
 Recently, mutations in the SLC41A1 Mg2+ transporter were described to be causative 
for a nephronophthisis-like phenotype (68). Localization studies showed expression in 
DCT, however the immunostainings were not conclusive about the subcellular localization 
(apical or basolateral) of SLC41A1 proteins (68). Using Mag-Fura, SLC41A1 was demonstrated 
to increase both Mg2+ absorption and Mg2+ extrusion (68, 79). These results suggest that 
SLC41A1 plays a role in DCT Mg2+ reabsorption, although further studies are necessary to 
elucidate the mechanisms by which SLC41A1 mediates Mg2+ transport.
 Since parvalbumin is within the kidney exclusively expressed in DCT, it has been 
suggested that this cytosolic protein acts as a Ca2+/Mg2+ buffer in DCT (122). Although 
parvalbumin has much higher affinity for Ca2+ than for Mg2+ (dissociation constants are 
5–10 nmol/L for Ca2+ and ±30 µmol/L for Mg2+), the cation binding sites of parvalbumin 
will be mainly occupied by Mg2+ (105). This can be explained by the fact that the 
intracellular concentration of Mg2+ (0.5–1.0 mmol/L) exceeds largely that of Ca2+ (50–100 
nmol/L). In mouse and human kidney, parvalbumin is exclusively expressed in the early 
DCT (11). In late DCT and CNT, calbindin-D28K is the main Ca2+-binding protein. The exact 
role of parvalbumin in DCT remains to be elucidated. Parvalbumin KO mice do not have 
altered serum or urine Mg2+ levels under basal conditions (11). The mice have reduced 
NCC expression, but display normal tubule morphology. DCT parvalbumin expression is 
highly sensitive to dietary Mg2+ availability, suggesting that parvalbumin plays an 
important role in DCT Mg2+ reabsorption.
 Disturbed Mg2+ reabsorption in the DCT inevitably results in renal Mg2+ wasting, 
since no Mg2+ is reabsorbed beyond this segment. An overview of genetic Mg2+ 
disorders due to DCT defects is presented in Box 2.
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Box 2  Genetic Disorders of DCT Mg2+ Reabsorption 
TRPM6 Hypomagnesemia with secondary hypocalcemia (HSH, OMIM: 602014) is 
characterized by extremely low serum Mg2+ levels (0.1-0.3 mmol/L) 
accompanied by low serum Ca2+ levels, which result in severe muscular and 
neurological complications including seizures and mental retardation (121, 
145). The disorder was first characterized by Paunier and colleagues and 1968 
and later mapped to a region at chromosome 9q in 1997 (108, 146). In 2002, 
two independent groups identified mutations in TRPM6 to be causative for 
HSH (121, 145). TRPM6 forms the epithelial Mg2+ channel responsible for 
transcellular Mg2+ transport in the colon and DCT segment of the kidney 
(144). Therefore, mutations result in reduced intestinal absorption and renal 
Mg2+ wasting. HSH has an autosomal-recessive mode of inheritance and until 
now a few dozen mutations have been identified. Patients are generally 
treated with Mg2+ supplements and anti-epileptic drugs against seizures. 
Serum Mg2+ levels improve after supplementation, but normally do not 
recover to normal levels (81).
EGF Isolated autosomal recessive hypomagnesemia (IRH, OMIM: 611718) is caused 
by mutations in the EGF gene (53). In a consanguine family from Dutch origin, 
two sisters presented with serum Mg2+ levels of 0.53 mmol/L and 0.56 mmol/L 
and urinary Mg2+ values of 3.9 mmol/24 h and 3.7 mmol/24 h, respectively (41). 
Serum Ca2+, Na+, K+, Cl–, HCO3–, and blood pH values were normal. The 
patients presented with epileptic seizures during their first year of life, which 
could be controlled by anti-epileptic drugs. Moreover, psychomotor 
retardation was observed in these patients. Plasma renin activity, plasma 
aldosterone, and parathyroid hormone concentrations were in the normal 
range. Homozygosity mapping and subsequent Sanger sequencing of gene 
candidates resulted in the identification of a homozygous c.3209C>T mutation 
in exon 22 resulting a p.P1070L missense mutation at protein level (53). This 
residue is particularly important for membrane targeting of the EGF molecule 
and the mutation results in impaired basolateral sorting of EGF. Therefore, 
TRPM6 is not stimulated, resulting in renal Mg2+ wasting (53, 141). Until now, 
only a single family has been described with EGF mutations, but studies with 
EGFR antagonists further underline the clinical importance of EGF for renal 
Mg2+ handling.
KCNA1 In a Brazilian family mutations in KCNA1 encoding voltage-gated K+ channel 
Kv1.1 were shown to cause autosomal dominant hypomagnesemia (OMIM: 
176260) (43). The patient presented in the clinic with muscle cramps, muscle, 
weakness, tetanic episodes and tremor. Serum Mg2+ values were low (0.37 
mmol/L), whereas other electrolytes and metabolites including Na+, K+, Ca2+, 
Pi, uric acid, bicarbonate, urea, creatinine, glucose, bilirubin, aminotransferases, 
alkaline phosphate, and lactate dehydrogenase were all normal. Urinary 
creatinine clearance, Mg2+ and Ca2+ excretion were within the normal range. 
KCNA1 mutations were previously linked to ataxia and myokymia (17, 36).
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Box 2  Continued 
KCNA1 Therefore, a cerebral MRI was performed in this patient, showing slight 
atrophia of the cerebral vermis. Family members suffer from myokymic 
discharge in electromyograph analysis, which is in line with the previously 
observed mixed phenotype. Intravenous Mg2+ infusion improved the clinical 
symptoms. Kv1.1 has been proposed to cause apical hyperpolarization, which 
allows the uptake of Mg2+ via TRPM6. The p.N255D (c.763A>G) mutation 
identified in the Brazilian family disrupts Kv1.1 activity and therefore may 
reduce the driving force for Mg2+ transport. Although many KCNA1 mutations 
have been reported, even in residues very close to the p.N255, none of these 
have been associated with hypomagnesemia (4, 71). Identification of 
additional hypomagnesemic families with Kv1.1 mutations may aid our 
understanding of Kv1.1 function in DCT. It has been suggested that other 
factors contribute to the apical membrane potential and may compensate for 
a loss of Kv1.1 function; ROMK may be one of them (34). 
SLC12A3 Hypomagnesemia with hypokalemia are the cardinal symptoms of a 
hereditary electrolyte disorder characterized by Dr. Gitelman in 1966, that has 
been known since as Gitelman’s syndrome (42). Patients present with tetany, 
paresthesias, and chondrocalcinosis (77). The severity of the symptoms often 
depends on the degree of the hypokalemia. Except hypokalemia and 
hypomagnesemia, laboratory investigations often show metabolic alkalosis 
and hypocalciuria, sometimes associated with a mild hypotension and 
prolonged QT interval. Mutations in SLC12A3 encoding the thiazide-sensitive 
Na+-Cl--co-transporter (NCC) cause Gitelman’s syndrome (39, 136). Patients 
with Gitelman’s syndrome are often treated with oral Mg2+ supplements (77). 
Interestingly, in some patients Mg2+ supplementation results in restoration 
of normal K+ levels, suggesting that hypokalemia is secondary to hypo-
magnesemia (54). This hypothesis is further substantiated by the NCC KO 
mouse, which is hypomagnesemic but does not display K+ disturbances 
under basal conditions (125). NCC KO mice have markedly reduced TRPM6 
expression levels, which may explain the renal Mg2+ wasting observed in 
Gitelman’s syndrome (102). However, the mechanisms explaining why a loss of 
NCC function results in reduced TRPM6 expression remains unresolved. It has 
been suggested that atrophy of the DCT segment observed in KO mice, may 
partially explain this phenomenon (89).
CNNM2 Mutations in CNNM2 have been shown to be causative for hypomagnesemia 
with seizures and mental retardation (HSMR, OMIM: 613882). Originally, two 
unrelated families with seizures and dominant hypomagnesemia were 
reported to carry CNNM2 mutations (138). In these patients, serum Mg2+ levels 
range between 0.3-0.5 mmol/L, but no other electrolyte disturbances were 
detected. The patients’ symptoms include seizures, loss of consciousness, loss 
of muscle tone, headaches and staring (94). HSMR patients are treated with 
anti-epileptic drugs and Mg2+ supplements. Mg2+ levels improve after sup-
plementation but didn’t reach to normal levels. 
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KCNJ10 Mutations in KCNJ10 encoding the Kir4.1 K+ channel are causative for Seizures, 
sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance / 
epilepsy, ataxia, sensorineural deafness, and renal tubulopathy syndrome 
(SeSAME/EAST, OMIM: 612780) (14, 116, 123). Patients have marked electrolyte 
abnormalities, including hypokalemic metabolic alkalosis without hypertension, 
severe hypomagnesemia and renal Na+, K+ and Mg2+ wasting. In some patients, 
high renin and aldosterone levels, salt craving and polyuria were observed. 
Kir4.1 is hypothesized to be involved in K+ recycling at the basolateral membrane 
of DCT cells. When Kir4.1 is mutated, K+ availability becomes rate limiting for 
Na+-K+-ATPase activity. Thus, the Na+-K+-ATPase will be inhibited resulting in a 
reduced potential across the basolateral membrane. Consequently, Na+ and 
Mg2+ transport will be reduced in DCT. To compensate for this, ENaC activity in 
CNT will be increased at the expense of K+ excretion via ROMK. Therefore, 
SeSAME/EAST patients suffer from severe hypomagnesemia and hypokalemia. 
To treat the hypomagnesemia, patients are often treated with Mg2+ and K+ 
supplements in combination with aldosterone antagonists or ENaC inhibitors 
(9). SeSAME/EAST patients suffer from a severe neurological phenotype 
consisting of tonic-clonic seizures in infancy, cerebellar ataxia and hearing loss. 
Moreover, magnetic resonance imaging evidenced subtle symmetrical signal 
changes in the cerebellar dentate nuclei (29).
FXYD2 Gene linkage studies identified FXYD domain containing ion transport 
regulator 2 (FXYD2) mutations in a family with dominant isolated renal Mg2+ 
wasting (IDH, OMIM: 154020) (93). The patients in this family suffered from low 
serum Mg2+ values (±0.4 mmol/L), without other plasma electrolyte 
abnormalities including Na+, K+, Ca2+, Cl-, HCO3-. Urinary Mg2+ excretion was 
increased, whereas Ca2+ excretion was slightly low (40). The c.121G>A mutation 
results in a p.G41R missense mutation at protein level which causes misrouting 
of FXYD2 to the membrane (19). FXYD2 encodes for the γ-subunit of the 
Na+-K+-ATPase. Although the exact role of FXYD2 in the DCT it is unknown. It 
has been hypothesized to stabilize the Na+-K+-ATPase, influencing the 
membrane potential necessary for Mg2+ transport (96). However, other 
reports suggest that it may function as inward rectifier channel on its own 
(127). Functional analysis of patient’s proximal tubular cells showed no 
differences in Na+, K+ or ATP-affinity of the Na+-K+-ATPase, but demonstrated 
a lower FXYD2 protein expression (20).
HNF1B Renal cysts and diabetes syndrome (RCAD, OMIM: 137920) is caused by 
mutations in Hepatocyte nuclear factor 1B (HNF1B) and consists of a 
heterogenous group of symptoms including renal cysts (± 70 % of patients), 
maturity onset diabetes of the young subtype 5 (MODY5, ± 50 %) and 
hypomagnesemia (± 45 %) (3, 25). HNF1β is a transcription factor regulating 
gene expression in kidney development (91). Amongst others, FXYD2b 
expression has been shown to be regulated by HNF1β (37), which may explain 
its role in renal Mg2+ handling. However, it cannot be excluded that HNF1β 
additionally regulates other DCT genes involved in renal Mg2+ transport.
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Outline of this Thesis
The aim of this thesis was to understand the physiological mechanism of Mg2+ 
reabsorption in the DCT. Dissecting the biochemical and molecular basis of Mg2+ transport 
pathways and their regulatory mechanisms may aid to provide clinical tools for patients 
with genetic or acquired Mg2+ deficiencies. In particular, this thesis aims to identify and to 
characterize new genes involved in DCT Mg2+ transport. Chapter 2 provides a large-scale 
screening of Mg2+ sensitive gene expression in the DCT by microarray analysis on isolated 
DCT cells form mice fed Mg2+-enriched and Mg2+-deficient diets. This study resulted in 
the identification of several new genes regulating Mg2+ reabsorption in the DCT, including 
PCBD1 and SLC41A3. In Chapter 3, the role of PCBD1 as transcriptional co-activator of 
HNF1B has been further characterized using luciferase assays to determine its effect on 
FXYD2 transcription. It was acknowledged that patients with mutations in PCBD1 develop 
hypomagnesemia and MODY5-like diabetes, which may partially be the result of reduced 
FXYD2 transcription in the kidney. Within the DCT cell the extrusion mechanism for Mg2+ 
remains to be identified. In Chapter 4, two new patient families with hypomagnesemia 
caused by FXYD2 mutation were described. Extensive clinical examinations aimed to 
further describe the clinical presentation of patients with FXYD2 mutations. Moreover, 
haplotype and genealogical analysis was performed to identify the genetic origin of 
FXYD2 mutations. Several transporters have been proposed to mediate Mg2+ transport at 
the basolateral membrane of the DCT cell. Chapter 5 aimed to examine whether SLC41A3 
may be one of these extrusion mechanisms. Using Slc41a3 knockout mice, the effect on 
Mg2+ homeostasis and renal function was investigated. 
 Although patients with CNNM2 mutations develop severe hypomagnesemia and 
renal Mg2+ wasting, CNNM2 was excluded as Mg2+ extrusion protein. In Chapter 6, 
biochemical and molecular characterization of the CNNM2 protein aimed to elucidate the 
structure and regulation of CNNM2. Using epitope-stainings the membrane topology was 
determined and by homology modeling the ability of CNNM2 to bind Mg-ATP was 
studied. In Chapter 7, it was shown that patients with CNNM2 mutations develop severe 
seizures and mental retardation. By introducing 25Mg2+ uptakes studies to measure Mg2+ 
transport, the goal was test which patient mutations could alter CNNM2 function. 
Moreover, we used the zebrafish knockdown system to test the effect of CNNM2 on brain 
development and activity. 
 The last part of this thesis is dedicated to new regulatory mechanisms of TRPM6 
activity. In Chapter 8, expression profiling of P2X purinoreceptors aimed to identify the 
purinoreceptors involved in ATP-mediated regulation of Mg2+ transport. By patch clamp 
analysis the effect of ATP was studied on TRPM6 activity via P2X4 purinoreceptors. 
Chapter 9 examines the effect of the small molecules belonging to the flavagline class of 
compounds, on TRPM6 activity using patch clamp analysis. Studying new activators of 
TRPM6-mediated Mg2+ transport may provide new potential treatment for patients with 
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hypomagnesemia. In chapter 10 the findings of this thesis are summarized and discussed 
by placing them in the context of the current knowledge of renal Mg2+ transport in the 
DCT.
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Abstract
The kidney plays a key role in the maintenance of the magnesium (Mg2+) homeostasis. 
Specifically, the distal convoluted tubule (DCT) is instrumental in fine-tuning of the renal 
Mg2+ handling. In recent years hereditary Mg2+ transport disorders have helped to identify 
important players in DCT Mg2+ homeostasis. Nevertheless, several proteins involved in 
DCT-mediated Mg2+ reabsorption remains to be discovered and a full expression profile of 
this complex nephron segment may facilitate the discovery of new Mg2+-related genes. 
Here, we report the Mg2+-sensitive expression of the DCT transcriptome. To this end, 
transgenic mice expressing eGFP under a DCT-specific parvalbumin promoter were 
subjected to Mg2+-deficient or Mg2+-enriched diets. Subsequently, the Complex Object 
Parametric Analyzer and Sorter (COPAS) allowed for the first time isolation of eGFP-positive 
DCT cells. RNA extracts thereof were analyzed by DNA microarrays comparing high vs. 
low Mg2+ to identify Mg2+ regulatory genes. Based on statistical significance and a 
fold-change of at least two, 46 genes showed differential expression. Several known 
magnesiotropic genes, such as Trpm6 and Parvalbumin, were upregulated under low 
dietary Mg2+. Moreover, new genes were identified that are potentially involved in renal 
Mg2+ handling. To confirm that the selected candidate genes were regulated by dietary 
Mg2+ availability, the expression levels of Slc41a3, Pcbd1, Tbc1d4 and Umod were determined 
by RT-PCR analysis. Indeed, all four genes show significant upregulation in the DCT of mice 
fed the Mg2+-deficient diet. 
By elucidating the Mg2+-sensitive DCT transcriptome new candidate genes in renal Mg2+ 
handling have been identified. 
Keywords: Magnesium Homeostasis, Hypomagnesemia, Gene Expression Microarray, COPAS, 
Distal Convoluted Tubule
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Introduction
Hypomagnesemia is a common clinical manifestation associated with type 2 diabetes, 
hypertension, osteoporosis, tetany, seizures, depression and the use of a variety of drugs 
(6, 21). Clinical studies addressing the Mg2+ status of critically ill patients showed that a 
substantial number of patients is hypomagnesemic. Moreover, low blood Mg2+ levels are 
associated with a poor clinical outcome (23, 40). Regulation of blood Mg2+ levels is an 
equilibrium between intestinal Mg2+ absorption and renal Mg2+ reabsorption. In kidney, 
Mg2+ reabsorption in the proximal tubule (PT) and the thick ascending limb of Henle (TAL) 
is a passive paracellular process, whereas in the distal convoluted tubule (DCT) Mg2+ 
reabsorption is a highly regulated and transcellular mechanism. This latter segment 
facilitates the fine-tuning of renal Mg2+ uptake, since no reabsorption takes places beyond 
DCT. 
 Over the last decade, the elucidation of the molecular origin of human genetic 
diseases has helped to identify new proteins involved in Mg2+ transport in DCT (6). 
In patients with hypomagnesemia and secondary hypocalcemia (HSH), mutations were 
identified in the transient receptor potential melastatin 6 (TRPM6), the gatekeeper of Mg2+ 
entry in the DCT cell (39, 47). The abundance of TRPM6 at the plasma membrane is 
regulated by the epidermal growth factor (EGF) and as a result mutations in the pro-EGF 
gene are causative for hypomagnesemia (16). Mg2+ transport via TRPM6 is a passive 
process that depends on the membrane potential across the luminal membrane (14). 
Therefore, several players involved in the maintenance of this membrane potential have 
been identified by gene-linkage analyses in patients with hereditary hypomagnesemia. 
For instance, a mutation in KCNA1 encoding the voltage-gated K+ channel Kv1.1 impairs 
the luminal extrusion of K+ ions necessary to maintain a substantial luminal membrane 
potential (14). At the basolateral membrane, the K+ channel Kir4.1 acts an important player 
in the K+ recycling which seems necessary to maintain a high Na+-K+-ATPase activity (1). 
Indeed, mutations in KCNJ10 coding for Kir4.1 and mutations in the γ-subunit of the 
Na+-K+-ATPase, FYXD2, are linked to hypomagnesemia (1, 4). Moreover, mutations in 
transcription factor HNF1β, that regulates the transcription of FXYD2, cause a similar 
phenotype (27). Recently, mutations in the DCT-expressed CNNM2 gene were linked to 
hypomagnesemia (43). It was postulated that CNNM2 may act as an intracellular Mg2+ 
sensor regulating Mg2+ transport (7). Although gene-linkage studies have gained insight 
in Mg2+ reabsorption in DCT over the last years, several factors remain unidentified. For 
instance, the Mg2+ extrusion mechanism of DCT cells is still unknown.
 The aim of the present study was, therefore, to elucidate the Mg2+-sensitive transcriptome 
of the DCT cell. To this end, primary DCT cells were isolated from mice kidneys and a 
comprehensive expression profile specific for DCT cells was established using gene 
expression microarrays. Furthermore, by comparing DCT expression profiles of mice fed 
high and low Mg2+-containing diets, the Mg2+-sensitivity of the DCT transcriptome has 
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been determined. Here, we describe the identification of new candidate genes potentially 
involved in Mg2+ reabsorption in DCT.
Results
Experimental Design
In our study, transgenic mice, that express enhanced Green Fluorescent Protein (eGFP) 
downstream a parvalbumin (Pv) promoter, were subjected to Mg2+ diets. Within the 
kidney, PV is exclusively expressed in DCT (3). Combining Pv-eGFP mice with the COPAS 
tissue sorting system allowed the specific isolation of DCT cells (26). Here, Pv-eGFP mice 
were subdivided into 2 groups consisting of 12 mice each. Each group was subjected to a 
high (0.48 % (w/w)) Mg2+ or a low (0.02 % (w/w)) Mg2+-containing diet for 15 days. 
Subsequently, DCT tubules were isolated using COPAS and total RNA was extracted 
(Figure 1A). 4 out of 12 pairs of RNA extracts were processed for and subjected to pair-wise 
(high vs. low) microarray analysis. The 8 remaining RNA extracts per group were used to 
validate the results of the microarray experiments by RT-PCR. 
 As a control for purity, transcriptional expression levels of DCT marker genes, Trpm6 
and Ncc were determined by RT-PCR (Figure 1B-1C). Indeed, the expression of the thiazide- 
sensitive sodium-chloride cotransporter (Ncc) and Trpm6 are enriched 200-fold and 8-fold, 
respectively, compared to total kidney material of the same mice. Moreover, expression of 
protein markers for proximal tubules (Aqp1) and the collecting duct (Aqp2) was reduced. 
Slight overlap was detected with thick ascending limb and connecting tubules, when 
testing for marker genes, Nkcc2 and Trpv5, respectively (Figure 1B). These results indicate 
that the COPAS-sorted tubules contain primarily DCT transcripts. 
Effects of Mg2+ Diets
Before subjecting mRNA transcripts to microarray hybridization, the effect of the Mg2+ 
diets on plasma and urinary Mg2+ levels were assessed (Figure 2A-2C). In line with our 
previous experiments, the serum Mg2+ concentration dropped significantly in the mice 
fed with the Mg2+-deficient diet (Figure 2A)(15). The Mg2+-enriched diet resulted in a 
slight, albeit significant, hypermagnesemia (Figure 2A). The urinary Mg2+ excretion 
showed the same pattern: high excretion in the Mg2+-enriched diets and low excretion in 
the Mg2+-deficient mice (Figure 2B). Serum Ca2+ concentrations did not change 
significantly (Figure 2C). In contrast, the urinary Ca2+ concentration was significantly 
increased in mice fed a high Mg2+ diet (Figure 2D). Urinary and serum Na+ and K+ values 
were not significantly altered by the dietary Mg2+ availability (Figure 2E-H).
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DCT Transcriptome Analysis
The DCT transcriptome was first analyzed for abundance of individual mRNAs. This was 
achieved by analyzing the average log2 intensity of the two channel microarray data (the 
so-called A value, A=½log2(RG)) after normalization between the two channels. Although the 
A value is influenced by the amplification of the transcripts and the position of microarray 
feature sequences, it gives a qualitative view of the gene expression levels in the DCT 
Figure 1  Isolation of Distal Convoluted Tubule Cells
A, Timeline of animal experiment. Mice were placed on Mg2+ diets for 15 days (gray bar). Blood samplings 
are indicated by black arrows, metabolic cages are represented by the black bar. B-C, mRNA expression 
levels of Aqp1, Nkcc2, Trpm6, Trpv5, Aqp2 (B) and Ncc (C) in COPAS-selected mouse DCT (black bar) 
and control (none-selected, white bar) kidney tubules were measured by quantitative RT-PCR and 
normalized for Gapdh expression. Data represent means (n=8) ± SEM and are expressed as fold 
difference when compared with the expression in none-selected tubules. *P < 0.05 indicates significant 
difference from none-selected tubules.
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Figure 2   Effect of Dietary Mg2+ Availability on Serum and Urinary Mg2+ and  
Ca2+  Concentrations. 
A-H, Serum Mg2+ (A) and Ca2+ (C) concentrations at day 0 (black bars) and day 15 (white bars) of mice 
fed with a low or high Mg2+-containing diet for 15 days. 24hrs urinary Mg2+ (B) and Ca2+ (D) excretion 
at day 15 of mice fed with a low or high Mg2+-containing diet for 15 days. Serum Na+ (E) and K+ (G) 
concentrations at day 15 of mice fed with a low or high Mg2+-containing diet for 15 days. 24hr urinary 
Na+ (F) and K+ (H) excretion at day 15 of mice fed with a low or high Mg2+-containing diet for 15 days. 
Values are presented as means ± SEM (n=12). *P < 0.05 is considered statistically significant compared 
to day 0. #P < 0.05 is considered statistically significant to the low Mg2+ group.
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tubules. Of the most abundant transcripts more then a third are directly linked to 
mitochondrial function (Table 1). DCT cells are the cells with the highest mitochondrial 
density in the mammalian kidney (9). Moreover, DCT marker genes have moderate to high 
A values. Ncc gave an average expression signal of 11.9 and Trpm6 had a value of 11.7. 
Several genes implicated in DCT-mediated Mg2+ transport were highly expressed. Egf and 
Fxyd2 were with expression values of 16.7 and 16.5 among the 50 most expressed DCT 
genes. Interestingly, marker proteins of the TAL showed low expression levels. For instance, 
Slc12a1 had a value of 8.6 and Claudin16 had an expression level of 6.9. Taken together 
these results confirm the purity of the COPAS-selected DCT cells.
Mg2+-sensitive Gene Expression
To identify DCT genes involved in Mg2+ homeostasis, the Mg2+-sensitive differential 
expression of the transcriptome was determined by pair-wise comparison of high versus 
low Mg2+ samples. As a first approach, we examined the expression of the genes that are 
associated with hypomagnesemia in genetic disease (6). Interestingly, only Trpm6 and Egf 
were shown significantly upregulated in the low Mg2+ diet compared to mice fed with 
high Mg2+ diets (Table 2).  To assess the reproducibility of our microarray data, the 
microarray results were validated by RT-PCR on a separate set of DCT mRNA transcripts 
(Figure 3A-3H). Indeed, this analysis confirmed that dietary Mg2+ regulates Trpm6 
expression. The Trpm6 expression in the low Mg2+-fed diet mice was 2.3 fold enriched in 
comparison to mice fed with high Mg2+ diets (Figure 3A). Additionally, only Egf and Cnnm2 
were differentially regulated (Figure 3B and 3F). RT-PCR analyses showed enrichment in 
the low Mg2+ diet-fed mice of 1.5 and 2.1 fold, respectively, relatively to high Mg2+ diet-fed 
mice. The enrichment of Cnnm2 was not significant in the microarray data (P=0.68), but 
was highly significant in the RT-PCR analysis (P<0.002). Kcna1 transcripts, encoding Kv1.1, 
were not detectable in the pure DCT material (Figure 3C), confirming the low signal in the 
microarray (A value: 5.7).  No major differences between microarray and RT-PCR data were 
observed, indicating high reproducibility between the RT-PCR and microarray analyses.
 Next, we analyzed the microarray Mg2+ sensitivity of all potential mammalian Mg2+ 
transporters that have been described in literature (34). In comparison with mice fed an 
Mg2+-enriched diet, only Trpm6 and Slc41a3 mRNA transcripts show a significant 
enrichment in mice fed a Mg2+-deficient diet (Table 3). Slc41a3 has been previously linked 
to Mg2+ transport, although the exact function of this gene was never examined (34). 
Cnnm1, Cnnm3, Cnnm4, Slc41a1, Slc41a2 and all other transporters of the Nipa, MagT, MMgT, 
Mrs and Zdhhc families are not Mg2+ sensitive and present a relatively low A value, 
suggesting low DCT abundance.
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Table 1   Most Abundantly Expressed Genes in the Distal Convoluted Tubule
Gene
Name
Gene
Description
Average
Signal
(A value)
Fjx1 four jointed box 1  17.2
Olfr215 olfactory receptor 215 17.1
Klk1b5 kallikrein 1-related peptidase b5 17.1
Neurog3 neurogenin 3 17.1
mt-Co2 mitochondrially encoded cytochrome c oxidase II 17.1
Fth1 ferritin heavy chain 1 17.1
Ccdc78 coiled-coil domain containing 78 17.1
Ccl4 chemokine (C-C motif ) ligand 4 17.1
Klk1b26 kallikrein 1-related petidase b26 17.1
Aspscr1 alveolar soft part sarcoma chromosome region, candidate 1 (human) 17.1
Slc45a3 solute carrier family 45, member 3 17.0
Atp5a1 ATP synthase, H+ transporting, alpha subunit 1 17.0
Olfr214 olfactory receptor 214 17.0
Lrsam1 leucine rich repeat and sterile alpha motif containing 1 17.0
mt-Nd4 mitochondrially encoded NADH dehydrogenase 4 17.0
mt-Nd2 mitochondrially encoded NADH dehydrogenase 2 16.9
Atp5g3 ATP synthase, H+ transporting, subunit C3 (subunit 9) 16.9
Dnajc19 DnaJ (Hsp40) homolog, subfamily C, member 19 16.9
Ddx51 DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 16.9
Porcn porcupine homolog  16.9
Fgf17 fibroblast growth factor 17 16.9
Gabarapl1 gamma-aminobutyric acid  A receptor-associated protein-like 1 16.9
Atp5b ATP synthase, H+ transporting beta subunit 16.9
mt-Atp8 mitochondrially encoded ATP synthase 8 16.9
Mdh1 malate dehydrogenase 1, NAD (soluble) 16.9
mt-Nd3 mitochondrially encoded NADH dehydrogenase 3 16.8
Nudt4 nudix (nucleoside diphosphate linked moiety X)-type motif 4 16.8
Olfr15 olfactory receptor 15 16.8
mt-Cytb mitochondrially encoded cytochrome b 16.8
Ulk1 Unc-51 like kinase 1 16.8
mt-Co3 mitochondrially encoded cytochrome c oxidase III 16.8
Avpr2 arginine vasopressin receptor 2 16.8
Entpd4 ectonucleoside triphosphate diphosphohydrolase 4 16.8
Plekho2 pleckstrin homology domain containing, family O member 2 16.8
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Table 1   Continued
Gene
Name
Gene
Description
Average
Signal
(A value)
Vsig10l ZV-set and immunoglobulin domain containing 10 like 16.7
Chchd2 coiled-coil-helix-coiled-coil-helix domain containing 2 16.7
Egf epidermal growth factor 16.7
Atp1a1 ATPase, Na+/K+ transporting, alpha 1 polypeptide 16.7
Eef1a1 eukaryotic translation elongation factor 1 alpha 1 16.7
mt-Atp6 mitochondrially encoded ATP synthase 6 16.7
Uqcrh ubiquinol-cytochrome c reductase hinge protein 16.7
Oxct1 3-oxoacid CoA transferase 1 16.6
Uqcrfs1 ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 16.6
Slc25a3 solute carrier family 25 member 3 16.5
SNORA17 Small nucleolar RNA SNORA17  16.5
Cox6c cytochrome c oxidase, subunit VIc 16.5
Ldhb lactate dehydrogenase B 16.5
Mtx1 metaxin 1 16.5
Fxyd2 FXYD domain-containing ion transport regulator 2 16.5
Id3 inhibitor of DNA binding 3 16.4
Hspa12b heat shock protein 12B 16.4
Wfdc15b WAP four-disulfide core domain 15B 16.4
Umod uromodulin 16.3
Atp5l ATP synthase, H+ transporting, mitochondrial F0 complex, subunit g 16.3
Mal myelin and lymphocyte protein, T-cell differentiation protein 16.3
Cox8a cytochrome c oxidase, subunit VIIIa 16.2
Igfbp7 insulin-like growth factor binding protein 7 16.2
Ndufa4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4 16.2
Stat5b signal transducer and activator of transcription 5B 16.2
Kcnj1 potassium inwardly-rectifying channel, subfamily J, member 1 16.2
Krt16 keratin 16 16.1
Cox6a1 cytochrome c oxidase, subunit VI a, polypeptide 1 16.1
Dlx3 distal-less homeobox 3 16.1
Rpl7 ribosomal protein L7 16.1
Rpl10 ribosomal protein 10 16.1
Slc48a1 solute carrier family 48 (heme transporter), member 1 16.0
Cox7c cytochrome c oxidase, subunit VIIc 16.0
Cox7a2 cytochrome c oxidase, subunit VIIa 2 16.0
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Table 1   Continued
Gene
Name
Gene
Description
Average
Signal
(A value)
Efhd1 EF hand domain containing 1 16.0
Atp5h ATP synthase, H+ transporting, subunit d 16.0
Rpl23 ribosomal protein L23 16.0
Ndufa1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1 16.0
Fryl furry homolog-like 16.0
This table summarizes the genes that are most abundantly expressed (A value >16) in the distal 
convoluted tubule (DCT) of mice, as determined by microarray expression analysis on mRNA specifically 
isolated from DCT material. The total signal is expressed as the 2log of the sum of the red and green 
signal divided by 2, A=½log2 (RG). 
Table 2   Mg2+-sensitivity in the Distal Convoluted Tubule of Genes Associated with 
Hypomagnesemia.
Name Average Signal
(A value)
Fold Change in the 
Low Mg2+ group
P value
Trpm6 11.8 2.05 0.03
Egf 16.7 1.74 0.05
Kcna1 5.7 0.97 1
Kcnj10 14.9 1.08 1
Fxyd2 16.5 0.88 1
Hnf1b 8.7 0.84 1
Cnnm2 10.4 1.69 0.68
Slc12a3 11.9 1.11 1
Shown is a summary of Mg2+-sensitive expression of all distal convoluted tubule (DCT) genes 
previously linked with human genetic forms of hypomagnesemia by microarray expression analysis 
on mRNA specifically isolated from DCT material. The average signal is expressed as the ½log2 of the 
sum of the red and green signal. The fold change is the differential expression between high- and 
low-Mg2+ diet-fed mice and is expressed as enrichment in the low-Mg2+ diet compared with the 
high-Mg2+ diet. Numbers above 1 indicate enrichment in mice fed a low-Mg2+ diet. Numbers below 
1 designate enrichment in mice fed with high-Mg2+ diet. The P value shows the statistical significance 
of the differential expression. 
Trpm6, transient receptor potential cation channel, subfamily M, member 6; Egf, Epidermal growth 
factor; Kcna1, K+ voltage-gated channel, shaker-related subfamily, member 1; Kcnj10, K+ inwardly 
rectifying channel, subfamily J, member 10; Fxyd2, FXYD domain containing ion transport regulator 
2; Hnf1b, hepatocyte nuclear factor-1β; Cnnm2, cyclin M2; Slc12a3, solute carrier family 12, member 3. 
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Figure 3   Effects of Dietary Mg2+ Availability on mRNA Transcript Expression of  
Hypomagnesemia-linked Genes
A–H, the mRNA expression levels of Trpm6 (A), Egf (B), Kcna1 (C), Kcnj10 (D), Fxyd2 (E), Hnf1b (F), Cnnm2 
(G) and Ncc (H) in COPAS-selected DCT tubules of mice fed with a low or high Mg2+-containing 
diet for 15 days were measured by quantitative RT-PCR and normalized for Gapdh expression. Data 
represent means (n=8) ± SEM and are expressed fold difference when compared to the expression 
in the high Mg2+ group. ND = Not detectable. *P < 0.05 indicates significant difference from the 
high Mg2+ group.
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New Candidate Genes
The main objective of this study was to identify new players in renal Mg2+ handling. 
Therefore, we subsequently selected differentially expressed genes with statistical 
significance (P < 0.05) and a minimal fold-change in expression of two. As a result of this 
Table 3   Distal Convoluted Tubule Mg2+-sensitivity of Mg2+ Channels and Transporters
Name Average Signal
(A value)
Fold Change in the Low 
Mg2+ group
P-value
Trpm6 11.8 2.05 0.03
Trpm7 14.3 1.37 0.49
Cnnm1 8.4 0.86 1
Cnnm2 13.5 1.69 0.68
Cnnm3 11.5 1.21 1
Cnnm4 7.1 0.95 1
Slc41a1 6.8 1.03 1
Slc41a2 5.6 0.99 1
Slc41a3 7.8 0.49 0.02
Nipa1 8.6 0.98 1
Nipa2 9.9 1.15 1
Nipal1 5.9 1.01 1
Nipal2 5.8 0.94 1
Nipal3 11.8 1.09 1
Nipal4 5.1 1.00 1
Mrs2 8.3 0.75 1
MagT1 7.8 0.98 1
MMgT1 7.8 1.06 1
MMgT2 8.3 1.29 1
Tusc3 8.7 0.98 1
Zdhhc17 7.9 1.20 1
Zdhhc13 8.5 1.05 1
Shown is Mg2+ sensitive expression of all putative mammalian Mg2+ transporters by microarray 
expression analysis on mRNA specifically isolated from DCT material. The average signal is expressed 
as the ½log2 of the sum of the red and green signal. The fold change gives the differential expression 
between high and low Mg2+-fed mice and is expressed as enrichment in the low diet compared to 
the high Mg2+ diet. Numbers above 1 indicate enrichment in mice fed with a low Mg2+-diet. 
Numbers smaller than 1 designate enrichment in mice fed with a high Mg2+-diet. The P value shows 
the statistical significance of the differential expression. 
Nipa, NaCl-inducible protein; MMgT, membrane Mg2+ transporter; Tusc3, tumor suppressor candidate 
3; Zdhhc, putative ZDHHC-type palmitoyltransferase 6-like.
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stringent analysis, 46 gene candidates were identified (Table 4). Among the genes that 
were enriched in Mg2+-deficient mice, the previously mentioned Trpm6 and Slc41a3 were 
detected. Additionally, 33 genes were identified that were enriched in the low Mg2+ group 
(compared to the high Mg2+ group). The gene with the highest fold change was Sox9 
encoding a transcription factor involved in renal development. Other high ranking genes 
are the DCT marker Pv, glycoprotein Umod and complement factor Cd55. Furthermore, we 
identified direct and indirect regulators of the Na+-K+-ATPase, Tbc1d4 and Pcbd1. Notable 
is the presence of several genes that are mainly known for their role in Ca2+ homeostasis, 
such as calbindin28K and the vitamin D receptor. Only 11 genes were significantly enriched 
with a minimal fold change of 2 in the high Mg2+ group, compared to low Mg2+-fed mice. 
None of these genes were earlier linked to Mg2+ homeostasis. The most profound 
differential expression was measured with the Ptger3 gene, a prostaglandin receptor. 
 To confirm the results of the microarray analysis, mRNA transcript levels of all major 
candidate genes were determined using RT-PCR (Figure 4A-D). Indeed, Slc41a3 mRNA 
expression was 1.8 fold enriched in the Mg2+-deficient mice, similar to the values observed 
Table 4   Mg2+-regulated Genes in the Distal Convoluted Tubule
Name Average Signal
(A value)
Fold Change in the Low 
Mg2+ group
P value
Sox9 9.6 4.83 0.01
Cd55 7.1 4.16 0.00
Dnaja4 11.8 3.28 0.00
Gulo 8.4 3.27 0.02
Pck1 9.0 3.27 0.03
Prkd1 9.7 3.17 0.0004
Calb1 13.5 3.01 0.02
Umod 16.3 2.91 0.01
Pvalb 13.4 2.71 0.01
Ptgs1 10.0 2.52 0.0008
Tppp 6.4 2.52 0.01
Unc5b 10.6 2.37 0.00
Rd3 9.5 2.36 0.01
Acss1 15.7 2.30 0.03
Wdr72 11.8 2.27 0.02
Pdlim1 7.8 2.20 0.03
Pcbd1 14.8 2.20 0.01
Tbc1d4 11.6 2.18 0.01
Gsn 12.8 2.17 0.02
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Table 4   Continued
Name Average Signal
(A value)
Fold Change in the Low 
Mg2+ group
P value
Ilvbl 8.2 2.12 0.01
Spag5 6.5 2.12 0.03
Etv5 10.3 2.11 0.01
Vdr 10.7 2.10 0.01
Hmgcll1 8.1 2.09 0.0012
Iyd 7.4 2.08 0.03
Zscan4c 9.4 2.08 0.02
Plekha1 12.0 2.08 0.0018
Trpm6 11.8 2.05 0.03
Tspan33 10.8 2.04 0.01
Abcg1 8.1 2.04 0.02
Dusp6 10.6 2.03 0.02
Gpm6b 8.7 2.02 0.01
Slc41a3 7.8 2.02 0.02
Cwh43 13.3 2.01 0.03
Tdrd3 12.9 2.00 0.0008
Pdpn 9.0 0.49 0.002
Gpc3 7.0 0.49 0.02
Lrtm2 8.3 0.48 0.05
Nqo1 8.3 0.46 0.03
Tmed6 8.7 0.45 0.0004
Grin3a 6.8 0.44 0.01
Ell3 8.3 0.42 0.00
Kap 9.2 0.40 0.01
Mreg 9.6 0.38 0.00
Ndrg4 9.1 0.37 0.01
Ptger3 9.5 0.23 0.01
Shown is a summary of all genes that are significantly (P < 0.05) differentially expressed with a 
minimal fold change of 2 in the distal convoluted tubule (DCT) of mice fed with a high or low Mg2+ 
diet for 15 days, as determined by microarray expression analysis on mRNA specifically isolated from 
DCT material. The average signal is expressed as the ½log2 of the sum of the red and green signal. 
The fold change gives the differential expression between high and low Mg2+-fed mice and is 
expressed as enrichment in the low diet compared to the high Mg2+ diet. Numbers above 1 indicate 
enrichment in mice fed with a low Mg2+-diet. Numbers smaller than 1 designate enrichment in mice 
fed with a high Mg2+-diet. The P-value shows the statistical significance of the differential expression. 
The full lists of 35,000 genes can be accessed at GEO database Ac: GSE40208.
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on the microarray (Figure 4A). Likewise, mRNA expression levels were determined for 
Pcbd1, Tbc1d4 and Umod, since all three genes are potentially involved in Mg2+ handling 
(Figure 4B-D). Pcbd1 is a regulator of HNF1β function, Tbc1d4 has been shown to modulate 
Na+-K+-ATPase activity and uromodulin effects transcellular Na+ transport (2, 28, 31). The 
fold enrichment values for these three genes estimated by RT-PCR correspond to the 
values obtained by the microarray analysis. Since Umod is mainly described as TAL gene, 
we further examined uromodulin DCT expression with immunohistological staining and 
RT-PCR. Interestingly, Umod was 3.5 times more expressed in DCT cells compared to total 
kidney material (Figure 5A). Uromodulin co-localized with NCC in early DCT cells (Figure 5C). 
Moreover, only the DCT fraction of Umod expression, but not the total kidney sample 
mainly containing TAL Umod expression, was shown to be Mg2+-sensitive (Figure 5B). 
 To determine whether the differentially regulated genes belong to the same functional 
pathways or cellular processes, GO-term enrichment analysis was performed by gene set 
enrichment analysis (GSEA, Table 5). In the DCT samples from Mg2+-deficient mice EGF 
Figure 4   Effects of Dietary Mg2+ Availability on mRNA Transcript Expression of  
Newly Identified Candidate Genes
A–D, the mRNA expression levels of Slc41a3 (A), Pcbd1 (B), Tbc1d4 (C) and Umod (D) in COPAS-select-
ed DCT tubules of mice fed with a low or high Mg2+-containing diet were measured by quantitative 
RT-PCR and normalized for Gapdh expression. Data represent means (n=8) ± SEM and are expressed 
fold difference when compared to the expression in the high Mg2+ group. *P < 0.05 indicates significant 
difference from the high Mg2+ group.
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Figure 5   Expression of Uromodulin in Distal Convoluted Tubules
A, the mRNA expression levels of Umod, in COPAS-selected mouse DCT and control (none-selected) 
kidney tubules were measured by quantitative RT-PCR and normalized for Gapdh expression. Data 
represent means (n=8) ± SEM and are expressed as fold difference when compared with the expres-
sion in none-selected tubules. *P < 0.05 indicates significant difference from none-selected tubules. 
B, the mRNA expression levels of Umod in COPAS-selected DCT tubules and control (none-selected) 
kidney tubules of mice fed with a low or high Mg2+-containing diet were measured by quantitative 
RT-PCR and normalized for Gapdh expression. Data represent means (n=8) ± SEM and are expressed 
fold difference when compared to the expression in the high Mg2+ group. *P < 0.05 indicates sig-
nificant difference from the high Mg2+ group. C. Double immunofluorescence staining of mouse 
kidney sections for NCC (in green) and UMOD (in red). Bars represent 20 µm. 
TAL: Thick ascending limb of Henle’s loop. DCT: Distal Convoluted Tubule.
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Table 5   GO-term Enrichment Analysis of Mg2+-sensitive Expression in the  
Distal Convoluted Tubule
GO-Term Description P value Mean  
Difference
GO:0060009 Sertoli cell development 0.0004 -0.26
GO:0061036 positive regulation of cartilage development 0.0002 -0.26
GO:0030238 male sex determination 0.0018 -0.25
GO:0060170 cilium membrane 2.4E-05 -0.25
GO:0002237 response to molecule of bacterial origin 0.0043 -0.23
GO:0001158 enhancer sequence-specific DNA binding 0.0015 -0.22
GO:0030502 negative regulation of bone mineralization 0.0056 -0.21
GO:0016585 chromatin remodeling complex 0.0001 -0.20
GO:0043536 positive regulation of blood vessel endothelial  
cell migration
0.0065 -0.20
GO:0030903 notochord development 0.0053 -0.20
GO:0007173 epidermal growth factor receptor signaling pathway 0.0011 -0.18
GO:0032331 negative regulation of chondrocyte differentiation 4.2E-07 -0.17
GO:0006107 oxaloacetate metabolic process 0.0059 -0.17
GO:0030279 negative regulation of ossification 0.0001 -0.16
GO:0010634 positive regulation of epithelial cell migration 9.5E-06 -0.15
GO:0045732 positive regulation of protein catabolic process 0.0090 -0.14
GO:0071347 cellular response to interleukin-1 0.0010 -0.13
GO:0016614 oxidoreductase activity, acting on CH-OH group  
of donors
0.0054 -0.13
GO:0035924 cellular response to vascular endothelial growth factor 
stimulus
0.0075 -0.11
GO:0005840 ribosome 2.3E-20 0.10
GO:0003735 structural constituent of ribosome 9.4E-20 0.10
GO:0006694 steroid biosynthetic process 0.0001 0.11
GO:0022627 cytosolic small ribosomal subunit 0.0007 0.12
GO:0022900 electron transport chain 7.7E-14 0.14
GO:0005903 brush border 0.0010 0.14
GO:0006637 acyl-CoA metabolic process 0.0032 0.16
GO:0005762 mitochondrial large ribosomal subunit 1.1E-05 0.18
GO:0005747 mitochondrial respiratory chain complex I 2.4E-12 0.20
GO:0070469 respiratory chain 3.7E-19 0.21
GO:0008137 NADH dehydrogenase (ubiquinone) activity 5.3E-10 0.23
GO:0015238 drug transmembrane transporter activity 0.0003 0.23
GO:0015893 drug transport 0.0035 0.24
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signaling was upregulated, as evidenced by the differentially regulated GO-term ‘EGF 
pathway’. EGF activates a signaling pathway leading to increased TRPM6 plasma membrane 
expression, hence more Mg2+ reabsorption (44). Interestingly, ‘bone mineralization’ was 
also among the enriched GO-terms in the mice fed with low Mg2+-diets. Mg2+ plays an 
important role in this latter process (38). The most evidently enriched functional pathways 
were observed in the high Mg2+ fed mice. Among the upregulated functions many 
GO-terms indicating mitochondrial activity were evidenced. 
Discussion
In this study, the Mg2+-sensitive transcriptome of the DCT was elucidated. By taking 
advantage of the COPAS sorting system, we are the first to isolate primary DCT material with 
high purity for gene expression analysis. As a result of our approach new promising candidate 
players in renal Mg2+ homeostasis were identified. Among the candidates: i) SLC41A3 has 
been proposed as a potential Na+/Mg2+ exchanging mechanism; ii) PCBD1 might influence 
HNF1β activity; iii) TBC1D4 is a possible regulator of ion channel membrane availability; 
iv) Uromodulin could regulate Mg2+ transport by decreasing the urinary flow rate.  
 We isolated DCT cells from mice kidneys combining the COPAS sorting system with 
Pv-eGFP mice. Until now, it was difficult to obtain high quality expression profiles of the 
isolated DCT fraction because of the quantitative limits of the microdissection technique. 
Therefore, previously reported expression analyses resulted in a gene expression profile of 
the combined DCT and CNT fraction (33). The COPAS system provides the only high 
efficiency and high quality alternative for microdissection. The purity of the COPAS-sorted 
DCT cells was significantly higher then previous reports, as was demonstrated by the 
impressive fold-enrichments of 200 and 8 for Ncc and Trpm6 (26). The high abundance of 
mitochondrial genes in our microarray data set further showed sample purity. In kidney, 
Table 5   Continued
GO-Term Description P-value Mean  
Difference
GO:0003954 NADH dehydrogenase activity 0.0004 0.24
GO:0035634 response to stilbenoid 0.0002 0.26
GO:0016651 oxidoreductase activity, acting on NADH or NADPH 6.7E-06 0.28
Shown is a summary of the significantly differentially expressed GO-terms in the Distal Convoluted 
Tubule of mice fed with a high or low Mg2+ diets with a minimal difference of 0.1. GO-term 
enrichment was determined by gene set enrichment analysis (GSEA) analysis of the microarray 
expression data from mRNA specifically isolated from DCT material.
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DCT cells contain the highest amount of mitochondria (9). Inevitably, COPAS-sorted DCT 
cells can contain adjacent TAL and CNT cells. Although the TAL marker Slc12a1, encoding 
NKCC2, was not significantly enriched compared to total kidney samples, transcripts 
isolated from COPAS-sorted cells may contain genes expressed in TAL. More importantly, 
Trpv5 expression was upregulated in COPAS-sorted DCT cells, which can be explained by 
the gradual transition of DCT1, via DCT2 to CNT region, causing a partial overlap of Pv and 
Trpv5 expression. Since the aim of our study was to identify Mg2+-sensitive gene 
transcription, the potential limit of sample purity will not affect the results of the microarray 
analysis. Altogether, this approach allowed the identification of magnesiotropic DCT genes. 
 Slc41a3 is probably the most interesting candidate among the newly identified 
Mg2+-sensitive DCT genes. SLC41A3 is part of a family of three putative Mg2+ transporters 
that were first described by Quamme et al. (34) Using the Xenopus laevis oocyte 
voltage-clamp model it was shown that all three SLC41 proteins transport Mg2+ within its 
physiological range, although these findings have never been repeated in mammalian 
cell models (19, 34). SLC41A3 has never been investigated in detail, but lessons from the 
other SLC41 family members have learned that it consists of 11 transmembrane domains 
(24). Recent reports claim that SLC41A1 could act as a Na+/Mg2+ exchanger (20). Likewise, 
the highly homologous SLC41A3 protein could have a similar function. Since SLC41A1 and 
SLC41A2 are not differentially regulated in DCT, it seems possible that SLC41A3 is the 
DCT-specific Mg2+ extrusion mechanism. Further research characterizing the function of 
SLC41A3 is needed to confirm this hypothesis.
 Interestingly, the expression of Hnf1b and Fxyd2 were not differentially regulated in 
this study. Nevertheless, we identified in Pcbd1 a potential modulator of HNF1β/FXYD2 
activity. First described in 1991, PCBD1 is a protein with a dual activity (28). PCBD1 can 
stimulate the HNF1α and HNF1β transcription and has a role in tetrahydrobiopterin 
regeneration (42). HNF1 transcriptional activation by PCBD1 does not depend on its 
enzymatic activity (17). Its role in HNF1β activation seems of special interest with respect 
to the Mg2+ homeostasis. HNF1β is a transcription factor that stimulates FXYD2 expression, 
encoding the γ-subunit of the Na+-K+-ATPase (11). PCBD1, also known as Dimerization 
Cofactor of HNF1 (DCOH), stabilizes HNF1 dimer formation necessary for Fxyd2 transcription. 
Although PCBD1 activation has never been linked to FXYD2 directly, PCBD1 could 
indirectly stimulate Fxyd2 transcription by enhancing HNF1β function. Given that Pcbd1 is 
transcriptionally upregulated in Mg2+-deficient conditions and that such regulation is 
absent for Fxyd2 and Hnf1b, PCBD1 might be the trigger in FXYD2-mediated fine-tuning of 
Mg2+ reabsorption in DCT. 
 During analyses of the microarray data, another modulator of Na+-K+-ATPase activity 
caught attention. Tbc1d4, previously known as AS160, was significantly upregulated in the 
low Mg2+-fed mice. TBC1D4 has been described as Rab-GTPase activating kinase involved in 
the regulation of Na+-K+-ATPase plasma membrane availability (2). In this ability, it might 
directly influence the transmembrane potential that is necessary for Mg2+ reabsorption. 
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Interestingly, the function of TBC1D4 is not limited to regulation of the Na+-K+-ATPase. 
Originally described as regulator of GLUT4 glucose transporters, TBC1D4 has recently been 
linked to the regulation of channels including AQP2 and ENaC (18, 22, 30). Thus, it might be 
relevant to consider TBC1D4 as a modulator of TRPM6 plasma membrane trafficking. This 
notion is further supported by the fact that a PI3K/Akt/RAC1-mediated pathway activated 
upon EGF stimulation regulates TRPM6 plasma membrane abundance and that TBC1D4 is an 
Akt-substrate that can also be stimulated by EGF (12, 44). GO-term enrichment analysis of our 
microarray results taught that the EGF pathway was upregulated in the low Mg2+ diet-fed mice.
 Although previously implicated in renal ion homeostasis, our finding that Umod 
expression is highly Mg2+-sensitive is unprecedented (31). Uromodulin, also described as 
Tamm-Horshfall glycoprotein, is the most abundant protein in urine, but its exact function 
remains to be determined (8). It has been proposed that after excretion in the pro-urine 
uromodulin forms an anionic gel-like structure that retards the flow of positively charged 
ions (46). Then, increasing Umod expression would decrease the urinary flow rate and 
thereby enhance the uptake of cations, such as Mg2+. Although often used as a marker for 
the TAL, Umod expression has been described to be not exclusively restricted to TAL, but 
also to be profound in the early DCT (33, 41). Studies using gene expression microarrays of 
microdissected DCT tubules are inconclusive. Whereas Pradervand and colleagues 
showed clear enrichment of Umod mRNA expression, other studies detected barely Umod 
mRNA transcripts in DCT (5, 33). Immunohistological stainings confirmed co-localization 
of uromodulin with the DCT-marker NCC, although it cannot be excluded that TAL-cleaved 
uromodulin reached DCT by urinary flow and sticked to the luminal membranes. 
Interestingly, RT-PCR analysis showed that only DCT expression of Umod was shown to be 
Mg2+ sensitive, in contrary to Umod expression in total kidney samples. This suggests 
different functional roles of UMOD in DCT and TAL segments of the kidney.
 Of all genes that have been linked to hypomagnesemia in human genetic diseases, 
only a few are transcriptionally regulated (6). Trpm6, Egf and Cnnm2 were modulated, 
indicating that Mg2+ transport is partially regulated on the transcriptional level. Major 
regulatory pathways are executed on protein level. The EGF signaling pathway is one of 
the best-described regulatory mechanisms of TRPM6-mediated Mg2+ transport in DCT 
(16, 44). Although its mean effectors, such as PI3K, Akt and RAC1, are not transcriptionally 
affected by alterations in dietary Mg2+ availability, EGF is among the enriched GO-terms. 
Futhermore, Kcna1 coding for K+ channel Kv1.1 could not be detected in the mouse DCT 
material by RT-PCR. Kcna1 is part of a larger family of voltage-gated K+ channels that are 
known to form heteromeric complexes. Although Kv1.1 has been implicated in Mg2+ 
handling in patients, its function might be compensated for by other K+-channels in the 
Pv-eGFP mouse model (14). In this context, it is interesting to note that ROMK is 1.7-fold 
upregulated in the low Mg2+ mice. Although this result does not reach statistical 
significance (P=0.06), it suggests that ROMK might play a role in the maintenance of the 
luminal membrane potential necessary for Mg2+ reabsorption in DCT.
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 Inevitably, although changing only the dietary Mg2+ availability, our approach also 
led to the detection of many Ca2+ homeostasis-related genes, such as vitamin D receptor, 
klotho and calbindin-D28K (35). Activation of the calcium-sensing receptor (CaSR) is 
hypothesized to explain this phenomenon (10). The CaSR is not only sensitive to Ca2+ ions, 
but is also activated upon Mg2+ binding. As a result, changes in Mg2+ availability activate 
the Ca2+-regulatory pathways at the local and whole-body level. Hypomagnesemia is, 
therefore, often associated with a disturbed Ca2+ balance in patients (39, 47). In a similar 
fashion the dietary Mg2+ availability influenced the Ca2+ homeostasis in our mice, as 
evidenced by the altered serum and urinary Ca2+ levels in the present and previous studies 
(15). Therefore, differential gene expression induced by dietary Mg2+ should be analyzed 
with care. Although serum Ca2+ and Mg2+ measurements showed that the alterations in 
Mg2+ balance are more profound, it has to be taken into account that differential gene 
expression might be the effect of Ca2+ alterations. Interlink between Ca2+ and Mg2+ 
homeostasis was further evidenced in the GO-term analysis of the microarray data. 
Although analyzing renal samples, bone mineralization was among the enriched 
GO-terms. This might be explained by the fact that many genes involved in renal mineral 
homeostasis play similar roles in bone formation (6, 38, 44). In addition, GO-term analysis 
identified upregulation of mitochondrial genes in mice fed the Mg2+-rich diet.  This could 
be a response to an increased intracellular Mg2+ concentration in these mice. Intracellular 
Mg2+ is an important ATP-binding factor. Therefore, high Mg2+ concentrations in the cell 
could result in a low unbound ATP availability. Mitochondrial activation will lead to 
increased ATP production and thereby compensate for the Mg2+ binding.
 In conclusion, gene expression microarray analysis on primary DCT cells allowed the 
identification of ample Mg2+-sensitive genes of the mouse genome. Particularly, Slc41a3, 
Pcbd1, Tbc1d4 and Umod are candidates that require further investigation. We suggest that 
patients suffering from hereditary hypomagnesemia of unknown cause are screened for 
mutations in these candidate genes. The COPAS sorting system provides an excellent 
mechanism to obtain primary DCT cells. Establishing COPAS-sorted DCT monolayers have 
been proven to be an accurate method to study thiazide-sensitive Na+ transport (26, 36). 
By the use of stable Mg2+ isotopes such as 25Mg2+ and 26Mg2+, this primary DCT culture 
could provide a unique model to examine DCT-specific Mg2+ transport. Furthermore, 
crossbreeding of Pv-eGFP mice with the available knock out mouse models including 
TRPM6 and NCC knock out mice, further expands the possibilities of the established 
procedure. It will in particular further substantiate the physiological importance of the 
studied target molecule (6, 48).
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Methods
Animal Studies
All the experimental procedures are in compliance with the animal ethics board of the 
Radboud University Nijmegen. Transgenic C57Bl/6 mice expressing eGFP under the 
parvalbumin (Pv) promotor were kindly provided by Dr. Hannah Monyer (University of 
Heidelberg, Germany)(29). Genotype was determined under UV light by checking 
fluorescent emission of muscular PV expression in the mouse legs. Littermates were 
housed in a temperature- and light-controlled room with the standard pellet chow 
(SSNIFF spezialdiäten GmbH, Soest, Germany) and deionized drinking water available ad 
libitum until the start of the experiment. Pv-eGFP positive mice were selected for 
experiments at the age of 4-6 weeks. During the experiments the mice were fed low (0.02 
% (w/w)) or high (0.48 % (w/w)) Mg2+-containing diets for 15 days (SSNIFF spezialdiäten 
GmbH, Soest, Germany). During the last 48 hrs of the experiment the mice were housed 
in metabolic cages for urine and faeces collection (24 hrs adaptation, 24 hrs sampling). 
Blood samples were taken at the start of the experiment and just before sacrifice. 
Isolation of DCT using COPAS Sorting
Pv-eGFP positive tubules were isolated as described previously (26). In short, mice aged 
from 4 to 6 weeks were anesthetized and perfused transcardially with ice-cold KREBS 
buffer (in mmol/L: 145 NaCl, 5 KCl, 1 NaH2PO4, 2.5 CaCl2, 1.8 MgSO4, 10 glucose, 10 HEPES/
NaOH pH: 7.4). Directly after perfusion of the mice, the whole kidneys were harvested and 
GFP-positive kidney material was manually selected under a microscope. This part of the 
procedure may take up 30-45 min. Subsequently, the kidney fragments were digested in 
KREBS buffer containing 1 mg/mL collagenase (Worthington, Lakewood, NJ, USA) and 
2,000 units/mL hyaluronidase (Sigma, Houten, the Netherlands) for 15 min at 37 °C. 
Subsequently, the kidney tubules sized between 100 μm and 40 μm were collected by 
filtration. Oversized material was digested again in two additional cycles of 10 min 
digestion and filtration. Tubules collected from the three digestions were ice-cooled and 
sorted by the Complex Object Parametric Analyzer and Sorter (COPAS, Union Biometrica, 
Holliston, MA, USA) at a rate of 2,000-4,000 tubules / hr. Sorted tubules were directly 
collected in 1 % (v/v) β-mercaptoethanol containing RLT buffer that was supplied by the 
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RNeasy RNA extraction kit (Qiagen, Venlo, the Netherlands). In total the sorting procedure 
of tubules from one mouse takes several hours. Per mouse, 4,000 eGFP-fluorescent tubules 
were collected and as control an additional 4,000 tubules were sorted from the same 
kidney sample without selection for eGFP positive cells. This control sample contained 
both eGFP-positive and eGFP-negative cells of the same size as the selected sample. 
4,000 tubules were pooled on a Qiagen Rneasy micro column for RNA extraction according 
to the manufacturer’s protocol.
Microarray Analysis
For microarray experiments RNA from two male and two female mice per group was 
taken. RNA from the low Mg2+ and the high Mg2+ group was matched in pairs based on 
gender of the mice. Double round RNA amplifications and labeling were performed as 
described before (37) on an automated system (Caliper Life Sciences NV/SA, Belgium) with 
10-50 ng total RNA from each sample. Briefly, total RNA was amplified twice from ~50,000 
cells by cDNA synthesis with oligo(dT) double-anchored primers, followed by in vitro 
transcription using a T7 RNA polymerase kit (Ambion, Bleiswijk, the Netherlands). During 
second round of transcription, 5-(3-aminoallyl)-UTP was incorporated into the single 
stranded cRNA. Cy3 and Cy5 NHS-esters (Amersham Biosciences, Roosendaal, the 
Netherlands) were coupled to 2 μg cRNA. RNA quality was monitored after each successive 
step using the equipment described above. Mouse Whole Genome Gene Expression 
Microarrays V2 (Agilent Technologies, Belgium) representing 39,429 mus musculus 60-mer 
probes in a 4x44K layout were used for hybridizations with 1 μg of each alternatively 
labeled cRNA on a HS4800PRO system supplemented with QuadChambers (Tecan 
Benelux B.V.B.A.) according to van de Peppel et al. (45). Two independent dye-swap 
hybridizations (4 arrays) were performed for each experimental group. After hybridization 
the slides were washed extensively and scanned using the Agilent G2565AA DNA 
Microarray Scanner. 
 After automated data extraction using Imagene 8.0 Software (BioDiscovery), Lowess 
normalization was performed on mean spot-intensities, followed by dye bias correction 
based on a within-set estimate as described before (25, 50). Data was analysed using 
MAANOVA (49). In a fixed effect analysis, sample, array and dye effects were modeled. 
P-values were determined by a permutation F2-test, in which residuals were shuffled 
5,000 times globally. Genes with P < 0.05 after family wise error correction (FWER) were 
considered significantly changed. Additionally a 2-fold change cutoff was applied. The 
complete microarray dataset is deposited in Gene expression omnibus (GEO) database 
(http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE40208. The 8,000 mos t 
expressed DCT genes are also available via http://helixweb.nih.gov/ESBL/Database/Non_
ESBL_datasets/Nijmegen-Webpage/index1.html.
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Mg2+ and Ca2+ Analysis
Serum and urine total Mg2+ and Ca2+ concentrations were determined using a colorimetric 
assay kit according to the manufacturer’s protocol (Roche Diagnostics, Woerden, the 
Netherlands). Urine volume was measured to calculate 24 hrs Mg2+ excretion.
Quantitative Real Time PCR 
The obtained mRNA from 4,000 tubules was reverse transribed using M-MLV reverse 
transcriptase (Invitrogen, Bleiswijk, the Netherlands) for 1 hr at 37 °C. The cDNA was 
subsequently used to measure Pv, Ncc, Trpm6, Kcna1, Kcnj10, Egf, Fxyd2, Hnf1b, Cnnm2, 
Slc41a3, Pcbd1, Tbc1d4 and Umod mRNA levels. Gene expression levels were determined by 
quantitative real-time PCR on a Bio-Rad analyzer and normalized for Gapdh expression. 
Primer sequences are provided in Table 6.
Immunohistochemistry
Immunohistochemistry was performed as described previously (13). In short, co-staining 
for Uromodulin with thiazide-sensitive Na+-Cl- cotransporter (NCC) was performed on 5 
µm sections of fixed frozen mouse kidney samples. The sections were incubated for 16 hrs 
at 4 °C with the following primary antibodies: guinea pig anti-UMOD (1:750, BioTrend, Köln, 
Germany) and rabbit anti-NCC (1:100 (32)). For detection, kidney sections were incubated 
with Alexa Fluor-conjugated secondary antibodies. Images were taken with an AxioCam 
camera and AxioVision software (Zeiss, Sliedrecht, the Netherlands).
Table 6   Primer Sequenced Used for RT-PCR Analysis.
Gene Forward Primer Reverse Primer
Parvalbumin 5’-CGCTGAGGACATCAAGAAGG-3’ 5’-AGCTTTCAGCCACCAGAGTG-3’
Ncc 5’-CTTCGGCCACTGGCATTCTG-3’ 5’-GATGGCAAGGTAGGAGATGG-3’
Trpm6 5’-AAAGCCATGCGAGTTATCAGC-3’ 5’-CTTCACAATGAAAACCTGCCC-3’
Egf 5’-GAGTTGCCCTGACTCTACCG-3’ 5’-CCACCATTGAGGCAGTATCC-3’
Kcna1 5’-CTGTGACAATTGGAGGCAAGATC-3’ 5’-GAGCAACTGAGCCTGCTCTTC-3’
Kcnj10 5’-CCGCGATTTATCAGAGC-3’ 5’-AGATCCTTGAGGTAGAGGAA-3’
Fxyd2 5’-TCAGCCTTTCTTGTGACTGG-3’ 5’-GGTCTTCCTGTGGCCTCTACT-3’
Hnf1b 5’-CATTGCACAGAGCCTCAACACC-3’ 5’-GTTGAGAGAACTGGACGGGCTG-3’
Cnnm2 5’-GGAGGATACGAACGACGTG-3’ 5’-TTGATGTTCTGCCCGTACAC-3’
Slc41a3 5’-TGAAGGGAAACCTGGAAATG-3’ 5’-GGTTGCTGCTGATGATTTTG-3’
Pcbd1 5’-TGGACATGGCCGGCAAGGC-3’ 5’-CCCACAGCCCTCAGGTTTG-3’
Tbc1d4 5’-CTCGAGCCAAGCTGGTAATC-3’ 5’-ACCCGTTCAAAGATGTCAGC-3’
Umod 5’-TGCAGGGTAGATGAAGATTGC-3’ 5’-GGCACTTTCTGAGGGACATC-3’
Gapdh 5’-TAACATCAAATGGGGTGAGG-3’ 5’-GGTTCACACCCATCACAAAC-3’
 Elucidation of the Mg2+-sensitive DCT Transcriptome | 65
Statistical Analysis
For RT-PCR experiments statistical significance was determined using an unpaired Student’s 
t test. In all experiments, data is expressed as mean ± SEM. Differences with P < 0.05 were 
regarded as statistically significant.
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Abstract
Mutations in PCBD1 are causative for transient neonatal hyperphenylalaninemia and pri-
mapterinuria (HPABH4D). Until now HPABH4D has been regarded as a transient and 
benign neonatal syndrome without complications in adulthood.
 In our study, two adult patients out of three individuals with homozygous mutations 
in the PCBD1 gene were diagnosed with hypomagnesemia and renal Mg2+ loss. Two 
patients also developed diabetes with characteristics of maturity onset diabetes of the 
young (MODY) regardless of the serum Mg2+ levels. Our results suggest that these clinical 
findings are related to the function of PCBD1 as dimerization cofactor for the transcription 
factor HNF1B. Mutations in the HNF1B gene have previously been shown to cause renal 
malformations, hypomagnesemia and MODY. Gene expression studies in combination 
with immunohistochemical analysis in the kidney showed that PCBD1 is expressed in the 
distal convoluted tubule (DCT) where Pcbd1 transcript levels are upregulated by a low 
Mg2+-containing diet. Overexpression in a human kidney cell line demonstrated that 
wild-type PCBD1 binds HNF1B to co-stimulate the FXYD2-promoter, whose activity is 
instrumental in Mg2+ reabsorption in DCT. Five out of seven PCBD1 mutations previously 
reported in HPABH4D patients caused proteolytic instability leading to a reduced FXYD2- 
promoter activity. Furthermore, HNF1B mutations may disturb the nuclear localisation of 
PCBD1, since PCBD1 showed an increased cytosolic localization when co-expressed with 
HNF1B mutants. 
 Overall, our findings establish PCBD1 as an important co-activator of the HNF1B- 
mediated transcription necessary for fine-tuning of FXYD2 transcription in DCT. Thus, 
patients with HPABH4D should be monitored for previously unrecognised late complications, 
such as hypomagnesemia and MODY diabetes.
Keywords: HNF1B, PCBD1/DCOH, HPABH4D, MODY, Diabetes, Tetrahydrobiopterin
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Introduction
Hypomagnesemia is a common clinical manifestation in patients with mutations in the 
transcription factor hepatocyte nuclear factor 1 homeobox B (HNF1B, OMIM #189907)(1). 
Mutations in HNF1B are associated with an autosomal dominant syndrome characterized 
by renal malformations with or without cysts, liver and genital tract abnormalities, gout, 
and maturity-onset diabetes of the young type 5 (MODY5; renal cysts and diabetes 
syndrome, OMIM #137920)(1, 13). Hypomagnesemia (plasma Mg2+ levels <0.7 mmol/L) 
with hypermagnesuria affects up to 50 % of the HNF1B patients (1, 15). 
 In adult kidney HNF1B is expressed in epithelial cells along all segments of the 
nephron. The role of HNF1B in renal Mg2+ handling was, however, pinpointed to the distal 
convoluted tubule (DCT), where the final urinary Mg2+ excretion is determined (1, 18). In 
DCT, the Na+/K+-ATPase provides the necessary driving force for active Mg2+ reabsorption 
from the pro-urine into the blood (18). Heterozygous mutations in the FXYD2 gene, 
encoding the γ-subunit of the Na+/K+-ATPase, result in an autosomal dominant renal 
hypomagnesemia with hypocalciuria (IDH, OMIM #154020)(29). More recently, functional 
HNF1B binding sites were identified in the promoter region of FXYD2 suggesting that 
impaired transcription of FXYD2 by HNF1B results in renal Mg2+ wasting (1, 16). Additional 
HNF1B target genes in kidney include renal cystic genes (19-21) as well as genes involved 
in tubular electrolyte transport (23, 24). 
 HNF1B forms heterotetrameric complexes with the protein pterin-4 alpha-carbinolamine 
dehydratase / dimerization cofactor of hepatocyte nuclear factor 1 alpha (PCBD1 / DCOH, 
OMIM #126090)(30). PCBD1 is a protein of 12 kDa with two distinct biological functions: 
 transcriptional co-activator of HNF1A-mediated transcription within the nucleus, and pterin- 
4α-carbinolamine dehydratase (EC 4.2.1.96) in the cell cytosol (10, 30). The enzymatic activity of 
PCBD1, together with dihydropteridine reductase, regenerates tetrahydrobiopterin (BH4), which 
is the cofactor for phenylalanine hydroxylase (PAH) and other aromatic amino acid hydrolases 
(42). The crystal structure of PCBD1 revealed that the protein forms a tetramer of identical 
subunits comprising two saddle-like shaped dimers (14, 17). HNF1 binding sites are located 
at the same surface that mediates interaction of the PCBD1 homodimers, on the opposite 
side of the catalytic domain (34). PCBD1 knockout mice display hyperphenylalaninemia, 
predisposition to cataracts and mild glucose-intolerance (4). Homozygous or compound 
heterozygous PCBD1 mutations in humans are associated with transient neonatal hyper-
phenyalaninemia and high urinary levels of primapterin (HPABH4D, or primapterinuria, 
OMIM #264070)(11, 38, 39). To date there have been no reports of late complications, or 
possible phenotypic consequences of impaired stimulation of the HNF1 transcription factors. 
 In our study, the occurrence of hypomagnesemia and MODY diabetes was investigated 
in three patients carrying PCBD1 mutations. We evaluated whether PCBD1 plays a role in 
renal Mg2+ reabsorption by directly affecting HNF1B-regulated FXYD2 transcription, in 
order to gain new insight into the molecular basis of the PCBD1-HNF1B interaction. 
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Results
Homozygous PCBD1 Mutations Cause Hypomagnesemia and  
Renal Mg2+ Wasting 
We diagnosed hypomagnesemia and hypermagnesuria in two patients carrying 
mutations on both alleles in the PCBD1 gene (Table 1). In patient 1, hypomagnesemia was 
partially corrected with oral Mg2+ supplements at a dose of 500 mg/day (0.64 mmol/L to 
0.76 mmol/L at first measurement, 0.66 mmol/L to 0.69 mmol/L at second measurement, 
N 0.7-1.1 mmol/L), though at the expense of increased magnesuria (FEMg 4.6 % to 7.8 %, 
N <4 %). He had non-specific symptoms that might be related to hypomagnesemia 
including fatigue, muscular pain, weakness and cramps in arms, numbness, difficulty 
with memory, chest pains, and blurred vision, with some improvement after Mg2+ 
 supplementation. An abdominal ultrasound showed slightly increased echogenicity of 
both liver and kidney of uncertain cause; renal size was normal, with no cysts present 
(Figure 1A-B). Renal function was normal (GFR 128 mL/min per 1.73 m2). Laboratory 
investigations of patient 2 revealed a relatively high 24h urinary Mg2+ excretion (5.25 
mmol/24 hrs, N 2-8; Table 1) in the presence of hypomagnesemia (0.65 mmol/L), with no 
secondary symptoms. Serum and 24h urinary Ca2+ excretion were within the normal 
range as well as creatinine clearance (126 mL/min, N 89-143). Ultrasound examinations 
excluded the presence of renal hypoplasia or cysts (Figure 1C). Patient 3 showed borderline 
serum Mg2+ levels (0.74 mmol/L), but displayed normal urinary Mg2+ excretion (FEMg 2.5 %).
Maturity Onset Diabetes of the Young (MODY) in Two Patients  
with PCBD1 Mutations
In addition to hypomagnesemia, patient 1 was diagnosed with diabetes. Type 1 autoimmune 
diabetes was unlikely, since the patient lacked islet-cell antibodies and showed normal 
serum C-peptide levels (0.69 nmol/L, N 0.3-1.32 nmol/L). Since MODY patients are generally 
highly sensitive to sulphonylureas (37), he was treated with Gliclazide 80 mg/bid to which he 
responded well, allowing his previous insulin treatment of 20-30 units/day to be discontinued. 
Additional extrarenal manifestations in HNF1B disease include liver test abnormalities (6, 7). 
Liver function tests in patient 1 revealed that the plasma levels of high sensitivity C-reactive 
protein (hs-CRP) were significantly low at <0.1 mg/L (N <8 mg/L) (Table 2). IgG was slightly low 
at 5.66 g/L (N 6.94-16.18 g/L), whereas the remaining liver function tests were all within the 
normal range. Based on his glycosylated haemoglobin levels, we concluded that patient 2 did 
not develop diabetes (HbA1c 4.95 %, N 4.3-6.1 %; Table 1). Abdominal ultrasound analysis 
showed that pancreas and liver were normal (Figure 1D-E). Patient 3 was also diagnosed 
with diabetes of no autoimmune origin due to the absence of islet-cell antibodies. HbA1c 
levels were 6.5 % (N 4.3-6.1 %) and glucose was 6.4 mmol/L (N 4.4-6.1 mmol/L). MODY type 
1, 2 and 3 due to mutations in HNF4A, GCK, and HNF1A, respectively, were excluded by DNA 
analysis. Presently the patient is not receiving medications nor insulin treatment. 
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Pcbd1 Expression in DCT is Modulated by Dietary Mg2+ Content
We examined Pcbd1 mRNA expression levels in a mouse tissue panel using real-time 
RT-PCR. Highest expression was measured in kidney and liver (Figure 2A). Furthermore, 
immunohistochemical analysis of mouse pancreas sections revealed that PCBD1 is 
expressed in pancreatic cells (Figure 2B). Mouse kidney sections were stained for PCBD1 to 
evaluate whether PCBD1 locates to the sites of renal Mg2+ reabsorption (Figure 2C-G). 
PCBD1 staining co-localized with NCC in DCT, and in part with Tamm Horsfall and 
calbindin-D28K expression in the cortical thick ascending limb of Henle’s loop (TAL) and 
connecting tubule (CNT), respectively. No co-localization of PCBD1 was detected with 
markers of the proximal tubule (PT) or collecting duct (CD), BCRP and AQP2, respectively. 
The expression of Pcbd1 in DCT was confirmed in isolated DCT fragments. Pcbd1 expression 
was significantly higher in DCT in comparison with whole kidney (Figure 2H). Hnf1b 
transcript was not enriched in the DCT fraction. Interestingly, Pcbd1 expression in the DCT 
was significantly upregulated when mice were fed a low Mg2+-containing diet compared 
to a high Mg2+-containing diet (Figure 2I). Mice on a Mg2+-deficient diet displayed a 
significantly lower 24hrs Mg2+ excretion (Figure 3B) in response to the hypomagnesemia 
(1.1 mmol/L versus 2.2 mmol/L, N 1.2-1.5 mmol/L (9), Figure 3A). Differences were not 
observed in the serum and urinary levels of phenylalanine between the experimental 
groups (Figure 3C-D). 
Figure 1  Abdominal Ultrasound Examination of Patient 1 and 2
In patient 1, size of the right (A) and left (B) kidney with normal with no cysts. Ultrasound analysis of 
kidney (C), pancreas (D) and liver (E) in patient 2 showed normal organ morphology.
Patient 2 (BIODEF 329) 
Patient 1 (BIODEF 272)
A
C
B
D E
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Table 1   Pertinent Laboratory Investigations for Three Patients with PCBD1 Mutations
Parameter Patient 1
(BIODEF 272)
Patient 2
(BIODEF 329)
Patient 3
(BIODEF 319)
Reference 
range
Baseline On 500 mg /
day Mg2+
Baseline Baseline
Serum indices
    Na+ (mmol/L) 141 — 138 139 135-145
    K+ (mmol/L) 4.0 — 4.5 4.0 3.5-5.0
    Mg2+ (mmol/L) 0.64* 0.76 0.65* 0.74 0.7-1.1
    Ca2+ (mmol/L) 2.41 2.55 2.25 2.43 2.20-2.65
    Pi (mmol/L) 1.13 1.16 — 1.15 0.8-1.4
    Creatinine (mmol/L) 0.069 0.066 0.062 0.056 0.045-0.110
    HbA1c (%) 7.2* — 4.95 6.5* 4.3-6.1
    Uric acid ((μmol/L) 310 — — — 135-510
Urinary indices
    Mg2+ (mmol/L) 6.16 3.96 — 2.6 —
    Mg2+ (mmol/24h) — — 5.25 — 2-8
    FeMg (%) 6.6* 11.1* — 3.5 <4
    Ca2+ (mmol/L) 4.47 3.04 — 2.99 —
    Ca2+ (mmol/24h) — — 5.61 — <7.5
    FeCa (%) 0.9 1.8 — 0.86 >1
    Pi (mmol/L) 40.29 13.61 — 18.2 —
    FePi (%) 17 17.6 — — 5-20
    Creatinine (mmol/L) 14.29 4.40 — 8.0 —
    Creatinine (mmol/24h) — — 14 — 9-18
GFR (mL/min per 1.73 m2) 128 135 — 124 ≥90
CCr (mL/min) — — 126 — 89-143
HbA1c: glycosylated haemoglobin; FEMg: fractional excretion of Mg2+. The FEMg was calculated 
using the following formula: FEMg = (UMg x PCr) / [(0.7 x PMg) x UCr x 100]; FeCa: fractional excretion 
of Ca2+; FEPi: fractional excretion of phosphate (Pi); GFR: glomerular filtration rate by Modification of 
Diet in Renal Disease (MDRD) formula; CCr: creatinine clearance.
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PCBD1 Enhances FXYD2 and PKHD1 Promoter Activation by HNF1B
In order to investigate whether the PCBD1 p.Glu26*, p.Arg87Gln, p.Glu96Lys and p.Gln97* 
mutations can lead to an impairment of the interaction with HNF1B, we generated a 
structural homology model of the PCBD1–HNF1B dimerization domain (HNF1B-D) 
complex using the structure of the PCBD1–HNF1A dimerization domain tetramer (Figure 
4A and B). The p.Glu26* mutation leads to a major protein truncation and complete loss of 
the interaction domain with HNF1B (Figure 4B). Although p.Gln97* does not directly affect 
the HNF1-binding domain of PCBD1, the mutation results in a truncation of the central 
α-helix of the protein. Consequently, the interaction domain might be destabilized 
explaining the PCBD1 dysfunction. Similarly, the negatively charged p.Glu96 residue could 
be important for the stabilization of the interaction domain, which may be hampered by 
the p.Glu96Lys mutation. 
 To test the effects of the mutations on PCBD1 function, we studied all previously 
described patient mutations in their ability to co-activate FXYD2 transcription in a luciferase 
assay (Figure 4C)(11, 38, 39). Expression of wild-type PCBD1 did not change the luciferase 
activity compared to mock-transfected cells, while HNF1B significantly enhanced the 
FXYD2 promoter activity (Figure 4D). Interestingly, co-expression of PCBD1 with HNF1B 
Table 2   Liver Function Tests in Patient 1 (BIODEF 272)
Parameter Patient 1
(BIODEF 272)
Reference  
range
Albumin (g/L) 41 38-50
Prealbumin (g/L) 0.381 0.1-0.4
hs-CRP (mg/L) <0.1* <8
α-1 antitrypsin (g/L) 1.4 0.9-2.6
C3 (g/L) 1.17 0.8-2.1
C4 (g/L) 0.18 0.15-0.5
IgG (g/L) 5.66* 6.94-16.18
IgM (g/L) 0.75 0.6-3.0
IgA (g/L) 1.99 0.7-4.0
ALT (U/L) 20* 21-72
AST (U/L) 26 15-46
ALP (U/L) 108 30-130
hs-CRP: high-sensitivity C reactive protein; C3: complement component 3; C4: complement component 4; 
 IgG: immunoglobulin G; IgM: immunoglobulin M; IgA: immunoglobulin A; ALT: alanine transaminase; 
AST: aspartate transaminase; ALP: alkaline phosphatase. 
* indicates value outside of reference range
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Figure 2  Pcbd1 is Expressed in the DCT of the Kidney
A, Tissue expression pattern of the Pcbd1 transcript. Pcbd1 mRNA expression level was measured in a 
panel of mouse tissues by quantitative RT-PCR and normalized for Gapdh expression. Data represent 
the mean of three individual experiments ±SEM and are expressed as the percentage of the total 
tissue expression. B, Immunohistochemical analysis of PCBD1 in mouse pancreas tissue. Scale bar, 
20 µm. C–G, Mouse kidney sections were costained for PCBD1 (green) and (C) BCRP (red), (D) TH (red), 
(E) NCC (red), (F) 28K (red), or (G) AQP2 (red). Nuclei are shown by 4’,6-diamidino-2-phenylindole 
staining (DAPI, blue). Scale bar, 20 mm. H, Kidney expression pattern of Pcbd1 shows the highest 
expression in DCT. The mRNA expression levels of Pcbd1 and Hnf1b in (black bars) COPAS-selected 
mouse DCT and (white bars) control (nonselected) kidneys were measured by quantitative RT-PCR 
and normalized for Gapdh expression. Data represent the mean of three individual experiments 
±SEM and are expressed as fold difference compared with the expression in nonselected tubules. 
*P < 0.05 versus total kidney. I, DCT expression of Pcbd1 is regulated by dietary Mg2+ intake. The mRNA 
expression levels of Pcbd1 and Hnf1b in COPAS-selected mouse DCT kidney tubules from mice fed 
with (white bars) low and (black bars) high Mg2+-containing diets were measured by realtime RT-
PCR and normalized for Gapdh expression. Data represent the mean of four individual experiments 
±SEM and are expressed as fold difference compared with the expression in high Mg2+-containing 
diets. *P < 0.05 versus high Mg2+. 
PCBD1: pterin-4 alpha-carbinolamine dehydratase; AQP2, aquaporin 2; BCRP, breast cancer resistance 
 protein; TH, Tamm Horsfall; NCC, Na+-Cl--cotransporter; 28K, calbindin-D28K.
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Figure 2  Continued
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further increased FXYD2 promoter activation by ±1.5 fold (Figure 4D). Of all PCBD1 mutants, 
only PCBD1 p.Arg87Gln and p.Cys81Arg maintained their co-activator properties (Figure 4D). 
The transcription of PKHD1, another established target gene of HNF1B in the kidney (21), 
was assessed in the presence of PCBD1. PKHD1 promoter activity showed a ~1.5 fold 
increase expression levels when HNF1B and PCBD1 were co-expressed (Figure 4E). PCBD1 
p.Arg87Gln, but not p.Cys81Arg, was the only PCBD1 mutant that retained its co-activator 
activity (Figure 4E).
Mutations Detected in HPABH4D Patients Cause Protein Degradation  
of PCBD1
To explain why the PCBD1 mutants are not capable of enhancing HNF1B-induced 
transcription, we examined their subcellular localization and their capacity to bind HNF1B. 
Immunostaining for PCBD1 in transiently transfected HEK293 cells revealed that wild-type 
PCBD1 translocates to the nucleus upon co-expression with HNF1B compared to mock 
Figure 3  Effect of Dietary Mg2+ on Serum and Urinary Mg2+ and Phenylalanine Levels
C57Bl/6 mice were fed low or high Mg2+-containing diets for 15 days. Before sacrifice, serum and 
24 hrs urine samples were collected for Mg2+ (A-B) and phenylalanine (C-D) levels determination. 
Results are depicted as mean ±SEM, * P < 0.05 versus low Mg2+ (n=10).
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Figure 4  PCBD1 Coactivates HNF1B-induced FXYD2 and PKHD1 Promoter Activity 
A, Homology model of the PCBD1–HNF1B dimerization domain (HNF1B–D) tetramer modeled using 
the structure of the PCBD1–HNF1A dimerization domain (HNF1A–D) complex (Protein Data Bank ID 
code 1F93). (Light blue and grey) The PCBD1 dimer binds the (orange and grey) HNF1B dimer through 
helix sequences. The HNF1A–D monomer is shown in yellow. Residues in the PCBD1 protein that were 
found mutates in patients affected by hyperphenylalaninemia are depicted in red. B, Homology 
model of the interaction site within the PCBD1–HNF1B dimerization domain (HNF1A–D) complex. 
(Orange) The bound HNF1B monomer forms a helix bundle with the (light blue) PCBD1 monomer. 
The HNF1A–D monomer is shown in yellow. The residues that differ between HNF1B–D and HNF1A–D 
are visualized in grey. C, Linear representation of the secondary structure elements of the human 
PCBD1 protein. Red arrowheads indicate the positions of the patient mutations described in the 
literature. Green balls indicate the histidine residues involved in the dehydratase active site (p.His61, 
p.His62, and p.His79). D-E, A luciferase assay was performed in HEK293 cells transiently cotransfected 
with a (D) firefly luciferase FXYD2 and (E) PKHD1 promoter construct and HNF1B or mock DNA in the 
presence of wild-type or mutant PCBD1. A Renilla luciferase construct was cotransfected to correct 
for transfection efficiency. Firefly/renilla luciferase ratios were determined as a measure of promoter 
activity. Results are depicted as percentage compared with HNF1B-Mock transfected cells. *P < 0.05 
versus HNF1B/Mock (n=0). 
Mock, mock DNA; WT, wild type; 26, p.Glu26*; 78, p.Thr78lle; 81, p.Cys81Arg; 86, p.Glu86*; 87, Arg87Gln; 96, 
p.Glu96Lys; 97, p.Gln97*
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DNA (Figure 5A). Furthermore, PCBD1 p.Glu26*, p.Glu86*, p.Glu96Lys and p.Gln97* were 
not expressed, whereas p.Thr78Ile and p.Cys81Arg were detected significantly less than 
the wild-type protein. PCBD1 p.Arg87Gln was the only mutant showing a comparable 
expression level to wild-type PCBD1 (Figure 5A). Co-immunoprecipitation studies 
confirmed that only PCBD1 p.Arg87Gln, p.Thr78Ile and p.Cys81Arg were expressed and 
able to bind HNF1B (Figure 5B, upper and lower panel). Importantly HNF1B was equally 
expressed in all conditions (Figure 5B, middle panel). To examine whether mutated PCBD1 
proteins are degraded by the proteasomal pathway for misfolded proteins, PCBD1- 
expressing HEK293 cells were treated for 24hrs with 10 nM of the proteasome inhibitor 
MG-132. Protein expression was restored for all of the PCBD1 mutants, with the only 
exception of p.Glu26* (Figure 5C).
HNF1B Mutations Affect the Subcellular Localization of PCBD1 
We evaluated five HNF1B mutations (p.Lys156Glu, p.Gln253Pro, p.Arg276Gly, p.His324-
Ser325fsdelCA, p.Tyr352fsinsA) for their ability to bind and functionally respond to PCBD1 
(Figure 6A)(1, 15). All HNF1B mutants, except HNF1B Δ2-30, bound PCBD1 in co-immuno-
precipitation studies in transiently transfected HEK293 cells (Figure 6B, upper panel). 
PCBD1 and HNF1B were expressed in all conditions tested (Figure 6B, middle and lower 
Figure 4  Continued 
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Figure 5  Several PCBD1 Mutations Lead to Protein Degradation HEK293 Cells 
A, Immunocytochemistry analysis of the subcellular localization of HA-tagged PCDB1 wild type or 
HA-tagged PCDB1 mutants when coexpressed in a 1:1 ratio with FLAG-tagged HNF1B or mock DNA in 
HEK293 cells. Red signal represents immunodetected HA epitopes. Nuclei stained with 4’,6-diamidino- 2-
phenylindole (DAPI) are shown in blue. Scale bar: 10 µm. Representation immunocytochemical images 
are shown. B, HA-tagged PCDB1 wild-type, PCDB1 mutant, or mock DNA were transiently expressed 
in HEK293 cells with or without FLAG-tagged HNF1B. Immunoprecipitations on nuclear extracts using 
an anti-FLAG antibody were separated by SDS-PAGE, and Western blots were probed with (top) anti-HA 
and (middle) anti-FLAG antibodies. (Bottom) HAPCDB1 input (25 %) expression was also included in the 
analysis. The immunoblots shown are representative of three independent experiments. C, Western 
blot analysis of HA-tagged PCDB1 mutants expressed in HEK293 cells treated with (+) or without (2) 
10 nM MG-132 for 24 hrs. A representative immunoblot is shown. 
IP, immunoprecipitation; Mock, mock DNA; WB, Western blot;W T, wild-type; 26, p.Glu26*; 78, p.Thr78lle; 81, 
p.Cys81Arg; 86,  p.Glu86*; 87, Arg87Gln; 96, p.Glu96Lys; 97, p.Gln97*.
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Figure 6  HNF1B Mutations Result in Cytosolic Localization of PCBD1 
A, Linear representation of the human HNF1B protein. Red arrowheads indicate patient mutations 
that were tested in this study. B, HA-tagged HNF1B wild-type (WT), HNF1B mutants, or HNF1B lacking 
the extracts using an anti-FLAG antibody were separated by SDS-PAGE, and Western blots (WBs) 
were probed with (top) anti-HA or (middle) anti-FLAG antibodies. (Lower) HA-HNF1B input (25 %) 
expression was also included in the analysis. The immunoblots shown are representative for three 
independent experiments. C, A luciferase assay was performed in HEK293 cells expressing a firefly 
luciferase FXYD2 promoter construct and each of the HNF1B variants (black bars) with and (white 
bars) without PCDB1. Results are depicted as percentage compared with HNF1B/Mock transfected 
cells (±SEM). *P < 0.05 compared with the HNF1B/Mock condition (n=9). D, Immunocytochemistry 
analysis of FLAG-tagged PCDB1 when coexpressed HNF1B WTs, HNF1B mutants, or mock DNA. Red 
signal represents immunodetected FLAG epitopes. Scale bar: 20 µm. The immunocytochemical 
 images shown are representative for three independent experiments. E, Quantification of the nuclear 
versus cytosolic localization of PCDB1 when co-expressed with mock DNA (n=24), HNF1B D1–32 
(n=33), WT (n=41), 156 (n=38), 253 (n=35), 276 (n=33), 324_325 (n=37), or 352 (n=36) (mean ±SEM). 
*P < 0.05 compared with Mock. #P < 0.05 compared with WT. 
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panel). FXYD2 promoter-luciferase assays showed that only HNF1B p.His324Ser325fsdelCA and 
p.Tyr352fsinsA, that retained partial transcriptional activity, respond to the co-activation by 
PCBD1 to the same extent as HNF1B wild-type (±1.5 fold, Figure 6C). Importantly, immuno-
cytochemical analysis revealed that co-expression of PCBD1 with the HNF1B mutants 
p.Gln253Pro and p.His324Ser325fsdelCA causes a predominant cytosolic localization of 
PCBD1 compared to the nuclear translocation observed upon co-expression with HNF1B 
wild-type (Figure 6D-E). 
Discussion
Mutations in PCBD1 have been shown to cause a transient and benign form of neonatal 
hyperphenylalaninemia (HPABH4D)(11, 38, 39). Here, we present the first follow-up study 
of HPABH4D patients reporting the onset of late complications linked to the deficient 
activity of PCBD1 as transcriptional co-activator of HNF1B. Our results suggest that PCBD1 
acts as an important transcriptional regulator of FXYD2 contributing to renal Mg2+ 
reabsorption in DCT. Our observations are based on the following results: i) hypo-
magnesemia with renal Mg2+ wasting was reported in two out of three patients carrying 
mutations in the PCBD1 gene; ii) two patients were diagnosed with MODY; iii) PCBD1 is 
present in pancreas and kidney, predominantly in DCT, where its expression is sensitive to 
dietary Mg2+ content; iv) in vitro data demonstrated that PCBD1 binds HNF1B to 
co-stimulate the FXYD2-promoter, whose activity contributes to Mg2+ reabsorption in 
DCT; v) PCBD1 mutations reported in HPABH4D patients caused proteolytic instability 
leading to degradation via the proteasomal pathway. 
 To our knowledge, we are the first to report that PCBD1 mutations associate with 
hypomagnesemia due to renal Mg2+ wasting as well as MODY. In kidney, the key sites for 
Mg2+ reabsorption are TAL and DCT. While defects in the molecular pathway for Mg2+ 
handling in TAL lead to a concomitant waste of Ca2+, shortcomings in DCT cause hyper-
magnesuria associated with hypo- or normocalciuria. Based on the serum Ca2+ levels and 
urinary Ca2+ excretion values, it is likely that in our patients the DCT is primarily affected. 
Fluorescence-based sorting of DCT-eGFP tubules using a COPAS apparatus coupled to 
real-time PCR analysis confirmed an enrichment of Pcbd1 expression in DCT tubules 
compared to other nephron segments. Pcbd1 expression in DCT was increased in mice fed 
with a low Mg2+ diet, suggesting that PCBD1 is important for renal Mg2+ reabsorption in 
D, dimerization domain; NLS, nuclear localization signal; POUH, atypical POU homeodomain; POUS, 
POU-specific domain; IP, immunoprecipitation; Mock, mock DNA; D1–32, HNF1B lacking the dimerization 
domain; 156, p.Lys156Glu; 253, p.Gln253Pro; 276, p.Arg276Gly; 324_325, p.His324Ser325fsdelCA; 352, 
p.Tyr352fsinsA.
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DCT. Serum and urinary phenylalanine levels were stable in the mice, thus did not 
modulate PCBD1 expression. Immunohistochemical analysis showed that PCBD1 
expression is not limited to DCT, but partially extended to cortical TAL and CNT. Overall, 
these findings confirm previous immunohistochemical studies showing PCBD1 expression 
in the cortex of the kidney (33). Since PCBD1 was present in the cytosol of renal cells, we 
hypothesized that the relative abundance of PCBD1 and HNF1B in the kidney may favor 
the cytosolic localization. Nevertheless, a nuclear localization of PCBD1 in the kidney 
could occur according to tissue-specific dynamics of the PCBD1-HNF1B complex. 
 Our results demonstrated that PCBD1 enhances the FXYD2 promoter activation by 
HNF1B in vitro. The relevance of FXYD2 activity in Mg2+ handling in DCT has been suggested 
previously, since both patients with FXYD2 mutations and patients carrying HNF1B 
mutations may present with hypomagnesemia (1, 29). It was demonstrated that HNF1B 
binds the FXYD2 promoter to specifically regulate the transcription of the γ-subunit of the 
Na+/K+-ATPase isoform α (1, 16). γα-subunit is mainly expressed in PT and medullary TAL, 
but also in DCT (Figure 7)(2, 16), where PCBD1 is expressed. To date, the exact molecular 
mechanism by which the γ-subunit regulates Mg2+ handling in DCT remains elusive (18). 
 In kidney, HNF1B is ubiquitously expressed where it regulates the transcription of 
several cystic genes, like PKHD1 (20). Mutations in PKHD1 are causative for autosomal 
recessive polycystic kidney disease (ARPKD, OMIM #263200)(21). Similar to the FXYD2 
promoter, a PKHD1 reporter construct showed increased expression levels when HNF1B 
and PCBD1 were co-transfected in HEK293 cells. However, the renal expression of PKHD1 
in vivo is restricted to TAL and CD, where PCBD1 expression is negligible (41). Thus, under 
physiological conditions, renal PKHD1 gene transcription seems not affected by PCBD1. 
This finding is supported by the absence of kidney abnormalities in patients with PCBD1 
mutations.
 Further evidence for an impaired HNF1-mediated transcription in HPABH4D patients 
was provided by the diagnosis of MODY in patients 1 and 3. MODY is a monogenic form 
of autosomal dominant type II diabetes characterized by age of onset often below 25 
years and negative pancreatic autoantibodies. Heterozygous mutations in HNF1B or its 
homolog HNF1A associate with MODY type 5 and type 3, respectively (26). We 
demonstrated that PCBD1 is localized in the nuclei of pancreatic cells. Knowing that 
PCBD1 acts as transcriptional co-activator of both HNF1B and HNF1A, a dysregulation of 
HNF1B and/or HNF1A is potentially responsible for the MODY diagnosed in patients 1 and 
3. Interestingly, the low plasma hs-CRP levels in patient 1 are in line with two recent studies 
showing lower hs-CRP levels in MODY3 patients than individuals with other forms of 
diabetes or nondiabetic controls (28, 32). This evidence favors the diagnosis of MODY3-like 
diabetes in patient 1. Patient 2 was not diagnosed with diabetes, but he will be monitored 
for later onset. 
 In this study, we showed that the HPABH4D patient mutations reported in literature 
lead to protein degradation of PCBD1 via the proteasome pathway. Our data together 
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with previous studies on proteolytic instability for the same mutants in both mammalian 
and bacterial expression systems support the hypothesis that this degradation process 
may also occur in HPABH4D patients (22, 38, 39). Considering the inheritance of the 
disease, HNF1-mediated transcription seems to be sensitive to changes in PCBD1 quantity 
only when both PCBD1 alleles are affected, suggesting that PCBD1 probably belongs to an 
ancillary regulatory mechanism to which other HNF1B partners may participate (12). 
In vitro data in HEK293 cells revealed that PCBD1 p.Arg87Gln was the only mutant showing 
an expression level comparable to the wild-type protein. Nevertheless, in patient 2 p.
Arg87Gln is homozygously present on both alleles with a p.Glu26* mutation that leads to 
a significant decrease in the cellular content of PCBD1 (39). PCBD1 p.Glu26* degradation 
could not be rescued by proteasome inhibition, suggesting that its transcript is degraded 
by mRNA surveillance mechanisms (3, 5). PCBD1 p.Thr78Ile and p.Cys81Arg were 
significantly less expressed than the wild-type protein. Both mutants showed binding to 
HNF1B, but only PCBD1 p.Cys81Arg co-activated the FXYD2 promoter. PCBD1 p.Cys81Arg 
did not co-activate the PKHD1 promoter suggesting insufficient expression to enhance 
the transcription of PKHD1.  In the near future, it would be of interest to screen patients 
with PCBD1 p.Thr78Ile and p.Cys81Arg mutations for complications related to the HNF1B 
disease. 
 PCBD1 monomers are small molecules that can passively diffuse from the cytosol into 
the nucleus (36). It was suggested that, by assembling via the same interface, PCBD1 
homotetramer and PCBD1–HNF1 complexes are mutually exclusive (34). In our immuno-
cytochemical analysis, the HNF1B mutants p.Gln253Pro and p.His324Ser325fsdelCA 
significantly stimulated a cytosolic localization of PCBD1 compared to the nuclear PCBD1 
localization observed in the presence of wild-type HNF1B. This suggests that HNF1B 
mutations may disturb the stability of the PCBD1–HNF1 complexes in the nucleus and 
therefore favour the formation of PCBD1 homotetramers in the cytosol of the cell (1, 15). 
The reduced nuclear localization of PCBD1 will indirectly result in a decreased co-activation 
of HNF1B and could contribute to the hypomagnesemia observed in some HNF1B 
patients. Since the presentation and development of HNF1B disease is diverse, variations 
Figure 7  Schematic Diagram of Gene Expression in the Kidney
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in HNF1B interacting proteins may be responsible for the phenotypic heterogeneity. 
Screening of HNF1B patients for polymorphisms in PCBD1 should, therefore, be considered.
 In conclusion, we identified PCBD1 as a new molecular player in renal Mg2+ handling. 
Our results suggest that PCBD1 regulates the HNF1B-mediated FXYD2 transcription, influencing 
active renal Mg2+ reabsorption in DCT. So far, HPABH4D due to PCBD1 mutations has been 
considered a transient, benign condition, primarily related to impaired BH4 regeneration. 
To date, 23 patients with PCBD1 mutations linked to HPABH4D are listed in the International 
Database of Tetrahydrobiopterin Deficiencies (BIODEF database, Opladen T, Blau N., http://
www.biopku.org/biodef/)(8). Here, we suggest that patients affected by HPABH4D should 
be monitored for late complications related to the interactions with HNF1 transcription 
factors, including hypomagnesemia and MODY. 
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Patients and Methods
Patients
The three patients reported in this study were ascertained by contacting authors of 
papers related to hyperphenylalaninemia, tetrahydrobiopterin-deficient, due to pter-
in-4-alpha-carbinolamine dehydratase deficiency (HPABH4D, OMIM #264070)(11, 38, 39). 
Out of the 23 patients listed in the International Database of Tetrahydrobiopterin 
Deficiencies (BIODEF database, Opladen T, Blau N., http://www.biopku.org/biodef/)(8), 
BIODEF 272, BIODEF 329 and BIODEF 319 were assessed by Dr. Ferreira (Canada), Dr. 
Germann (Germany) and Dr. de Klerk (The Netherlands), respectively. The results are 
included in this study. Informed consent to participate in this study was obtained and the 
procedures followed were in accordance with the standards of the medical ethics 
committee of each participating institution. Patients were not treated with any medication 
that could affect serum levels of Mg2+ (e.g. diuretics, calcineurin inhibitors, corticosteroids).
Patient 1 (BIODEF 272) was reported in detail previously (38). In summary, he was found to 
have borderline hyperphenylalaninemia on newborn screening, but this markedly 
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increased to a peak of 2589 µmol/L at 3.5 weeks. The diagnosis of HPABH4D was suspected 
because of primapterinuria (7-biopterin), as well as a marked response to BH4. There was 
no parental consanguinity; molecular analysis confirmed the diagnosis showing that he 
was homozygous for a c.312C>T (p.Gln97*) mutation in the PCBD1 gene. He was treated 
with phenylalanine restriction and BH4 until 4 months of age, at which time his 
phenylalanine levels normalised without further treatment, on a normal diet. Intermittent 
follow-up into adolescence revealed normal health, growth and cognitive development. 
He was re-contacted for this study at age of 19 years; at that time it was noticed that he 
had become an insulin-dependent diabetic about 6 months previously. 
Patient 2 (BIODEF 329) Initial neonatal screening had shown hyperphenylalaninemia with 
high urinary levels of primapterin (7-biopterin)(38, 39). This resolved after daily treatment 
with BH4. There was parental consanguinity, and molecular studies showed that he was 
homozygote for two separate mutations in the PCBD1 gene: c.99G>T (p.Glu26*), and 
283G>A (p.Arg87Gln). He was followed by paediatricians at the Klinik für Kinder- und 
Jugendmedizin (Karlsruhe, Germany).
 
Patient 3 (BIODEF 319) is the first child of non-consanguineous parents.  A previous sibling 
of the patient died neonatally, while a younger brother was born healthy. The patient was 
diagnosed with hyperphenylalaninemia and primapterinuria at the age of one month (39). 
Molecular analysis revealed compound heterozygous c.309G>A/c.312C>T (p.Glu96Lys/p.
Gln97*) mutations in the PCBD1 gene. She needed cofactor BH4 replacement therapy, on 
a normal diet, to maintain phenylalanine levels within the reference range. At the moment 
of recruitment for this study, she was 17 years old. At that time she had stopped taking BH4 
around a year earlier and had slightly elevated phenylalanine levels 120 μmol/L (N <60 
μmol/L). It was also noticed that, just before turning 16 years old, she was diagnosed with 
diabetes. MODY diabetes type 1, 2 and 3 were excluded by DNA analysis. The patient is 
presently healthy and developing normally. 
Calculation of FEMg
The FEMg was calculated using the following formula: FEMg = (UMg x PCr) / [(0.7 x PMg) x UCr 
x 100]. U and P refer to the urine and serum concentrations of Mg2+(Mg) and creatinine 
(Cr). Serum Mg2+ concentration was multiplied by 0.7 since only approximately 70 % of the 
circulating Mg2+ was unbound by albumin and therefore able to be filtered across the 
glomerulus. 
Animal Study
All the experimental procedures are in compliance with the animal ethics board of the 
Radboud University Nijmegen. The transgenic parvalbumin-eGFP mice were a kind gift 
from Dr. Monyer (University of Heidelberg, Germany)(31). In the Mg2+ diet experiment, the 
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mice were fed low (0.02 % (w/w)) or high (0.48 % (w/w)) Mg2+-containing diets for 15 days 
(SSNIFF spezialdiäten GmbH, Soest, Germany). During the last 48hrs of the experiment the 
mice were housed in metabolic cages for urine collection (24hrs adaptation, 24hrs 
sampling). Blood samples were taken at the start of the experiment and just before the 
sacrifice. Pv-eGFP positive tubules were isolated as described previously (27). In short, 
mice aged from 4 to 6 weeks were anesthetized and perfused transcardially with ice-cold 
KREBS buffer (in mmol/L: 145 NaCl, 5 KCl, 1 NaH2PO4, 2.5 CaCl2, 1.8 MgSO4, 10 glucose, 10 
HEPES/NaOH pH: 7.4). Kidneys were harvested and digested in KREBS buffer containing 1 
mg/mL collagenase (Worthington, Lakewood, NJ, USA) and 2,000 units/mL hyaluronidase 
(Sigma, Houten, the Netherlands) for three cycles of maximal 15 min each at 37 °C. 
Subsequently, the kidney tubules sized between 40-100 μm were collected by filtration. 
Tubules collected from the three digestions were ice-cooled and sorted by the Complex 
Object Parameric Analyzer and Sorter (COPAS, Union Biometrica, Holliston, MA, USA). 
Sorted tubules were directly collected in 1 % (v/v) β-mercaptoethanol containing RLT 
buffer that was supplied by the RNeasy RNA extraction kit (Qiagen, Venlo, the Netherlands). 
Per mouse, 4,000 eGFP-fluorescent tubules were collected. 4,000 tubules were pooled on 
a micro column for RNA extraction according to the manufacturer’s protocol. Subsequently, 
reverse transcription of the RNA by M-MLV reverse transcriptase (Invitrogen) was 
performed 1 hr at 37 °C. Gene expression levels were determined by quantitative real-time 
PCR on a BioRad Analyzer and normalized for Gapdh expression levels. Real-time PCR 
primers (Table 3) were designed using the online computer program NCBI/Primer-BLAST 
software.
Phenylalanine Measurements
Phenylalanine in plasma and urine samples was measured by LC-MS/MS by a standardized 
method, in which the MS was operated in positive mode. For these MS measurements, a 
Waters Premier triple quadrupole mass spectrometer (tandem MS) interfaced with an 
electrospray ionization (ESI) source and equipped with an Alliance UPLC (Waters, 
Etten-Leur, the Netherlands) was used.  Briefly, to 10 µL plasma or urine sample, 13C6-labeled 
phenylalanine was added as an internal control to correct for possible ion-suppression. 
Samples were deproteinized with methanol, diluted with water and injected on a RP C18 
column (Waters Atlantis T3, 3 µm, 2,1 x 100 mm). Samples were eluted in 17.5 % methanol 
/ 0.1 mol/L formic acid. Positively charged [M-H]+ phenylalanine  (m/z 166) and 
13C6-phenylalanine (m/z172) were selected as parent ions. After collision induced 
dissociation (CID), the loss of –NH3 and –COOH groups were chosen as quantifier ion (m/z 
120 and 126, respectively) and the loss of –NH3 ,  –COOH and  –OH2  groups (m/z 103 and 
109, respectively) as qualifier ions. In Multiple Reaction Monitoring (MRM) mode, the 
transitions m/z 166  120and m/z 166  103 (for phenylalanine) and m/z 172  126 and 
m/z 172  109 (for 13C6-phenylalanine) were measured. Phenylalanine concentrations 
were calculated using a calibration curve.
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DNA Constructs
Human HNF1B wild-type and mutants were cloned into the pCINeo HA IRES GFP vector as 
described previously (16). HNF1B was Flag-tagged at the NH2-terminal by Phusion PCR 
using NheI and AgeI restriction sites. To obtain a HNF1B lacking the dimerization domain 
spanning residues 2-30 (Δ2-30), HNF1B was amplified using a Phusion polymerase 
(Finnzymes, Vantaa, Finland) with specific primers covering from residue p.Glu31. The 
HNF1B-Δ2-30 was ligated into pCINeo IRES GFP using AscI/AgeI restriction sites. The open 
reading frame of human PCBD1 was amplified using Phusion polymerase from PCBD1 
pCMV-SPORT6 (Genbank BC006324, ImaGenes) and subcloned into the pCINeo HA IRES 
GFP vector using AgeI/EcoRI restriction sites. Wild-type PCBD1 was Flag-tagged at the 
NH2-terminal by PCR using NheI/XhoI restriction sites. PCBD1 mutations were inserted in 
the construct using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, 
CA) according to the manufacturer’s protocol. The luciferase reporter plasmid containing 
the FXYD2 promoter linked to the coding region of firefly luciferase was produced as 
previously described (16). Briefly, the human FXYD2 promoter region that controls 
transcription of the γ-subunit isoform alpha (-3229/+91 bp from the transcription start site) 
was amplified from genomic DNA using Phusion polymerase (Finnzymes, Vantaa, Finland), 
and cloned into pGL3-Basic (Promega) using KpnI/BglII restriction sites. The human PKHD1 
promoter region extending from exon 1 to 1.5 kb upstream to the transcription start site 
was amplified from genomic DNA and cloned into pGL3-Basic using KpnI/HindIII sites. 
The pRL-CMV vector encoding Renilla luciferase under control of a CMV promoter was 
commercially available (Promega, Fitchburg, USA). All constructs were verified by sequence 
analysis. 
Cell Culture 
Human Embryonic Kidney cells (HEK293) were grown in DMEM (Bio Whittaker-Europe, 
Verviers, Belgium) containing 10 % (v/v) FCS (Thermo Fisher HyClone), 10 μL/mL non - 
essential amino acids and 2 mmol/L L-glutamine at 37 °C in a humidity-controlled 
incubator with 5 % (v/v) CO2. The cells were transiently transfected with the respective 
Table 3   Primer sequences used for real-time PCR analysis
Gene  
product
Forward Reverse
Pcbd1 5’-TGGACATGGCCGGCAAGGC-3’ 5’-CCCACAGCCCTCAGGTTTG-3’
Hnf1b 5’-CAAGATGTCAGGAGTGCGCTAC-3’ 5’-CTGGTCACCATGGCACTGTTAC-3’
Gapdh 5’-TAACATCAAATGGGGTGAGG-3’ 5’-GGTTCACACCCATCACAAAC-3’
Pcbd1: pterin-4-alpha-carbinolamine dehydratase; Hnf1b: hepatocyte nuclear factor 1b; Gapdh: 
glyceraldehyde 3-phospgate dehydrogenase
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constructs using polyethylenimine cationic polymer (PEI, Polysciences Inc.) at 1:6 DNA:PEI 
ratio for 48 hrs unless otherwise stated.
Western Blotting
HEK293 cells were transfected for 24 hrs with HA-PCBD1 mutants and treated at the same 
time with 10 mmol/L MG-132 (Company). Protein lysates were denatured in Laemmli 
containing 100 mmol/L DTT for 30 min at 37 °C and subsequently subjected to SDS-PAGE. 
Then, immunoblots were incubated with a mouse anti-HA (Roche, high affinity 3F10, 
1:5,000) primary antibody and peroxidase conjugated sheep anti-mouse secondary 
antibodies (Jackson Immunoresearch, 1:10,000). 
Immunocytochemistry
HEK293 cells were seeded in 12-well plates on glass cover slips and co-transfected with 
400 ng PCBD1 constructs and 400 ng HNF1B constructs or empty pCINeo IRES GFP vector 
(mock DNA). After 48 hrs, HEK293 cells were fixed with 4 % (w/v) paraformaldehyde (PFA) 
for 30 min at 4 °C, followed by the subsequent steps at room temperature: permeabilization 
for 15 min with 0.3 % (v/v) Triton X-100 in PBS, incubation for 15 min with 50 mmol/L NH4Cl, 
and finally incubation in blocking buffer (16 % (v/v) goat serum, 0.3 %  (v/v) Triton X-100 
and 0.3 mol/L NaCl in PBS). After incubation overnight at 4 °C with a rabbit anti-Flag M2 
(Sigma F7425, 1:100) or a mouse anti-HA (Cell signaling technology, 6E2, 1:100), cells were 
washed three times with Tris-buffered NaCl Tween-20 (TNT; 150 mmol/L NaCl, 0.1 mol/L 
Tris/HCl, pH 7.5, 0.05 % (v/v) Tween-20) and subsequently incubated with a secondary goat 
anti-rabbit antibody (Sigma A4914, 1:300) or a sheep anti-mouse (Jackson Immunoresearch, 
1:300), coupled to AlexaFluor 594, for 45 min at room temperature. After incubation with 
4’,6-diamidino-2-phenylindole (DAPI) for 30 min at room temperature, cells were washed 
three times with TNT and finally mount with Fluoromount-G (SouthernBiotech). Photographs 
were taken using a Zeiss Axio Imager 1 microscope (Oberkochen, Germany) equipped 
with a HXP120 Kubler Codix fluorescence lamp and a Zeiss Axiocam MRm digital camera. 
Images were analysed by use of the software ImageJ (35).
Immunohistochemistry
Staining was performed on 5 μm sections of periodate-lysine-paraformaldehyde (PLP) 
fixed frozen mouse kidney or pancreas samples. Subsequently, sections were washed 
three times with TN buffer (0.15 mol/L NaCl, 0.1 mol/L Tris/HCl, pH 7.6). Antigen retrieval 
was done with 10 mmol/L sodium citrate pH 6.0 and non-specific binding was blocked 
by incubation in blocking buffer for 1 hr. Sections were stained overnight at 4 °C with 
a polyclonal rabbit anti-PCBD1 antibody (F3862, 1:5000, kind gift by Prof. Thöny)(33). The 
following day, sections were washed and incubated with a goat anti-rabbit secondary 
antibody coupled to Alexa Fluor 488 (1:300; Invitrogen, A11008) for 1 hr at room temperature. 
Kidney sections were costained for the breast cancer resistance protein (BCRP), Tamm 
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Horsfall (TH), Na+/Cl- cotransporter (NCC), calbindin-D28k (D28K) or aquaporin-2 (AQP2). 
Briefly, sections were washed and incubated for 2 hrs at room temperature with rat 
anti-BCRP (Clone BXP-9, Kamya Biomedical Company MC-980, 1:200), sheep anti-TH (AbD 
serotec 8595-0054, 1:1500), guinea-pig anti-NCC (1:50, kind gift by Prof. Jan Loffing), mouse 
anti-28K (1:1500, Sigma C-9848) or guinea-pig anti-AQP2 (1:1000, kind gift by Prof. Peter 
Deen). Secondary antibodies were coupled with Alexa Fluor 495 (1:300; Invitrogen) and 
incubated for 45 min at room temperature. Subsequently, sections were washed, 
incubated for 10 min with DAPI and mounted with Mowiol. Photographs were taken using 
a Zeiss Axio Imager 1 microscope (Oberkochen, Germany) equipped with a HXP120 Kubler 
Codix fluorescence lamp and a Zeiss Axiocam MRm digital camera.
Co-Immunoprecipitation
HEK293 cells were seeded on 55 mm petri dishes and co-transfected with 5 μg PCBD1 
constructs and 5 μg of HNF1B constructs or a empty pCINeo IRES GFP vector (mock DNA). 
48hrs after transfection, nuclear and cytosolic fractions were prepared using the NE-PER 
Nuclear Protein Extraction Kit (Pierce). The next incubation steps were all done under 
rotary agitation at 4 °C. 35 μL of protein A-agarose beads (Santa Cruz Biotechnology) were 
previously incubated overnight at 4 °C with 2.5 μg rabbit anti-Flag antibody (Sigma F7425) 
and washed with IPP500 (500 mmol/L NaCl, 10 mmol/L Tris/HCl pH 8.0, 0.1 % (v/v) NP-40, 
0.1 % (v/v) Tween-20, 0.1 % (w/v) BSA and protein inhibitors) four times. After sampling 60 
μL as input control, the remaining 180 μL of the lysate samples was added to the 
antibody-beads mixture overnight at 4 °C. Then, the beads were collected by centrifugation 
at 2000 rpm for 2 min at 4 °C and washed four times with lysis buffer. The proteins were 
separated from the beads by incubation for 30 min at 37 °C in 1x Laemmli sample buffer 
supplemented with 100 mmol/L DTT and detected by immunoblotting using a mouse 
anti-HA (Roche, high affinity 3F10, 1:5,000) or a mouse anti-Flag M2 (Sigma F3165, 1:5,000) 
primary antibodies, and peroxidase conjugated sheep anti-mouse secondary antibodies 
(Jackson Immunoresearch, 1:10,000). 
Luciferase Reporter Assay
HEK293 cells were seeded on 12-well plates and transfected with the following DNA 
amounts: 700 ng of the FXYD2 promoter-luciferase construct, 50 ng PCBD1 constructs, 50 
ng HNF1B constructs or empty pCINeo IRES GFP vector (mock DNA). To correct for 
transfection efficiency, 10 ng of pRL-CMV was used as a reference. Firefly and Renilla 
luciferase activities were measured by use of a Dual-Luciferase Reporter Assay (Promega) 
48hrs after transfection.
Homology Modelling
A homology model was built using the modelling script in the WHAT IF & YASARA Twinset 
with standard parameters (25, 40). The structure of the PCBD1 dimer in complex with the 
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HNF1A dimerization domain dimer was used as a template for modelling of HNF1B (PDB 
file: 1f93). Our model contains only the dimerization domain (31 amino acids) of HNF1B 
and this has 68 % sequence identity with the dimerization domain of HNF1A.
Statistical Analysis
All results are depicted as mean ± standard error of the mean (SEM). Statistical analyses 
were conducted by unpaired student’s t-test when comparing two experimental 
conditions, and one-way ANOVA with Bonferroni test when comparing more conditions, 
P values less than 0.05 were considered significant.
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Abstract
Magnesium (Mg2+) is an essential ion for cell growth, neuroplasticity and muscle 
contraction. Blood Mg2+ levels below 0.7 mmol/L may cause a heterogenous clinical 
phenotype, including muscle cramps and epilepsy and disturbances in K+ and Ca2+ 
homeostasis. Over the last decade, the genetic origin of several familial forms of 
hypomagnesemia has been found. In 2000, mutations in FXYD2, encoding the γ-subunit 
of the Na+-K+-ATPase, were identified to cause isolated dominant hypomagnesemia (IDH) in 
a large Dutch family suffering from hypomagnesemia, hypocalcuria and chondrocalcinosis. 
However, no additional patients were identified since then.
 Here, we report a p.Gly41Arg FXYD2 mutation in two families with hypomagnesemia 
and hypocalciuria. Interestingly, this is the same mutation as was described in the original 
study. Therefore, the patients were clinically and genetically characterized. As in the initial 
family, several patients suffered from muscle cramps, chondrocalcinosis and epilepsy. 
Haplotype analysis revealed an overlapping haplotype in all families, suggesting a founder 
effect.
 In conclusion, the recurrent p.Gly41Arg FXYD2 mutation in two new families with isolated 
dominant hypomagnesemia confirms that FXYD2 mutation causes hypomagnesemia. Until 
now, no other FXYD2 mutations have been reported which could indicate that other 
FXYD2 mutations will not cause hypomagnesemia.
Keywords: Na+-K+-ATPase, Magnesium, Kidney, Distal Convoluted Tubule
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Introduction
Hypomagnesemia is a common electrolyte imbalance resulting in muscle cramps, muscle 
weakness and cardiac arrhytmias (11). The use of certain types of drugs including 
calcineurin inhibitors, proton-pump inhibitors and diuretics may cause low serum 
magnesium (Mg2+) levels (10). In a small percentage of patients the Mg2+ disturbance is of 
genetic origin (5). Hypomagnesemia-causing mutations often affect Mg2+ transport 
processes operating in the renal distal convoluted tubule (DCT). The final urinary Mg2+ 
excretion is determined in the DCT, since Mg2+ reabsorption does not take place beyond 
that nephron segment (5). As a consequence, patients with reduced Mg2+ uptake in DCT 
have renal Mg2+ wasting.
 In 2000, we identified a c.115G>A (p.Gly41Arg) mutation in the FXYD domain containing 
ion transport regulator 2 gene (FXYD2) causative for isolated dominant hypomagnesemia 
(IDH, OMIM #154020) in a large Dutch family (12-14). Although originally described as two 
families, haplotype analysis revealed a 10.5 cM overlapping region suggesting a founder 
effect (14). Patients in this family had normal urinary Mg2+ values, but showed lowered 
urinary Ca2+ excretion and suffered from episodes of convulsions (8). Some patients 
developed symptoms of chondrocalcinosis, related to chronic hypomagnesemia (16).
 FXYD2 encodes the γ–subunit of the Na+-K+-ATPase and is involved in stabilization of 
the α-subunit of that complex (15). Moreover, the γ–subunit decreases the affinity of the 
Na+-K+-ATPase for Na+ and K+ and increases the affinity for ATP (2). The p.Gly41Arg 
mutation causes a trafficking defect preventing the γ–subunit to reach the basolateral 
membrane (4, 13). In the kidney, three splice variants of FXYD2 are expressed. FXYD2a is 
expressed strongly in the thick ascending limb (TAL) and proximal tubule and only 
discretely in DCT (3). In contrast, FXYD2b expression is restricted to the basolateral 
membrane of the DCT and connecting tubule (CNT). Additionally, HNF1β can activate 
FXYD2a transcription and mutations in the HNF1β transcription factor gene (HNF1B) cause 
hypomagnesemia (1, 6, 7). Given that each FXYD2 splice variant differentially modifies 
Na+-K+-ATPase activity, it has been hypothesized that the ratio between FXYD2a and 
FXYD2b expression may determine Na+-K+-ATPase activity. However, the mechanism by 
which changes in basolateral FXYD2 expression affects renal Mg2+ reabsorption remains 
to be elucidated.
 Since the report of the original family in 2000, new families with FXYD2 mutations 
have not been described. As a result the relevance of FXYD2 mutations for hypomagnesemia 
has been questioned over the years. For the first time since the initial report, we now 
present two new families harboring the same p.Glu41Arg mutation in FXYD2. To provide 
further insight into the role of this mutation in hypomagnesemia, full molecular and 
genealogical analyses were performed. Furthermore, we aimed to increase the current 
phenotypic knowledge and describe the clinical presentations and treatment of patients 
with FXYD2 mutations.
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Results
Recurrent FXYD2 Mutation in Patients with Hypomagnesemia
In two families with hypomagnesemia a c.115G>A mutation in the FXYD2 gene was 
identified by mutation analysis. The mutation results in a p.Gly41Arg change at amino acid 
level. Interestingly, the c.115G>A mutation has previously been reported in a large Dutch 
family in 2000 and no other FXYD2 mutations have been found since (13).
FXYD2 Mutation in a Dutch Family 
The first family is a Dutch family with 3 affected family members (Figure 1). The proband 
(Figure 1, NL II.1) was discovered suffering from hypokalemia and hypomagnesemia 
during admission for lung embolism at the age of 34 years (Table 1). He had a chronic 
history of muscle cramps and fatigue and reported a spacious fluid intake. He is an only 
child and his parents are deceased. He reported no relevant symptoms of his father (Figure 1, 
NL I.1) besides a spacious fluid intake and recurrent miscarriages of his mother (Figure 1, NL I.2). 
The proband was suspected of having Gitelman syndrome and he was treated with Mg2+ 
and K+ supplements. 
 Hereafter, his two children were admitted to the outpatient clinic for evaluation 
because of muscle cramps. They both showed hypomagnesemia. The daughter (Figure 1, 
NL III.1), 9 years old, reported muscle cramps and uncertainty about keeping balance, 
without falling. His son (Figure 1, NL III.2), 7 years old, reported an increased fluid intake 
Figure 1  Family with Isolated Hypomagnesemia from the Netherlands
A, Pedigree of the Dutch family with hypomagnesemia. Black-filled symbols denote affected and 
genetically confirmed family members, grey symbols denote potentially affected family members. 
B, Mutation analysis chromatogram of the proband (NL II.1). The mutation is indicated by an arrow. 
Nucleotide changes and resulting effect at the amino acid level are shown.
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and nightly muscle cramps and is known with an attention deficit disorder. Both children 
had a normal growth pattern, normal blood pressure, no dysmorphic features and 
unremarkable renal ultrasound and X-ray of the hand. Laboratory evaluation revealed 
isolated hypomagnesemia with hypermagnesuria and hypocalciuria (with normal serum 
creatinine) (Table 1). Because the dominant inheritance of hypomagnesemia in this family was 
not compatible with Gitelman syndrome, genetic analysis was performed for diagnostic 
purposes. No mutations were found in the HNF1B and SLC12A3 genes. A heterozygous 
missense mutation in the FXYD2 gene (c.121G>A (p.(Gly41Arg)) was found in all 3 affected 
individuals. The children are free of symptoms with Mg2+ supplementation 3 times a day, 
achieving serum Mg2+ concentrations in the low normal range. 
FXYD2 Mutation in a Belgian Family 
The second family originates from Belgium. The proband is a 67-year old man admitted for 
a work-up of hypokalemia and hypomagnesemia (Figure 2, B II.1). Hypomagnesemia was 
first discovered at age 44, during a blood electrolyte analysis following an episode of 
tetanic cramps. Magnesium supplements were then initiated, with variable compliance. 
The patient reported chronic fatigue, with general weakness, dysesthesia of the face and 
hands, and frequent cramps of the lower limbs, which generated difficulties in walking. He 
complained about continuous thirst and nocturia. Blood pressure was 180/85 mmHg 
Table 1   Laboratory Investigations of Affected Individuals
NL II.1 NL III.1 NL III.2 B II.1 B III.2 B IV.1
Serum Mg2+
(mmol/L, N 0.7-0.95)
0.38 0.45 0.45 0.56 0.35 0.50
Serum K+
(mmol/L, N 3.5-5.1
3.3 4.2 3.8 4.0 3.0 3.6
Serum HCO3-
(mmol/L, N 21-27)
29.6 24 22 26 27 31
eGFR 
(mL/1.73 mL/min, N > 90)
123 133 124 43 125 85
Urinary Mg2+ excretion / 24 hrs
(mmoL/day, N 3.0-5.0)
8.9 8.1 10.6 8.4
Fractional Mg2+ excretion 
(%, nl < 4 %)
11.9 6
Urinary Ca2+ excretion / 24 hrs
(mmoL/day, N 1.5-7.5)
1.3 0.8 1.5 0.3 
Urinary Ca2+/creat
(mmol/mmol, N <0.7)
0.04 0.05
1 mEq Mg2+ = 0.5 mmol Mg2+ = 12.3 mg Mg2+.  
1 mEq Ca2+ = 0.5 mmol Ca2+ = 20.5 mg Ca2+.
104 | Chapter 4
(supine) and 150/90 mmHg (standing). The clinical examination was otherwise unremarkable. 
The patient had chondrocalcinosis evidenced by X-ray of the knees.
 Blood and urine analyses revealed renal failure (plasma creatinine 1.62 mg/dL, eGFR 
43 mL/min/m2), with hypomagnesemia (all serum electrolytes within normal range) hy-
permagnesuria and hypocalciuria (Table 1). Facing the chronic history of hypomagnesemia 
with inappropriate urinary Mg2+ loss and hypocalciuria, Gitelman syndrome was suspected. 
Genetic testing of SLC12A3, CLCNKB and HNF1B (sequencing of all exons, exon-intron 
boundaries plus MLPA) was negative.
 The patient reported that his mother (Figure 2, B I.2, deceased at age 62) was known for 
Mg2+ problems. She suffered from chronic fatigue and articulation problems. Additionally, she 
also took Mg2+ supplements, as well as the probands daughter (B III.2) and granddaughter (B IV.1).
 The daughter of the proband (Figure 2, B III.2), aged 41 years, complained of fatigue 
since childhood, with limited physical activity. She had cramps and dysesthesia of the face 
and hands. She was diagnosed with hypomagnesemia as a young adult and has taking 
Mg2+ supplements since then. Plasma analyses revealed persistent hypomagnesemia and 
hypokalemia, with normal HCO3- and normal renal function. The urinary Mg2+ loss was 
inappropriately high (Table 1). 
 The granddaughter of the proband (B IV.1), age 16 years, experienced two epileptic 
crises at 5 and 15 years of age and complained of chronic fatigue. The neurological work-up 
was negative but hypomagnesemia and hypokalemia were noticed, with inappropriate 
urinary Mg2+ loss and hypocalciuria (Table 1). Renal function was normal. Over the years, 
plasma Mg2+ remained low despite supplementation.
Figure 2  Family with Isolated Hypomagnesemia from Belgium
A, Pedigree of the Belgian family with hypomagnesemia. Blackened symbols denote affected and 
genetically confirmed family members, grey symbols denote potentially affected family members. 
B, Mutation analysis chromatogram of the proband (B II.1). The mutation is indicated by an arrow and 
the nucleotide changes and resulting effect at the amino acid level are shown.
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Common Haplotype Bearing the FXYD2 Mutation
To examine whether the newly identified families share the same haplotype as the original 
family, marker analysis was initiated. Five markers encompassing the FXYD2 gene were 
selected: D11S4092, D11S4127, D11S939, D11S1356, D11S4195 (Figure 3). For this analysis, 
relatives from the original family were included. Indeed, patients from all three families 
share the same haplotype, suggesting that the families are related through a common 
ancestor. Genealogical analysis did not result in the identification of this common ancestor. 
Although the Belgian family was shown to originate from the same geographical region 
(surroundings of Liège, Belgium) as the family described in the original paper from 2000, 
no common ancestor was found in 9-12 generations back. 
Discussion
In this study, a c.115G>A (p.Gly41Arg) mutation in FXYD2 was identified in two families with 
hereditary hypomagnesemia. Importantly, these are the first new patients reported since 
2000 confirming that FXYD2 mutations cause hypomagnesemia. In both patient families 
the same c.115G>A mutation was detected that was previously described in a large Dutch 
family. All three families shared the same haplotype, suggesting a founder effect. 
 Although the genetic cause was only found in 2000 (14), the first patients with 
mutations in the FXYD2 gene were clinically evaluated in 1987 (9, 17). Twenty-two individuals 
harboring FXYD2 mutations showed isolated dominant hypomagnesemia, hypocalciuria 
and occasionally also hypomagnesemia-associated chondrocalcinosis was detected. 
Since the first identification of the FXYD2 p.Gly41Arg mutation in 2000 (6), no other FXYD2 
mutations have been reported in literature or detected in our diagnostic testing facility. 
Figure 3  Haplotype Analysis of Patients with FXYD2 Mutations
STS marker analysis of patients with FXYD2 mutations with markers from the chromosome 11q23 
(Chr11:117,250,000-118,000,000, hg38). All families share the same haplotype.
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Therefore, the role of FXYD2 in hypomagnesemia has been questioned. The identification 
of the new Dutch and Belgian families with FXYD2 mutations confirms its importance in 
renal Mg2+ handling. Moreover, several regulatory factors of FXYD2 have additionally 
been implicated in Mg2+ homeostasis. The transcription of FXYD2 is induced by HNF1β (7) 
and patients with HNF1B mutations also develop hypomagnesemia (1). Recently, pterin- 
4-alpha-carbinolamine dehydratase (encoded by PCBD1) was identified as additional 
 transcriptional regulator of FXYD2 and again patients with PCBD1 mutations showed 
hypomagnesemia (6). Although the exact molecular mechanism by which the PCBD1-
HNF1B-FXYD2 axis regulates renal Mg2+ reabsorption is still unclear, the effects of 
FXYD2-encoded γ–subunit on Na+-K+-ATPase activity have been well established. 
The γ–subunit increases the affinity of the Na+-K+-ATPase for ATP and decreases the 
affinity for Na+ and K+ (2). The p.Gly41 residue is located central in the alpha-helix that 
forms the γ–subunit (PDB: 2mkv). Mutation of the small glycine residue in the larger 
arginine residue may disrupt the structure of the γ–subunit. To date other FXYD2 mutations 
have not been identified, suggesting that other FXYD2 mutations may not cause 
hypomagnesemia. Alternativity, the importance of γ–subunit for Na+-K+-ATPase activity 
could suggest that more severe mutations in FXYD2 render a dysfunctional Na+-K+-ATPase 
and therefore may be embryonic lethal. 
 In the new families from the Netherlands and Belgium, both hypomagnesemia and 
hypocalciuria could be confirmed in all patients. Of note, hypomagnesemia was associated 
with moderate hypokalemia in the two patients with lowest serum Mg2+ values. 
Hypokalemia is often secondary to hypomagnesemia (13). Hypomagnesemia results in 
decreased intracellular Mg2+ levels in the distal part of the nephron, possibly due to the 
fact the Mg2+ normally inhibits the renal ROMK K+ channel minimizing renal K+ secretion. 
Other clinical manifestations of the patients harboring FXYD2 mutations include renal 
failure (CKD stage 3)(B II.1), but additional factors in the development of renal failure 
cannot be excluded (e.g. analgesics and NSAID for chronic pain due to chondrocalcinosis). 
All affected family members reported muscle cramps. Additionally, one patient suffered 
from episodes of epilepsy (B IV.1). Moreover, chrondrocalcinosis was detected in the 
proband of the Belgian family (B II.1). Both epilepsy and chondrocalcinosis were observed 
in the other patients from the original family (1, 7), and are classical complications of 
hypomagnesemia. In the Dutch family, daily supplementation using Mg(OH)2 achieved 
plasma Mg2+ levels in the low normal range.   
 Genealogical analysis, going back to 1700 of all three patients families with the similar 
FXYD2 mutation did not result in the identification of a common ancestor. Interestingly, 
the ancestry of two families could be traced back to the same geographical area near 
Liège in Belgium. If indeed the common ancestor lived before 1700, the dominant 
inheritance of IDH suggests that more, still unidentified, descendants of this common 
ancestor could live in the Netherlands and Belgium. However, given the variety of this 
phenotype and the aspecificity of the symptoms these patients often remain undetected. 
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Increasing the awareness of this syndrome may help identifying more patients with FXYD2 
mutations and allow proper treatment by Mg2+ supplementation.
 In conclusion, this study reports two new families with isolated dominant hypo-
magnesemia caused by FXYD2 mutations. Further insight in the clinical spectrum associated 
with genetic Mg2+ disorders can provide useful information for clinicians to make an early 
differential diagnosis. FXYD2 mutations should be considered in patients with hypo-
magnesemia and hypocalciuria, especially when chondrocalcinosis or epilepsy are observed.
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Patients and Methods
Patients
All patients in this study were diagnosed with hypomagnesemia and were screened by 
the DNA diagnostics department of the Radboudumc Nijmegen for hypomagnesemia 
causing mutations. Informed consent for participation in research was obtained in 
accordance with Institutional Review Board guidelines. Serum and urine electrolytes were 
determined by general laboratory screenings. Laboratory findings of all patients are 
presented in Table 1.
Mutation Analysis
Extraction of DNA from whole blood was performed using standard protocols. FXYD2 
mutation screening was performed using polymerase chain reaction (PCR) primers 
designed on the coding sequence of the human FXYD2 gene (NM_001680.4, NM_021603.3) 
including exon/intron boundaries (13). Amplified sequences were separated on agarose 
gel by electrophoresis and directly Sanger sequenced according to standard methods on 
a 3730 Sequence Analyzer (Applied Biosystems). Mutation nomenclature is according to 
HGVS using NM_001680.4 as a reference sequence.
Haplotype Analysis
Microsatellite markers D11S4092, D11S4127, D11S939, D11S1356 and D11S4195 encompassing 
the FXYD2 gene on chromosome 11q23 were amplified by PCR using fluorescently labelled 
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primers. PCR products are denatured and analyzed on a 3730 Sequence Analyzer (Applied 
Biosystems).
 
Genealogy Study
In-depth genealogical analysis was performed to identify common ancestors of FXYD2 
patients. Lists of descendants from index patients were compiled and pedigrees were 
generated using Dutch and Belgian civil registers and church books.
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Abstract
Hypomagnesemia is a common clinical cause of muscle cramps, epilepsy and cardiac 
arrhythmias. Regulation of the body magnesium (Mg2+) balance is of critical importance 
and is largely regulated by the kidney and the intestine. In the distal convoluted tubule 
(DCT) of the kidney, a transcellular reabsorption process determines the final urinary Mg2+ 
excretion. The basolateral Mg2+ extrusion mechanism in DCT is still unknown, but recent 
findings suggest that proteins of the SLC41 family may contribute to cellular Mg2+ 
extrusion. The aim of this study was, therefore, to characterize the role of SLC41A3 in Mg2+ 
homeostasis using the Slc41a3 knockout mouse. 
 To this end, a tissue expression screening was performed by RT-PCR, showing that 
Slc41a3 is the only SLC41 isoform with enriched expression in DCT compared to other 
segments in the kidney. Interestingly, serum and urinary electrolyte determinations 
demonstrated that Slc41a3 knockout mice suffer from hypomagnesemia with renal Mg2+ 
wasting. Serum and urinary sodium, potassium and calcium levels were not affected. To 
determine the effect of SLC41A3 on intestinal Mg2+ absorption, the Mg2+ absorption 
capacity was measured using the stable 25Mg2+ isotope. 25Mg2+ uptake was similar in wild 
type and knockout mouse, although Slc41a3 knockout animals exhibited increased 
intestinal expression of Mg2+ transporters Trpm6 and Slc41a1. Remarkably, 10% of the 
Slc41a3 knockout mice developed severe unilateral hydronephrosis, as demonstrated by 
the presence of transitional epithelium lining the fluid cavity. Feeding the Slc41a3 knockout 
mice a low Mg2+ diet may have instigated the formation of hydronephrosis. 
 In conclusion, SLC41A3 was established as a new important factor for renal Mg2+ 
handling. In the future, SLC41A3 mutations should be considered in patients with unilateral 
hydronephrosis and/or hypomagnesemia.
Keywords: Hypomagnesemia, Kidney, Hydronephrosis, Distal Convoluted Tubule
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Introduction
The distal convoluted tubule (DCT) is essential for magnesium (Mg2+) homeostasis (4). 
Although only 10 % of the filtered Mg2+ is reabsorbed in this segment of the kidney, it 
determines the final urinary Mg2+ excretion since no reabsorption takes place beyond this 
segment. In the DCT, Mg2+ enters the cell via the Transient Receptor Potential Melastatin 
type 6 (TRPM6) divalent cation channel (31), while the basolateral Mg2+ extrusion 
mechanism remains to be identified. Disturbances in this latter process result in 
hypomagnesemia, which is characterized by a variety of clinical symptoms including 
cardiac arrhythmias, muscle cramps and fatigue (4). Additionally, drugs affecting the DCT 
such as epidermal growth factor receptor inhibitors, calcineurin inhibitors and diuretics 
may reduce blood Mg2+ levels (15). Therefore, understanding the molecular mechanism 
underlying Mg2+ reabsorption in the DCT is of major importance for the treatment of 
patients with hypomagnesemia.
 In a recent transcriptome screening study, Solute carrier family 41 member 3 (Slc41a3) 
was identified as highly regulated by dietary Mg2+ intake (3). In this study, mice were fed 
with various Mg2+-containing diets after which DCT segments were isolated. Using a 
quantitative gene expression microarray, the Mg2+-sensitive genes in the DCT were 
identified. Slc41a3 was among the genes with increased expression in response to a 
Mg2+-deficient diet.
 SLC41A3 was originally described by Quamme and colleagues as part of the solute 
carrier family 41 of putative Mg2+ transporters (22). Although SLC41A3 has never been 
studied in detail, few studies have addressed the structure, regulation and function of its 
close homologue SLC41A1 (52 % identity at amino acid level)(12, 13, 17). There is controversy 
about the structure of SLC41A1; some groups support a 10 transmembrane domain 
structure, while others suggest 11 transmembrane domains with an extracellular 
C-terminus (17, 28). On the functional level, initial experiments in Xenopus laevis oocytes 
demonstrated Mg2+ currents for SLC41A1 and SLC41A3 using physiological Mg2+ 
concentrations, proposing a channel-like function (5, 22). Indeed, SLC41 proteins posses 
conserved pore regions with the MgtE bacterial Mg2+ channel (9, 17, 32). In contrast, recent 
experiments using Mg2+-sensitive fluorescent probes showed Na+-dependent Mg2+ 
transport, suggesting that SLC41A1 may be the long-sought Na+/Mg2+-exchanger (13, 14). 
Interestingly, an exon-skipping mutation in SLC41A1 resulted in a nephronophthisis-like 
phenotype in a patient eventually requiring renal transplantation (10). Whether SLC41A3 
may have a similar function as SLC41A1 has never been examined. However, in contrast to 
Slc41a3, Mg2+-sensitive regulation of Slc41a1 expression was not observed in the DCT 
transcriptome study (3).
 The aim of the present study was to characterize the role of SLC41A3 in renal and 
intestinal Mg2+ (re)absorption. Slc41a3 knockout mice (Slc41a3-/-) were analyzed for ion 
homeostasis and kidney development. Furthermore, by challenging the mice with low 
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Mg2+ diets the compensatory mechanisms in intestine, kidney and brain were examined 
in detail. Using the 25Mg isotope, intestinal Mg2+ uptake studies were performed to 
determine the role of SLC41A3 in the intestine. 
Results
Expression Profile of Slc41 Isoforms
To examine the role of the SLC41 protein family in DCT Mg2+ transport, a tissue expression 
screening for Slc41a1, Slc41a2 and Slc41a3 was performed using RT-PCR (Figure 1). All three 
isoforms showed a ubiquitous expression pattern. High Slc41a1 expression was detected 
in brain, heart and lung, Slc41a2 was mostly expressed in the early intestine and Slc41a3 
expression was highest in heart, lung and small intestine. However, in RT-PCR analysis of 
isolated DCT tubules Slc41a3 transcript levels showed an impressive 10-fold enrichment 
compared to total kidney mRNA. Slc41a1 and Slc41a2 expression was not enriched in DCT 
compared to other segments; the latter was even significantly decreased, suggesting that 
SLC41A3 is the most relevant SLC41 family member for Mg2+ transport in DCT. 
Slc41a3 Mouse Breeding
To examine the function of SLC41A3 in Mg2+ homeostasis, Slc41a3-/- mice were generated. 
Breeding of Slc41a3+/- mice resulted in a normal Mendelian inheritance pattern in the 
offspring. Of a total of 181 mice 32 % was genotyped Slc41a3+/+, 46 % Slc41a3+/- and 22 % 
Slc41a3-/-. Since Shirpa screening by the Mouse Genetics Project reported abnormal 
locomotor coordination of Slc41a3-/- mice fed with a high fat diet (MGI: 1918949)(35), 
special attention to behavioral observations was given during the breeding procedure. 
However, no abnormalities in behavior of the mice including ataxia and locomotor 
behavior were observed. By visual inspection, it was not possible to distinguish between 
Slc41a3+/+, Slc41a3+/- and Slc41a3-/- mice based on behavior or phenotype. All offspring was 
genotyped for the insertion of the KO cassette and presence of the wild type Slc41a3 allele 
(Figure 2B). To confirm KO of Slc41a3 β-galactose stainings were performed, taking 
advantage of the insertion of the LacZ cassette in the Slc41a3 gene in the Slc41a3-/- mice. 
Indeed, LacZ staining was only observed in Slc41a3-/- mice (Figure 2C).
Hypomagnesemia in Slc41a3-/- Mice
To investigate the role of SLC41A3 in Mg2+ homeostasis, mice were subjected to normal or 
low Mg2+-containing diets for 14 days. Blood, urine and feces were collected at day 0 and 
day 14 of the experiment using metabolic cages (Figure 3A). At the end of the experiment 
the mice were sacrificed and tissues were collected for further analysis. No significant 
differences were observed between the body weights of Slc41a3+/+ mice and Slc41a3+/- 
and Slc41a3-/- littermates (Table 1). Food and water intake, urinary volume and fecal excretion 
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were comparable among all mice on the same diet (Table 1). On the normal diet, Slc41a3-/- 
mice serum Mg2+ concentrations were significantly decreased by 29 %(±2 %) compared 
to Slc41a3+/+ mice (Figure 3B). 24hrs urinary Mg2+ excretion was not significantly different, 
suggesting a renal Mg2+ leak in Slc41a3-/- mice (Figure 3C). Interestingly, both serum and 
urine Ca2+ levels were not significantly altered compared to Slc41a3+/+ mice, underlining 
Figure 1   Slc41a3 Expression is Enriched in the Distal Convoluted Tubule (DCT)
A-F, mRNA expression levels of Slc41a1 (A-B), Slc41a2 (C-D) and Slc41a3 (E-F) in a panel of mouse 
 tissues (A,C,E) and in COPAS-sorted DCT cells (B,D.F) were measured by quantitative RT-PCR and 
normalized for Gapdh expression. Data represent the mean of three individual experiments ± SEM 
and are expressed as the percentage of the total tissue expression (A,C,E) or enriched compared to 
total kidney expression (B,D,F). *P < 0.05 indicates a significant difference from total kidney expression.
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the specificity of the hypomagnesemia in these Slc41a3-/- mice (Figure 3D-E). Slc41a3+/+ 
mice fed a Mg2+-deficient diet for two weeks, displayed hypomagnesemia (serum Mg2+ 
levels of 0.43 ±0.04 mmol/L, Figure 3B). Although the serum Mg2+ levels of Slc41a3-/- mice 
on a low Mg2+ diet were even lower (0.32 ±0.02 mmol/L), they did not reach a significant 
difference compared to Slc41a3+/+ mice (p=0.14). On the low Mg2+ diet, no differences in 
urinary Mg2+ and Ca2+ excretion or serum Ca2+ concentrations were measured among 
the groups (Figure 3C-E).
Hydronephrosis in a Subset of Slc41a3-/- Mice 
Interestingly, in several male Slc41a3-/- mice on the low Mg2+ diet a severely increased 
kidney size was observed in the left kidney caused by a hydronephrosis (Figure 4A). The 
kidney volume was 6-8 fold higher than the other kidney of the same animal and caused 
a serious organ rearrangement in the peritoneal cavity. The hydronephrotic kidney was 
unilateral and was observed in 10 % of the Slc41a3-/- mice in the low Mg2+ group and 
was never detected in Slc41a3-/- mice fed the normal Mg2+ diet. To further assess the 
morphology of the hydronephrosis, the kidney tissue was stained using standard 
hematoxylin and eosin (H&E) stainings (Figure 4B, left image). The presence of transitional 
epithelium around the dilated tissue and the absence of dilated ureters suggest that the 
origin of the hydronephrosis is located in the renal calyx or renal pelvis. Indeed, umbrella 
Figure 2   Characteristics of the Slc41a3-/-  Mouse
A, Targeted insertion of the knockout (KO) cassette. Top: Slc41a3 locus on chromosome 6. Bottom: 
targeted allele in which the KO cassette is inserted before exon 5. Grey boxes indicate exons; black 
triangles depict LoxP sites; white triangles depict Flp sites; arrows depict genotype primers (A–C). 
SA: splice acceptor, IRES: interinal ribosome entry site, lacZ: β-galactosidase, pA: polyA, hBactP: 
 promoter, neo: neomycin resistance gene. B, Identification of the mouse genotype by PCR analysis 
of ear-derived DNA. The PCR product size ± 530 bp shows the presence of the wild-type allele (+/+) 
using primers A and C; the PCR product sized ± 800 bp shows the KO allele (–/–) using primers B and C. 
Both alleles are detected in heterozygous animals (+/–). C, β-galactosidase staining of Slc41a3-/- mice.
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cells were detected to further confirm the urothelial origin of the tissue (Figure 4B, middle 
image). However, major parts of the tissue lining the fluid-filled cavity were not covered 
with transitional epithelium, but existed of fibrous connective tissue. The ureter was filled 
with large cells that possibly obstructed the flow (Figure 4B, right image). Subsequently, 
the presence of Ca2+ deposits was examined to exclude urolithiasis as cause for the 
hydronephrosis. By alizarin red stainings, Ca2+ deposits were not detected in the ureter or 
Figure 3   Slc41a3-/- Mice Suffer from Isolated Hypomagnesemia
A, Slc41a3+/+, Slc41a3+/-, Slc41a3-/- mice were randomly assigned to the low or normal Mg2+ group 
(n=10). Subsequently, mice were fed with the Mg2+ diets for 14 days of which the animals were 
housed in metabolic cages during the last 48 hrs for urine and feces sampling (24 hrs adaptation, 
24 hrs sampling). At the end of the experiments, the animals were sacrificed and blood and or-
gans were taken for further analysis. B-E, Serum Mg2+ (B) and Ca2+ (D) concentrations at day 14 
of Slc41a3+/+ (black bars), Slc41a3+/- (grey bars) and Slc41a3-/- (white bars) mice fed with a low or 
normal Mg2+-containing diet for 14 days. 24 hrs urinary Mg2+ (C) and Ca2+ (E) excretion at day 14 of 
Slc41a3+/+ (black bars), Slc41a3+/- (grey bars) and Slc41a3-/- (white bars) mice fed with a low or normal 
Mg2+-containing diet for 14 days. Values are presented as means ± SEM (n=10). *P < 0.05 is consid-
ered statistically significant compared to Slc41a3+/+ mice fed the same diet. 
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Figure 4   Slc41a3-/- Mice Develop Hydronephrosis on Low Mg2+ Diets
A, Images of hydronephrotic kidneys found in 2 out of 20 of Slc41a3-/- mice fed with low Mg2+ diets. 
B, Hematoxylin and eosin stain of the hydronephrosis kidney detected in Slc41a3-/- mice showing 
transitional epithelium lining the hydronephrosis. The left image gives an overview of the total 
kidney (bar: 1 mm). The middle image shows the transitional epithelium with a black arrow indi-
cating the umbrella cells (bar: 20 µm). The right image indicates that the ureter is filled with large 
cells, which potentially cause obstruction (bar: 20 µm). C, Alizarin red staining of the hydronephrosis 
kidney did not show Ca2+ deposits in ureter, only minor Ca2+ stains in the connective tissue sur-
rounding the hydronephrosis (bar: 200 µm). D, Hematoxylin and eosin stain of normal kidney tissue 
from Slc41a3-/- mice fed with normal Mg2+ demonstrating venal en tubular dilations (left image bar: 
100µm, right image bar: 20 µm). E, Quantification of dilated surface in Slc41a3+/+ and Slc41a3-/- mice. 
Values are presented as means ± SEM (n=10).
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remnant kidney of the Slc41a3-/- mouse with hydronephrosis, only small deposits were 
present in the connective tissue lining the cavity (Figure 4C). To assess whether more 
initial stages of the development of the hydronephrosis could be detected, kidneys from 
Slc41a3-/- mice fed with the normal Mg2+ diet without apparent abnormalities at the 
exterior of the kidney were stained using a standard hematoxylin and eosin stain (Figure 
4D). Small tubular and venal dilations were observed in the cortex and medulla of 
Slc41a3+/+ and Slc41A3-/- mice. Quantification of the surface size of these dilations did not 
show differences between kidneys from Slc41a3+/+ and Slc41A3-/- mice, suggesting that 
these dilations are non-pathogenic (Figure 4E).
Increased Colonic Expression of Mg2+ Transporters in Slc41a3-/- Animals
To examine the compensatory mechanisms for the renal Mg2+ wasting in Slc41a3-/- mice, 
the expression of renal Mg2+ transporters was analyzed using RT-PCR (Figure 5). 
Interestingly, the renal transcript levels of Trpm6, Slc41a1, Cnnm2 and parvalbumin were not 
significantly different between Slc41a3+/+ and Slc41a3-/- mice (Figure 5A-D). Renal Slc41a1 
expression was significantly increased in the low Mg2+ diet fed mice compared to mice in 
the normal Mg2+ fed group for all genotypes (Figure 5B). Furthermore, the renal mRNA 
levels of Egf, Ncc, Cldn16 and Cldn19 were not significantly altered in Slc41a3-/- mice in 
comparison with their wild type littermates (Figure 5E-H). 
 Subsequently, the expression of Mg2+ transporters in the colon was examined by 
RT-PCR. In particular in the low Mg2+ groups, gene expression levels of Slc41a1, Cnnm4 and 
Trpm7 were significantly increased in the colon of Slc41a3-/- animals compared to colon of 
their wild-type littermates (Figure 6). In contrast, no difference in colonic Trpm6 expression 
was detected between Slc41a3+/+ and Slc41a3-/- mice.
 Since Slc41a3 was also expressed in brain (Figure 1) and SLC41A1 is associated with 
Parkinson’s disease (14, 25, 34), expression levels of Trpm7 and Slc41a1 in the brain were 
measured by RT-PCR. No significant changes in brain mRNA expression levels of Trpm7 
and Slc41a1 were observed among the genotypes (Figure 7). However, brain Trpm7 and 
Slc41a1 transcript levels were significantly increased in the low Mg2+ diet groups compared 
to mice on the normal Mg2+ diet.
Intestinal Absorption is the Similar in Slc41a3+/+ and Slc41a3-/- Mice
To further establish the intestinal function in Slc41a3-/- mice, the intestinal Mg2+ absorption 
capacity was determined using the stable 25Mg2+ isotope. The mice were subjected to 10 
days of low Mg2+ diets prior to the Mg2+ absorption analysis. At the day of the experiment, 
the mice were administrated 25Mg2+ by oral gavage and subsequently blood was taken 
from the tail up to 60 min after the administration. The natural abundance of 25Mg2+ in 
blood is 10 %, which is enriched by more than 100 % during 60 min of 25Mg2+ uptake to 
more than 20 % (Figure 8A). However, no significant differences in Mg2+ absorption were 
detected between Slc41a3+/+ and Slc41a3-/- mice (Figure 8A). Determination of the mRNA 
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Figure 5   Compensatory Mechanisms for the Loss of Slc41a3 Function in the Kidney
A-H, The mRNA expression levels of Trpm6 (A), Slc41a1 (B), Cnnm2 (C), Parvalbumin (D), Egf (E), Ncc 
(F), Cldn16 (G) and Cldn19 (H) in kidney of Slc41a3+/+ (black bars), Slc41a3+/- (striped bars) and Slc41a3-/- 
(white bars) mice fed with a low or normal Mg2+-containing diet for 14 days were measured by 
quantitative RT-PCR and normalized for Gapdh expression. Data represent means (n=10) ± SEM and 
are expressed fold difference when compared to the expression in normal diet fed Slc41a3+/+ mice. 
*P < 0.05 indicates a statistically significance compared to Slc41a3+/+ mice fed the same diet.
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Figure 6   Compensatory Mechanisms for the Loss of Slc41a3 Function in the Intestine
A-D, The mRNA expression levels of Trpm6 (A), Slc41a1 (B), Cnnm4 (C) and Trpm7 (D) in colon of 
Slc41a3+/+ (black bars), Slc41a3+/- (striped bars) and Slc41a3-/- (white bars) mice fed with a low or 
normal Mg2+-containing diet for 14 days were measured by quantitative RT-PCR and normalized 
for Gapdh expression. Data represent means (n=10) ± SEM and are expressed fold difference when 
compared to the expression in normal diet fed Slc41a3+/+ mice. *P < 0.05 indicates a statistically 
significance compared to Slc41a3+/+ mice fed the same diet.
Figure 7   Brain Expression of Mg2+ Transporters
A-B, The mRNA expression levels of Trpm7 (A) and Slc41a1 (B) in brain of Slc41a3+/+ (black bars), 
Slc41a3+/- (striped bars) and Slc41a3-/- (white bars) mice fed with a low or normal Mg2+-containing 
diet for 14 days were measured by quantitative RT-PCR and normalized for Gapdh expression. Data 
0. 0
0. 5
1. 0
1. 5
C
ol
on
 T
rp
m
6 
m
RN
A
 e
xp
re
ss
io
n
(fo
ld
 c
ha
ng
e 
co
m
pa
re
d 
to
 +
/+
)
0
1
2
3
4
5
C
ol
on
 C
nn
m
4 
m
RN
A
 e
xp
re
ss
io
n
(fo
ld
 c
ha
ng
e 
co
m
pa
re
d 
to
 +
/+
)
0
1
2
3
4
5
C
ol
on
 S
lc
41
a1
 m
RN
A
 e
xp
re
ss
io
n
(fo
ld
 c
ha
ng
e 
co
m
pa
re
d 
to
 +
/+
)
0
1
2
3
C
ol
on
 T
rp
m
7 
m
RN
A
 e
xp
re
ss
io
n
(fo
ld
 c
ha
ng
e 
co
m
pa
re
d 
to
 +
/+
)
*
A
C
B
D
* *
*
No
rm
al 
Mg
2+
Lo
w 
Mg
2+
No
rm
al 
Mg
2+
Lo
w 
Mg
2+
No
rm
al 
Mg
2+
Lo
w 
Mg
2+
No
rm
al 
Mg
2+
Lo
w 
Mg
2+
BA
0
1
2
3
4
Tr
pm
7 
m
RN
A
 e
xp
re
ss
io
n
0
1
2
3
Sl
c4
1a
1 
m
RN
A
 e
xp
re
ss
io
n
p=0.06
No
rm
al 
Mg
2+
Lo
w 
Mg
2+
No
rm
al 
Mg
2+
Lo
w 
Mg
2+
Hypomagnesemia in SLC41A3 KO Mice | 123
Figure 8   Increased Expression of Intestinal Mg2+ Transporters Compensate for Slc41a3 KO
A, 60 min intestinal 25Mg2+ absorption in Slc41a3+/+ (solid line) and Slc41a3-/- (dashed line) mice after 
10 days on low Mg2+ diets, B-E, The mRNA expression levels of Trpm6 (B,D) and Slc41a1 (C,E) in du-
odenum (B-C) or colon (D-E) of Slc41a3+/+ and Slc41a3-/- mice fed with a low Mg2+-containing diet 
for 10 days were measured by quantitative RT-PCR and normalized for Gapdh expression. Values 
are presented as means ± SEM (n=10). *P < 0.05 is considered statistically significant compared to 
Slc41a3+/+ mice.
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represent means (n=10) ± SEM and are expressed fold difference when compared to the expres-
sion in normal diet fed Slc41a3+/+ mice. *P < 0.05 indicates a statistically significance compared to 
Slc41a3+/+ mice fed the same diet.
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expression levels of Trpm6 and Slc41a1 to examine the role of other Mg2+ transporters in 
intestinal Mg2+ uptake showed that the expression of these genes was significantly 
increased in both colon and duodenum of Slc41a3-/- mice (Figure 8B-E). 
Discussion
This study identified SLC41A3 as a novel and essential player in Mg2+ homeostasis in 
general and in particular in renal Mg2+ transport. This conclusion is based on the following 
results: i) Slc41a3 is expressed in the kidney and intestine where Mg2+ is (re)absorbed; 
ii) Slc41a3-/- mice suffer from hypomagnesemia and normomagnesiuria indicating a renal 
Mg2+ leak; iii) Intestinal Mg2+ absorption is not altered in Slc41a3-/- mice; iv) Upregulation 
of Mg2+ transporters including Trpm6 and Slc41a1 in the intestine of Slc41a3-/- mice 
compensates for loss of SLC41A3 function. 
 The urine electrolyte levels in Slc41a3-/- mice point to a specific renal Mg2+ leak and 
copies the phenotype of patients with renal Mg2+ wasting (7, 26, 33), namely low serum 
Mg2+ levels accompanied by normal urinary Mg2+ excretion. Under normal physiological 
circumstances, renal Mg2+ excretion is diminished to compensate reduced blood Mg2+ 
levels. However, the Slc41a3-/- mice failed to counteract their urinary Mg2+ excretion. 
Additionally, the intestinal 25Mg2+ absorption after dietary Mg2+ deficiency was normal in 
Slc41a3-/- mice, suggesting that the hypomagnesemia in Slc41a3-/- mice is indeed due to 
renal Mg2+ wasting. The renal Mg2+ wasting in Slc41a3-/- mice can presumably be explained 
by impaired DCT function. In kidney, Slc41a3 was, in contrast to its close homologue 
Slc41a1, highly enriched in DCT. Likewise, the expression of Slc41a3, but not Slc41a1, in DCT 
is highly dependent on dietary Mg2+ intake (3). These results are comparable to the 
established findings concerning the Mg2+ channels TRPM6 and TRPM7. TRPM6 provides 
the specific apical Mg2+ uptake mechanism in intestine and kidney (6, 30, 31). Hence, the 
expression of TRPM6 is localized to the colon and the DCT and highly regulated by dietary 
Mg2+ availability (6). In contrast, TRPM7 is ubiquitously expressed and is involved in basic 
cellular Mg2+ handling (23, 27). Its expression is therefore insensitive to dietary Mg2+ 
changes (6). A comparable mechanism could apply to SLC41 proteins, in which SLC41A3 
would be specific for epithelial Mg2+ uptake in colon and DCT and SLC41A1 would serve 
as ubiquitously expressed general Mg2+ transporter.
 The molecular function of SLC41A3 in DCT remains elusive. SLC41A3 activity has only 
been examined in Xenopus laevis oocytes by voltage-clamp, showing Mg2+-evoked 
currents with a Km within the physiological range (22). However, when overexpressed in 
HEK293 cells Mg2+ currents could not be detected (unpublished data from our lab). The 
function of the close homologue SLC41A1 has been examined in more detail. As SLC41A3, 
SLC41A1 mediates Mg2+-evoked currents in Xenopus laevis oocytes (5). Moreover, its Mg2+ 
transport capacity was further established in the TRPM7-deficient DT40 cell line, where 
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SLC41A1 can restore cell growth (24). Importantly, recent data suggest that SLC41A1 acts 
as a Na+/Mg2+-exchanger (13). If SLC41 proteins indeed function as basolateral Mg2+ 
exchangers, knockout of Slc41a3 in the DCT region would seriously reduce the extrusion of 
Mg2+ across the basolateral membrane. As a consequence, intracellular Mg2+ concentrations 
will increase, preventing transcriptional activation of magnesiotropic genes. This could 
explain why the expression of DCT transcripts such as Trpm6, Egf and Parvalbumin were 
not altered in Slc41a3-/- mice. Moreover, these genes are mainly involved in apical uptake 
of Mg2+ and will, therefore, not be able to rescue the basolateral extrusion of Mg2+. 
 Although Slc41a3 is expressed in the small intestine, Slc41a3-/- mice exhibited normal 
intestinal Mg2+ absorption compared to their wild type littermates. However, the expression 
of Mg2+ transporters Slc41a1 and Trpm6 was increased in duodenum of Slc41a3-/- mice, 
suggesting that loss of SLC41A3 function induces a compensatory mechanism to facilitate 
normal Mg2+ uptake. Specifically, the upregulation of Slc41a1 is of interest because the 
structure of SLC41A1 is largely similar to SLC41A3 (17). Importantly, the pore region of 
SLC41A1 and SLC41A3 proteins is conserved from MgtE bacterial Mg2+ channels and 
essential for their function (9, 17, 32). If the increased expression of Slc41a1 indeed 
compensates for defects in intestinal Mg2+ absorption Slc41a3-/- mice, this would suggest 
that SLC41A1 and SLC41A3 are functionally redundant. Future in vitro studies should 
substantiate this hypothesis.
 The development of hydronephrosis in Slc41a3-/- mice is one of the striking findings 
of our study. H&E stainings showed transitional epithelia including umbrella cells lining 
the hydronephrotic region, excluding a cystic origin of the kidney malformation (1). 
However important parts of the lining tissue of the hydronephrosis were not covered 
with transitional epithelium, but with a layer of fibrous connective tissue that normally 
originates from the renal capsule. A similar phenotype of perinephric pseudocysts, in 
which fluid accumulates in a fibrous sac surrounding the kidney, has been observed 
previously in humans, mice and cats (2, 20, 21). In a previously described C57BL/6J mouse, 
extensive histological analysis showed that unilateral perinephric pseudocyst can be 
formed from an initial hydronephrosis that at some point ruptures when the integrity of 
the lining wall is compromised (20). The urine may then leak into the subcapsular space 
between the renal capsule and the remnant kidney. In concordance with these findings, 
histological analysis of the Slc41a3-/- mice demonstrated both transitional epithelium and 
connective tissue lining the cavity, suggesting that an initial hydronephrosis may have 
ruptured resulting in a perinephric pseudocyst. However, the absence of transitional 
epithelium may also be explained by atrophy due to the pressure of the hydronephrosis. 
Future extensive histological studies should further address this issue.
 Hydronephrosis is normally the consequence of obstruction of the ureter resulting in 
fluid retention in the renal calyx and pelvis (19). The cause of the obstruction in Slc41a3-/- 
mice could not be identified. Importantly, only a subset of the Slc41a3-/- mice developed 
hydronephrosis, suggesting that Slc41a3-/- mice are more sensitive to the development of 
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hydronephrosis, but that knockout of SLC41A3 is not causative of hydronephrosis per se. 
Speculatively, the dietary Mg2+ availability could have contributed to the development of 
the hydronephrosis, since hydronephrosis was only detected in mice fed a Mg2+-deficient 
diet. It is widely acknowledged that Mg2+ can prevent urolithiasis by reducing the 
formation of calcium oxalate (CaC2O4) and calcium phosphate (Ca(H2PO4)2) stones and 
deposits (8, 11, 29). Urolithiasis can cause obstruction of the ureter and, therefore, result in 
hydronephrosis (16). However, alizarin red stainings did not show Ca2+ deposits in the 
ureter of Slc41a3-/- mice on the low Mg2+ diet despite their extremely low urinary Mg2+ 
excretion. H&E stainings demonstrate the presence of large cells in the ureter that might 
obstruct the flow of urine. Future studies should address the origin of these cells and 
whether these cells are causing hydronephrosis in Slc41a3-/- mice.
 Interestingly, a mutation of SLC41A1 was recently shown to be causative for a nephro-
nophthisis-like (NPHP-like) phenotype in an Italian family (10). The kidneys of the patients 
showed irregular echogenicity when examined by kidney ultrasonography (10), suggesting 
kidney abnormalities such as renal cysts or hydronephrosis. However, hydronephrosis 
could be excluded by subsequent histological analysis, which showed periglomerular 
fibrosis, tubular ectasia, tubular basement membrane disruption and tubulointerstitial 
infiltrations (10). The aforementioned signs of inflammation and fibrosis were absent in the 
remnant kidney tissue of Slc41a3-/- mice. Moreover, in contrast to the NPHP-like phenotype 
in SLC41A1 patients, the kidney size was markedly increased in the Slc41a3-/- mice that 
suffered from hydronephrosis. More SLC41A1 patients should be identified and closely 
examined for hydronephrosis to allow final conclusions on the kidney phenotype of these 
patients. 
 In conclusion, SLC41A3 is novel player in renal and intestinal Mg2+ (re)absorption and 
a new factor in the formation of hydronephrosis. Consequently, SLC41A3 should be 
included in genetic screenings for hypomagnesemic patients. Future studies should 
further investigate the interaction between Mg2+ homeostasis and the formation of 
hydronephrosis.
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Methods
Expression Analysis
Three C57BL/6 mice were sacrificed; kidney, duodenum, ileum, jejunum, cecum, colon, 
brain, lung, liver, spleen, muscle, and heart tissues were collected. For the collection of DCT 
material, transgenic parvalbumin-eGFP mice were used as described previously (kind gift 
from Dr. Monyer, University of Heidelberg, Germany)(18). In short, mice were anesthetized 
by a mixture injection of domitor (0.01 mg/g of body weight) and ketamine (0.1 mg/g of 
body weight). Subsequently, the mice were perfused with 10 mL of Krebs buffer (in 
mmol/L: 145 NaCl, 5 KCl, 10 HEPES/NaOH pH 7.4, 1 NaH2PO4, 2.5 CaCl2, 1.8 MgSO4, 5 glucose) 
through the heart. The kidneys were removed, minced, and digested in collagenase (1 mg/mL 
collagenase A (Worthington, Lakewood, NJ, USA), 0.6 mg/mL hyaluronidase) in Krebs 
buffer. The digested tubules sized between 40 and 100 µm were sorted based on GFP 
fluorescence by COPAS (Complex Object Parametric Analysis and Sorting, Union 
Biometrica, Holliston, MA, USA). Per mouse, 4,000 eGFP-positive fluorescent DCT tubules 
were collected, and an additional 4,000 control tubules were sorted from the same kidney 
sample without selection for eGFP-positive cells. 
RNA Isolation
Total RNA was isolated using TRIzol total RNA isolation agent (Invitrogen, Bleiswijk, the 
Netherlands) according to the manufacturer’s protocol. Obtained RNA was treated with 
DNase (Promega, Fitchburg, WI, USA) to remove genomic DNA. Subsequently, reverse 
transcription of the mRNA by M-MLV reverse transcriptase (Invitrogen, Bleiswijk, the 
Netherlands) was performed for 1 hr at 37 °C. 
Real Time PCR
Gene expression levels were determined by quantitative real-time PCR on a BioRad 
(Hercules, CA, USA) analyzer using sybrgreen and normalized for Gapdh expression levels. 
Primer sequences are provided in Table 2. 
Animals
All experiments were performed in compliance with the animal ethics board of the 
Radboud University Nijmegen. Heterozygous male and female (Slc41a3+/–) mice of the Sl-
c41a3tm1a(KOMP)Wtsi strain were purchased from Knock Out Mouse Project repository (KOMP, 
Davis, CA, USA MGI: 1918949) and crossbred to C57Bl/6N wild-type mice. The heterozygous 
offspring was used to generate Slc41a3–/– mice. Littermates were housed in a temperature- 
and light-controlled room with standard pellet chow and deionized drinking water 
available ad libitum.
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Diet study
20 Slc41a3+/+, 20 Slc41a3+/- and 20 Slc41a3-/- mice aged between 8-12 weeks were randomly 
selected for this experiment (50 % male, 50 % female). The animals were housed in 
metabolic cages for 48 hrs (24 hrs adaptation, 24 hrs sampling) prior to collect urine and 
feces. Subsequently, the mice were randomly divided to a group and fed with normal (0.19 
% (wt/wt) Mg2+, SSNIFF Spezialitäten GmbH, Soest, Germany) and low Mg2+ diets (0.02 % 
(wt/wt) Mg2+, SSNIFF) (n=10 per group per genotype) for 14 days. Blood samples were 
taken before and after the diets via submandibular facial vein puncture. The last 48 hrs of 
the experiment the animals were housed in the metabolic cages again to collect urine 
and feces. Then, animals were sacrificed, blood was collected and kidney, brain and colon 
tissues were sampled and frozen immediately in liquid nitrogen for further analysis.
25Mg2+ Absorption Study
Intestinal absorption of Mg2+ was measured by analyzing serum 25Mg2+ as percentage of 
total Mg2+. In short, 20 male animals aged 8-10 weeks (10 Slc41a3+/+, 10 Slc41a3-/-) were 
fasted (food, not water) overnight on wire-mesh raised floors to prevent coprophagia. At 
time-point 0, mice were administered a solution containing 44 mmol/L 25Mg2+ (MgO, 
isotopic enrichment of > 98 %, CortectNet, Voisins-Le-Bretonneux, France), 125 mmol/L 
NaCl, 17 mmol/L Tris/HCl pH 7.5, 1.8 g/L fructose. Animals were administered a volume of 
15 uL/g bodyweight via oral gavage. Subsequently, blood was taken at serial time-points 
via a small tail-cut and collected in Microvette serum tubes (Sarstedt, Etten-Leur, The 
Netherlands). After serum collection from the coagulated blood samples, sera were 
Table 2   Primer Sequences for RT-PCR Analysis
Forward primer Reverse primer
Gapdh 5’-TAACATCAAATGGGGTGAGG-3’ 5’-GGTTCACACCCATCACAAAC-3’
Slc41a1 5’-CATCCCACACGCCTTCCTGC-3’ 5’-CGGCTGGCCTGCACAGCCAC-3’
Slc41a2 5’-TGGCATGGTTTTGGACATAG-3’ 5’-AGCGTCATTTCCAAGTTTCC-3’
Slc41a3 5’-TGAAGGGAAACCTGGAAATG-3’ 5’-GGTTGCTGCTGATGATTTTG-3’
Trpm6 5’-AAAGCCATGCGAGTTATCAGC-3’ 5’-CTTCACAATGAAAACCTGCCC-3’
Trpm7 5’-GGTTCCTCCTGTGGTGCCTT-3’ 5’-CCCCATGTCGTCTCTGTCGT-3’
Cnnm2 5’-GGAGGATACGAACGACGTG-3’ 5’-TTGATGTTCTGCCCGTACAC-3’
Cnnm4 5’-TCTGGGCCAGTATGTCTCTG-3’ 5’-CACAGCCATCGAAGGTAGG-3’
Parvalbumin 5’-CGCTGAGGACATCAAGAAGG-3’ 5’-AGCTTTCAGCCACCAGAGTG-3’
Egf 5’-GAGTTGCCCTGACTCTACCG-3’ 5’-CCACCATTGAGGCAGTATCC-3’
Ncc 5’-CTTCGGCCACTGGCATTCTG-3’ 5’-GATGGCAAGGTAGGAGATGG-3’
Cldn16 5’-GTTGCAGGGACCACATTAC-3’ 5’-GAGGAGCGTTCGACGTAAAC-3’
Cldn19 5’-GGTTCCTTTCTCTGCTGCAC-3’ 5’-CGGGCAACTTAACAACAGG-3’
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digested in nitric acid (65 % concentrated, Sigma, Zwijndrecht, The Netherlands) for 1 hr at 
70 ºC followed by an overnight incubation at room temperature. Subsequently, samples 
were diluted in milliQ and subjected to ICP-MS analysis (X1 series, Thermo Fisher Scientific, 
Breda, The Netherlands).
Histology
After the sampling, the tissues specimens were immediately fixed in 4 % PFA (w/v) and 
embedded in paraffin or frozen in liquid nitrogen. 5 mm sections were cut in embedding 
media (Tissue-Tek, OCT medium, Sakura, Alphen aan den Rijn, The Netherlands), mounted 
onto Superfrost Plus slides (Thermo Scientific, Menzel-Glaser, Braunschweig, Germany) 
and stored at -20 °C. Paraffin sections were deparaffinized and rehydrated and stained 
with a hematoxylin and eosin (H&E) staining. Slides were put in hematoxillin and 
differentiated in tapwater. Thereafter the slides were counterstained with eosin Y, 
dehydrated and mounted. Pictures were made with a Zeiss (Oberkochen, Germany) 
microscope.
Β-galactosidase Staining 
Slides were pretreated for immunohistochemistry with 10 mmol/L sodium citrate. 
Endogen peroxidase was blocked with 0.3 % (v/v) H2O2 and endogen biotin was blocked 
with avidin-biotin (Vector Laboratories, SP-2001, Burlingame, CA, USA). Rabbit anti-NCC 
antibody (1:2000;, Millipore, Darmstadt, Germany) was incubated ON in 1 % (w/v) BSA in 
PBS and labeled with goat anti-rabbit-biotin-SP secondary antibody and coupled to 
horseradish peroxidase (HRP). NCC was visualized with 3,3’-Diaminobenzidine (DAB). To 
visualize the LacZ insert in the Slc41a3-/- animals, tissue was rinsed in PBS containing 2 
mmol/L MgCl2, thereafter the slides were incubated overnight with staining solution 
containing 10 mg/mL 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal, in di-
methylformamide), 35 mmol/L potassium ferrocyanide, 35 mmol/L potassium ferricyanide, 
2 mmol/L MgCl2, 0.01 % (w/v) deoxycholate and 0.02 % (v/v) NP40 in PBS. After incubation 
slides were rinsed in PBS containing 2 mmol/L MgCl2, and mounted for analysis.  
Alizarin Red Staining
Slides were pretreated for alizarin red staining with 50 % ethanol. Subsequently, cells were 
stained with alizarin red (2 % (v/v)) for 5 min. After staining, the slides were rinced with 
acetone and xylene and mounted for analysis.
Mg2+ and Ca2+ Measurements
Serum and urine total Mg2+ and Ca2+ concentrations were determined using a colorimetric 
assay kit according to the manufacturer’s protocol (Roche Diagnostics, Woerden, The 
Netherlands). Urine volume was measured to calculate 24 hrs excretion.
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Statistical Analysis
Data are expressed as mean ± SEM. Statistical comparisons were analyzed by two-way 
ANOVA with a Tukey’s multiple comparison test or by unpaired student’s t-test. P < 0.05 
was considered statistically significant.
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Abstract
Recently, mutations in the Cyclin M2 (CNNM2) gene were identified to be causative for 
severe hypomagnesemia. In kidney, CNNM2 is a basolaterally expressed protein with 
predominant expression in the distal convoluted tubule (DCT). Transcellular magnesium 
(Mg2+) reabsorption in DCT represents the final step before Mg2+ is excreted into the 
urine, thus fine-tuning its final excretion via a tightly regulated mechanism. 
 The present study aims to get insight in the structure of CNNM2 and to characterize 
its post-translational modifications. Here, membrane topology studies using intramolecular 
epitopes and immunocytochemistry showed that CNNM2 has an extracellular amino 
(N)-terminus and an intracellular carboxy (C)-terminus. This suggests that one of the 
predicted transmembrane regions might be reentrant. By homology modeling we 
demonstrated that the loss-of-function mutation as found in patients disturbs the 
potential ATP binding by the intracellular cysthationine β-synthase domains. In addition, 
the cellular processing pathway of CNNM2 was exposed in detail. In the endoplasmic 
reticulum, the signal peptidase complex cleaves off a large N-terminal signal peptide of 
about 64 amino acids. Mutagenesis screening showed that CNNM2 is glycosylated at 
residue p.Asn112 stabilizing CNNM2 on the plasma membrane. Interestingly, co-immuno-
precipitation studies evidenced that CNNM2a forms heterodimers with the smaller 
isoform CNNM2b. 
 These new findings on CNNM2 structure and processing may aid to elucidate the 
physiological role of CNNM2 in Mg2+ reabsorption in the kidney.
Keywords: CNNM2, Magnesium, Distal Convoluted Tubule, Hypomagnesemia, Kidney
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Introduction
As the second most abundant intracellular cation in humans, magnesium (Mg2+) constitutes 
an essential co-factor in vital processes such as energy metabolism, DNA transcription 
and protein synthesis. Balance between intestinal absorption and renal excretion is tightly 
regulated to keep the plasma Mg2+ concentration in its physiological range (0.7-1.1 
mmol/L) (7). Specifically, bulk Mg2+ reabsorption in kidney from the pro-urine is dependent 
on passive, paracellular transport in the proximal tubule (PT) and the thick ascending limb 
of Henle’s loop (TAL), whereas fine-tuning is achieved by active, transcellular transport in 
the distal convoluted tubule (DCT) (7). In the latter segment, tight regulation of Mg2+ 
transport will determine the final urinary Mg2+ excretion, since no Mg2+ reabsorption 
takes places beyond the DCT. The TRPM6 ion channel, expressed at the apical side of the 
DCT, constitutes the gatekeeper in active Mg2+ uptake (37), whereas a basolateral Mg2+ 
extrusion mechanism remains to be identified.
 Recently, mutations in the Cyclin M2 (CNNM2) gene were described leading to a 
dominant form of hypomagnesemia caused by renal Mg2+ wasting (32). Patients suffer from 
muscle weakness, tremor and headaches accompanied by low Mg2+ serum concentrations 
(0.3-0.5 mmol/L) (21, 32). Interestingly, no other electrolyte disturbance was detected (32). 
CNNM2, formerly known as Ancient Conserved Domain Protein 2 (ACDP2), belongs to the 
CNNM family consisting of four proteins (CNNM1-4) which share homology to cyclins, 
although no cyclin-related function has been described (40). Two predicted CNNM2 protein 
isoforms are conserved between man and mouse. Whereas the 875 amino acid CNNM2a is 
encoded by splice variant 1 (CNNM2v1, NM_017649), the 22 residues shorter isoform b is 
translated from splice variant 2 (CNNM2v2, NM_199076), which lacks exon 6. CNNM2 
expressed in Xenopus laevis oocytes and in the Mg2+-deficient Salmonella enterica strain 
MM281, has been suggested to be involved in Mg2+ transport (8, 31). However, electro-
physiological analysis using mammalian cells expressing CNNM2 showed Mg2+-sensitive 
Na+ currents instead of Mg2+ currents (32). This last finding could indicate that instead of 
transporting Mg2+ itself, CNNM2 might be involved in a Mg2+-sensing mechanism which, in 
turn, could regulate renal Mg2+ uptake. At present, no studies have been reported showing 
the structure of CNNM2, or any of the other CNNM family members. 
 The aim of this study was to elucidate the membrane topology of CNNM2 and to 
provide a molecular characterization of the intracellular processing mechanisms.
Results
Expression Profile of the CNNM Family
To examine the transcript expression levels for Cnnm1-4 in various tissues, a mouse tissue 
cDNA panel was constructed and Cnnm mRNA expressions were quantified by real-time 
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PCR analysis. Gapdh expression was used to normalize values. Cnnm3v1 and Cnnm3v2 
(containing an alternative last exon) show a ubiquitous expression pattern with highest 
expression in kidney, brain, lung, spleen and heart (Figure 1D-E). Cnnm1 expression is 
predominantly found in brain and testis (Figure 1A), whereas Cnnm4 shows highest 
expression along the gastrointestinal tract (Figure 1F). Interestingly, Cnnm2 shows a 
ubiquitous expression pattern with highest expression in kidney, lung, spleen and testis 
(Figure 1B-C). CNNM2A and CNNM2B (encoded by Cnnm2v1 and Cnnm2v2, lacking exon 6) 
share a similar pattern; only minor differences between the tissue expression levels were 
measured. 
 Since CNNM2 has been described to be causative for hypomagnesemia due to 
excessive renal Mg2+ wasting (32), its kidney localization was investigated in detail. Using 
immunohistochemistry, co-expression of CNNM2 with markers of different distal nephron 
segments was examined: The Na+-K+-Cl--cotransporter (NKCC2, TAL), the thiazide-sensi-
tive Na+-Cl--cotransporter (NCC, DCT), Calbindin-D28k (CaBP28K, CNT and cortical collecting 
duct (CCD)) and Aquaporin-2 (AQP2, collecting duct, CD). CNNM2 was expressed on the 
basolateral side of the cells (Figure 2A-D, green), opposed to the luminal expression of the 
marker proteins (Figure 2A-D, red). CNNM2 immunopositive tubules were negative for 
AQP2 staining, but did co-stain with NCC positive tubules. Only a part of the tubules 
positive for CaBP28k showed CNNM2 staining. Whereas most of NKCC2 positive tubules are 
negative for CNNM2, only a few NKCC2 positive tubules show faint CNNM2 staining. These 
results indicate that CNNM2 is predominantly expressed in DCT. mRNA expression levels 
measured by real-time PCR on GFP-sorted DCT and CNT tubules showed an equivalent 
pattern; expression of Cnnm2v1 and Cnnm2v2 was high in DCT and to a lesser extent also 
in the CNT (Figure 2E). As a control for DCT and CNT specificity of the mRNA, we examined 
the expression of the transcripts for the marker proteins TRPM6 and TRPV5 respectively 
(Figure 2E). These and previous results (32) indicate that CNNM2 is predominantly 
expressed basolaterally in DCT and also, but minorly, present in TAL and CNT (Figure 2F).
CNNM2 Has an Intracellular C-terminus Containing CBS Domains
The consensus topology prediction for the plasma membrane protein CNNM2 indicates 5 
potential transmembrane domains (TM) and an extracellular C-terminus (32), which would 
locate the cystathionine β-synthase (CBS) domains in an unprecedented, extracellular 
position. We decided to investigate the topology in detail using an intramolecular epitope 
strategy by expression of various epitope-tagged CNNM2 proteins (Figure 3A) in COS-7 
cells with subsequent immunocytochemistry. A similar approach was used successfully to 
aid in the topology determination of other plasma membrane transporters like multidrug 
resistance proteins (17) and an iron transporter (6). Immunocytochemistry of cells 
overexpressing CNNM2a proteins with HA-epitopes at positions 211 (HA211), 745 (HA745) 
or at the extreme C-terminus revealed these proteins to be targeted to the plasma 
membrane of the cells (Figure 3B, upper panels), similar to the results obtained in MDCK-C7 
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cells (32). Importantly, C-terminally HA-tagged CNNM2b showed a localization that is un-
distinguishable from that of CNNM2a, indicating that the absence of the amino acids 
translated from exon 6 does not influence sorting to the plasma membrane.
 To determine whether the epitopes are located on the inside or the outside of the 
cells, formaldehyde fixed cells, both intact and permeabilized, were immunostained for 
the HA-epitope. The HA-tag at position 211 could be detected on intact cells (Figure 3B, 
lower panels), indicating extracellular localization. On the contrary, detection of HA745 or 
Figure 1   Tissue Expression Pattern of the CNNM Isoform-encoding Transcripts
A-F, The mRNA expression levels of Cnnm1 (A), Cnnm2 splice variant 1 (B), Cnnm2 splice variant 2 
(C), Cnnm3 splice variant 1 (D), Cnnm3 splice variant 2 (E) and Cnnm4 (F) in a panel of mouse tissues 
were measured by quantitative RT-PCR and normalized for Gapdh expression. Data represent the mean 
of 3 individual experiments ± SEM and are expressed as the percentage of the total tissue expression. 
A B
D
FE
  0
30
Ile
um
40
Kid
ne
y
Du
od
en
um
Je
jun
um
Co
lon
Ce
cu
m
Bra
in
Lu
ng
Liv
er
Sp
lee
n
Te
sti
s
Mu
sc
le
He
artC
nn
m
3v
2 
 m
RN
A 
Ex
pr
es
si
on
  
(%
 o
f T
ot
al
)
10
20
10
  0
20
Ile
um
30
Kid
ne
y
Du
od
en
um
Je
jun
um
Co
lon
Ce
cu
m
Bra
in
Lu
ng
Liv
er
Sp
lee
n
Te
sti
s
Mu
sc
le
He
artC
nn
m
2v
1 
 m
RN
A 
Ex
pr
es
si
on
 
(%
 o
f T
ot
al
) 
10
  0
20
Ile
um
30
Kid
ne
y
Du
od
en
um
Je
jun
um
Co
lon
Ce
cu
m
Bra
in
Lu
ng
Liv
er
Sp
lee
n
Te
sti
s
Mu
sc
le
He
artC
nn
m
3v
1 
 m
RN
A 
Ex
pr
es
si
on
  
(%
 o
f T
ot
al
)
10
  0
20
Ile
um
30
Kid
ne
y
Du
od
en
um
Je
jun
um
Co
lon
Ce
cu
m
Bra
in
Lu
ng
Liv
er
Sp
lee
n
Te
sti
s
Mu
sc
le
He
art
Cn
nm
4 
 m
RN
A 
Ex
pr
es
si
on
 
(%
 o
f T
ot
al
) 
C
10
  0
20
Ile
um
30
Kid
ne
y
Du
od
en
um
Je
jun
um
Co
lon
Ce
cu
m
Bra
in
Lu
ng
Liv
er
Sp
lee
n
Te
sti
s
Mu
sc
le
He
art
Cn
nm
2v
2 
 m
RN
A 
Ex
pr
es
si
on
 
(%
 o
f T
ot
al
) 
30
20
10
  0
40
Ile
um
50
60
Du
od
en
um
Je
jun
um
Co
lon
Bra
in
Lu
ng
Liv
er
Sp
lee
n
Te
sti
s
Mu
sc
le
Cn
nm
1 
 m
RN
A 
Ex
pr
es
si
on
 
(%
 o
f T
ot
al
) 
He
art
Kid
ne
y
Ce
cu
m
140 | Chapter 6
Figure 2   Kidney Expression Pattern of CNNM2 Shows Highest Expression in DCT
A-D, Double immunofluorescence staining of mouse kidney cortex sections for CNNM2 (in green) 
and NKCC2 (A, red), NCC (B, red), Calbindin-D28k (C, red) or Aquaporin-2 (D, red). Bars represent 
20 µm. E, The mRNA expression levels of Cnnm2v1 (black bars), Cnnm2v2 (white bars), Trpm6 (red 
bars) and Trpv5 (green bars) in COPAS selected mouse DCT, CNT and control (none-selected)  kidney 
 tubules were measured by quantitative RT-PCR and normalized for Gapdh expression. Data represent 
the mean of 3 individual experiments ±SEM and are expressed as fold difference compared to the 
expression in none-selected tubules. F, A schematic overview of marker protein kidney expression. 
PT: Proximal Tubule, DTL: descending thin limb of Henle’s loop, ATL: ascending thin limb of Henle’s loop, 
TAL: Thick Ascending Limb, DCT: Distal Convoluted Tubule, CNT: Connecting Tubule, CD: Collecting Duct.
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Figure 3   CNNM2 Topology Determination
A, Linear representation of the CNNM2 protein with domain structures based on Uniprot Q3TWN3. 
Predicted TM domains are indicated in dark blue, CBS domains in purple and the exon 6 coding region, 
which is absent in CNNM2b, in gray. The position of the epitope tags and the epitope recognized by the 
Abcam 111351 antibody are indicated by narrow and wide arrow heads, respectively. B-E, Immuno-
fluorescence images of transiently transfected COS-7 cells. Bars represent 50 µm in each panel. Red signal 
represents immunodetected HA-epitopes. Nuclei stained with DAPI are shown in blue. B, Permeabilized 
(upper panels) and intact (lower panels) cells expressing, from left to right: CNNM2a with an HA-tag at 
positions 211, 745 or at the C-terminus and CNNM2b with a C-terminal HA-tag. C, Cells, expressing CNNM2a 
with an HA-tag at position 211, were additionally stained with Ab111351 (in green) under permeabilized 
and non-permeabilized conditions (upper and lower panels, respectively). D, Permeabilized (top) 
and intact (bottom) cells transfected with C-terminally HA-tagged CNNM4. E, Cells transfected with 
C-terminally FLAG-tagged CNNM2a with an intramolecular HA-epitope at position 25. Immuno-
detection of permeabilized cells for the HA-tag (left), FLAG-tag (middle, in green) and the merged 
image on the right are indicated.
A
B
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the epitope at the C-terminus required cell permeabilization, suggesting that these latter 
two are located intracellularly. Similar results were obtained when living cells were 
incubated with anti-HA antibodies prior to fixation (Figure 4).
 As an alternative approach to confirm that the C-terminus is located intracellularly, 
cells that expressed HA211 were immunostained with Abcam antibody 111351, raised 
against amino acids 590-640, located just after the pair of CBS domains. Also here, the 
epitope could only be detected after permeabilization (Figure 3C), indicative for an 
intracellular position of the C-terminus that importantly includes the two CBS domains.
 To investigate whether the intracellular localization of the C-terminus is shared with 
other members of the CNNM family, the same permeabilization assay was performed on 
cells transfected with C-terminally HA-tagged CNNM4 (Figure 3D). Again, the plasma 
membrane staining was only observed after permeabilization, indicating that also for 
CNNM4, the C-terminus resides inside the cell. In conclusion, the CNNM2 protein has a 
membrane topology with its C-terminus inside of the cell.
The CNNM2 N-terminus Contains a Large Signal Peptide and  
a Glycosylation Site
We observed that the HA-epitope at the extreme N-terminus or at position 25 of CNNM2a 
was not detected at the plasma membrane, but rather in distinct perinuclear structures 
(Figure 5), which suggested that the N-terminus might contain a signal peptide and, 
therefore, ultimately results in cleavage of the HA-epitope. To exclude incorrect processing 
of the recombinant protein, a construct was expressed with the HA-epitope at position 25 
of CNNM2a and a FLAG-epitope at the C-terminus. We observed that the FLAG-epitope 
was correctly targeted at the plasma membrane, but the HA-epitope was retained in 
perinuclear structures (Figure 3E). Colocalization studies with an antibody against Calnexin 
(Figure 5B) showed that these perinuclear structures are part of the endoplasmic reticulum 
(ER), which is in line with the presence of a signal peptide.
 Signal peptide prediction software (SignalP, (3)) predicts a long N-terminal signal 
peptide of 64 amino acids. Examination of the N-terminally HA-tagged CNNM2 construct 
by immunoblotting confirmed that the CNNM2 N-terminus is cleaved (Figure 6A, upper 
panel), since the HA-tag was undetectable. Mutation of the predicted cleavage region 
Figure 3   Continued
A
B
C
E
D
Molecular Characterization of CNNM2 Structure | 143
(p.Gly62/p.Cys63/p.Thr64/p.Ala65) to hydrophobic residues (p.Leu62/p.Leu63/p.Leu64/ 
p.Val65) marred this cleavage event, evidenced by detection of a HA-positive band in the 
mutant (Figure 6A, upper panel, right). To identify the exact cleavage site, constructs were 
generated in which the p.Cys63/p.Ala65 and the p.Gly62/p.Thr64 positions were mutated 
to hydrophobic amino acids. However, none of these two mutations were able to impair 
the cleavage of CNNM2 (Figure 6A, upper panel). 
 To confirm that the signal peptidase complex (SPC, a protein complex expressed on 
the ER-membrane known to be involved in signal peptide cleavage) facilitates cleavage, 
an in vitro protein translation assay in presence of SPC inhibitor AAPV-CMK was performed. 
SPC inhibition by AAPV-CMK prevented signal peptide cleavage, as shown by a higher 
molecular weight on gel (MW, Figure 6B). Together, we conclude that SPC is responsible 
for CNNM2 signal peptide cleavage.
 In eukaryotic cells, trafficking of membrane proteins to the cell surface is often 
regulated by glycosylation of asparagine residues present in extracellular domains. To 
determine the CNNM2 glycosylation profile, four potential candidate asparagine residues 
were mutated to alanine; namely p.Asn112, p.Asn327, p.Asn527 and p.Asn591 (based on 
prediction software NetNGlyc 1.0, http://www.cbs.dtu.dk/services/NetNGlyc/). Subsequently, 
the presence of N-linked glycans in the mutants was discerned by immunoblotting the 
proteins after treatment with PNGase F, an enzyme causing N-glycan cleavage. The glyco - 
Figure 4   Epitope Labelling of Living Cells Confirms Results on Fixed Cells
COS7 cells transfected with CNNM2a expression constructs with a HA-tag at positions 211 (HA211), 
745 (HA745) or at the C-terminus (C-HA) showed correct targeting to the plasma membrane as 
demonstrated by immunostaining (in red) after formaldehyde fixation and permeabilization (upper 
panels). Immunostaining of living COS7 cells for the HA-epitope before fixation resulted in detection 
of HA211 only (lower panels). Nuclei stained with DAPI are shown in blue, size bar represents 50 µm 
in each panel.
intact (labeling of living cells)
permeabilized
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sylated wild type CNNM2 runs at approximately 105 kDa, but PNGase F treatment reduced 
its MW to ±96 kDa (Figure 7A). Of all the candidates, only residue p.Asn112 was identified 
as a glycosylation target in CNNM2, since the p.Asn112A mutation resulted in a MW of 96 kDa 
(Figure 7A). PNGase F treatment did not cause a further reduction of the MW indicating 
that no N-glycan is present in this mutant. To determine the effect of the N-glycan at 
position 112 on membrane expression of the CNNM2 protein, cell surface biotinylation 
studies of the p.Asn112Ala mutant were performed (Figure 7B, left panel). A reduction of 
Figure 5   The CNNM2 N-terminus is Retained in the Endoplasmic Reticulum
A, COS7 cells transfected with CNNM2a expression constructs with an HA-tag at the N-terminus 
(N-HA) or at position 25 without (HA25) or with (HA25-FLAG) an additional C-terminal FLAG-tag 
were permeabilized and co-immunostained with anti-HA (in red) and anti-Calnexin (CNX, in green). 
Merged images on the right show colocalization (in yellow) of the HA-tag with perinuclear parts 
of the ER. B, The identical experiment as shown in the lower panel of (A), except for the omission of the 
primary antibody anti-CNX, excluding cross-staining of the anti-HA antibody. Nuclei stained with 
DAPI are shown in blue. Size bars represent 25 µm in each panel.
A
B
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90 % in plasma membrane expression of the CNNM2-N112A mutant was observed when 
compared to the wild type CNNM2 protein (Figure 7B, right panel), suggesting that 
p.Asn112 glycosylation is necessary for CNNM2 membrane stability. Taken together, 
the CNNM2 extracellular N-terminus provides important sites for post-translational 
modifications necessary for proper plasma membrane expression. 
The C-terminal CBS Domains are Disrupted by the p.Thr568Ile Mutation 
One of the mutations recently described to be causative for hypomagnesemia is located 
in the CBS domains within the C-terminus (32). Therefore, emphasis was placed on 
determining the structure of the intracellular CBS domains (Figure 3A) that have been 
associated amongst others, with ATP binding (2). Here, we provide a homology model of 
the CNNM2 CBS domains based on the Bordetella Parapertussis CorC Mg2+/Co2+ efflux 
protein (Figure 8A). Analysis of this model showed conservation of the potential ATP 
binding site in the CBS dimer of CNNM2 (Figure 8A, ATP in yellow). Interestingly, the 
p.Thr568Ile mutation, identified in a Czech family to be causative for hypomagnesemia (32), 
is lining the ATP binding site in the CBS domain (Figure 8B). In our model, mutation of the 
threonine into the bigger isoleucine residue causes steric bumps with the ATP molecule. 
Besides that, T568 also forms a hydrogen bond that stabilizes the position of the p.Glu570 
and p.Asp571 residues (Figure 8B, hydrogen bonds in yellow). These two residues form 
Figure 6   The Signal Peptidase Complex Cleaves the CNNM2 Signal Peptide
A, Cleavage analysis of the CNNM2 protein by immunoblotting of double tagged CNNM2  transfected 
HEK293 cells against the N-terminal HA-tag (upper blot). As a control for CNNM2 expression, the 
CNNM2 C-terminus was targeted by immunoblotting against the VSV-tag (lower blot). Blot shown is 
representative for 5 independent experiments. B, Coupled in vitro transcription/translation protein 
synthesis of the CNNM2-HA protein in the presence (+) and absence (-) of SPC-inhibitor MeoSuc- 
Ala-Ala-Pro-Val-Chloromethylketone (AAPV-CMK). Gel shown is representative for 3 independent 
experiments.
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important hydrogen bonds and ionic interactions to the ATP molecule and residues lining 
the ATP-binding pocket, respectively. According to the model, the patient’s p.Thr568Ile 
mutation will also affect the position of the p.Glu570 and p.Asp571 residues and could, 
therefore, severely affect ATP binding. In conclusion, this model might explain why the 
patient’s p.Thr568Ile mutation is causative for non-functional CNNM2.
CNNM2a and CNNM2b Form Multimers
In GenBank, two splice variants exist that are conserved between man and mouse, 
the first being full length, the second lacking exon 6. Interestingly, splice variant 2 
was consistently found in conjunction with that of splice variant 1 in all tissues examined, 
including kidney (Figure 1). Further examination of potential interactions between CNNM2a 
Figure 7   Glycosylation on Residue N112 Regulates CNNM2 Membrane Trafficking
A, Immunoblot of C-terminally HA-tagged wild type CNNM2 (WT) and CNNM2 glycosylation  mutants 
treated with (+) or without (-) PNGase F. B, Cell surface biotinylation of HEK293 cells expressing 
 HA-tagged wild type CNNM2 or glycosylation mutant p.Asn112Ala. A representative immunoblot 
showing that glycosylation at position p.Asn112 is necessary for CNNM2 membrane expression 
(upper blot), and a CNNM2 expression control (lower blot). On the right, a quantification by blot 
intensities is shown of cell surface expression of CNNM2-WT (n=6) and CNNM2-p.Asn112Ala (n=6) 
corrected for total protein expression. Error bars represent SEM; *P < 0.05 versus CNNM2-WT.
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Figure 8   The CBS Domains are Potentially Involved in ATP Binding
A, Homology model of the CBS domain pair of CNNM2, modeled using the structure of the CorC 
Mg2+ and Co2+ efflux protein from Bordetella Parapertussis (PDB file 3jtf). The two CBS domain 
 monomers are shown in dark and light blue with the p.Thr568 highlighted in red. ATP is shown 
in yellow. B, Detail of the ATP binding region in the CBS domain. ATP is shown in light blue in this 
model. The wild type p.Thr568 residue is highlighted in green, the extra side-chain of the mutant 
p.Ile568 is shown in red. Hydrogen bonds with the surrounding p.Glu570 and p.Asp571 residues are 
demonstrated in yellow.
Figure 9   CNNM2a and CNNM2b Form Homo- and Heterotypic Interactions
A, Western blot analysis of CNNM2 protein showing CNNM2a and CNNM2b monomers at approximately 
100 kDa and potential CNNM2 dimers at approximately 200 kDa. B, Co-immunoprecipitation studies 
of CNNM proteins in COS-7 cells. C-terminal FLAG-tagged CNNM2a or CNNM2b were co-expressed 
with C-terminal HA-tagged CNNM2a, CNNM2b or CNNM4 as indicated in the two top rows. The upper 
blot shows the detection of the FLAG-tagged proteins in anti-HA precipitated cell lysates. The lower 
two blots show input controls (10 %) of HA-tagged and FLAG-tagged proteins respectively. The results 
shown are representative of three individual experiments.
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and CNNM2b was performed by studying the dimerization of CNNM2 isoforms. Interestingly, 
besides the CNNM2 monomer (with an expected MW of 105 kDa) (40), additional 
complexes were visualized in the immunoblot at approximately 200 kDa (Figure 9A). This 
molecular weight matches the mass of a hypothetical CNNM2 dimer. To confirm CNNM2 
oligomerization events, co-immunoprecipitation assays of CNNM2 isoforms were 
performed. CNNM2a-HA and CNNM2b-HA were each able to co-immunoprecipitate both 
C-terminally FLAG-tagged CNNM2a and CNNM2b. CNNM4-HA only weakly co-immuno-
precipitated, even though it was highly expressed, indicating the specificity of these 
interactions (Figure 9B). These data show that CNNM2a and CNNM2b are able to form 
specific homo- and hetero multimeric complexes. 
Discussion
Mutations in CNNM2 have, recently, been described to be causative for a severe form of 
hypomagnesemia (32). Initially described as nuclear proteins involved in cell cycle 
regulation (40), the family of CNNM proteins has now been shown to reside at the plasma 
membrane (8, 32). Although their physiological role is still poorly understood, all members 
are likely involved in electrolyte homeostasis. CNNM1 has been identified as a cytosolic 
copper chaperone, CNNM2 was shown to mediate Mg2+-sensitive Na+ currents in HEK293 
cells and CNNM2, CNNM3 and CNNM4 have been linked with serum Mg2+ levels (1, 23, 32). 
Furthermore, CNNM2 has been associated with coronary artery disease and hypertension 
(24, 30, 33). Finally, mutations in CNNM4 were shown to be causative for recessive cone-rod 
dystrophy with amelogenesis imperfecta (28, 29).  In the present study, we aimed to 
elucidate the CNNM2 protein topology and characterize its post-translational modifications. 
 Although Gómez García and colleagues have been working on structural elucidation 
of the CBS domains of CNNM4 (9), complete structural information for any of the CNNM 
proteins is presently unknown. Using immunocytochemical methods we examined the 
membrane topology of CNNM2. Based on our results showing an extracellular N-terminus 
and an intracellular C-terminus (Figure 3), we propose a structure comparable to that of 
the glutamate receptor (GluR) ion channels (34), containing 3 full membrane-spanning 
regions and an additional reentrant loop. In silico analysis of the CNNM2 protein sequence 
showed that of the 4 hydrophobic regions, the second one is the shortest and the least 
hydrophobic, indicating that the second hydrophobic region might not be completely 
membrane-spanning, but instead forms a reentrant loop (Figure 10).
 Similar to the GluR family, CNNM2 contains an N-terminal signal peptide that is 
cleaved in the ER. Here, the SPC seems to be the protease complex responsible for CNNM2 
cleavage (Figure 6B). The human SPC is a complex of five proteins expressed on the ER 
membrane and recruited post-translationally to the signal recognition particle (SRP) to 
perform signal peptide cleavage (27). Our results do not identify the exact position of the 
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cleavage site. Signal peptide recognition is known to be dependent on the residues at 
positions -1 and -3 of the actual cleavage site (25). Nevertheless, conversion of the -1 and -3 
position of the predicted site (p.Gly62/p.Thr64) to hydrophobic residues did not prevent 
cleavage. Likewise, the cleavage was also not impaired when the alternative cleavage site 
(p.Cys63/p.Ala65) was mutated. Only mutation of both sites prevented CNNM2 cleavage, 
suggesting that the SPC can cleave CNNM2 at the preferential site between p.Thr64 and 
p.Ala65, but also at an alternate site between p.Ala65 and p.Ala66. Thus, CNNM2 contains 
a remarkable lengthy signal peptide of approximately 64 amino acids. Long signal 
peptides have been associated with multiple functions, but might serve as a mechanism 
to achieve proper membrane insertion of the protein (12). This also suggests that the first 
predicted transmembrane domain (Figure 3A), actually represents the hydrophobic core 
of the signal peptide that, after cleavage, will remain at the ER membrane (Figure 10).  After 
cleavage in the ER, CNNM2 is further processed by glycosylation in the Golgi apparatus. 
N-glycosylation is known to facilitate plasma membrane trafficking for several membrane 
proteins (35). Here, p.Asn112 was identified as the residue that is glycosylated and 
implicated in CNNM2 membrane stability (Figure 7A-B). This can be interpreted as an 
additional argument showing that the N-terminus is located on the extracellular side of 
Figure 10   Schematical Model of CNNM2 Structure
Model representing the structure of the CNNM2 protein at the plasma membrane and showing 
the signal peptide cleavage in the endoplasmic reticulum. Crosses represent the locations of 
the mutations. The glycosylation site at position p.Asn112 is shown in the extracellular N-terminus. 
The CBS domains are represented in purple binding ATP in red. 
ER: endoplasmic reticulum SP: signal peptide TM: transmembrane helix CBS: cysthationine β-synthase domain.
TM2 TM3
CBS1
CBS2
CBS1TM1
TM2
TM3
SP
CBS2
ER membrane Plasma membrane
Extracellular
Intracellular
N112
T568I
I40SfsX15
150 | Chapter 6
the membrane. Interestingly, our immunoblotting data showed a shift of the MW of the 
CNNM2 protein when the alternative residue N327 was mutated. However, PNGase F 
treatment still lowers the MW of the p.Asn327Ala mutant, indicating that the protein is not 
deglycosylated (Figure 7A). Since p.Asn327 is predicted to be located in the second TM 
domain, we suspect that mutation of this residue instigates an altered protein folding that 
runs different on gel, explaining the observed shift.
 Once at the plasma membrane, the functional CNNM2 unit likely represents a multimer. 
Interestingly, we showed that both CNNM2a and CNNM2b can form homomultimers 
as well as heteromultimers (Figure 9B). This interaction is specific, as evidenced by the 
fact that CNNM2a and CNNM2b hardly dimerize with CNNM4, which shares the highest 
sequence homology with CNNM2 (96.7 % similarity and 81.4 % identity at the protein 
level) (40). 
 In magnesium research, CNNM2 function is heavily debated. CNNM2 was first reported 
as a Mg2+ transporter (8, 31), but recent findings questioned the ability of CNNM2 to 
transport Mg2+ and proposed a Mg2+-sensing function (32). We, therefore, examined 
whether our topological findings could further elucidate the function of CNNM2. We 
reasoned that, although CNNM2 might contain a re-entrant region, it is unlikely that this 
region forms a pore for Mg2+ transport. The re-entrant loop does not include negatively 
charged residues that could provide Mg2+ specificity. Furthermore, the protein topology 
of only 3 transmembrane segments would be small in comparison with known eukaryotic 
Mg2+ transporters such as TRPM6/7 (tetramers of 6 TM proteins) and SLC41A1 (10/11 TM 
domains) (37, 39). Thus, our topological findings strengthen the previously reported patch 
clamp data (32), suggesting that CNNM2 might be a Mg2+ sensor indirectly regulating 
Mg2+ transport. 
 To further substantiate this hypothesis, we focused on the CBS domains during 
analysis of the CNNM2 structure. CBS domains are found in 100-200 mammalian proteins 
and play a role in a variety of functions such as adenosine phosphate binding and ionic 
strength sensing (4, 15). The CBS domains in CNNM2 are highly homologous to those 
found in the Bordetella Parapertussis Co2+/Mg2+ efflux protein CorC of which the structure 
has been crystallized recently (PDB 3jtf). As shown by homology modelling based on the 
CorC structure, the CBS domains in the CNNM2 C-terminus contain a potential ATP-binding 
domain (Figure 4B). ATP binding in CBS domains has been reported to activate or further 
inhibit protein function in eukaryotic CBS domain-containing proteins (2). 
 Our model does not allow discrimination between ATP and Mg-ATP binding, but we 
expect that the CBS domains of CNNM2 are also able to bind Mg-ATP. This theory is 
strengthened by the recently elucidated crystal structure of the bacterial Mg2+ transporter 
MgtE in which its CBS domains are involved in Mg2+ binding (PDB 2yvy, (11, 16)). As the 
majority of intracellular Mg2+ is ATP bound, the intracellular Mg-ATP concentrations are 
representative for the cellular Mg2+ content. The suggestion that CNNM2 binds Mg-ATP 
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implies that rather than ATP being an energy source for active transport, the Mg-ATP 
binding would provide a Mg2+-sensing mechanism. Given that the CNNM2 p.Thr568Ile 
loss-of-function mutation found in patients (32) is located at the region predicted to form 
the ATP binding pocket (Figure 8B), the (Mg-)ATP binding is likely of major importance for 
CNNM2 function. Since the p.Thr568Ile mutation is specifically disturbing the ATP binding 
pocket, Mg2+ alone will possibly not be able to activate CNNM2. 
 In conclusion, we propose a protein topology of CNNM2 consisting of three 
membrane- spanning domains and a re-entrant loop (Figure 8). CNNM2 is extensively 
post-translationally modified by signal peptide cleavage and glycosylation, before being 
functional in multimers at the plasma membrane. Rather than transporting Mg2+ itself, 
we hypothesize CNNM2 would sense intracellular Mg2+ concentrations and regulate 
other Mg2+ transporters. Future research should focus on the identification of CNNM2 
protein partners to further elucidate its role in Mg2+ homeostasis.
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Methods
Expression Profiling
Three C57BL/6 mice were sacrificed; kidney, duodenum, ileum, jejunum, colon, cecum, 
brain, lung, liver, spleen, testis, muscle and heart tissues were collected. The transgenic 
parvalbumin-EGFP mice were a gift kind from Dr. Monyer (University of Heidelberg, 
Germany, (22)) and TRPV5-GFP mice were kindly provided by Dr. Praetorius from the 
University of Aarhus (14). They were used to isolate the DCT and CNT respectively. Mice 
were anesthetized by a cocktail injection of ketamine (0.1 mg/g body weight) and xylazine 
(0.01 mg/g body weight) and perfused with 20 mL PBS (in mmol/L: 137 NaCl, 2.7 KCl, 10 
Na2HPO4, 1.76 KH2PO4) through the heart. The kidneys were removed, minced and 
digested in collagenase (1 mg/mL collagenase A Worthington, Lakewood, NJ, USA, 1 mg/
mL hyaluronidase) in KREBS buffer (in mmol/L: 145 NaCl, 5 KCl, 10 HEPES/NaOH pH:7.4, 1 
NaH2PO4, 2.5 CaCl2, 1.8 MgSO4, 5 glucose) at 37 °C for 18 min. The collagenase-digested 
tubules sized between 40 μm and 100 μm were sorted based on GFP fluorescence by 
COPAS (Complex Object Parametric Analysis and Sorting, Union Biometrica, USA). 
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 Total RNA was isolated using TRIzol Total RNA Isolation Agent (Invitrogen). Obtained 
RNA was DNase (Promega) treated to remove genomic DNA. Subsequently, reverse 
transcription of the RNA by M-MLV reverse transcriptase (Invitrogen) was performed 1 hr at 
37 °C. Gene expression levels were determined by quantitative real-time PCR on a BioRad 
Analyzer and normalized for Gapdh expression levels. Primer sequences are provided in 
Table 1.
Immunohistochemistry
Immunohistochemistry was performed as previously described (13). In short, costaining 
for CNNM2 with Na+-K+-Cl- cotransporter (NKCC2), thiazide-sensitive Na+-Cl- cotransporter 
(NCC), Calbindin-D28k and Aquaporin-2 (AQP2), was performed on 7 μm sections of fixed 
frozen mouse kidney samples. The sections were incubated for 16 hrs at 4 °C with the 
following primary antibodies: guinea pig anti-CNNM2 (1:100, (32)), rabbit anti-NKCC2 (1:100, 
(20)), rabbit anti-NCC (1:100, (26)), rabbit anti-Calbindin-D28k (1:500, (5)) and rabbit anti-AQP2 
(1:300, kindly provided by Dr. Deen, Nijmegen, the Netherlands). For detection, kidney 
sections were incubated with Alexa-conjugated secondary antibodies. Images were taken 
with an AxioCam camera (Zeiss) and AxioVision software (Zeiss).
DNA Constructs
Mouse Cnnm2 was cloned into the pCINeo HA IRES GFP vector as described previously 
(32). To obtain a C-terminal VSV-epitope, an XbaI restriction site was introduced before 
the stop codon using the QuikChange site-directed mutagenesis kit (Agilent, Amstelveen, 
the Netherlands) according to the manufacturer’s protocol. Subsequently, oligos 
(F: 5’- GAATCGCTTGGGGAAGTAGCTCGAGAATTCCGCCCC-3’ R: 5’- GGGGCGGAATTCTCGAG-
CTACTTCCCCAAGCGATTC-3’) encoding the VSV-epitope were hybridized and ligated into 
the pCINEO HA-CNNM2 IRES GFP vector using the XbaI and XhoI restriction sites. CNNM2 
Table 1   Primer Sequences Used for RT-PCR Analysis
Forward Reverse
Cnnm1 5’-ACAGGTCACAGCAAGTCTCG-3’ 5’-CCCATGTTTTCCTCAGAGTC-3’
Cnnm2v1 5’-GTCTCGCACCTTTGTTGTCA-3’ 5’-GTCGCTCCGACTGAGAGAAT-3’
Cnnm2v2 5’-CTCACAGCCTCTCCAGGG-3’ 5’-AGGAAGAGCTGAGCTGGTTG-3’
Cnnm3v1 5’-CCTTAATGCACTCCTGGCTAC-3’ 5’-CTGGGTCTGCTGTTGGTG-3’
Cnnm3v2 5’-CCTTAATGCACTCCTGGCTAC-3’ 5’-AAAGAGGGAAAGGTGGACTG-3’
Cnnm4 5’-TCTGGGCCAGTATGTCTCTG-3’ 5’-CACAGCCATCGAAGGTAGG-3’
Trpm6 5’-GTCTCGCACCTTTGTTGTCA-3’ 5’-GTCGCTCCGACTGAGAGAAT-3’
Trpv5 5’-CCATGACTTCCGCTAGTTGAG-3’ 5’-TGGATGTCACGTGTCCAGTT-3’
Gapdh 5’-TAACATCAAATGGGGTGAGG-3’ 5’-GGTTCACACCCATCACAAAC-3’
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mutations were inserted in the construct using the QuikChange site-directed mutagenesis 
kit according to the manufacturer’s protocol. Human CNNM4 full-length cDNA clone 
(GenBank accession BC063295) was amplified using Phusion polymerase (Finnzymes, 
Vantaa, Finland) and primers (Forward: 5’-CGGCTAGCGCCACCATGGCGCCGGTGG-3’, Reverse: 
5’-CGACCGGTCTATGCGTAGTCTGGCACGTCGTATGGGTAGATGGCATTCTCGTGGGAG-3’) to introduce 
an in frame HA-tag before the stop codon and AgeI and NheI restriction sites. The 
amplicons were cloned into the pCINeo IRES GFP expression vector using the AgeI and 
NheI restriction sites. All constructs were verified by sequence analysis.
 Mouse Cnnm2 was cloned into pcDNA3 (Invitrogen) as described previously (32). To 
obtain splice variant 2 with a 66 nucleotide deletion corresponding to exon 6, site-directed 
mutagenesis (QuikChange, Agilent) was used, according to the two stage PCR mutagenesis 
protocol described by Wang and Malcolm (41). The same protocol was used to delete the 
C-terminal tag and to insert internal HA-tags with an additional serine residue (NH2-YPYD-
VPDYAS-COOH) (18) after residues p.Thr24, p.Gly210 or p.Pro744 or to replace the C-terminal 
HA-tag with a FLAG sequence. Mutagenesis primer sequences are available upon request. 
To obtain an N-terminal HA-tagged expression clone, the ORF in pFLCI-mCnnm2WT (32) 
was amplified using Expand polymerase (Roche) using forward primer 5’- ATGGGGTAC-
CATGGCTTACCCATATGATGTTCCAGATTACGCTATTGGCTGTGGCGCTTGTG-3’ containing an 
in frame HA-tag after the Kozak sequence and reverse primer 5’- ATCTTCTAGAGGTCAGAC-
CAAGTCCAGGAG-3’ and subsequently cloned in pcDNA3 as described previously (10). The 
complete ORFs of all expression constructs were sequence verified.
Cell Culture and Transfection
HEK293 cells were grown at 37 °C in DMEM (Bio Whittaker Europe, Vervier, Belgium) 
supplemented with 10 % (v/v) FCS (PAA, Linz, Austria), non-essential amino acids and 2 
mmol/L L-glutamine in a humidified 5 % (v/v) CO2 atmosphere. Few hours before 
transfection with Lipofectamine 2000 (Invitrogen), cells were seeded in 12-well plates and 
subsequently transiently transfected with 0.5 μg pCINeo-IRES-GFP constructs encoding 
HA-tagged wild type or mutated CNNM2 proteins at a 1:2 DNA to lipofectamine ratio. 
 COS-7 cells (ATCC CRL-1651) were grown in DMEM supplemented with 10 % FBS, 100 U/mL 
penicillin and 100 µg/mL streptomycin (Biochrom, Berlin) in a humidified environment of 
5 % (v/v) CO2 at 37 °C.
Immunocytochemistry
COS-7 cells were seeded on glass cover slips and transfected using Lipofectamine 2000 
according to the manufacturer’s protocol with constructs expressing epitope-tagged 
CNNM2 or CNNM4. After 2 days of growth in medium supplemented with 20 mmol/L 
MgCl2, the cells were rinsed with PBS and fixed for 10 min with 4 % (w/v) methanol-free 
formaldehyde solution (Thermo Scientific) in PBS. In a control experiment (Figure 4, 
lower panels), living cells were incubated with primary antibody rat anti-HA (Roche, 
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high affinity 3F10, 1:250) for 60 min at 4 °C before formaldehyde fixation. After rinses in 
PBS, some of the cells were incubated for 10 min with 0.2 % (v/v) Triton X-100 in PBS for 
permeabilization. After PBS rinses, the cells were incubated with blocking buffer (5 % (v/v) 
donkey serum (Sigma) in PBS) for 1 hr and immuno-labeled with the primary antibodies 
rat anti-HA (1:250), mouse anti-FLAG M2 (Sigma, 1:250), rabbit anti-Calnexin (C5C9, Cell 
Signaling Technology, 1:50) or rabbit anti-CNNM2 (Abcam, Ab111351, 1:50) in blocking 
buffer for 90 min. After rinses in PBS, cells were incubated with Alexa Fluor 488 conjugated 
donkey anti-rabbit or anti-mouse IgG or Alexa Fluor 594 conjugated donkey anti-rat IgG 
secondary antibodies (Invitrogen, 1:500) and DAPI (2 µg/mL) for 45 min. After PBS and 
ethanol rinses, the cells were mounted on slides using ProLong Gold antifade reagent 
(Invitrogen). Fluorescence microscopy was performed with a Leica DMIRE2 inverted 
microscope, and images taken with Openlab software. 
Homology Modeling
A homology model was built using the modeling script in the WHATIF & YASARA Twinset 
with standard parameters (19, 38). We used the structure of a cysthationine B-synthase 
(CBS) domain pair structure of the Mg2+ and Co2+ efflux protein CorC from Bordetella 
Parapertussis (PDB file 3jtf) as a template for modeling.
Cell Surface Biotinylation, PNGase Treatment and Immunoblotting
Biotinylation experiments were performed as previously described (36). In short, HEK293 
cells were transfected for 48 hrs and cell surfaces were biotinylated at 4 °C for 1 hr by 
adding sulfo-NHS-LC-LC-biotin. Subsequently protein lysates were incubated overnight 
with Neutravidin-agarose beads (Pierce).
 Protein lysates were denatured in Laemmli containing 100 mmol/L DTT for 30 min at 
37 °C and subsequently subjected to SDS-PAGE. Then, immunoblots were incubated with 
mouse anti-HA (Cell Signaling Technology, Danvers, MA, USA) primary antibodies and 
peroxidase conjugated sheep anti-mouse secondary antibodies (Sigma). PNGase F (New 
England Biolabs) was added to the protein lysates in Laemmli-DTT buffer and incubated 
at 37 °C for 1 hr before loading the protein samples on gel.
 
Co-Immunoprecipitation
COS-7 cells were cultured and transfected as described above with expression vectors for 
HA and FLAG-tagged wild type CNNM2 or CNNM4 isoforms. 48 hrs after transfection, cells 
were scraped from dishes in ice-cold 50 mmol/L Tris/HCl pH 8.0, followed by centrifugation 
at 5,000 g. The pellets were lysed in lysis buffer (150 mmol/L NaCl; 0,1 % (v/v) Nonidet P-40; 
50 mmol/L Tris/HCl pH 7.5 and Complete protease inhibitor cocktail (Roche)) by repeated 
passage through a 26-gauge needle. Protein concentration measurement was performed 
using a BCA assay (Pierce). The next incubation steps were all done under rotary agitation 
at 4 °C. Protein aliquots of 100 µg in lysis buffer were pre-cleared by incubation with 
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protein G-Sepharose (Sigma-Aldrich) for 2 hrs after which the pre-cleared lysate was 
incubated for 18 hrs with 2.5 µg anti-HA antibody (Roche, high affinity 3F10). The anti-
body-lysate mixture was added to 50 µL fresh protein G-Sepharose beads and incubated 
for 1 hr. The beads were collected by centrifugation at 1,000 g for 1 min at 4 °C and washed 
four times with lysis buffer. The proteins were separated from the beads by boiling for 5 
min in 1x Laemmli sample buffer and detected by immunoblotting using a mouse 
monoclonal antibody against FLAG M2 (Sigma-Aldrich, 1:1000).
In Vitro Transcriptiona and Translation
The cDNA template for in vitro transcription contained the CNNM2-HA sequence 
downstream of a T7 promoter sequence in a pT7Ts vector. The coupled in vitro 
transcription/translation reaction was incubated at 30 °C for 90 min. The reaction mixture 
contained 2 μg of cDNA template, 2 μL reaction buffer, 1 μL T7 RNA polymerase, 1 μL of 
amino acid mix without methionine, 3 μL of 35S-Met (1 μCi/μl), RNasin and 25 μL of rabbit 
reticulocyte lysate (Promega). The reaction was performed with or without signal 
peptidase inhibitor MeoSuc-Ala-Ala-Pro-Val-Chloromethylketone (AAPV-CMK, Sigma). 
The protein mixture was separated on an 8 % (w/v) SDS-PAGE gel. The gel was fixed in 
a mixture of acetic acid, methanol and H2O (20:10:70) and incubated in 20 % (w/v) 
2,5- diphenyloxazole in DMSO to intensify the radioactive signal. The proteins were 
visualized using CL-X Posure films (Pierce, Etten-Leur, the Netherlands).
Statistical Analysis
In all experiments, data are expressed as mean ± standard error of the mean (SEM). 
Statistical significance was determined using an unpaired Student’s t-test, differences with 
P < 0.05 were regarded as statistically significant.
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Abstract
Intellectual disability and seizures are frequently associated with hypomagnesemia and 
have an important genetic component. However, to find the genetic origin of intellectual 
disability and seizures often remains challenging because of considerable genetic 
heterogeneity and clinical variability. 
 In this study, we have identified new mutations in the gene CNNM2 in five families 
suffering from mental retardation, seizures, and hypomagnesemia. For the first time, a 
recessive mode of inheritance of CNNM2 mutations was observed. Importantly, patients 
with recessive CNNM2 mutations suffer from severe brain malformations and severe 
intellectual disability. Additionally, three patients with moderate mental disability were 
shown to carry de novo heterozygous missense mutations in the CNNM2 gene. To elucidate 
the physiological role of CNNM2 and explain the pathomechanisms of disease, we studied 
CNNM2 function combining in vitro activity assays and the zebrafish knockdown model 
system. Using stable Mg2+ isotopes, we demonstrated that CNNM2 increases cellular Mg2+ 
uptake in HEK293 cells and that this process occurs through regulation of the 
Mg2+-permeable cation channel TRPM7. In contrast, cells expressing mutated CNNM2 
proteins did not show increased Mg2+ uptake. Knockdown of cnnm2 isoforms in zebrafish 
resulted in disturbed brain development including neurodevelopmental impairments 
such as increased embryonic spontaneous contractions and weak touch-evoked escape 
behaviour, and reduced body Mg content, indicative of impaired renal Mg2+ absorption. 
These phenotypes were rescued by injection of mammalian wild-type Cnnm2 cRNA, 
whereas mammalian mutant Cnnm2 cRNA did not improve the zebrafish knockdown 
phenotypes. 
 We therefore concluded that CNNM2 is fundamental for brain development, neurological 
functioning and Mg2+ homeostasis. By establishing the loss-of-function zebrafish model 
for CNNM2 genetic disease, we provide a unique system for testing therapeutic drugs 
targeting CNNM2 and for monitoring their effects on the brain and kidney phenotype. 
Keywords: Cyclin M2, Mental Retardation, Magnesium, Distal Convoluted Tubule
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Introduction
Brain defects including seizures, migraine, depression and intellectual disability are 
frequently associated with hypomagnesemia (7). Indeed, low Mg2+ concentrations may 
cause epileptiform activity during development (25). Specifically, the Mg2+ channel 
transient receptor potential melastatin 7 (TRPM7) is essential for brain function and 
development (18). Interestingly, patients with genetic defects in TRPM6, a close homologue 
of TRPM7, may have neurological complications (34). Although TRPM6 and TRPM7 share 
similar Mg2+ transporting properties, they are differentially expressed and regulated (27). 
TRPM7 is a ubiquitously expressed protein regulating intracellular Mg2+ levels in a broad 
range of cells, whereas TRPM6 is localized in the luminal membrane of renal and intestinal 
epithelia involved in Mg2+ absorption (7, 16, 32, 36). Recently, we have identified mutations 
in the gene encoding cyclin M2 (CNNM2) in two unrelated families with dominant isolated 
hypomagnesemia (CNNM2, OMIM #607803) (31). Patients suffered from symptoms 
associated with low serum Mg2+ levels (0.3-0.5 mmol/L) such as tremors, headaches and 
muscle weakness. The role of CNNM2 in the kidney for the maintenance of serum Mg2+ 
levels can be traced to the distal convoluted tubule (DCT), where also TRPM6 is expressed. 
Here, CNNM2 is present in the basolateral membrane of DCT cells and its expression is 
regulated by dietary Mg2+ availability (5, 31). 
 Although CNNM2 has been proposed as a Mg2+ transporter in overexpression studies 
in Xenopus laevis oocytes (12), Mg2+ transport could not be directly measured in 
mammalian cells using patch clamp analysis (31). On the other hand, modelling of the 
CNNM2 cystathionine β-synthase (CBS) domains resulted in the identification of an 
Mg2+-ATP binding site, suggesting a role in Mg2+ sensing within the cell (6). Consequently, 
the molecular mechanism explaining the role of CNNM2 in DCT-mediated Mg2+ transport 
remains to be elucidated.
 The CNNM2 gene is ubiquitously expressed in mammalian tissues, most prominently 
in kidney, brain and lung (6, 38). Although the role of CNNM2 beyond the kidney has never 
been studied, genome wide association studies have related the CNNM2 locus to blood 
pressure, coronary artery disease and schizophrenia, suggesting an important role of 
CNNM2 in the cardiovascular system and brain (4, 26). CNNM2 is widely conserved among 
species. In Danio rerio, a frequently used model for ion homeostasis and human genetic 
diseases in general (17, 22), the cnnm2 gene is duplicated and two paralogues, cnnm2a and 
cnnm2b, are described (1). Both paralogues share a high conservation with human CNNM2 
(79 % amino acid identity). In detail, transcripts are abundantly expressed in zebrafish brain 
and in ionregulatory organs such as kidney and gills, which act as a pseudokidney in fish 
(1). Consistent with the regulation of CNNM2 transcripts in mammals (12), the expression of 
cnnm2a and cnnm2b is regulated by Mg2+ in vivo (1).
 In the present study, we aim to elucidate the function of CNNM2 in brain and kidney. 
Hence, we can demonstrate the genetic origin of symptoms in five unrelated families 
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suffering from a distinct phenotype of mental retardation, seizures and hypomagnesemia, 
where we have identified novel mutations in the CNNM2 gene. By combining functional 
analyses and a loss-of-function approach in the zebrafish model, we provide evidence for 
a key role of CNNM2 in brain development, neurological activity and renal Mg2+ handling. 
Results
Patients
Patients F1.1 and F1.2 presented in the neonatal period with cerebral convulsions. Serum 
Mg2+ levels at manifestation were found to be 0.5 mmol/L in both patients (Table 1). 
Convulsions were refractory to conventional antiepileptic medications. Intravenous Mg2+ 
supplementation with ±1 mmol/kg body weight/day was initiated after oral Mg2+ failed to 
correct serum Mg2+ levels. However, seizure activity continued even in face of normo-
magnesemia. An extensive analysis for infectious causes or inborn errors of metabolism 
did not yield any positive results. Ultrasound examination of the kidneys did not reveal 
nephrocalcinosis, whereas basal ganglia calcifications were noted in early central nervous 
system (CNS) sonographies. During follow-up, severe developmental delay was noted 
accompanied by microcephaly (head circumference below third percentile for age and 
sex in both patients). A magnetic resonance imaging (MRI) at 5.5 years of age in patient 
F1.1 showed wide supratentorial outer cerebrospinal liquor spaces with failure of oper-
cularization together with a significantly reduced myelinization of the white matter tract 
(Figure 1C-D). The severe degree of intellectual disability, which became apparent with 
increasing age comprised major deficits in cognitive function, the inability to verbally 
communicate, and severely limited motor skills. Both children are not able to perform 
main activities of daily living and require full-time care by an attendant. Seizure activity is 
sufficiently controlled in the brother by valproate and lamotrigine, electroencephalo-
graphy (EEGs) merely shows generalized slowing, but no epileptic activity. In contrast, 
the younger sister suffers from ongoing generalized, myoclonic seizures despite 
antiepileptic treatment with valproate and levetiracetame. Laboratory investigations 
during follow-up demonstrated persistent hypomagnesemia of ±0.6 mmol/L despite 
oral Mg2+ supplementation. 
 Patients F2.1, F3.1, and F4.1 presented with seizures during infancy (between 4 and 12 
months of age). Laboratory evaluation yielded isolated hypomagnesemia of ±0.5 mmol/L 
(Table 1). Urine analyses demonstrated inappropriate fractional excretion for Mg2+ in face 
of persistent hypomagnesemia. In addition, the renal Mg2+ leak was verified by Mg2+ 
loading tests in patients F2.1 and F4.1 as described before (37). Urinary calcium excretion rates 
were normal, renal ultrasound excluded the presence of nephrocalcinosis. After acute therapy 
with intravenous Mg2+, the patients received a continuous oral Mg2+ supplementation of 0.5 
to 1 mmol/kg body weight/day of elemental Mg2+. This oral therapy however failed to 
correct the hypomagnesemia, serum Mg2+ remained in the subnormal range in all three 
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children. Because of recurrent cerebral seizures, patients F2.1 to F4.1 received diverse 
antiepileptic medications. Currently only patient F4.1 is still treated with clobazam. 
 In all three patients (F2.1 to F4.1), a significant degree of intellectual disability was 
already noted in early childhood with delayed speech development, but also impaired 
motor as well as cognitive skills. In addition, patient F4.1 was noted to exhibit disturbed 
social interaction, abnormal verbal and non-verbal communication, as well as stereotyped 
behaviour and finally received the formal diagnosis of early onset autism. All three patients 
F2.1 to F4.1 were not able to attend regular schools. Standardized intelligence testing in 
patients F2.1 and F3.1 revealed a significant degree of mental retardation (Table 1). While 
patients F2.1 and F3.1 are currently living with their parents, patient F4.1 is placed in a 
home for children with mental illness because of episodes of violence and destructive 
behaviour. The parents of all three children (F2.1-F4.1) had normal serum Mg2+ levels and 
no signs of intellectual disability.
 Finally, patient F5.1 presented with muscle spasms and dysesthesia in adolescence. 
Serum Mg2+ levels were found to be low (±0.6 mmol/L). Because of concomitant 
borderline hypokalemia, she was suspected to have Gitelman syndrome (OMIM #263800) 
and received oral Mg2+ and K+ supplements. Also this patient exhibited a mild degree of 
intellectual disability. Unfortunately, she was not available for further examination.
CNNM2 Mutations in Patients with Mental Retardation
Common genetic causes of mental retardation were excluded in patients F1.1 and F2.1 by 
array CGH (comparative genomic hybridization). The presence of two affected siblings 
together with the suspected parental consanguinity in family F1 suggested an auto somal-
recessive pattern of inheritance. Therefore, we subjected patients F1.1 and F1.2 to 
homozygosity mapping which, at a cut-off size of >1.7 megabases (Mb), yielded eleven 
critical intervals on autosomes with a cumulative size of 62 Mb. The gene list generated 
from these loci included 322 RefSeq genes and putative transcripts. CNNM2 in a critical 
interval of 7.1 Mb on chromosome 10 emerged as the most promising candidate gene 
because of its known role in Mg2+ metabolism (6, 12, 30, 31). Conventional Sanger 
sequencing of the complete coding region of the CNNM2 gene revealed a homozygous 
mutation, c.364G>A, leading to a non-conservative amino acid substitution of glutamate 
to lysine at position 122 of the CNNM2 protein (p.Glu122Lys, Figure 1A-B). The mutation 
was present in heterozygous state in both parents. After discovery of this homozygous 
mutation in patients F1.1 and F1.2, a larger cohort (n=34) of patients with Mg2+ deficiency 
of unknown origin was screened for mutations in the CNNM2 gene. Mutations in 
heterozygous state were discovered in patients F2.1 to F5.1 (Table 1). However, sequencing 
of the complete coding region and adjacent exon-intron boundaries did not reveal a 
second pathogenic allele. Next, we examined the CNNM2 gene in parents and unaffected 
siblings of families F2 to F4. The mutations previously identified in our patients were not 
detected in either of the parents pointing to de novo mutational events. Interestingly, 
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patients F2.1 and F4.1 exhibited the same mutation, p.Glu357Lys (c.1069G>A), affecting a 
highly conserved amino acid residue in the 2nd membrane-spanning domain of the 
CNNM2 protein. Also the p.Ser269Trp (c.806C>G) mutation detected in patient F3.1 affects 
a highly conserved residue located in the 1st transmembrane domain. All three mutations 
were ranked “probably damaging” by Polyphen-2 when tested for functional consequences 
of the mutations (p.Glu122Lys, p.Ser269Trp and p.Glu357Lys with scores of 0.981, 1.000 and 
1.000, respectively). Finally, in patient F5.1 with a late manifestation and putatively milder 
phenotype, the variant p.Leu330Phe (c.988C>T) was identified in heterozygous state. This 
variant affects an amino acid residue conserved among mammals, however a 
phenylalanine appears at this position in certain fish species. The variant is predicted to be 
possibly damaging by Polyphen-2 with a score of 0.711. None of the identified variants was 
detected in 204 controls or present in publically available exome data.
Table 1   Clinical and Biochemical Data of the Patients
Patient F1.1 F1.2 F2.1 F3.1 F4.1 F5.1
Gender Male Female Female Female Male Female
Ethnicity Serbian Serbian German German German Polish
Age at manifestation 1 day 6 days 7 months 1 years 4 months 16 years
Follow-up 12 years 8 years 12 years 20 years 12 years None
Symptoms at manifestation Seizures Seizures Seizures Seizures
Paresthesia
Seizures Myoclonus
Paresthesia
Treatment Valproate
Lamotrigine
Valproate
Levetiracetame
Phenobarbital Valproate Clobazam Unknown
Neuroimaging Myelinization defects
Opercularization defect
Widened outer cerebrospinal liquor spaces
Normal Normal Normal Unknown
Mental retardation Severe Severe Moderate Moderate Moderate Mild
Cognitive function IQ 55-57 IQ 55-59 Autism Unknown
Speech/ Communication No verbal speech
Limited communication skills
No verbal speech
Limited communication skills
Expressive language 
disorder
Expressive language 
disorder
Limited speech and 
vocabulary
Unknown
Additional symptoms Very limited motor skills Very limited motor skills Impaired motor skills, 
severe obesity
Impaired motor skills, 
severe obesity
Impaired motor skills Unknown
Initial serum 
Mg2+ (mmol/L)
0.5 0.5 0.56 0.44 0.5 0.66
Follow-up serum Mg2+ (mmol/L) 0.66 0.54 0.56 0.53 0.68 -
Mutation 
(DNA level)
c.364G>A c.364G>A c.1069G>A c.806C>G c.1069G>A c.988C>T
Mutation
(Protein level)
p.Glu122Lys p.Glu122Lys p.Glu357Lys p.Ser269Trp p.Glu357Lys p.Leu330Phe
Zygosity Homozygous Homozygous Heterozygous Heterozygous Heterozygous Heterozygous
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CNNM2 Increases Mg2+ Transport 
To clarify the function of CNNM2, Human Embryonic Kidney (HEK293) cells were transiently 
transfected with mouse Cnnm2 or mock constructs and examined for Mg2+ transport 
capacity using the stable 25Mg2+ isotope. At baseline, approximately 10 % of the total 
intracellular Mg2+ content consists of 25Mg2+, which is the natural abundance of 25Mg2+ 
(39). By incubating the cells in a physiological buffer containing pure 25Mg2+, the 
intracellular 25Mg2+ concentration increases over time. Interestingly, Cnnm2 expressing 
cells displayed a higher 25Mg2+ uptake compared to mock cells (Figure 2A). After 5 min, 
Cnnm2-expressing cells had approximately 2 times more 25Mg2+ uptake than mock-trans-
fected cells (Figure 2B). All further experiments were performed at the 5 min time point to 
cover the exponential phase of the uptake. To reduce the background in 25Mg2+ uptake, 
inhibitors of known Mg2+ channels and transporters were added during the uptake 
Table 1   Clinical and Biochemical Data of the Patients
Patient F1.1 F1.2 F2.1 F3.1 F4.1 F5.1
Gender Male Female Female Female Male Female
Ethnicity Serbian Serbian German German German Polish
Age at manifestation 1 day 6 days 7 months 1 years 4 months 16 years
Follow-up 12 years 8 years 12 years 20 years 12 years None
Symptoms at manifestation Seizures Seizures Seizures Seizures
Paresthesia
Seizures Myoclonus
Paresthesia
Treatment Valproate
Lamotrigine
Valproate
Levetiracetame
Phenobarbital Valproate Clobazam Unknown
Neuroimaging Myelinization defects
Opercularization defect
Widened outer cerebrospinal liquor spaces
Normal Normal Normal Unknown
Mental retardation Severe Severe Moderate Moderate Moderate Mild
Cognitive function IQ 55-57 IQ 55-59 Autism Unknown
Speech/ Communication No verbal speech
Limited communication skills
No verbal speech
Limited communication skills
Expressive language 
disorder
Expressive language 
disorder
Limited speech and 
vocabulary
Unknown
Additional symptoms Very limited motor skills Very limited motor skills Impaired motor skills, 
severe obesity
Impaired motor skills, 
severe obesity
Impaired motor skills Unknown
Initial serum 
Mg2+ (mmol/L)
0.5 0.5 0.56 0.44 0.5 0.66
Follow-up serum Mg2+ (mmol/L) 0.66 0.54 0.56 0.53 0.68 -
Mutation 
(DNA level)
c.364G>A c.364G>A c.1069G>A c.806C>G c.1069G>A c.988C>T
Mutation
(Protein level)
p.Glu122Lys p.Glu122Lys p.Glu357Lys p.Ser269Trp p.Glu357Lys p.Leu330Phe
Zygosity Homozygous Homozygous Heterozygous Heterozygous Heterozygous Heterozygous
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Figure 1   Pedigrees and Magnetic Resonance Imaging (MRI) Studies of Families with 
Primary Hypomagnesemia
A, Pedigrees of families F1-F5. Filled symbols represent affected individuals, mutant alleles are 
indicated by a minus (-) and plus (+) sign, respectively. B, Localization of the mutations in the CNNM2 
protein structure (Uniprot Q9H8M5). CNNM2 contains a long signal peptide (64 amino acids) that is 
cleaved at the membrane of the endoplasmic reticulum. The remaining part of the CNNM2 protein 
is trafficked to the plasma membrane, where it becomes functionally active. White dots show the 
locations of the mutations. C-D, MRI of the brain of patient F1.1 (C, T2 weighed images) and patient 
F2.1 (D, T2 weighed images). Left: Coronal images demonstrating a defect in myelinization of 
U-fibers (arrows) in patient F1.1 in contrast to a normal myelin pattern in patient F2.1. Center: Coronal 
T2 weighted images showing widened outer cerebrospinal liquor spaces (dashed arrows) and lack 
of opercularization (solid arrows) in patient F1.1, whereas a regular brain volume and insular lobe is 
observed in patient F2.1. Right: Absence of cerebellar structural abnormalities in patients F1.1 and 
F2.1 on axial T2 weighted images at the level of the trigeminal nerve.
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process; 2-Aminoethoxydiphenyl borate (2-APB) to inhibit TRPM7 (3), Ouabain to block the 
Na+-K+-ATPase (40), Quinidin for SLC41A1 (20) and Nitrendipin (13) for silencing MagT1 
activity (Figure 2C). Only 2-APB was capable of significantly inhibiting 25Mg2+ uptake in 
HEK293 cells. Moreover, 2-APB inhibition also abolished the CNNM2-dependent increase 
in 25Mg2+ uptake. Dose-response experiments confirmed that the IC50 of 2-APB inhibition 
is 22 μmol/L (Figure 2D). CNNM2-dependent 25Mg2+ uptake was found to be independent 
of Na+ and Cl- availability, when uptakes were performed in N-methyl-d-glucamine 
(NMDG) or Gluconate buffers (Figure 2E). Interestingly, the highest CNNM2-dependent 
25Mg2+ uptake was measured between 1-2 mmol/L, suggesting a Km in the physiological 
range of approximately 0.5 mmol/L (Figure 2F). At high Mg2+ concentrations (5 mmol/L), 
25Mg2+ uptake was inhibited. When subjected to 24 hours 25Mg2+ loading, Cnnm2- 
expressing cells showed a significantly higher 25Mg2+ content baseline. Subsequently, 
15 min extrusion of Cnnm2-expressing cells demonstrated no difference in Mg2+ extrusion 
rate compared to mock-transfected cells (Figure 2G).
Mutations Impair CNNM2-dependent Mg2+ Uptake
To characterize the effect of the CNNM2 mutations identified in our hypomagnesemic 
patients, 25Mg2+ uptake was determined in HEK293 cells expressing mutant CNNM2 
proteins. Of all missense mutations that are identified to date, only p.Leu330Phe was 
capable of increasing 25Mg2+ uptake to a similar extent as wild-type CNNM2 (Figure 3A). 
All other CNNM2 mutants exhibited severely decreased 25Mg2+ uptake or had lost their 
ability to increase 25Mg2+ uptake completely. To examine whether CNNM2 dysfunction 
can be explained by a reduced plasma membrane expression, all mutants were subjected 
to cell surface biotinylation analysis. Indeed, p.Glu122Lys CNNM2 membrane expression 
was significantly reduced compared with wild-type CNNM2 (66 % decrease, P < 0.05) and 
p.Ser269Trp CNNM2 showed a trend towards reduction (46 % decrease, Figure 3B).
Figure 1   Continued
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Figure 2   CNNM2 Increases Mg2+ Uptake in HEK293 Cells
A, Time curve of 25Mg2+ uptake in mock (circles) and CNNM2 (squares) transfected cells. B, Representation 
of the normalized Mg2+ uptake after 5 min. C, 25Mg2+ uptake in the presence of inhibitors of ion 
transporters, black bars represent mock cells and white bars represent CNNM2-transfected cells. 
D, Dose-response curve of 25Mg2+ transport inhibition by 2-APB in mock (circles) and CNNM2 (squares) 
transfected cells. E, The effect of Na+ and Cl- availability on 25Mg2+ uptake in mock (black bars) 
and CNNM2 (white bars) transfected cells. F, 25Mg2+ uptake as a function of extracellular 25Mg2+ 
availability in mock (circles) and CNNM2 (squares) transfected cells. G, 25Mg2+ extrusion in mock 
(circles) and CNNM2 (squares) transfected cells. Each data point represent the mean of 3 independent 
experiments ± SEM. * indicates significant differences compared to mock (P < 0.05).
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Figure 3   CNNM2 Mutations Impair Mg2+ Uptake in HEK293 Cells
A, Time curve of 25Mg2+ uptake in mock, wild-type CNNM2 and mutant CNNM2 transfected 
cells. Symbols indicate cells transfected with the vector empty ( mock) or containing CNNM2 
sequences encoding for wild-type or mutant CNNM2 proteins ( CNNM2,  CNNM2-p.Glu122Lys, 
 CNNM2-p.Ser269Trp,  CNNM2-p.Leu330Phe,  CNNM2-p.Glu357Lys,  CNNM2-p.Thr568Ile). 
Each data point represent the mean of 3 independent experiments ± SEM. * indicates significant 
differences compared to mock (P < 0.05). B, Representative immunoblots showing that p.Glu122Lys 
and p.Ser269Trp mutations reduce CNNM2 membrane expression (upper blot) and a CNNM2 
expression control (lower blot). Quantification of cell surface expression of wild-type (WT) and 
mutant CNNM2 proteins corrected for total protein expression. Results are the mean ± SEM of 3 
independent experiments. * indicate significant differences compared to WT CNNM2 transfected 
cells (P < 0.05).
0 5 10 15
0
50
100
150
200
250
Time (min)
25
M
g 
up
ta
ke
 (%
 o
f m
oc
k)
mock
CNNM2
CNNM2-p.Glu122Lys
CNNM2-p.Ser269Trp
CNNM2-p.Leu330Phe
CNNM2-p.Glu357Lys
CNNM2-p.Thr568Ile
*
*
*
*
A
B
116
 97
116
 97
–
CNNM2
p.Glu122Lys
CNNM2
p.Ser269Trp
CNNM2
p.Leu330Phe
CNNM2
p.Glu357Lys
CNNM2
p.Thr568Ile
CNNM2
WT
+ + + + + + + + + + + + +
mock
Biotin
Total protein
fraction
Cell surface
fraction
Bi
ot
in
yl
at
ed
 F
ra
ct
io
n 
(%
 o
f W
T)
kDa
W
T
p.G
lu1
22
Ly
s
p.S
er2
69
Trp
p.L
eu
33
0P
he
p.G
lu3
57
Ly
s
p.T
hr
56
8Il
e
0
50
100
150
172 | Chapter 7
Disturbed Mg2+ Homeostasis and Brain Abnormalities in cnnm2 
Morphant Zebrafish Larvae
Patients with mutations in CNNM2 suffer from hypomagnesemia. Therefore, zebrafish 
cnnm2 morphants were tested for disruptions of their Mg2+ homeostasis. Extraction of 
serum from zebrafish embryos is technically not feasible. Thus, total body Mg contents of 
controls and morphant larvae were examined at 5 days post-fertilization (dpf). During 
these 5 days of zebrafish development, intestinal absorption of Mg2+ does not take place 
since larvae do not eat and drink. For that reason, Mg2+ homeostasis is the result of the 
balance between Mg2+ excretion, passive Mg2+ uptake from the yolk, Mg2+ reabsorption 
in the kidney, and Mg2+ uptake in the integument, where ionocytes are analogous to renal 
tubular cells in terms of function and transporter and channel expression (17). Therefore, 
when knocking down a gene involved in active epithelial Mg2+ uptake, disturbances in 
total body Mg content reliably represent disturbances in active Mg2+ reabsorption and/or 
uptake, through pronephric (renal) tubular cells and/or their analogous in the skin, 
respectively.
 The cnnm2a gene, one of the two zebrafish cnnm2 paralogues, is expressed during 
early development (Figure 4A). Injection in embryos of higher doses than 2 ng of 
morpholino (MO) blocking cnnm2a translation resulted in a significantly reduced survival 
compared to controls at 5 dpf (Figure 4B). At non-lethal doses of MO (when mortality 
caused by the cnnm2a-MO does not differ significantly from mortality in controls), 
knockdown of cnnm2a resulted in morphological phenotypes characterized by enlarged 
pericardial cavities and notochord defects (Figure 4C-D). The biochemical equivalency 
between mammalian CNNM2 and its zebrafish orthologue Cnnm2a was demonstrated 
by the fact that co-injection of cnnm2a-MO with mouse wild-type Cnnm2 cRNA induced 
a rescue of all phenotypes observed (Fig. 4E). Conversely, co-injection with mouse mutant 
Cnnm2 cRNA did not result in any rescue. In line with the symptom of hypomagnesemia 
in patients with mutated CNNM2, cnnm2a morphants exhibited significantly reduced 
levels of Mg compared to controls when increasing doses of MO were injected (Figure 4F). 
Total Mg content in cnnm2a morphants was restored to control levels when cnnm2a-MO 
was co-injected with cRNA encoding for mouse wild-type CNNM2 and not with mutant 
Cnnm2 (Figure 4G). This demonstrated that the defects observed in morphants were 
indeed caused by dysfunctional cnnm2a and not by toxic off-target effects. 
 Zebrafish cnnm2b is also expressed during early development (Figure 5A). Survival in 
cnnm2b morphants was not affected by the knockdown (Figure 5B). The cnnm2b morphants 
were characterized by enlarged pericardial cavities, kidney cysts and, in agreement with 
the morphological brain abnormalities observed in the F1.1 patient, by accumulation of 
cerebrospinal fluid in the cerebrum (Figure 5C-D). Interestingly, most cnnm2b morphants 
were morphologically normal at the dose of 2 ng MO/embryo (Figure 5D). All morphological 
phenotypes were rescued by co-injection of cnnm2b-MO with mouse wild-type Cnnm2 
(Figure 5E). As for cnnm2a, cnnm2b was demonstrated to reduce Mg levels when knocked 
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Figure 4   Knockdown of cnnm2a Results in Mg Wasting in Zebrafish Larvae
A, mRNA expression of cnnm2a in developing zebrafish. Expression patterns were analysed by 
RT-qPCR (n=6). B, Survival curve at 5 dpf (n=3). The dose of zero represents injection with control-MO. 
C, Morphological phenotypes in zebrafish larvae (5 dpf) in cnnm2a knockdown experiments. 
D, Distribution of morphological phenotypes in zebrafish larvae (5 dpf) untreated (wild-type) or 
injected with different doses of cnnm2a-MO or control-MO. Numbers on top of the bars indicate the 
number of animals in each experimental condition. E, Distribution of morphological phenotypes 
in zebrafish larvae at 5 dpf in rescue experiments. The wild-type phenotype (class I) was restored 
in morphants by co-injection of cnnm2a-MO (2 ng MO/embryo) with wild-type CNNM2 cRNA 
(50 pg cRNA/embryo), but not with mutant (p.Glu357Lys) CNNM2 cRNA (50 pg cRNA/embryo). 
F, Magnesium content in zebrafish injected with different doses of cnnm2a-MO, the dose of zero 
represents injection with control-MO (n=10 except in 8 ng MO-injected zebrafish where n=5). 
G, Rescue of Mg wasting in morphant zebrafish by co-injection of cnnm2a-MO (2 ng MO/embryo) 
with cRNA encoding for wild-type (WT) CNNM2 (50 pg cRNA/embryo). Co-injection with cRNA 
encoding for mutant (MT, p.Glu357Lys) CNNM2 (50 pg cRNA/embryo) did not restore Mg levels 
(n = 10 per experimental condition). Data are presented as mean ± SEM. Different letters indicate 
significant differences between mean values in experimental groups (P < 0.05).
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Figure 4   Continued
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Figure 5   Knockdown of cnnm2b Results in Mg Wasting and Brain Malformations in 
Zebrafish Larvae 
A, mRNA expression of cnnm2b in developing zebrafish. Expression patterns were analysed by RT-
qPCR (n=6 per time point). B, Survival curve at 5 dpf (n=3). The dose of zero represents injection 
with control-MO. C, Morphological phenotypes in zebrafish larvae (5 dpf) in cnnm2b knockdown 
experiments. D, Distribution of morphological phenotypes in zebrafish larvae (5 dpf) untreated 
(wild-type) or injected with different doses of cnnm2b-MO or control-MO. Brain malformations 
(widened cerebrospinal fluid spaces, class IV phenotype) are prominent in morphants injected 
with 4-8 ng MO/embryo. Numbers on top of the bars indicate the number of animals in each 
experimental condition. E, Distribution of morphological phenotypes in zebrafish larvae at 5 dpf in 
rescue experiments. The wild-type phenotype (class I) was restored in morphants by co-injection 
of cnnm2b-MO (8 ng MO/embryo) with wild-type CNNM2 cRNA (50 pg cRNA/embryo), but not 
with mutant (p.Glu357Lys) CNNM2 cRNA (50 pg cRNA/embryo). F, Magnesium content in zebrafish 
injected with different doses of cnnm2b-MO. The dose of zero represents injection with control-MO 
(n=10). G, Rescue of Mg wasting in morphant zebrafish by co-injection of cnnm2b-MO (8 ng MO/
embryo) with cRNA encoding for wild-type (WT) CNNM2 (50 pg cRNA/embryo). Co-injection with 
cRNA encoding for mutant (MT, p.Glu357Lys) CNNM2 (50 pg cRNA/embryo) did not restore Mg levels 
(n=10). Data are presented as mean ± SEM. Different letters indicate significant differences between 
mean values in experimental groups (P < 0.05).
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down (Figure 5F) and to be functionally equivalent to mammalian CNNM2 in cRNA rescue 
experiments (Figure 5G). Phenotype rescue with mouse wild-type Cnnm2 demonstrated 
the absence of toxic off-target effects and the specificity of the cnnm2b-MO to produce 
defects attributable to impaired CNNM2 function. 
Brain Abnormalities and Increased Spontaneous Contractions in cnnm2 
Morphant Zebrafish Embryos
Patients with CNNM2 mutations suffer from mental retardation and seizures. As the severe 
neurological phenotype in patients F1.1 and F1.2 was diagnosed early after birth (Table 1), 
we hypothesized that the deleterious effects of mutant CNNM2 could result from early 
developmental defects in brain primordia. In zebrafish, the segmental organization of the 
brain rudiment, and morphologically visible boundaries and primordia are established at 
25 hours post-fertilization (hpf). At this stage, maldevelopment of the midbrain hindbrain 
boundary (MHB) is observed in cnnm2a morphant embryos (Figure 6A-B). Interestingly, 
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Figure 6   Dysfunctional cnnm2a Causes Brain Abnormalities and Increased Spontaneous 
Contractions in Zebrafish Embryos  
A, Phenotypes in zebrafish embryos untreated (wild-type, WT) or following treatment with (2 ng MO/
embryo) cnnm2a-MO or control-MO. M, midbrain; T, tectum; MHB, midbrain-hindbrain boundary; 
FV, fourth ventricle; and H, hindbrain. B-C, Distribution of (B) phenotypes and (C) Mg content in 
zebrafish embryos WT or injected with cnnm2a-MO or control-MO and exposed to a medium with 
a concentration of Mg2+ of 0.33 or 25 mmol/L. Numbers on top of the bars indicate the number 
of animals. D, Restoration of normal brain development by co-injection of cnnm2a-MO with cRNA 
encoding for WT CNNM2, and not by co-injection with cRNA encoding for mutant (MT, p.Glu357Lys) 
CNNM2. E, Spontaneous contractions in zebrafish embryos WT or injected with cnnm2a-MO 
or control-MO and exposed to a medium with a concentration of Mg2+ of 0.33 or 25 mmol/L. 
F, Restoration of normal spontaneous contraction activity by co-injection of cnnm2a-MO with cRNA 
encoding for WT CNNM2, and not by co-injection with cRNA encoding for MT CNNM2. Data are 
presented as mean ± SEM. *P < 0.05 versus WT and control. #P < 0.05 versus Mg2+-normal (0.33 mmol/L 
Mg2+) medium. Data are presented as mean ± SEM. Letters indicate significant differences between 
experimental groups (P < 0.05).
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these phenotypes could not be rescued by exposure to media with high Mg2+ concentrations 
(Figure 6B), even though these media significantly increased the Mg content of morphant 
embryos (Figure 6C). More importantly, phenotypes were rescued by co-injection with 
the mouse orthologue cRNA and not by co-injection with the mutant transcript (Figure 
6D). In addition to brain developmental defects, the frequency of spontaneous embryonic 
contractions was increased in cnnm2a morphants compared to controls (Figure 6E), which 
could indicate that (motor) neurons are hyperexcitable (24). This phenotype was not 
rescued by exposure to high Mg2+ concentrations in the medium (Figure 6E). In contrast, 
co-injection of the cnnm2a-MO with mouse wild-type Cnnm2 cRNA did result in a rescue 
of the neurological functioning (Figure 6F). Conspicuously, co-injection with the mutant 
Cnnm2 cRNA even worsened this motor neuronal phenotype by increasing the number of 
spontaneous contractions significantly compared to embryos injected only with cnnm2a-MO 
(Figure 6F). 
 In the case of cnnm2b morphants, enlarged tectums were also present in a 30 % of 
morphants in addition to the defects in the MHB, phenotypes that were not rescued by 
exposure to high Mg2+ concentrations (Figure 7A-C) but by co-injection of cnnm2b-MO 
with mouse wild-type Cnnm2 cRNA (Figure 7D). Spontaneous contraction frequency was 
increased in cnnm2b morphants (Figure 7E), restored to control levels with overexpression 
of mouse wild-type Cnnm2 (Figure 7F), and 4-fold increased with overexpression of mouse 
mutant Cnnm2 compared to cnnm2b morphants injected solely with cnnm2b-MO (Figure 7F).
Weaker Touch-evoked Escape Behaviour in cnnm2 Morphant Zebrafish 
Larvae
As our in vitro data pointed to a putative interaction between CNNM2 and TRPM7 and 
zebrafish morphants presented brain developmental defects, the touch-evoked escape 
behaviour in zebrafish was evaluated, a parameter largely dependent on TRPM7 activity in 
sensory neurons and/or brain development (10, 23, 28). Indeed, in cnnm2a and cnnm2b 
morphants (at 5 dpf), touch-evoked escape behaviour was significantly weaker than that 
in controls (Figures 8-9). Additionally, this phenotype was rescued by co-injection of the 
MO with wild-type Cnnm2 cRNA and not by mutant Cnnm2 cRNA. As for the other 
phenotypes, cRNA rescues proved the causality between the weak touch-evoked escape 
behaviour in morphants and dysfunctional cnnm2 paralogues.  
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Figure 7   Dysfunctional cnnm2b Causes Brain Abnormalities and Increased  Spontaneous 
Contractions in Zebrafish Embryos 
A, Phenotypes in zebrafish embryos untreated (wild-type, WT) or following treatment with cnnm2b-
MO (8 ng MO/embryo) or control-MO. See Figure 6 for an explanation of the abbreviations shown. 
B-C, Distribution of (B) phenotypes and (C) Mg content in zebrafish embryos WT or injected with 
cnnm2b-MO or control-MO and exposed to a medium with a concentration of Mg2+ of 0.33 or 25 
mmol/L. Numbers on top of the bars indicate the number of animals in each experimental condition. 
D, Restoration of normal brain development by co-injection of cnnm2b-MO with cRNA encoding for 
WT CNNM2 and not by co-injection with cRNA encoding for mutant (MT, p.Glu357Lys) CNNM2. E, 
Spontaneous contractions in zebrafish embryos WT or injected with cnnm2b-MO or control-MO 
and exposed to a medium with a concentration of Mg2+ of 0.33 or 25 mmol/L. F, Restoration of 
normal spontaneous contraction activity by co-injection of cnnm2b-MO with cRNA encoding for 
WT CNNM2 and not by co-injection with cRNA encoding for MT CNNM2. Data are presented as 
mean ± SEM. *P < 0.05 versus wild-type and control. #P < 0.05 versus Mg2+-normal (0.33 mmol/L 
Mg2+) medium. Data are presented as mean ± SEM. Different letters indicate significant differences 
between mean values in experimental groups (P < 0.05).
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Figure 8   Touch-evoked Escape Behaviour in cnnm2a Morphant Zebrafish 
Touch-evoked escape behaviour score in zebrafish cnnm2a morphants at 5 dpf after injection 
of 2 ng control-MO/embryo, 2 ng cnnm2a-MO/embryo, 2 ng cnnm2a-MO/embryo + 50 pg wild-
type (WT) CNNM2 cRNA/embryo, or 2 ng cnnm2a-MO/embryo + 50 pg mutant (MT, p.Glu357Lys) 
CNNM2 cRNA/embryo. Three categories were distinguished, responders, late responders and non-
responders, to which the following scores were given: 3 points for responders: fish quickly react 
(swimming or flicking the tail) to the stimuli after 1 or 2 twitches; 2 points for late responders: 
fish react (swimming or flicking the tail) to the stimuli after 3, 4 or 5 twitches; and 1 point for non- 
responders: fish do not react to the stimuli after more than 5 twitches. The upper part of the 
figure shows frames of videos showing touch-evoked escape contractions at 5 dpf of control 
and morphant zebrafish larvae. Time of each video frame is indicated in centiseconds (cs). Data 
are shown as mean ± SEM (n = 30). Different letters indicate significant differences between mean 
values in experimental groups (P < 0.05).
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Discussion
In the present study, a severe brain phenotype consisting of cerebral seizures, mental 
retardation and brain malformations in patients with hypomagnesemia was shown to be 
caused by mutations in CNNM2. Our experiments established CNNM2 as a new essential 
gene in brain development, neurological functioning and Mg2+ homeostasis. This notion 
Figure 9   Touch-evoked Escape Behaviour in cnnm2b Morphant Zebrafish
Touch-evoked escape behaviour score in zebrafish cnnm2b morphants at 5 dpf after injection 
of 8 ng control-MO/embryo, 8 ng cnnm2b-MO/embryo, 8 ng cnnm2b-MO/embryo + 50 pg wild-
type (WT) CNNM2 cRNA/embryo, or 2 ng cnnm2b-MO/embryo + 50 pg mutant (MT, p.Glu357Lys) 
CNNM2 cRNA/embryo. Three categories were distinguished, responders, late responders and non-
responders, to which the following scores were given: 3 points for responders: fish quickly react 
(swimming or flicking the tail) to the stimuli after 1 or 2 twitches; 2 points for late responders: fish 
 react (swimming or flicking the tail) to the stimuli after 3, 4 or 5 twitches; and 1 point for non-
responders: fish do not react to the stimuli after more than 5 twitches. The upper part of the 
figure shows frames of videos showing touch-evoked escape contractions at 5 dpf of control 
and morphant zebrafish larvae. Time of each video frame is indicated in centiseconds (cs). Data 
are shown as mean ± SEM (n = 30). Different letters indicate significant differences between mean 
values in experimental groups (P < 0.05).
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is supported by the following observations; i) hypomagnesemic patients with CNNM2 
mutations suffer from seizures, mental disability, and if mutations are present in recessive 
state, brain malformations are observed in addition; ii) Mg2+ supplementation does not 
improve the neurological phenotype of the patients; iii) CNNM2 increases Mg2+ uptake in 
HEK293 cells, whereas mutant CNNM2 does not; iv) knockdown of CNNM2 orthologues in 
zebrafish results in impaired development of the brain, abnormal neurodevelopmental 
phenotypes manifested as altered locomotor and touch-evoke escape behaviours, and 
Mg wasting; v) the zebrafish phenotype can be rescued by injection of mouse Cnnm2 
cRNA.
 In addition to the previously reported dominant mode of inheritance (31), the genetic 
findings in our patients support heterogenous patterns of inheritance. In family F1, a recessive 
mode of CNNM2 inheritance was observed. The homozygous CNNM2 p.Glu122Lys 
mutation in this family resulted in the manifestation of a neonatal onset and a considerably 
more severe cerebral involvement than in the remaining patients. Yet, a CNS phenotype 
with seizures and intellectual disability, which was not reported previously, represented 
the cardinal clinical symptom in all of our patients. Seizures constituted the major 
symptom at manifestation coinciding with hypomagnesemia, but were also seen during 
follow-up despite Mg2+ supplementation. Pronounced Mg2+ deficiency reflected by 
severely low serum Mg2+ levels clearly represents a promotive element in the development 
of seizures. However, the persistence of seizure activity despite Mg2+ supplementation 
might point to a genuine disturbance in brain function caused by defective CNNM2. 
Accordingly, the extent of hypomagnesemia found in the two siblings with the recessive 
mutation, F1.1 and F1.2, was identical to other patients (F2.1-F5.1) with heterozygous CNNM2 
mutations and a milder neurological phenotype. Continuous oral Mg2+ supplementation 
stabilized serum Mg2+ levels in the subnormal range, however a complete normalization 
of Mg2+ metabolism could not be achieved in any of the patients. 
 In three out of five families (F2, F3 and F4), the mutation of the patient was not present 
in the parents. This finding supports the recent advancements evidencing that de novo 
mutations provide an important mechanism in the development of mental disability 
disorders (35). Remarkably, the same de novo p.Glu357Lys mutation was identified in two 
unrelated individuals. Although the mutation rate along the human genome varies 
significantly (15), the chance to observe an identical de novo base pair change in two 
individuals is extremely small, supporting causality of this mutation. The clinical and 
genetic findings observed in patient F5.1 should be interpreted with caution. Though the 
p.Leu330Phe variant was not present in controls or exome variant databases, the presence 
of an innocuous polymorphism cannot be completely excluded. The clinical phenotype 
with a milder degree of intellectual disability and a later manifestation with 
hypomagnesemic symptoms during adolescence support a partial loss of CNNM2 
function caused by the p.Leu330Phe variant. Unfortunately, the patient was not available 
for clinical re-evaluation.
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 Over the recent years, the function of CNNM2 in the context of Mg2+ handling has 
been heavily debated (6, 12, 30, 31, 38). Therefore, an important question is how CNNM2 
mutations cause impaired Mg2+ metabolism and lead to CNS dysfunction. Functional 
studies in HEK293 cells demonstrated a putative role in cellular Mg2+ transport. 
Overexpression of CNNM2 increased cellular Mg2+ uptake, which was abrogated by 
introduction of the CNNM2 mutants identified in our patients. The p.Ser269Trp and 
p.Glu357Lys mutants as well as the previously published p.Thr568Ile mutant (31), all 
identified in heterozygous state, failed to enhance the cellular Mg2+ uptake, indicating a 
loss-of-function in mutated CNNM2. The recessively inherited p.Glu122Lys mutant 
identified in patients F1.1 and F1.2 displayed a small but significant residual function, while 
Mg2+ uptake was almost completely retained for mutant p.Leu330Phe. Biotinylation 
experiments demonstrated a trafficking defect of p.Glu122Lys and p.Ser269Trp mutants 
supporting a loss-of-function nature of CNNM2 mutations. Together, these findings argue 
for distinct degrees of severity of the disease depending on the number of affected alleles. 
Furthermore, a small residual function of p.Glu122Lys is in line with the lack of a clinical 
phenotype in the parents of family F1. The parents, however, declined a thorough 
evaluation of their Mg2+ status. 
 To further analyze the relevance of CNNM2 for brain and Mg2+ metabolism deduced 
from the human disease model, the translation of orthologues of CNNM2 (cnnm2a and 
cnnm2b) was knocked down in zebrafish. In line with the human disease, the concentration 
of total body Mg was decreased in zebrafish cnnm2a and cnnm2b morphants when 
compared to controls. The decrease in total body Mg content is interpreted as a decrease 
in the renal absorption and/or skin uptake (through ionocytes analogous to renal tubular 
cells) of the ionic fraction, Mg2+, since only Mg2+ is transported transcellularly and no 
intestinal Mg2+ uptake takes place in zebrafish larvae. Additionally, Mg losses observed in 
morphant larvae were rescued by expression of wild-type Cnnm2, but not by expression 
of mutant Cnnm2. This demonstrates the specificity of our MO antisense oligos, as well as 
the functional equivalence between mammalian CNNM2 and its zebrafish orthologues.
 Consistent with the human pathology, knockdown of cnnm2a or cnnm2b induced 
brain malformations. Specifically, the brain phenotype observed in cnnm2b morphants 
resembles that found in patient F1.1 showing enlarged outer cerebrospinal liquor spaces. 
This provides further consistency to link CNNM2 dysfunction with the brain morphological 
defects found in this homozygous patient. The absence of outer cerebrospinal liquor 
spaces in the cerebrum of cnnm2a morphants shows that cnnm2 paralogues in zebrafish 
are a case of subfunctionalization at the level of the cerebrum. CNS malformations were 
rescued in morphants by co-injection with mouse wild-type Cnnm2.
 In homozygous patients, the neurological defects became evident early after birth. In 
line with a developmental role for CNNM2 within the CNS, gene expression of zebrafish 
cnnm2a and cnnm2b peaked within the first 24 hpf. In addition, in situ hybridization located 
cnnm2a expression specifically in the MHB (33), an organizing center in the neural tube 
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that determines neural fate and differentiation in the CNS during development (8, 29). 
Indeed, the most striking brain developmental defect in our study is maldevelopment of 
the MHB. These defects were rescued with Cnnm2 cRNA. Interestingly, the brain 
phenotypes observed in both zebrafish and patients were independent of Mg2+, as Mg2+ 
supplementation was unsuccessful to rescue the phenotypes. Thus, our findings suggest 
that a brain-specific CNNM2 function is crucial for the development of constitutive regions 
of the CNS, which in the zebrafish model is illustrated by defects in the MHB.
 At 25 hpf, a time point in which the locomotor behaviour is unaffected by the brain 
and only depends on signals from the spinal cord (28), zebrafish morphant embryos 
displayed an increased frequency of spontaneous contractions, especially when the MOs 
were co-injected with mutant Cnnm2. This hyperexcitability of motor neurons suggests a 
function of zebrafish Cnnm2 proteins in the regulation of the activity of the neurological 
network in the spinal cord or in the synaptic junctions with muscle fibbers. Consistent 
with these findings, patients with mutations in CNNM2 presented impaired motor skills, 
which were severe in the case of homozygous patients.
 In the CNS, TRPM7 is essential during early development (19), as it modulates neuro-
transmitter release in sensory neurons (2, 21). Specifically, when using 2-APB, an inhibitor 
of TRPM7 (3), CNNM2-dependent Mg2+ transport was abolished in HEK293 cells. 
Remarkably, in a similar fashion to knockdown of trpm7 in zebrafish (10, 23), cnnm2a or 
cnnm2b morphants showed weaker touch-evoked escape behaviour compared to 
controls. In 5 dpf larvae, and unlike in 25 hpf embryos, locomotor behaviours elicited by 
touch require the involvement of high brain structures (28). Therefore, it is reasoned that 
CNNM2 conditions locomotor behaviour with an etiology that can be related to lack of 
excitation of sensory neurons via TRPM7 and/or to the defects in early brain development 
observed in zebrafish morphant embryos. In kidney, where CNNM2 is expressed at the 
basolateral membrane in DCT, specific regulation of TRPM7 Mg2+ reabsorption is unlikely, 
since TRPM6 is the main Mg2+ transporter in this segment. TRPM7 is a ubiquitously 
expressed gene regulating cellular Mg2+ metabolism, which is for instance involved in 
regulation of brain Mg2+ levels (16). Therefore, one could hypothesize that CNNM2 may 
regulate other proteins in addition to TRPM7 in kidney for the control of Mg2+ reabsorption, 
which remain to be identified.
 In conclusion, our findings of CNNM2 mutations in patients with hypomagnesemia 
and severe neurological impairment widen the clinical spectrum of CNNM2-related 
disease. By establishing a zebrafish CNNM2 loss-of-function model of the genetic disease, 
we provide a unique model for the testing of novel therapeutic drugs targeting CNNM2. 
Acknowledgements
The authors are grateful to the patients for their participation in this study. We thank 
Lonneke Duijkers, Jelle Eygensteyn, Margo Dona, Sami Mohammed and Andreas 
Kompatscher for excellent technical support. We thank W. Schwindt, Department of 
184 | Chapter 7
Clinical Radiology, and Heymut Omran, Department of General Pediatrics, University 
Hospital Münster for help with the interpretation of neuroimaging studies. This work was 
supported by grants from the Netherlands Organization for Scientific Research (ZonMw 
9120.8026, NWO ALW 818.02.001), a Dutch Kidney Foundation Innovation Grant (IP11.46), 
the EURenOmics project from the European Union seventh Framework Programme 
(FP7/2007–2013, agreement n° 305608) and NWO Vici Grant to JGJH (016.130.668). This 
work was further supported by the Hans-Joachim-Bodlee-Stifung and by the Peter-
Stiftung.
Patients and Methods
Ethics Statement
All genetic studies were approved by the local ethics committee. Patients or their parents 
provided written informed consent in accordance to the Declaration of Helsinki. All animal 
experiments were performed in agreement with European, National and Institutional regulations.
Patients 
We studied a cohort of six patients from five families with hypomagnesemia and mental 
retardation. Patients F1.1 to F4.1 are followed in secondary or tertiary care neuropediatric 
centres. Neuroimaging was performed in F1.1, F2.1, F3.1, and F4.1 by cranial MRI (magnetic 
resonance imaging). Psychological diagnostic evaluation in patients F2.1 and F3.1 was 
performed using Snijders Oomen Non-Verbal (SON) Intelligence Test (revised) 5.5-17 years. 
Copy number variations (CNVs) associated with neurodevelopmental delay and intellectual 
disability were excluded in patients F1.1 and F2.1 by array CGH (comparative genomic 
hybridization) using the Sureprint G3 Human CGH Microarray kit (Agilent Technologies, 
Boeblingen, Germany) in patient F1.1 and using the Affymetrix Cytogenetics Whole- 
Genome 2.7 Array in patient F2.1.    
Homozygosity Mapping and CNNM2 Mutational Analysis
Genomic DNA of affected individuals and available family members was extracted from 
whole blood using standard methods. A genome scan for shared homozygous regions 
was performed in the two affected children F1.1 and F1.2 with suspected parental 
consanguinity. Samples were genotyped on an Illumina human 660W Quad beadchip 
SNP array (Illumina, Eindhoven, The Netherlands). Merlin 1.1.2 (University of Michigan, Ann 
Arbor, MI, USA) was used to determine homozygous regions by linkage analysis. As exact 
information on pedigree structure was missing, we used a 1.7 Mb threshold for regions 
identical by descent that is very rarely crossed by non-consanguineous samples, but 
allows to identify most of the true homozygosity regions if parental consanguinity is 
present (14). A list of candidate genes within the identified homozygous intervals was 
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generated including known Refseq genes as well as novel transcripts using Ensembl 
Genome assembly GRCh37 via biomart (www.ensembl.org). At a cut-off size of >1.7 Mb, 
eleven critical intervals were yielded on autosomes with a cumulative size of 62 Mb. The 
gene list generated from these loci included 322 RefSeq genes and putative transcripts, 
including CNNM2 in a critical interval of 7.1 Mb on chromosome 10. The entire coding 
region and splice-sites of the most promising candidate gene CNNM2 were sequenced 
from both strands (Genbank: NM_017649.4, Uniprot: Q9H8M5). After discovery of a 
homozygous mutation in the index family F1, the mutational screening was extended to 
patients with hypomagnesemia without mutations in known genes involved in hereditary 
magnesium wasting. The presence of newly identified CNNM2 sequence variations was 
tested in at least 204 ethnically matched control alleles and compared to publically 
available exome data (www.1000genomes.org; evs.gs.washington.edu). Additionally, all 
identified mutations were ranked for potential damage on protein function using 
Polyphen-2 (genetics.bwh.harvard.edu/cgi-bin/ggi/ggi2.cgi).
DNA Constructs
Mouse wild-type Cnnm2 construct was cloned into the pCINeo HA IRES GFP vector as 
described previously (6). Cnnm2 mutations were inserted in the construct using the 
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the 
manufacturer’s protocol. All constructs were verified by sequence analysis. Primer 
sequences used for cloning or mutagenesis PCR are reported in Table 2.
Cell Culture 
HEK293 cells were grown in Dulbecco’s modified eagle’s medium (DMEM, Bio Whittaker- 
Europe, Verviers, Belgium) containing 10 % (v/v) fetal calf serum (PAA, Liz, Austria), 
2 mmol/L L-glutamine and 10 μg/mL non-essential amino acids, at 37 °C in a humidity-
controlled incubator with 5 % (v/v) CO2. The cells were transiently transfected with the 
Table 2   Primer Sequences for Mutagenesis PCR
Mutation Sequence
E122K GGTCCCGCATCGCCTTCACTAAGCACGAGCGGCGCCGGCAC F
GTGCCGGCGCCGCTCGTGCTTAGTGAAGGCGATGCGGGACC R
S269W CATCTCGCTGCTGCTGTGCCTGTGGGGCATGTTCAGCGGCCTCAAC F
GTTGAGGCCGCTGAACATGCCCCACAGGCACAGCAGCAGCGAGATG R
L330F GTACTGGTCAACACCACGTTCACCATCCTGCTGGACGAC F
GTCGTCCAGCAGGATGGTGAACGTGGTGTTGACCAGTAC R
E357K GGCATCGTCATCTTCGGAAAAATCGTGCCCCAAGCCATC F
GATGGCTTGGGGCACGATTTTTCCGAAGATGACGATGCC R
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respective DNA constructs using Lipofectamin 2000 (Invitrogen, Breda, The Netherlands) 
at 1:2 DNA:Lipofectamin ratio for 48 hrs unless otherwise stated.
Cell Surface Biotinylation
HEK293 cells were transfected with wild-type and mutant CNNM2 constructs for 48 hrs. 
Subsequently, cell surface proteins were biotinylated as described previously (11). Briefly, 
cell surface proteins were biotinylated for 30 min at 4 °C in 0.5 mg/mL sulfo-NHS-LC-LC-
biotin (Pierce, Rockford, IL, USA). Cells were washed and lysed in lysis buffer (150 mmol/L 
NaCl, 5 mmol/L EGTA, Triton 1 % (v/v), 1 µg/mL pepstatin, 1 mmol/L PMSF, 5 µg/mL 
leupeptin, 5 µg/mL aproptin, 50 mmol/L Tris/HCl pH 7.5). 10 % (v/v) of the sample was 
taken as input control and the rest of the protein lysates were incubated overnight with 
NeutrAvidin-agarose beads (Pierce, Rockford, IL, USA) at 4 °C. The next day, unbound 
protein was discarded by washing the beads 5 times with lysis buffer. The remaining 
protein lysates were denatured in Laemmli containing 100 mmol/L DTT for 30 min at 37 °C 
and subsequently subjected to SDS-PAGE. Then, immunoblots were incubated with 
mouse anti-HA 1:5,000 primary antibodies (Cell Signaling Technology, Danvers, MA, USA) 
and peroxidase conjugated sheep anti-mouse secondary antibodies 1:10,000 (Jackson 
Immunoresearch, Suffolk, UK).
Magnesium Transport Assays
HEK293 cells were transfected with wild-type and mutant CNNM2 constructs for 48 hrs 
and seeded on poly-L-lysine (Sigma, St Louis, MO, USA) coated 12-well plates. Mg2+ uptake 
was determined using a stable 25Mg2+ isotope (Cortecnet, Voisins Le Bretonneux, France), 
which has a natural abundance of ±10 %. Cells were washed with basic uptake buffer (in 
mmol/L: 125 NaCl, 5 KCl, 0.5 CaCl2, 0.5 Na2HPO4 0.5 Na2SO4, 15 HEPES/NaOH pH 7.5) and 
subsequently placed in basic uptake buffer containing 1 mmol/L 25Mg2+ (purity ±98 %) for 
5 min unless stated differently. After washing three times with ice-cold PBS, the cells were 
lysed in HNO3 (≥65 %, Sigma) and subjected to ICP-MS (inductively coupled plasma mass 
spectrometry) analysis. For extrusion experiments, cells were transfected with wild-type 
or mutant CNNM2 constructs for 24 hrs. After 24 hrs, cells were placed in culture medium 
containing 1 mmol/L 25Mg2+ (purity ±98 %) for an additional 48 hrs. Before the start of the 
experiment, the cells were briefly washed in basic uptake buffer and subsequently placed 
in basic uptake buffer containing 0.5 mmol/L Mg2+ (containing ±10 % 25Mg2+) for 5 min. 
After washing three times with ice-cold PBS, the cells were lysed in nitric acid and 
subjected to ICP-MS analysis.
Morpholino Knockdown and Rescue Experiments
Wild-type Tupfel long-fin zebrafish were bred and raised under standard conditions (28.5 
°C and 14 hrs of light: 10 hrs of dark cycle) in accordance with international and institutional 
guidelines. Zebrafish eggs were obtained from natural spawning. The following antisense 
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oligonucleotides (MOs) were raised against the translational start site of cnnm2a and 
cnnm2b, along with the standard mismatch control MO (Gene Tools, Philomath, OR, USA): 
cnnm2a, 5’-GCGGTCCATTGCTCTGCCATGTTGA-3’; cnnm2b, 5’-ACCGACGGTTCTGCCATGTT-
GATAA-3’; and the negative control (standard mismatch MO), directed against a human 
β-globin intron mutation, 5’-CCTCTTACCTCAGTTACAATTTATA. The underlined areas 
indicate the complementary sequences to the initial methionines of cnnm2a and cnnm2b. 
MOs were diluted in deionized, sterile water supplemented with 0.5 % (w/v) phenol red 
and injected in a volume of 1 nL into the yolk of one- to two-cell stage embryos using a 
Pneumatic PicoPump pv280 (World Precision Instruments, Sarasota, FL, USA). Wild-type 
(uninjected) embryos were also included in the experiments to control for the effects of 
the injection procedure per se. To determine the most effective dose of the cnnm2a- and 
cnnm2b-MO, 2, 4 and 8 ng were injected. In these experiments, control embryos were 
injected with 8 ng of the standard mismatch control MO (the highest dose). After injection, 
embryos from the same experimental condition were placed in 3 Petri dishes (at a 
maximum density of 45 embryos/dish, allowing statistical comparisons between survivals 
in the different experimental conditions) and cultured at 28.5 °C in E3 embryo medium (in 
mmol/L: 5 NaCl, 0.17 KCl, 0.33 CaCl2, 0.33 MgSO4), which was refreshed daily. As criteria for 
subsequent experiments, the dose of MO that caused major effects and induced a 
percentage of mortality non-significantly different from controls was injected (2 ng for 
cnnm2a-MO and 8 ng for cnnm2b-MO). In experiments that implied exposure to high 
Mg2+ concentrations, the high Mg2+ medium had a composition of 5 mmol/L NaCl, 0.17 
mmol/L KCl, 0.33 mmol/L CaCl2 and 25 mmol/L MgSO4. In order to control for the 
specificity of the MOs blocking the translation of cnnm2a and cnnm2b, as well as for toxic 
off-target effects, in vivo cRNA rescue experiments were performed (9). For these 
experiments, mouse wild-type CNNM2 and mutant (p.Glu357Lys) CNNM2 cRNAs were 
prepared using the mMESSAGE mMACHINE Kit (Ambion, Austin, TX, USA) according to the 
manufacturer’s instructions. The cRNAs, in an amount of 50 pg, as based on other studies 
(24), were (co)injected together with MOs or alone as described above. Zebrafish embryos 
and larvae were phenotyped at 25 hpf or 5 dpf, respectively.
Analysis of Phenotypes in Zebrafish Embryos and Larvae
For the analyses of brain phenotypes, the brain rudiment of zebrafish embryos at 25 hpf 
was observed for morphological changes under a Leica MZFLIII microscope (Leica 
Microsystems Ltd, Heerburgg, Germany). Morphological phenotypes, which also included 
the brain, were also analysed in larvae at 5 dpf. Embryos or larvae were classified into 
different classes of phenotypes on the basis of comparisons with stage-matched control 
embryos of the same clutch. In cnnm2a morphant embryos (25 hpf), two phenotype 
classes were distinguished: class I, normal; and class II, embryos with underdeveloped 
MHB. In cnnm2a morphant larvae (5 dpf), the following classes were distinguished: class I, 
normal; class II, normal with non-inflated swim bladder; class III, larvae with enlarged 
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pericardial cavity (edema) and non-inflated swim bladder; class IV, larvae with notochord 
defects, enlarged pericardial cavity and non-inflated swim bladder; and class V, larvae with 
severely enlarged pericardial cavity, notochord defects and non-inflated swim bladder. In 
cnnm2b morphant embryos (25 hpf), three different phenotypes were distinguished: class 
I, normal; class II, embryos with underdeveloped MHB; and class III, embryos with 
underdeveloped MHB and enlarged tectum. In cnnm2b morphant larvae (5 dpf), the 
number of different phenotypes distinguished were four: class I, normal; class II, normal 
with non-inflated swim bladder; class III, larvae with enlarged pericardial cavity (edema) 
and non-inflated swim bladder; and class IV, larvae with widened outer cerebrospinal fluid 
spaces, kidney cysts, severely enlarged pericardial cavity and non-inflated swim bladder. 
Representative images were obtained with a DFC450C camera (Leica Microsystems Ltd) 
after anaesthetising embryos or larvae with tricaine/Tris pH 7.0 solution. Prior to 
anaesthesia and image acquisition, zebrafish embryos were manually dechorionated.  
Mg2+ Determinations in Embryos and Larvae
Zebrafish embryos or larvae were anesthetized with tricaine/Tris pH 7.0 solution and 5-7 
individuals were pooled as one sample. Samples were then snap frozen in liquid nitrogen 
and stored at -80°C in order to ensure euthanasia of animals and remained at these storage 
conditions until the beginning of the analytical procedures.
Analytical procedures started by quickly washing the samples with nanopure water in 
order to avoid contamination of remaining waterborne Mg2+. The washing procedure was 
repeated twice. Fish were then dried at 65 °C for 1.5 hrs, at which time 2.5 µL of HNO3 (≥65 
%, Sigma) was added to each tube. Samples were digested at 65 °C during 1.5 hrs. After, 
digested samples were diluted 1:10 with 22.5 µL nanopure water. The total Mg content in 
each sample was determined with a commercial colorimetric assay (Roche Diagnostics, 
Woerden, The Netherlands) following the manufacturer’s protocol. Blanks (HNO3 diluted 
1:10 with nanopure water) were added during assays and values were equal to zero. 
Within-run precision and accuracy was controlled by means of an internal control 
Precinorm (Roche Diagnostics). Samples from embryos exposed to 25 mmol/L Mg2+ were 
further diluted (1:20). Furthermore, samples were normalized by protein content, which 
was determined in 1:20 (embryos at 25 hpf) or 1:50 (larvae at 5 dpf) diluted samples using 
the PierceTM BCA protein assay kit (Pierce Biotechnology, Rockford, IL, USA).    
Total RNA Isolation, cDNA Synthesis and Real Time PCR Analysis
Zebrafish embryos or larvae at specific developmental times (6, 12, 24, 48, 72, 96 and 120 
hpf) were anaesthetised with tricaine/Tris pH 7 solution and 10 individuals were pooled as 
one sample. RNA isolation, cDNA synthesis and quantitative real-time PCR (RT-qPCR) 
measurements were carried out as previously described using validated cnnm2a and 
cnnm2b primers (1). Samples were normalized to the expression level of the housekeeping 
gene elongation factor-1α (elf1α) (1). Relative mRNA expression was analysed using the 
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Livak method (2−ΔΔCt), where results are expressed relative to the gene expression at 6 hpf 
(time point chosen as calibrator).
Spontaneous Contraction Analysis and Touch-evoked Escape Behaviour
At 25 hpf, 10 zebrafish embryos per Petri dish (n=30 per experimental condition) were 
randomly selected. The number of complete body contractions each zebrafish made in 
30 s period was counted and was used as indicative of motor neuron activity (28). 
Representative videos of each experimental condition were taken using Leica Application 
Suite (Leica Microsystems Ltd) and a Leica MZFLIII microscope (Leica Microsystems Ltd) 
equipped with a DFC450C camera (Leica Microsystems Ltd).
 For the analysis of the touch-evoked escape behaviour, 10 zebrafish larvae per Petri 
dish (n=30 per experimental condition) were randomly selected. Touch-evoked escape 
behaviours were elicited by touching a larva in the tail up to 6 times with a pair of forceps 
at 5 dpf. Three categories were distinguished, responders, late responders and non-
responders, to which the following scores were given: 3 points for responders: fish quickly 
react (swimming or flicking the tail) to the stimuli after 1 or 2 twitches; 2 points for late 
responders: fish react (swimming or flicking the tail) to the stimuli after 3, 4 or 5 twitches; 
and 1 point for non-responders: fish do not react to the stimuli after more than 5 twitches. 
Representative videos were recorded with the system described above.
  
Statistical Analysis
All results are depicted as mean ± standard error of the mean (SEM). Statistical analyses 
were conducted by one- or two-way (for experiments where zebrafish embryos were 
exposed to different Mg2+ concentrations, then two factors of variance appear: Mg2+ 
concentration and treatment) ANOVA. Where appropriate, data were logarithmically 
transformed to fulfil the requirements for ANOVA, but all data are shown in their decimal 
values for clarity. When data did not comply with the premises of the parametric ANOVA, 
data were analyzed using a Kruskal-Wallis ANOVA on ranks. Tukey’s post-test was used to 
identify significantly different groups. Statistical significance was accepted at P < 0.05.
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Abstract
The transient receptor potential melastatin type 6 (TRPM6) ion channel regulates the body 
Mg2+ homeostasis by mediating transcellular Mg2+ absorption in kidney and intestine. 
 Here, the P2X4 receptor was established as a novel regulator of TRPM6 activity. Using 
RT-qPCR on a mouse tissue panel, P2x4 and P2x6 were shown to be expressed in the 
epithelium of the colon and of the kidney, two major sites of Mg2+ reabsorption. While 
P2x4 was highly expressed in the colon, both P2x4 and P2x6 mRNA were prominently 
expressed in the distal convoluted tubule (DCT) segment of the kidney, a segment with 
high Trpm6 expression. Using whole-cell patch clamp, an inhibitory role of P2X4 on TRPM6 
activity was determined. Expression of P2X6, which does not form functional channels in 
mammalian cells, did not affect the function of TRPM6. The inhibition was dependent on 
the activity of P2X4, since a P2X4 mutant with altered ATP sensitivity was not able to inhibit 
TRPM6. Additionally, P2X4 was unable to inhibit TRPM7, a close homologue of TRPM6, 
suggesting that the inhibition is specific for TRPM6. To identify the intracellular signaling 
molecules that mediate the P2X4-dependent inhibition of TRPM6, the cells were treated 
with inhibitors of PKC, PKA and PI3K. However, none of these inhibitors prevented the 
inhibition of TRPM6 by P2X4.  
 In conclusion, we propose that P2X4 receptor mediated purinergic signaling is a new 
regulatory mechanism of TRPM6 Mg2+ channels. 
Keywords: Magnesium, Colon, Purinergic Receptor, P2X4, TRPM6
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Introduction
Magnesium (Mg2+) plays a key role in bone formation, neuronal excitability and muscular 
function, which can be explained by its numerous cellular functions such as Ca2+-channel 
antagonist, inhibitor of Ca2+ signaling, NMDA receptor blocker and cofactor in over 
300 enzymatic reactions. Among patients in the intensive care unit more than 50 % 
present disturbed Mg2+ balance (25).  To keep serum Mg2+ levels within a constant range 
(0.7-1.1 mmol/L), the intestine facilitates uptake of Mg2+, bone serves as the body Mg2+ 
store and the kidney regulates the excretion of Mg2+ (9). 
 Two separate absorption mechanisms facilitate Mg2+ uptake in the gut and the 
kidney. First, paracellular uptake allows the passive transport of Mg2+ from the lumen of 
the small intestine to the blood through the tight junctions between the cells (34). The 
fine-tuning of Mg2+ absorption is achieved in the colon and in the distal convoluted 
tubule (DCT) segment of the nephron, where the transient receptor potential melastatin 
type 6 (TRPM6) channels function as the gatekeepers of transcellular Mg2+ transport (34, 
45).  Mutations causing loss of function of TRPM6 are the predominant cause for familial 
hypomagnesaemia where blood Mg2+ falls below the normal range (9, 35, 46). Knockout 
(KO) of Trpm6 is lethal in mice, whereas the heterozygous animals display a mild hypomag-
nesaemia due to reduced intestinal and renal Mg2+ (re)absorption (52). In the DCT, TRPM6 
has been shown to be regulated by a variety of factors, including: epidermal growth 
factor (EGF)(14, 40), insulin (29), estrogens (13) and acid-base status (30). In addition, various 
transporters and channels are necessary to maintain a favorable electrochemical gradient 
for transcellular Mg2+ uptake (reviewed in (9)).  In contrast, factors regulating intestinal 
Mg2+ absorption are largely unknown although it was demonstrated that dietary Mg2+ 
intake modulates the expression of TRPM6 (13).
 ATP acts as an autocrine and paracrine modulator of ion transport processes in the 
kidney and intestine (24, 32). In the intestine, high amounts of ATP (25-500 µmol/L) are 
released in response to different stimuli, such as flow and neuronal activation (5). Two 
types of P2 purinergic receptors are expressed at the cell surface of epithelial cells. Whereas 
P2Y receptors act as G-protein coupled receptors, P2X receptors form ATP-activated ion 
channels (3, 31). The P2X receptor family consists of seven subtypes (P2X1-7) with distinct 
expression profiles and biophysical properties (3, 31). P2X receptors assemble in homo- or 
heterotrimers with large extracellular loops forming one or multiple ATP binding sites (3, 
18). Activation of P2X receptors by extracellular ATP leads to the non-selective influx of 
cations into the cell. P2X receptors are commonly described as inhibitors of ion transport 
processes (24). In the kidney, P2X receptors negatively modulate water, Mg2+ and Na+ 
reabsorption (7, 26, 48, 51). Interestingly, a previous study described the P2X-dependent 
inhibition of Mg2+ influx in mouse DCT cells (7). Although the number of studies on the 
effects of P2X receptors on transport activity beyond the kidney is limited, recent 
publications support an inhibitory role in bone and intestine (1, 33).
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 In the present study, we aim to clarify the expression and the role of P2X receptors in 
the regulation of transcellular epithelial Mg2+ transport in the intestine and the kidney. 
After providing a transcriptional profile of P2X subunits in a mouse tissue panel, the renal 
expression of P2X4 and P2X6 was examined in detail using immunohistochemistry. With a 
combination of biochemistry and electrophysiology, a previously unknown inhibitory role 
of P2X4 on TRPM6 activity was demonstrated, suggesting that purinergic signaling is an 
important modulator of Mg2+ homeostasis. 
Results
Expression Profile of P2X1-7 Subunits
In order to determine the expression of P2X channels in Mg2+-transporting epithelia, the 
distribution of P2x1-7 subunits was assessed in a mouse cDNA tissue panel using RT-PCR. 
A broad range of intestinal tissues were chosen with the aim of pinpointing the expression 
of the different P2x to the distinct segments of the gut. Notably, P2x4 is the most expressed 
P2x subunit in the distal intestine, including colon and cecum, which are known for high 
capacity in transcellular Mg2+ reabsorption via TRPM6 (13). The expression of P2x4 is 
generally high in tissues with strong ion transporting capacities such as intestines, kidney 
and lung (Figure 1D). P2x6 mRNA levels are most prominent in the kidney, although it is 
present in all additionally examined tissues including intestine, lung and heart (Figure 1F). 
All other P2X receptors showed a distinct expression pattern that is less specific for ion 
transporting epithelia. Although present in duodenum, P2x1 mRNA levels are highest in 
spleen and lung (Figure 1A). P2x2 is exclusively expressed in testes (Figure 1B). P2x3 shows 
a broad expression pattern with presence in all parts of the intestines (Figure 1C). P2x5 is 
prominently expressed in heart, lung and testes (Figure 1E). P2x7 is present in lung, spleen 
and testes (Figure 1G). 
 Transcellular Mg2+ reabsorption occurs in the DCT segment of the kidney. The 
expression of the different P2x isoforms in the DCT was further examined using RT-PCR on 
COPAS sorted kidney material and immunohistochemistry on kidney slices. Interestingly, 
the DCT almost exclusively expresses transcripts for P2x4 and P2x6 (Figure 2A).
 Total kidney samples from the same mice revealed that all P2x subunits are present in 
kidney tissue, although P2x3 and P2x7 mRNA transcript levels were low (Figure 2B). The 
localization of P2X4 and P2X6 proteins was further examined using immunohistochemis-
try on mouse kidney tissue. Remarkably, a conspicuous co-localization of P2X6 and NCC 
was found, of which the latter serves as a marker for DCT (Figure 3A). Conversely, immuno-
histochemical stainings on mouse kidney did not show co-localization of P2X4 and NCC 
(Figure 3B).
P2X4 Regulates the Activity of TRPM6 | 199
Fi
gu
re
 1
   T
is
su
e 
D
is
tr
ib
ut
io
n 
of
 P
2x
1-
7 
Su
bu
ni
ts
 
A
-G
, T
he
 m
RN
A 
ex
pr
es
sio
n 
le
ve
ls 
of
 P
2x
1 
(A
), 
P2
x2
 (B
), 
P2
x3
 (C
), 
P2
x4
 (D
), 
P2
x5
 (E
), 
P2
x6
 (F
) a
nd
 P
2x
7 
(G
) i
n 
a 
pa
ne
l o
f m
ou
se
 ti
ss
ue
s 
w
er
e 
m
ea
su
re
d 
by
 q
ua
nt
ita
tiv
e  
RT
-P
CR
 a
nd
 n
or
m
al
ize
d 
fo
r G
ap
dh
 e
xp
re
ss
io
n.
 D
at
a 
ar
e 
ex
pr
es
se
d 
as
 p
er
ce
nt
ag
e 
of
 to
ta
l t
iss
ue
 e
xp
re
ss
io
n 
an
d 
re
pr
es
en
t t
he
 m
ea
n 
of
 3
 in
di
vi
du
al
 e
xp
er
im
en
ts
 ±
 S
EM
.
A
Kid
ne
y
Du
od
en
um
Ile
um Je
jun
um
Co
lon C
ec
um
Bra
in H
ea
rt L
un
g L
ive
r
Sp
lee
n Te
ste
s Mu
scl
e
0204060
02040608010
0 K
idn
ey
Du
od
en
um
Ile
um Je
jun
um
Co
lon C
ec
um
Bra
in H
ea
rt L
un
g L
ive
r Sp
lee
n Te
ste
s Mu
sc
le
010203040
Kid
ne
y
Du
od
en
um
Ile
um Je
jun
um
Co
lon C
ec
um
Bra
in H
ea
rt L
un
g L
ive
r Sp
lee
n Te
ste
s Mu
scl
e
010203040
Kid
ne
y
Du
od
en
um
Ile
um Je
jun
um
Co
lon C
ec
um
Bra
in H
ea
rt L
un
g L
iv
er Sp
lee
n Te
ste
s Mu
scl
e
C
B
P2x1 mRNA expression
(% of total expression)
P2x2 mRNA expression
(% of total expression)
P2x3 mRNA expression
(% of total expression)
E
P2x5 mRNA expression
(% of total expression)
010203040
Kid
ne
y
Du
od
en
um
Ile
um Je
jun
um
Co
lon C
ec
um
Bra
in H
ea
rt L
un
g L
ive
r Sp
lee
n Te
ste
s Mu
scl
e
G
P2x7 mRNA expression
(% of total expression)
0102030
Kid
ne
y
Du
od
en
um
Ile
um Je
jun
um
Co
lon C
ec
um
Bra
in H
ea
rt L
un
g L
ive
r Sp
lee
n Te
ste
s Mu
scl
e
D
P2x4 mRNA expression
(% of total expression)
01020304050
F
P2x6 mRNA expression
(% of total expression)
Kid
ne
y
Du
od
en
um
Ile
um Je
jun
um
Co
lon C
ec
um
Bra
in H
ea
rt L
un
g L
ive
r Sp
lee
n Te
ste
s Mu
scl
e
200 | Chapter 8
Figure 2   P2x4 and P2x6 are Expressed in the DCT Segment of the Kidney 
A-B, The mRNA expression levels of P2x1, P2x2, P2x3, P2x4, P2x5, P2x6, and P2x7 were measured from 
COPAS-sorted DCT cells (A) or from COPAS-sorted cells from same kidney sample without selection 
for EGFP (B). mRNA levels were measured by quantitative RT-PCR and normalized for Gapdh expression. 
Data represent the mean of 4 experiments ± SEM.
Figure 3   P2X6 Co-localizes with NCC in the DCT 
A, Mouse kidney sections were co-stained for NCC (in green) and P2X6 (in red). B, Mouse kidney 
sections were co-stained for P2X4 (in green) and NCC (in red). Bars represent 100 µm (upper panel), 
50 µm (middle panel) or 10 µm (bottom panel).
A
D
C
T 
m
RN
A
 e
xp
re
ss
io
n
(c
op
y 
nu
m
be
r /
 G
A
PD
H
 X
10
-2
)
P2
X1
P2
X2
P2
X3
P2
X4
P2
X5
P2
X6
P2
X7
0
0.5
1.0
1.5
2.0
B
P2
X1
P2
X2
P2
X3
P2
X4
P2
X5
P2
X6
P2
X7
0
0.2
0.4
0.6
0.8
1.0
C
or
te
x 
m
RN
A
 e
xp
re
ss
io
n
(c
op
y 
nu
m
be
r /
 G
A
PD
H
 X
10
-2
)
A
B
P2X4 Regulates the Activity of TRPM6 | 201
P2X4 Inhibits the Activity of TRPM6 
Given the co-expression of TRPM6 with P2X4 in the colon, protein expression of P2X4 in 
the rat colonic crypts (38) and previous reports demonstrating P2X4-dependent inhibition 
of Mg2+ transport in the kidney (7), we investigated whether there is a functional 
interaction between P2X4 and TRPM6. Constructs of TRPM6 and P2X4 were either 
expressed alone or together in HEK293 cells and their function was investigated using 
whole-cell patch clamp.
 Cells were perfused with a Mg2+-free pipette solution as described previously (45). 
Voltage ramps evoked slowly-developing outwardly rectifying currents, a signature 
feature of TRPM6 under our recording conditions (Figure 4A-B, (45)). Measurement of the 
voltage-evoked current density at +80 mV revealed that co-transfection of P2X4 and 
TRPM6 led to the constitutive inhibition of TRPM6 activity near endogenous levels (Figure 
4A-C), while ATP-evoked current increased from undetectable levels to -304 ± 54 pA/pF at 
-60 mV (n≥42, data not shown). Non-transfected cells showed an average voltage-evoked 
current density of 35 ± 5 pA/pF at +80 mV (Figure 4C). Co-transfection of P2X6 subunit 
together with TRPM6 yielded a current density not significantly different from TRPM6 
alone (Figure 4C). In agreement with previous reports (4, 43), ATP-evoked current were 
absent from cells expressing P2X6 alone (n=9, data not shown). The expression of P2X6 at 
the membrane was confirmed by cell surface biotinylation (data not shown). In addition, 
the co-expression of TRPM6 and a P2X4 mutant (p.Tyr315Cys, P2X4mut (37)) with a reduced 
ATP sensitivity did not lead to the inhibition of TRPM6 (Figure 4C). A plot of TRPM6 current 
density versus the ATP-evoked current density revealed a dose-dependent inhibition of 
TRPM6 by P2X4 (Figure 4D). TRPM6 is made of a channel domain and a C-terminal 
intracellular kinase domain (35, 46). Co-transfection of P2X4 and the kinase-inactive TRPM6 
mutant (p.Lys1804Arg, (41)) resulted in a similar inhibition (n≥9, data not shown), therefore 
excluding a role of the kinase domain of TRPM6. Interestingly, co-expression of P2X4 with 
TRPM7, a close homolog of TRPM6, did not inhibit TRPM7 (Figure 4E). The average 
ATP-evoked current in the presence of P2X4 and TRPM7 was 85 ± 16 pA/pF (n=10, data not 
shown). Cell surface biotinylation showed that TRPM6 membrane availability is not 
abolished when co-expressed with P2X4 (Figure 4F).  These data demonstrates that P2X4 
specifically inhibits TRPM6 in a way that requires the ion channel activity of P2X4.
TRPM6 Inhibition Does not Depend on PKC, PKA or PI3K
Given the Ca2+-permeability of P2X4 and the requirement of functional P2X4 channels for 
the inhibition of TRPM6, we hypothesized that the constitutive activity of P2X4 would lead 
to an increase in the cytosolic free Ca2+ concentration. Rising intracellular Ca2+ levels will 
activate Ca2+-dependent kinases such as protein kinase C (PKC). Cells were incubated with 
the PKC inhibitor Chelerythrine Chloride (≥ 2 hrs, 1 mmol/L). This protocol did not 
significantly affect basal TRPM6 currents or TRPM6 currents in the presence of P2X4 (Figure 
5A, left panel). ATP-evoked currents were also unaffected by this treatment (Figure 5A, 
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Figure 4   P2X4 Inhibits the Activity of TRPM6 Channels 
A, TRPM6 currents were evoked by a 500 ms voltage ramp from -100 to +100 mV applied every 2 s 
(top left inset). The activity of P2X4 channels was assessed by perfusion of 100 mmol/L ATP on cells 
held at -60 mV. Typical voltage-evoked traces (left) and ATP-evoked traces (right) obtained with or 
without P2X4 co-expression. B, Time course of TRPM6 current development at +80 mV ( , )  and 
-80 mV ( , ) . Co-expression of P2X4 strongly reduces the current amplitude of TRPM6 currents 
(n=7). C, Co-expression of TRPM6 with P2X4 (n≥39), but not P2X6 (n≥13), reduces the average volt-
age-evoked current density. Non-transfected cells are shown for comparison (NT, n=10).  A mutant 
with altered sensitivity to ATP (p.Tyr315Cys) does not inhibit TRPM6 currents (n≥10). D, The TRPM6 
current density is plotted against the logarithm of the peak ATP-evoked inward current density mea-
sured at -60 mV in the same cells. The star indicates the average current density obtained without 
P2X4. A linear fit was performed to evidence a correlation between the activity of TRPM6 and P2X4. 
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E, TRPM7 currents were compared with or without coexpression of P2X4. P2X4 does not inhibit the 
function of TRPM7 channels (n≥11). F, Cell surface biotinylation of HEK293 cells co-expressing HA-
tagged TRPM6 and Mock or HA-tagged P2X4. Representative immunoblots showing that P2X4 ex-
pression does not impair TRPM6 membrane expression (left). Total protein expression was assessed 
as control for expression of P2X4 (right).
Figure 5   PKA, PKC and PI3K are not Involved in the Inhibition of TRPM6 by P2X4
A, The PKC inhibitor chelerythrin chloride (CC, ≥ 2 hrs, 1 mmol/L) did not reverse the inhibition of 
TRPM6 by P2X4 (n≥9, left panel). ATP evoked currents were unaffected by the treatment with CC 
(n=8, right panel). B, The PKA inhibitor H-89 (1 mmol/L, 20 min) did not reverse the inhibition of 
TRPM6 by P2X4 (n≥6, left panel). Inhibition of PKA with H-89 increased ATP-evoked currents in cells 
co-expressing TRPM6 and P2X4 (n≥15, right panel). C, The PI3K inhibitor Wortmannin (100 nmol/L, 
30 min) did not reverse the inhibition of TRPM6 by P2X4 (n≥6, left panel). Wortmannin did not affect 
ATP-evoked currents in cells co-expressing TRPM6 and P2X4 (n≥9, right panel).
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right panel). Next, to test whether the inhibition is dependent on protein kinase A (PKA), 
cells were incubated with the PKA inhibitor H-89 (10 mmol/L, 20 min). The treatment with 
H-89 did not affect the baseline TRPM6 current and current from cells expressing TRPM6 
and P2X4 (Figure 5B, left panel). Under these conditions, the ATP-evoked currents were 
significantly increased compared to the control treatment (Figure 5B, right panel). The 
activation of PI3K was previously shown to modulate the epithelial Na+ channel function 
(ENaC) in Xenopus laevis oocytes (50, 51). Cells were incubated with the PI3K inhibitor 
Wortmannin (30 min, 10 nmol/L). This protocol did not induce any change in current 
density for TRPM6 alone or TRPM6 together with P2X4 (Figure 5C, left panel). The 
ATP-evoked currents were unaffected by the treatment with Wortmannin (Figure 5C, right 
panel).
P2X4 KO Mice Show Normal Mg2+ Levels
To assess the involvement of P2X4 in the maintenance of Mg2+ levels under normal 
conditions, the serum Mg2+ levels and urinary Mg2+ excretion of P2X4 KO mice were 
determined. Average basal serum Mg2+ concentration (Figure 6A), nor the urinary Mg2+ 
excretion were significantly changed in P2X4 KO mice compared to wild type littermates 
(Figure 6B).
Figure 6   P2X4 Knockout Mice Exhibit Normal Serum and Urinary Mg2+ Concentrations 
A, Serum Mg2+ concentrations of wild type and knockout P2X4 mice. B, 24hr urinary Mg2+ excretion 
of wild type and knockout P2X4 mice. Values are presented as means ± SEM (n=6).
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Discussion
Transcellular transport of Mg2+ via TRPM6 is the last step in Mg2+ (re)absorption in the 
intestine and kidney and is, therefore, an important regulator of blood Mg2+ levels (9). 
Here, we establish P2X4 as a novel player in the regulation of TRPM6 activity. Although 
P2X4 was previously suggested to inhibit Mg2+ transport in kidney (7), we are the first to 
establish its role in the regulation of TRPM6 activity.
 TRPM6 forms constitutively active Mg2+-permeant ion channels inhibited by physiological 
concentrations of intracellular Mg2+ (45). A functional TRPM6 channel comprises four 
subunits, each containing seven transmembrane domains and intracellular COOH and 
NH2 amino termini. In analogy with the well-described voltage-gated ion channels, a pore 
and a selectivity filter are formed at the interface between the fifth and sixth 
transmembrane domains of the four monomers (42). TRPM6 and its close homologue 
TRPM7 exhibit a peculiar C-terminal kinase domain (35, 46), the function of which is not 
completely understood. Due to their kinase moiety, TRPM6 and TRPM7 undergo auto-
phosphorylation at multiple sites within their intracellular domains (2). P2X channels 
comprise three subunits, each containing two transmembrane domains separated by a 
large extracellular loop (18). P2X4 channels are characterized by a rapid activation upon 
ATP binding, resulting in a slowly desensitizing non-selective influx of mono- and divalent 
cations such as Ca2+ (3, 10, 31).
 Here, it is demonstrated for the first time that the P2X4 purinergic receptors inhibit 
the activity of TRPM6. Our data show that the inhibition of TRPM6 occurs at the membrane 
since P2X4 did not disrupt the levels of TRPM6 membrane expression in a cell surface 
biotinylation assay. The inhibition is dependent on the function of the P2X4 receptors 
since the ATP-insensitive P2X4-p.Tyr315Cys mutant was not able to inhibit TRPM6. This 
suggests that the inhibition of TRPM6 is dependent on activity-evoked P2X4 signaling. 
Due to the strong intracellular divalent chelation needed to record TRPM6 currents in 
whole-cell patch clamp, it is not possible to test the hypothesis that P2X4 receptor 
activation directly inhibits TRPM6. The scenario in which TRPM6 and P2X4 participate in a 
macromolecular complex and influence each other’s function via physical interaction 
cannot be discarded. Such physical interactions between neuronal ligand-gated ion 
channels, TRPV channels and P2X receptors have been previously demonstrated (19, 36). 
Until now, P2X4 has been shown to interact with WNT4, MCM2 and CDH5 (12, 47). However, 
there has been no large-scale P2X4 interaction studies published and there are no reports 
of interactions with other ion channels. Therefore, it would be of interest to find P2X4 
interacting partners to further examine this latter possibility.  
 P2X4 receptors have been previously described as inhibitors of ion transport 
processes (7, 24, 49). Specifically, P2X4 receptors were shown to modulate the activity of 
ENaC by promoting retrieval of the channel from the membrane (49, 50). Interestingly, the 
authors found that among the tested functional P2X receptors, only the slowly-desensitizing 
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P2X2 and P2X4 were able to inhibit ENaC (50). Rapidly inactivating P2X channels (P2X1, 
P2X3) failed to inhibit ENaC, suggesting that the intensity and duration of ion influx 
dictates the extent of target channel inhibition. In agreement with previous reports, we 
could not detect ATP-evoked currents from cells expressing P2X6 (16, 22, 43). In contrast to 
P2X4, P2X6 failed to inhibit TRPM6. It is tempting to speculate that other functional and 
slowly desensitizing homo- or heterotrimeric P2X receptors (P2X2, P2X5, P2X7, P2X2/X4, 
P2X2/X5, etc) could alter the function of different ion channels in different tissues, thereby 
forming a new general mechanism of ion channel regulation. This hypothesis is supported 
by recent findings in the Thick Ascending Limb of Henle’s loop (TAL) (26), but further 
investigations are necessary to confirm this proposition.
  Although P2X receptors have been established as important regulators of ion 
transport in a broad range of tissues, their exact mechanism of signaling is largely 
unknown (1, 7, 23, 24, 26, 49). Indeed, our pharmacological screening could not identify 
which kinases are involved in TRPM6 inhibition. A supporting role of PKA and PKC in the 
P2X4-dependent TRPM6 inhibition could not be evidenced from our experiments. The 
PI3K kinase has previously been implicated in P2X4-induced retrieval of ENaC from the 
membrane (51). Using wortmannin, we demonstrate that PI3K was not involved in such 
regulation of P2X4-mediated TRPM6 inhibition. Moreover, TRPM6 membrane expression 
is largely preserved in the presence of P2X4, suggesting that ENaC and TRPM6 are 
differentially regulated. TRPM6 has multiple predicted phosphorylation sites for numerous 
protein kinases, with few of them characterized. Future large-scale pharmacological 
screening and mutagenesis studies should identify the molecular mechanism responsible 
for the P2X4-dependent TRPM6 inhibition. 
 The expression of P2X receptors was previously demonstrated in tissues and cells 
from kidney and intestinal origin (1, 7, 15, 38, 39, 44). In our study, we found the protein 
expression and colocalization of P2X6 with NCC, a marker of the DCT. Unfortunately, 
despite high mRNA transcript levels in the DCT, we were not able to evidence the protein 
expression of P2X4 in this segment of the kidney. This is in contradiction to a previous 
report demonstrating basolateral expression of P2X4 and P2X6 throughout rat kidney, 
including the DCT (44). The reasons for this discrepancy are not clear. However, given the 
expression of P2X4 and P2X6 transcripts in the DCT and the tendency of P2X receptors to 
form heteromultimers, one could speculate that P2X4 participates in protein complexes 
with P2X6 in such a way that the P2X4 epitope is not accessible for antibody binding. In 
addition, it is possible that certain metabolic conditions are required to trigger P2X4 
protein expression in the DCT. However, future experiments will be needed to clarify this 
issue.  
 In recent years, an increasing amount of reports from the clinic claim that the use of 
certain types of drugs dramatically reduces intestinal Mg2+ absorption (17, 21). Nevertheless, 
our knowledge of the regulation of intestinal Mg2+ absorption is limited. The colon is the 
most important site of transcellular Mg2+ absorption via TRPM6 in the intestine (20, 45). 
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Although the regulation of TRPM6 has been widely studied in the kidney (13, 14, 29, 40), 
this is the first identification of a regulatory mechanism of TRPM6 in the gut. Our results 
provided evidence that P2X4 is expressed in colon and cecum, which is in line with 
previous studies (6, 11, 38, 39). Interestingly, the intestines are among the tissues with the 
highest ATP secreting capacities (5, 23). Physical force applied by the content of the colonic 
lumen can activate mechanosensors resulting in luminal and basolateral ATP release (5). 
Luminal ATP serves an autocrine and paracrine regulator of channel and transporter 
activity at the luminal membrane (23, 27, 53). In addition, the role of P2X4 on TRPM6 
activity may extend beyond the intestine, since TRPM6 and P2X4 are also highly expressed 
in lung (13). In basal conditions, P2X4 KO mice have normal serum Mg2+ levels and urinary 
Mg2+ excretion. These results suggest that other mechanisms may compensate for the 
loss of P2X4 function in basal conditions. TRPM6 activity is regulated by growth factors 
such as EGF and insulin, which may play a compensatory role (14, 29). Therefore, it would 
be of interest to further challenge the P2X4 KO mouse with low Mg2+ diets. 
 In conclusion, a novel regulatory mechanism of intestinal TRPM6 activity has been 
identified. ATP release in colon may activate the P2X4 purinergic receptor leading to the 
inhibition of the activity of TRPM6. Our results are an important next step in understanding 
the complex regulatory mechanism of intestinal Mg2+ absorption.
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Methods
Expression Profiling
Three male C57BL/6 mice were sacrificed; kidney, duodenum, ileum, jejunum, colon, 
cecum, brain, lung, liver, spleen, testis, muscle, and heart tissues were collected. For the 
analysis of segment-specific kidney expression we used parvalbumin-EGFP (PV-EGFP) 
mice, which express the EGFP under the parvalbumin promoter and allow selection of 
EGFP-positive DCT tubules (kind gift from Dr. Monyer, University of Heidelberg, Germany, 
(28)). Selection of DCT tubules was performed as described previously (8). In short, mice 
were perfused with 20 mL of PBS (in mmol/L: 137 NaCl, 2.7 KCl, 10 Na2HPO4, 1.76 KH2PO4) 
through the heart. The kidneys were removed, minced, and digested in 1 mg/mL 
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collagenase A (Worthington, Lakewood, NJ, USA) and 1 mg/mL hyaluronidase (Sigma, 
Houten, The Netherlands) in Krebs buffer (in mmol/L: 145 NaCl, 5 KCl, 10 HEPES, 1 NaH2PO4, 
2.5 CaCl2, 1.8 MgSO4 and 5 glucose) at 37 °C for three cycles of 5-15 min. The collagenase- 
digested tubules were sorted by COPAS (Complex Object Parametric Analysis and Sorting, 
Union Biometrica) based on EGFP-fluorescence intensity. Per mouse, 4,000 EGFP-positive 
fluorescent tubules were collected. To use as a control, an additional 4,000 tubules were 
sorted from the same kidney sample without selection for EGFP-positive cells.
 Total RNA was isolated using TRIzol total RNA isolation agent (Invitrogen, Breda, the 
Netherlands) and treated with DNase (1U/μg RNA, Promega, Leiden, the Netherlands) to 
remove genomic DNA. Subsequently, reverse transcription of the RNA by M-MLV reverse 
transcriptase (Invitrogen) was performed for 1 hr at 37 °C. Gene expression levels were 
determined by quantitative real-time PCR on a Bio-Rad analyzer using iQ Sybr Green 
(BioRad, Veenendaal, the Netherlands) and normalized for Gapdh expression levels. Primer 
sequences are listed in Table 1.
Immunohistochemistry
Co-staining for P2X4 and P2X6 with the thiazide-sensitive Na+-Cl- cotransporter (NCC) 
were performed on 5 μm sections of frozen mouse kidney samples. Sections were heat 
treated with sodium-citrate and endogenous peroxidase was blocked. Unspecific binding 
sites were blocked with blocking buffer (TSA fluorescence System, Perkin Elmer). The sections 
were incubated for 16 hrs at 4 °C with the following primary antibodies: goat anti-P2X6 
(1:100, A58sc-15197, Santa Cruz, Heidelberg, Germany), mouse anti-P2X4 (1:100, A58SC-28764, 
Santa Cruz, Heidelberg, Germany), rabbit anti-NCC (1:100, (8)). P2X4 staining was enhanced 
using TSA fluorescence System (Perkin Elmer, Groningen, The Netherlands). For detection, 
kidney sections were incubated with Alexa Fluor-conjugated secondary antibodies. 
Images were taken with an AxioCam camera and AxioVision software (Zeiss, Sliedrecht, 
the Netherlands).
Table 1   Primer Sequences
F R
P2x1 5’-CCGAAGCCTTGCTGAGAA-3’ 5’-GGTTTGCAGTGCCGTACAT-3’
P2x2 5’-CACCACCACTCGAACTCTCA-3’ 5’-GGTACGCACCTTGTCGAACT-3’
P2x3 5’-GGTGGCTGCCTTCACTTC-3’ 5’-TCAGCCCCTTTGAGGAAA-3’
P2x4 5’-TTGGCTCTGGCTTGGCGCTC-3’ 5’-TCTCCGGAAAGACCCTGCTCG-3’
P2x5 5’-GAGCGAGTTTTACCGAGACAAG-3’ 5’-GATGAACCCTCTCCAGTGGC-3’
P2x6 5’-CTCCTGGAGGTGGTTCATGTG-3’ 5’-GGCTTTGGCAAGCTTTACTTC-3’
P2x7 5’-GGGGGTTTACCCCTACTGTAA-3’ 5’-GCTCGTCGACAAAGGACAC-3’
Gapdh 5’-TAACATCAAATGGGGTGAGG-3’ 5’-GGTTCACACCCATCACAAAC-3’
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DNA Constructs
The pCINeo TRPM6 IRES GFP expression construct was described previously (45). To obtain 
P2X4 and P2X6 expression constructs, we used the full-length human P2X4 and P2X6 cDNA 
clones with Genbank accession numbers BC033826 and BC033488 respectively (Source 
BioScience LifeSciences, Nottingham, United Kingdom). The coding sequences of P2X4 
was amplified using Phusion polymerase (Finnzymes, Vantaa, Finland) and primers F: 
5’-ccgctagcgATGGCGGGCTGCTGCGC-3’ and R: 5’-CGCTCGAGTCACTGGTCCAGCTCAC-3’) to 
introduce NheI and XhoI restriction sites. For P2X6, we introduced NheI and XmaI with 
primers F; 5’-cggctagcATGGGCTCCCCAGGGGC-3’ and R: 5’-GCCCCGGGCGCAGGCTCCCG-
GAATGGG-3’. The amplicons were cloned into the pCINeo-IRES-GFP expression vectors 
containing an in frame N-terminal HA-tag using the NheI, XmaI and XhoI restriction sites. 
The P2X4 p.Tyr315Cys mutation was introduced using the QuikChange site-directed 
mutagenesis kit (Agilent, Amstelveen, The Netherlands). All constructs were verified by 
sequence analysis. GFP-tagged P2X6 constructs were created by introducing BspEI and 
EcoRI restriction by RT-PCR (F: 5’-cgtccggaATGGGCTCCCCAGGGGC-3’ and R: 5’-GCGAAT-
TCCTACAGGCTCCCGGAATG-3’) and ligation in a pEGFP vector containing an in frame 
N-terminal GFP. Flag-tag was inserted using Phusion polymerase and primers containing 
AgeI and XhoI restrictions sites (F: 5’-CAGaccggtcgccaccGACTACAAGGATGACGATGA-
CAAGGCGGGCTGCTGCGCCGCG-3’ and R: 5’-CGCTCGAGTCACTGGTCCAGCTCAC-3’). The 
PCR product was digested and ligated into the pCINeo vector using AgeI and XhoI. The 
pTracer mTRPM7 construct (kind gift from Dr. David E. Clapham) was transfected using an 
identical protocol.
Cell Culture and Transfection
Human embryonic kidney cells (HEK293) were grown at 37 °C in DMEM (Biowhittaker 
Europe, Vervier, Belgium) supplemented with 10 % (v/v) FCS (PAA Laboratories, Linz, 
Austria), nonessential amino acids, and 2 mmol/L L-glutamine in a humidified 5 % (v/v) 
CO2 atmosphere. Cells were seeded in 12-well plates and subsequently transfected with 
1-1.25 μg of HA- of FLAG-tagged constructs in the pCINeo-IRES-GFP or pcINeo-IRES-mCherry 
vectors using Lipofectamine 2000  (Invitrogen) at 1:3 DNA:Lipofectamine ratio. 
 For patch-clamp experiments, cells were seeded two days after transfection on glass 
coverslips coated with 50 mg/mL of fibronectin (Roche, Mannheim, Germany). Two hrs 
later, cells were placed in the recording chamber and selected based on the intensity of 
the fluorescent reporter.
Immunoblotting
HEK293 cells were lysed for 1 hr at 4° C in TNE lysis buffer containing (in mmol/L): 50 Tris/
HCl pH 8.0, 150 NaCl, 5 EDTA, 1 % Triton X-100 (v/v) and pepstatin 1 µg/mL, PMSF 1 mmol/L, 
leupeptin 5 µg/mL and aproptin 5 µg/mL. Protein lysates were denatured in Laemmli 
containing 100 mM DTT for 30 min at 37 °C and subsequently subjected to SDS-PAGE. 
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Immunoblots were then incubated with a mouse anti-HA (Roche, high affinity 3F10, 
1:5,000) primary antibody and peroxidase conjugated sheep anti-mouse secondary 
antibodies (Jackson Immunoresearch, 1:10,000).
Electrophysiology 
Whole-cell voltage-clamp experiments were carried out using an EPC-9 amplifier (HEKA 
electronics, Lambrecht, Germany). Data acquisition and analysis were performed using 
Pulse or Patchmaster software (HEKA). The sampling interval was set to 200 ms for all 
experiments. Pipettes were pulled from thin-walled borosilicate glass (Harvard Apparatus) 
and had resistance between 1 and 3 MW, when filled with the pipette solution. Series 
resistance compensation was set to 50-95 % in all experiments. Measurements of TRPM6 
and TRPM7 activity were performed by applying 500 ms voltage ramps from -100 to +100 
mV every 2 s from a holding potential of 0 mV. TRPM6-expressing cells displayed a 
time-dependent increase in outwardly-rectifying currents upon whole-cell break-in. This 
is partly due to the chelation of intracellular Mg2+, which inhibits TRPM6. Consequently, 
the reported current values were obtained at +80 mV 100 s after break-in. Consistent with 
the endogenous expression of TRPM7 in HEK293 cells, non-transfected cells displayed 
small voltage-evoked currents under these recording conditions (45).  The activity of P2X 
channels was assessed by perfusion of 100 mmol/L ATP on cells held at -60 mV using a fast 
quartz micromanifold solution applicator (ALA scientific instruments, Farmingdale, NY). 
 The extracellular solution contained (in mmol/L): 150 NaCl, 1 CaCl2, 10 HEPES/NaOH 
pH 7.4. The pipette solution was made of (in mmol/L): 150 NaCl, 10 Na2EDTA, 10 HEPES/
NaOH, pH 7.2. 
P2X4 KO Mice
P2X4 KO mice were provided by GlaxoSmithKline UK and maintained in a C57BL/6 genetic 
background. 24 hrs urine collection was performed in mouse metabolic cages for two 
consecutive days. Blood samples were drawn by cardiac puncture in isoflurane-anesthe-
tized mice. Urine measurements were performed on the sample of the second 24 hrs.
Mg2+ Analysis
Serum and urine total Mg2+ concentrations were determined using a colorimetric assay kit 
according to the manufacturer’s protocol (Roche Diagnostics, Woerden, the Netherlands). 
Statistical Analysis 
All results are depicted as mean ± standard error of the mean (SEM). All statistical analyses 
were conducted by one-way ANOVA followed by Tukey post hoc test when comparing 
two treatment groups or experimental conditions. Difference in means with P values 
< 0.05 were considered statistically significant.
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Abstract
Magnesium (Mg2+) is essential for enzymatic activity, brain function and muscle 
contraction. Blood Mg2+ concentrations are tightly regulated between 0.7 and 1.1 mmol/L 
by Mg2+ (re)absorption in kidney and intestine. The apical entry of Mg2+ in (re)absorbing 
epithelial cells is mediated by the transient receptor potential melastatin type 6 (TRPM6) ion 
channel. 
 Here, flavaglines are described as a novel class of stimulatory compounds for TRPM6 
activity. Flavaglines are a group of natural and synthetic compounds that target the 
ubiquitously expressed prohibitins and thereby affect cellular signaling. By whole-cell 
patch clamp analyses, it was demonstrated that nanomolar concentrations of flavaglines 
increases TRPM6 activity by ±2 fold. The stimulatory effects were dependent on the 
presence of the alpha-kinase domain of TRPM6, but did not require its phosphotransfer-
ase activity. Interestingly, it was observed that two natural occurring TRPM6 mutants with 
impaired insulin-sensitivity, TRPM6-p.Val1393Ile and TRPM6-p.Lys1584Glu, are not sensitive 
to flavagline stimulation. To examine the therapeutic potential of flavaglines, mice were 
injected with a low dose of FL3 for 7 days. Serum concentration and 24 hrs urinary Mg2+ 
excretion were not changed after treatment. 
 In conclusion, we have identified flavaglines as potent activators of TRPM6 activity. 
Our results suggest that flavaglines stimulate TRPM6 via the insulin receptor signaling 
pathway. 
Keywords: Magnesium, Kidney, Intestine, Homeostasis, Prohibitin, Flavagline
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Introduction
Magnesium (Mg2+) is an essential electrolyte for cell growth, protein synthesis and 
enzymatic activity. Therefore, physiological mechanisms maintain blood Mg2+ 
concentrations within a tightly regulated range (0.7-1.1 mmol/L, (11, 12)). The apically 
expressed Transient Receptor Potential Melastatin type 6 (TRPM6) channels are the 
gatekeepers of epithelial Mg2+ transport in colon and in the distal convoluted tubule 
segment (DCT) of the kidney nephron (29). Loss-of-function mutations of TRPM6 cause 
intestinal Mg2+ malabsorption and renal Mg2+ wasting, as evidenced in patients suffering 
from hypomagnesemia with secondary hypocalcemia (HSH, OMIM #602014, (20, 30)).
 TRPM6 channels are thought to form tetramers of subunits comprising six 
transmembrane segments, with a central divalent-selective pore (Ba2+>Ni2+>Mg2+>Ca2+, 
(29)). Functional channels are inhibited by intracellular Mg2+ (29, 33) and consequently 
display a time-dependent increase in currents upon dialysis of cells with a pipette solution 
containing a strong Mg2+ chelator such as ethylenediaminetetraacetic acid (EDTA). Like its 
close homolog TRPM7, TRPM6 channels comprise an intrinsic intracellular Ser/Thr kinase 
domain, which has similarities to proteins of the alpha-kinase family (19). TRPM6 channels 
undergo autophosphorylation, but the role of the alpha-kinase on channel function and 
cell physiology is still incompletely understood (5, 21, 24, 28, 33). 
 Over the last decade, the epidermal growth factor (EGF) and insulin were shown to 
stimulate the activity and membrane expression of TRPM6 (16, 23). Two TRPM6 single 
nucleotide polymorphisms (SNPs: p.Val1393Ile and p.Lys1584Glu) were recently associated 
with an increased risk of diabetes development in humans (16, 22). Subsequently, it was 
shown that these mutations prevent a rapid insulin-evoked increase in channel plasma 
membrane expression (16).
 By combined pull down and mass spectrometry studies of the TRPM6 alpha-kinase 
domain, three interacting proteins have been identified: I) Methionine sulfoxide reductase 
B1 (MSRB1) which reduces the sensitivity of TRPM6 to oxidative stress (6), II) Guanine nucleotide- 
binding protein subunit beta-2-like 1 (GNB2L1/RACK1) which inhibits TRPM6 activity in a 
 alpha-kinase-dependent manner (7). III) Prohibitin 2 or Repressor protein of Estrogen 
receptor Activity (PHB2/REA) which inhibits TRPM6, an effect that is relieved by estrogens (8). 
 Prohibitins (PHB1 and PHB2) are ubiquitously expressed members of the family of 
stomatin/prohibitin/flotillin and HflK/C (SPFH) domain containing proteins (9). PHBs are 
found in the nucleus, cytoplasm and plasma membrane, where they play an important 
role in cellular differentiation, anti-proliferation and mitochondrial morphogenesis (9). 
PHBs modulate the cell cycle progression, regulate transcription and facilitate cell surface 
signaling (9). Recently, a family of natural compounds named flavaglines was established 
as high affinity ligand of PHBs (18).
 Flavaglines are a family of natural compounds characterized by a cyclopenta[b]
benzofuran structure (14). Natural flavaglines and synthetic analogs have been intensively 
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studied, owing to their pleiotropic favorable properties (anti-inflammatory, anticancer, 
cardioprotective and neuroprotective, (2)). Flavaglines bind PHB1 and PHB2 (with nmol/L 
affinity) and the CRaf-mediated activation of oncogenic MAPK signaling (18). In addition, 
the PHB binding properties of flavaglines lead to the induction of apoptosis in apoptosis 
inducing factor (AIF) and caspase-12-dependent manners (2). Additionally and independently 
from PHBs, flavaglines inhibit eIF4A-dependent oncogenic protein synthesis (2). The 
mechanism of flavaglines neuro- and cardioprotection are likely mediated by their PHB- 
interacting properties, thereby reducing oxidative stress, deleterious growth factor 
signaling and release of inflammatory mediators (2). 
 Given the previously described inhibitory interaction of PHB2 on TRPM6 and the high 
affinity binding of flavaglines to PHB1 and PHB2, this study aims to identify and characterize 
the effect of flavaglines on TRPM6 activity. The molecular effects of flavaglines are studied 
using patch clamp, while their in vivo properties were assessed in mice injected with a 
flavagline. 
Results
Synthetic Flavaglines Stimulate TRPM6 Activity
HEK293 cells were transfected with the previously described pCINeo-TRPM6-HA-IRES-GFP 
vector (29). This construct allows the visual identification of cells expressing TRPM6. Cells 
were then subjected to whole-cell patch clamp analysis, as previously described (29). 
Briefly, currents were elicited by a series of voltage ramps applied at 0.5 Hz from a holding 
voltage of 0 mV. Due to the dialysis of the cytoplasm with a pipette solution containing 
EDTA, time-dependent outwardly rectifying currents were observed in response to this 
ramp protocol (Figure 1A). In order to assess the effect of flavaglines on TRPM6, cells were 
first exposed to FL23 (50 nmol/L, (26)), a potent analog of the established PHB2 ligand FL3 
(18). This protocol yielded a significant increase in the current density without affecting 
the characteristic shape of the current-voltage (IV) curve (Figure 1B) or the current time- 
development characteristics (Figure 1C). The average time-development curves were 
fitted with a logistic equation (see Methods). This analysis revealed that the time of 
half-maximal activation (t1/2) was not changed between control and FL23-treated cells 
(control: 48 ± 2 s, FL23: 43 ± 3 s). The rate of current development (the slope h) was 
increased with FL23 treatment (control: 1.8 ± 0.1 pApF-1s-1, FL23: 3.0 ± 0.2 pApF-1s-1). 
Pre-incubation of the cells with concentrations of FL23 ranging from 0.01 to 50 nmol/L 
revealed a concentration-dependent stimulation of TRPM6 activity with an EC50=1.4 ± 0.2 
nmol/L (see Methods, Figure 1D). A similar increase in TRPM6 activity was observed with 
FL3 (50 nmol/L, Figure 2A-B).  Next, cells were pre-incubated with FL2 (50 nmol/L), a 
flavagline that does not display significant cytotoxicity in cancer cells (25). In contrast to 
FL3 and FL23, this treatment did not significantly alter the current density of TRPM6- 
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Figure 1   Flavaglines Stimulate TRPM6 at Nanomolar Concentration 
A, TRPM6 currents were evoked by a series of 500 ms voltage ramp from -100 to +100 mV applied 
every 2 s (0.5 Hz) from a holding potential of 0 mV (top left inset). A typical set of current-voltage 
curves obtained from a single cell is shown. B, Typical current-voltage curves obtained 200 s after 
break-in from cells pre-incubated 15 min with vehicle or FL23 (50 nmol/L). C, The average time-course 
of TRPM6 current development with (n=19) or without (n=19) FL23 pre-treatment are shown for 
current values measured at +80 mV. D, FL23 increases TRPM6 current density in a concentration- 
dependent manner (n≥3 per data points). Line represents the fit of data points with a Hill equation 
(see Methods). E, Incubation of TRPM6 expressing cells with FL3 (50 nmol/L, n≥10), FL23 (50 nmol/L, 
n≥22) or estradiol (17βE) (50 nmol/L, n≥9) significantly increased the average current densities 
 measured at +80 mV 200 s after break-in. Mock-transfected cells showed a similar increase in current 
density (n≥8). TRPM6 currents were not sensitive to FL2 (n≥10). Stars indicate statistically significant 
difference between vehicle- (white bar) and compound-treated cells (black bar). F, The chemical 
structures of FL2, FL3 and FL23 are shown. A bromide atom at position 4’ is necessary for the high 
 affinity stimulating effects of FL3 and FL23. G, Cells were pre-incubated with vehicle, FL23 (50 
 nmol/L) or 17βE (50 nmol/L). Total lysate were subjected to Western blot analysis using an anti-HA 
primary antibody. FL23 and 17βE did not significantly affect the expression of TRPM6. Stars indicate 
statistically significant difference (P < 0.05) between vehicle and compound-treated cells.
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expressing cells (Figure 2C-D). As previously reported, estradiol (17βE) significantly stimulated 
TRPM6 currents (Figure 1E, (8)). On average, 17βE, FL3 and FL23 stimulated TRPM6 activity by 
1.5 to 2-fold (Figure 1E). Interestingly, mock-transfected cells demonstrated a similar 
±2-fold increase in current density upon FL23 treatment, indicating that TRPM7 is also a 
likely target of flavaglines action (Figure 1E). As expected from the short pre-incubation 
period, the expression of TRPM6 was not influenced by FL23 or 17βE (Figure 1G). 
The Stimulating Effects of Flavaglines Require the Intrinsic Kinase 
Domain of TRPM6
To assess the involvement of the intrinsic alpha-kinase domain in the flavagline-mediated 
potentiation of TRPM6 currents, cells were transfected with the previously described 
 kinase-truncated (p.Leu1749*, Δkinase) or kinase-inactive (p.Lys1804Arg, KI) TRPM6 constructs 
(24). While the first construct produces mutant channels lacking the complete kinase 
Figure 2   Analogs of FL23 Show Distinct Effects on TRPM6 Currents 
A, Typical current-voltage curves obtained 200 s after break-in are shown for vehicle and FL23 (50 
nmol/L) pre-incubated cells. B, The average time-course of TRPM6 current development with (n=8) 
or without (n=11) FL23 (50 nmol/L) is shown for current values measured at +80 mV. C, The average 
time-course of TRPM6 current development with FL2 (50 nmol/L, n=12), vehicle (n=10) or FL23 (50 
nmol/L, n=10) pre-treatment is shown for current values measured at +80 mV. D, FL2 incubation 
does not significantly stimulate TRPM6 activity (n≥10). Stars indicate statistically significant difference 
(P < 0.05) between vehicle and compound-treated cells.
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domain, the KI construct form channels without intrinsic alpha-kinase phosphotransfer-
ase activity. Both constructs produce functional proteins with apparently normal channel 
function in the absence of intracellular Mg2+. Using an identical pre-incubation protocol, 
cells expressing the KI mutant demonstrated a FL23-mediated increase in current densities 
similar to wild type (Figure 3A and C). In contrast, the Δkinase mutant failed to respond to 
this treatment (Figure 3B-C).
Flavaglines Act along a Shared Pathway with Insulin 
The intracellular amino acid residues p.Val1393 and p.Lys1584 have been shown to 
independently confer sensitivity of TRPM6 channels to insulin stimulation, probably by 
altering the phosphorylation of the neighboring p.Thr1393 and p.Ser1583 residues, 
respectively (16). Phosphomimicking mutations of either p.Thr1391Asp or p.Ser1583Asp 
were shown to be permissive in the insulin-mediated potentiation of TRPM6 (16). To 
address whether flavaglines act on TRPM6 in a similar way as insulin, cells expressing either 
of two naturally occurring insulin-insensitive TRPM6 SNPs (p.Val1393Ile or p.Lys1584Glu) 
were pre-incubated with FL23 (50 nmol/L). These mutants failed to respond to FL23 
(Figure 4A-B,E). 
 Following the activation of the insulin receptor, a complex multi-branched signaling 
cascade is activated. One of these branches involves the activation of Phosphoinositide 
3-kinase (PI3K), Akt and Ras-related C3 botulinum toxin substrate 1 (Rac1)(4). Co-expression 
of TRPM6 together with the constitutively active (p.Gly12Val) or dominant-negative 
(p.Thr17Asn) mutants of Rac1 have been shown to respectively allow and prevent the 
increase of TRPM6 membrane expression by insulin (16). Here, cells were co-transfected 
with TRPM6 and either the p.Thr17Asn or p.Gly12Val Rac1 mutants. Both mutants prevented 
the stimulation of TRPM6 by FL23 (Figure 4C-D,F). 
Flavaglines Do not Affect Akt Phosphorylation
Given the previously described modulation of Akt by PHBs (1)4,5-triphosphate (PIP3, the 
effects of flavaglines on Akt phosphorylation were examined using the same experimental 
conditions as were used in the patch clamp experiments. Following 15 min of incubation, 
phosphorylation of Akt was not induced by FL2 and FL3 (50 nmol/L, Figure 5). It has been 
previously demonstrated that flavaglines prevent ERK1/2 phosphorylation in a manner 
that depends on CRaf (18). Here, basal ERK1/2 phosphorylation was not apparent in control 
condition and no additional phosphorylation was detected upon flavaglines stimulation 
(Figure 5). 
Flavaglines Do not Modulate In Vivo Mg2+ Homeostasis 
To explore the therapeutic potential of flavaglines, twenty C57/Bl6 mice were injected 
daily with 0.1 mg/kg FL3 or placebo for 7 days, a dose previously shown to provide cardi-
oprotective benefits in mice (3). On days 1, 3 and 7 mice were transferred to metabolic 
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cages for 24 hrs to collect urine and feces; blood was collected by submandibular facial 
vein puncture. No differences were detected in serum Mg2+ concentrations and 24 hrs 
Mg2+ total excretion between FL3-treated mice and mice receiving placebo (Figure 6A-B). 
Interestingly, minor, but significant, changes were detected in serum Na+ and Ca2+ values. 
FL3-treated mice had decreased serum Ca2+ at day 1, but showed elevated serum Ca2+ 
levels at day 7 (Figure 6C). However, these changes were not reflected in urinary Ca2+ 
excretion (Figure 6D). Serum Na+ was slightly lower at day 7 in FL3-treated mice (Table 1).
Given that Trpm6 mRNA expression is sensitive to changes in Mg2+ homeostasis and 
reduced Trpm6 expression may compensate for increased Tprm6 activity (11, 13), kidney 
and colon mRNA was isolated and analyzed. Trpm6 expression in both colon and kidney 
was not altered by FL3 treatment (Figure 7A-B). Since serum Na+ was slightly reduced in 
FL3-treated mice, the expression of Na+ transporters was analyzed by RT-PCR. The expression 
Figure 3   The Presence of the Intrinsic Alpha-Kinase Domain of the Channel but not its 
Activity is Required for Flavagline-Mediated Stimulation of TRPM6 
A, The average time-course of current development of the kinase-inactive (TRPM6K1804R) with (n=7, 
full symbols) or without (n=9, empty symbols) FL23 (50 nmol/L) pre-incubation is shown for current 
values measured at +80 mV. B, The average time-course of current development of TRPM6L1749X 
(Δkinase) with (n=8, full symbols) or without (n=9, empty symbols) FL23 (50 nmol/L) pre-incubation 
is shown for current values measured at +80 mV. C, Pre-incubation of cells with FL23 (50 nmol/L) 
stimulated wild type (n≥22), K1804R (n≥9), but not Δkinase (n≥8) channel activity. Right panel shows 
current values normalized to each control condition. Stars indicate statistically significant difference 
(P < 0.05) between vehicle- (white bar) and compound-treated cells (black bar).
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of the thiazide-sensitive Na+-Cl--co-transporter (Ncc) and the epithelial Na+ channel (Enac) 
were not affected (Figure 7C-D).
Figure 4   Flavaglines Act upon a Common Pathway with Insulin Receptor Signaling 
A-D, The average time-course of current development of cells pre-incubated with (full symbols) or 
without (empty symbols) FL23 (50 nmol/L) for: (A) TRPM6V1393I (n≥8), (B) TRPM6K1584E (n≥7), (C) wild 
type TRPM6 together with Rac1T17N (n≥6) and (D) wild type TRPM6 together with Rac1G12V (n≥11). 
E, FL23 pre-incubation failed to alter currents in cells expressing TRPM6V1391I (n=11), TRPM6K1584E 
(n≥8) and cells co-expressing wild type TRPM6 together with Rac1T17N (n=8) and TRPM6 together 
with Rac1G12V (n≥14). Right panel shows current values normalized to each control condition. Stars indicate 
statistically significant difference (P < 0.05) between vehicle- (white bar) and compound-treated 
cells (black bar).
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Figure 5   Cell Akt and ERK Signaling is Unaffected by FL3
HEK293 cells were incubated with FL2 (50 nmol/L), FL3 (50 nmol/L), PMA (100 nmol/L) or insulin (10 
nmol/L) for 15 min. Protein lysates were immediately obtained and immunoblots were performed 
to detect pERK1/2 and pAkt.
Figure 6   Serum and Urine Mg2+ and Ca2+ in FL3-Treated Mice 
A-D, Serum Mg2+ (A) and Ca2+ (C) concentrations of placebo-treated (white bars) and FL3-treated 
(black bars) mice were measured after 1, 3 or 7 days. 24 hrs urinary Mg2+ (B) and Ca2+ (D) excretion of 
placebo-treated (black bars) and FL3-treated (white bars) mice was determined after 1, 3 or 7 days (n=10). 
Stars indicate statistically significant difference (P < 0.05) between placebo- and FL3-treated mice.
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Discussion
The present study demonstrates that the activity of the Mg2+-permeant TRPM6 channel is 
stimulated ±2-fold by the flavaglines compounds FL3 and FL23. This is the first report of 
an exogenous natural compound that stimulates TRPM6 activity.
 The activity of TRPM6 and its plasma membrane expression have been shown to be 
increased upon stimulation with insulin. This effect relied on the PI3K, Akt and Rac1 
signaling cascade (Figure 8). Detailed electrophysiological and total internal reflection 
fluorescence (TIRF) microscopy analyses have revealed a permissive role for TRPM6-p.
Val1391 and TRPM6-p.Lys1584 sites in insulin-evoked insertion of channels in the plasma 
membrane (16). Here, it is proposed that flavaglines stimulate TRPM6 by acting along the 
same pathway (Figure 8). This hypothesis is based on the following observations: (I) 
flavaglines increased TRPM6 activity ±1.5-2 fold, which is quantitatively similar to the 
previously described action of insulin on TRPM6 activity (16); (II) the insulin-insensitive 
Figure 7   mRNA Expression of Na+ and Mg2+ Transporters after FL3 Treatment
A-D, The mRNA expression levels of Trpm6 (A-B). Ncc (C) and Enac (D) in kidney (A, C-D) or colon (B) 
of placebo- (black bars) or FL3-treated (white bars) mice for 7 days were measured by quantitative 
RT-PCR and normalized for Gapdh expression (n=10). Stars indicate statistically significant difference 
(P < 0.05) between placebo- and FL3-treated mice.
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(TRPM6-p.Val1391Ile and TRPM6-Lys1584Glu) TRPM6 mutants were not potentiated by 
flavaglines; (III) flavaglines-induced TRPM6 stimulation was absent when overexpressing 
TRPM6 together with Rac1 mutants; (IV) in concordance with the mechanism of insulin 
action on TRPM6, flavaglines stimulated the kinase-inactive (TRPM6-p.Lys1804Arg) 
mutant. Taken together, it is hypothesized that flavaglines act by triggering or relieving a 
tonic inhibition on one (or more) of the molecular player(s) involved in insulin signaling, 
effectively promoting the plasma membrane insertion of wild type TRPM6 channels but 
not of TRPM6 channels containing insulin-insensitive SNP mutants. Our data suggest that 
the effects of flavagline-stimulation take place downstream of Akt, since no additional Akt 
phosphorylation was evident upon treatment with FL3. Further experiments investigating 
the detailed molecular action of flavaglines on the localization and phosphorylation of 
the known kinases involved in growth-factor stimulation of TRPM6 (PI3K/Akt/RAC1/CDK5) 
will be necessary to elucidate the exact molecular targets. 
 Flavaglines have recently been identified as potent interactors of PHBs (9). Interestingly, 
PHB1 and PHB2 are enriched in detergent resistant (lipid rafts) fractions of the plasma membrane 
(9). Given the previously described action of PHBs as chaperone of Ras-dependent CRaf 
Figure 8   Proposed Model of Flavaglines Action  
Flavaglines stimulate TRPM6 activity by stimulating downstream effector(s) of the insulin receptor. 
PHB2 and CDK5, proteins which are known to regulate TRPM6 are localized in lipid rafts.
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activation in the plasma membrane (18), a general function of PHBs is to provide spatial 
constraints necessary for the proper regulation of proteins in specialized regions (eg the 
lipid rafts) of the plasma membrane. It can be hypothesized that TRPM6 channels 
transiently or permanently localize together with PHB in the lipid raft fractions of the 
plasma/vesicular membrane, where channels undergo regulatory phosphorylation. The 
following facts support this hypothesis:  (I) TRPM6 has been shown to establish a inhibitory 
interaction with PHB2 (8); (II) TRPM6 requires CDK5 phosphorylation for proper insulin- 
mediated regulation, CDK5 localizing and being activated in the lipid raft fraction of 
plasma membrane (17); (III) the close homolog TRPM7 has been reported to localize in 
lipid rafts (32), (IV) TRPM6 requires PIP2 for proper function (31), a lipid that is enriched in 
lipid rafts. Therefore, it is tempting to speculate that PHBs binding to TRPM6 promotes the 
formation of a macromolecular regulatory complex in the lipid rafts of the plasma 
membrane. In this perspective, it is interesting to note that the insulin-induced signaling 
pathway becomes more active when the insulin receptor is expressed in lipid rafts (10, 15, 
27). Altogether, these findings point towards a compartmentalized insulin signaling 
cascade on/near the lipid rafts in the vesicular/plasma membrane. In this model, expression 
of TRPM6 and the insulin receptor in the lipid rafts allows for the rapid local regulation of 
TRPM6 by insulin. 
 Comparison of structure-function activity between active (FL3, FL23) and inactive 
(FL2) flavaglines analogs revealed a positive correlation between cytostatic/cytotoxic 
properties of flavaglines in cancer cell lines and their action on TRPM6 (18, 25, 26). While 
the effects of flavaglines on cellular proliferation and growth factor signaling were evident 
starting from 2 hours after compound application, the stimulatory effect shown here 
occurs within 15 minutes. These results suggest that the short-term effects of flavaglines 
on TRPM6 take place independently from any translational effect (eg eIF4A-dependent). 
However, the concurrent structure-function relationship of flavaglines in their TRPM6- 
stimulatory effects and in their cytotoxic properties suggests that both mechanisms are 
PHB-dependent. It has previously been shown that PHB2 interacts with TRPM6 and that 
17βE reduces this inhibitory interaction (8). However, the current results suggest that 17βE 
and FL23 only share a partly overlapping mechanism of action. Exogenous PHB2 inhibits 
TRPM6 in an alpha-kinase phosphotransferase-dependent manner (8). In contrast, 
flavaglines stimulated the kinase-inactive TRPM6-p.Lys1804Arg mutant. Moreover, 
flavaglines induce an increase in endogenous TRPM7 currents, while TRPM7 currents were 
insensitive to PHB2-mediated inhibition (8). Further work identifying the major players that 
are part of the TRPM6-PHB macromolecular complex and its regulation by flavaglines and 
17βE are necessary to further understand the stimulatory but slightly distinct effects of 
these compounds on the activity of TRPM6.
 Reduced TRPM6 channel activity results in a clinically relevant hypomagnesemia due 
to renal Mg2+ wasting. Because insulin and EGF stimulate TRPM6 function, patients with 
diabetes mellitus type 2 or users of EGFR inhibitors are at risk to develop hypomagnesemia 
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(16, 23). Given that FL3 and FL23 stimulate TRPM6 activity, flavaglines may provide an 
important therapeutic potential for these patient groups. However, at the dose of 0.1 mg/
kg used in this study, FL3 did not significantly alter serum and/or 24 hrs urinary Mg2+ 
excretion in mice treated over the course of one week. In a recent experiment with a 
mouse model of cardiotoxicity, FL3 injection caused reduced mortality and demonstrated 
several cardioprotective effects using the same dose of FL3 as in our experiments (3). Both 
its cardioprotective role and its effects on TRPM6 are likely PHB-dependent, and therefore 
a similar dose was used. However, the actual dose of FL3 reaching the DCT cells in the 
kidney where TRPM6 is located may be much lower and challenging to assess. Future 
experiments assessing the bioavailability of flavaglines should be performed to allow final 
conclusions on its putative magnesiotropic effects in vivo. Additionally, given the 
physiological mechanism of intestinal and/or renal compensation of Mg2+ transport, the 
effects of flavaglines should be assessed in a murine model of hypomagnesemia.
 In conclusion, the natural compounds flavaglines stimulate the activity of TRPM6 
Mg2+ channels at nanomolar concentrations. The effect is rapid (within 15 min) and 
probably relies on a near-plasma membrane mechanism that likely involves PHBs. Further 
in vivo experiments will be needed to validate the putative magnesiotropic properties of 
these compounds with a plethora of beneficial effects. 
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Methods
Cell Culture
Human embryonic kidney cells (HEK293) were grown at 37 °C in DMEM (Biowhittaker 
Europe, Vervier, Belgium) supplemented with 10 % (v/v) fetal calf serum (PAA Laboratories, 
Linz, Austria), non-essential amino acids, and 2 mmol/L L-glutamine in a humidified 5 % 
(v/v) CO2 atmosphere. Cells were seeded in 12-well plates and subsequently transfected 
with 1 μg of HA-tagged TRPM6 cDNA using Lipofectamine 2000 (Invitrogen) at 1:3 DNA:-
Lipofectamine ratio. For patch-clamp experiments, cells were seeded two days after 
transfection on glass coverslips coated with 50 mL/cm2 of 50 μg/mL fibronectin (Roche, 
Mannheim, Germany). Two hours later, cells were placed in the recording chamber and 
selected based on the intensity of the fluorescent reporter.
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Electrophysiology
All experiments were undertaken and analyzed using an EPC-9 amplifier and the 
Patchmaster software (HEKA electronics, Lambrecht, Germany). The sampling interval was 
set to 200 ms and data was low-pass filtered at 2.9 kHz. Patch clamp pipettes were pulled 
from thin-walled borosilicate glass (Harvard Apparatus, March-Hugstetten, Germany) and 
had resistance between 1 and 3 MW when filled with the pipette solution. Series resistance 
compensation was set to 75-95 % in all experiments. Current densities were obtained by 
normalizing the current amplitude to the cell capacitance.
Solutions and Compound Application
The extracellular solution contained (in mmol/L): 150 NaCl, 1 CaCl2, 10 HEPES/NaOH pH 7.4. 
The pipette solution was made of: 150 NaCl, 10 Na2EDTA, 10 HEPES/NaOH pH 7.2 (29). Cells 
were pre-incubated 15 min at 37 °C in bath solution containing the compound of interest 
or vehicle (0.1 % (v/v) dimethyl sulfoxide (DMSO)).
Immunoblotting
HEK293 cells were lysed for 1 hr at 4 °C in TNE lysis buffer containing (in mmol/L): 50 Tris/
HCl pH 8.0, 150 NaCl, 5 EDTA, 1 % (v/v) Triton X-100 and protease inhibitors (pepstatin 1 µg/
mL, PMSF 1 mmol/L, leupeptin 5 µg/mL and aproptin 5 µg/mL). Protein lysates were 
denatured in Laemmli containing 100 mmol/L dithiothreitol (DTT, 30 min, 37 °C) and 
subsequently subjected to SDS-PAGE. Immunoblots were incubated with mouse anti-HA 
(Roche, high affinity 3F10, 1:5,000), rabbit anti-Akt (Cell signaling, 1:1,000) and rabbit 
anti-ERK1/2 (Cell signaling, 1:1,000) primary antibodies and peroxidase conjugated sheep 
anti-mouse secondary antibodies (Jackson Immunoresearch, 1:10,000).
Animal Experiment
Twenty male C57BL/6 mice aged between 8-12 weeks were housed in a light and 
temperature controlled room with ad libitum access to food and water. The animals were 
randomly divided in two groups and received daily intraperitoneal injections (0.1 mg/kg) of 
FL3 or placebo (polyethylene glycol 400 (PEG400). FL3 was dissolved in absolute ethanol 
(2 mg/mL) and diluted 100 fold (v/v) in PEG400 (4 g/10 ml). Blood was collected at day 1, 
day 3 and day 7 by submandibular facial vein puncture. Mice were housed for 24 hrs in 
metabolic cages at day 0-1, day 2-3 and day 6-7 to collect feces and urine. At day 7, the animals 
were sacrificed and kidneys and intestine were taken and immediately frozen in liquid nitrogen. 
Animal experiments were performed in concordance with national and institutional 
guidelines and approved by the Radboud University Nijmegen animal ethics board.
Electrolytes Measurements
Serum concentrations and urinary total Ca2+ and Mg2+ excretions were determined using 
colorimetric assay kits according to the manufacturer’s protocols (Lancer, St. Louis, MO, 
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USA and Roche Diagnostics, Woerden, the Netherlands, respectively). Serum and urinary 
Na+ and K+ were analyzed using a Hitachi automatic analyzer (Hitachi, Laval, Quebec, 
Canada).
Expression Analysis
Total RNA was isolated using TRIzol total RNA isolation agent (Invitrogen, Breda, the 
Netherlands) and treated with DNase (1U/μg RNA, Promega, Leiden, the Netherlands) to 
remove genomic DNA. Subsequently, reverse transcription of the RNA by M-MLV reverse 
transcriptase (Invitrogen) was performed for 1 hr at 37 °C. Gene expression levels were 
determined by quantitative real-time PCR on a Bio-Rad analyzer using iQ Sybr Green 
(BioRad, Veenendaal, the Netherlands) and normalized for Gapdh expression levels. Primer 
sequences are listed in Table 2.
Statistical and Data Analysis 
All results are depicted as mean ± standard error of the mean (SEM). Statistical analysis was 
conducted by one-way Student’s t-test when comparing two treatment groups or 
experimental conditions. When comparing multiple groups statistical comparisons were 
analyzed by two-way ANOVA with a Tukey’s multiple comparison test. Difference in means 
with P values <0.05 were considered statistically significant and indicated by a star (*).
 Current time-development curves were fitted with a logistic equation: I=I0+((Imax-I0)/
(1+(t/t1/2)-h)s), with I the current density, I0 the baseline current density, t the time, t1/2 the 
time of half-maximal current density, h the slope and s a parameter. Half-maximal 
stimulatory concentration (EC50) was obtained by fitting a Hill equation to the data points: 
I =I0+(Imax – I0) *(([FL23]n)/(IC50n+[FL23]n)), with I the current density, I0 the baseline current 
density obtained in control conditions, Imax the maximal current value and n the Hill 
number.
Table 2   Primer Sequences
Forward primer Reverse primer
Trpm6 5’-AAAGCCATGCGAGTTATCAGC-3’ 5’-CTTCACAATGAAAACCTGCCC-3’
Ncc 5’-CTTCGGCCACTGGCATTCTG-3’ 5’-GATGGCAAGGTAGGAGATGG-3’
Enac 5’-CATGCCTGGAGTCAACAATG-3’ 5’-CCATAAAAGCAGGCTCATCC-3’
Gapdh 5’-TAACATCAAATGGGGTGAGG-3’ 5’-GGTTCACACCCATCACAAAC-3’
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Magnesium Homeostasis
Magnesium (Mg2+) homeostasis is the balance between intestinal uptake, storage in bone 
and renal excretion. Animal studies with various Mg2+ diets have demonstrated that the 
adaptability to differences in Mg2+ intake mainly takes place in the kidney (Chapter 2)(46, 
133). Within the kidney, the distal convoluted tubule (DCT) is responsible for reabsorption 
of about 10 % of the filtered Mg2+ (9). Although the amount of Mg2+ reabsorption in the 
DCT is much lower than the reabsorption in the proximal tubule (PT, 10-25%) and the thick 
ascending limb of Henle’s Loop (TAL, 50-70 %), it is the most tightly regulated part of Mg2+ 
reabsorption in the kidney (23). Mg2+ transport in the DCT determines the final urinary 
Mg2+ excretion, since no reabsorption takes places beyond this segment. Animal studies 
using loop diuretics, severely reducing the Mg2+ reabsorption in TAL, did not result in renal 
Mg2+ wasting (60, 134). Indeed, increased Mg2+ reabsorption in DCT compensated for the 
reduced TAL reabsorption, suggesting that the DCT is capable to double, triple or even 
quadruple its reabsorption capacity (60). Several key players in Mg2+ reabsorption in DCT 
have been described to date, mainly driven by the advances that were made over the last 
decade elucidating monogenetic Mg2+-related tubulopathies (23). For instance, TRPM6 
was identified as the apical cation channel mediating Mg2+ uptake in the DCT cell by 
linkage-analysis of patients with hypomagnesemia and secondary hypocalcemia (HSH)
(111, 140). However, the basolateral extrusion mechanism for Mg2+ remains to be identified. 
Additionally, the complex regulatory network of Mg2+ reabsorption in the DCT is only 
partially deciphered. Therefore, this thesis aimed to identify new molecular players in DCT 
Mg2+ transport. 
The Distal Convoluted Tubule
The DCT is the segment of the nephron that is anatomically defined as the convoluted 
tubule segment that starts from the macula densa and runs until the connecting tubule 
(CNT)(13). The DCT can be subdivided in two segments: DCT1, which consists entirely of 
DCT cells and DCT2, where DCT cells are present together with intercalated cells (30). 
Functionally, DCT2 is responsive to the mineralocorticoid hormone aldosterone, whereas 
DCT1 cells are not (100). DCT cells have a distinct morphology characterized by extensive 
invaginations of the basolateral membrane (Figure 1)(61). In the cytoplasm between 
the lamella-like structures formed by the basolateral membranes, a high amount of 
mitochondria are located which provide the energy for Na+-K+-ATPase activity. Within the 
kidney, the DCT cells contain the largest number of mitochondria compared to any other 
segment. Because of the invaginations, the cell nucleus and endoplasmic reticulum are 
located near the apical membrane of the cell. The cell nuclei may even have a flattened 
appearance in histological analyses (100). At the molecular level, DCT cells can by identified 
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by the expression of marker proteins such as the thiazide-sensitive Na+-Cl--cotransporter 
(NCC) and parvalbumin (PV). DCT2 cells also express the Epithelial Na+ Channel (ENaC). As 
a result, in DCT1 the NCC protein exclusively mediates Na+ transport. In DCT2, Na+ uptake 
Figure 1   Overview of Ion Transport in the Distal Convoluted Tubule Cell
Fine-tuning (10 %) of Mg2+ transport takes place transcellular in the distal convoluted tubule (DCT). 
At the apical membrane, Na+ and Cl- enter the cell via NCC. TRPM6 mediates Mg2+ uptake from the 
pro-urine, which depends on the voltage-gradient set by back leak of K+ via ROMK and Kv1.1 potassium 
channels. Mg2+ transport via TRPM6 can be activated by EGF and insulin. Upon activation of the 
EGFR and IR an intracellular signaling cascade including PI3K, Akt and Rac1 results in an increased 
TRPM6 membrane expression and increased channel activity. Within the cell, Mg2+ is bound by 
parvalbumin. At the basolateral membrane, Mg2+ extrusion may be facilitated by SLC41A3, which 
may be regulated by CNNM2 acting as Mg2+-sensor. Mg2+ extrusion depends on the Na+ gradient, 
set by the Na+-K+-ATPase. The activity of the Na+-K+-ATPase is in turn dependent on K+ recycling 
via Kir4.1. FXYD2 transcription encoding the γ-subunit of the Na+-K+-ATPase, is regulated by HNF1β. 
ROMK: Renal Outer Medulla K+ channel, ClC-Kb: Chloride channel Kb, Kv1.1: Voltage gated K+ channel 
1.1, TRPM6: Transient receptor potential melastatin type 6, NCC: Na+-Cl- co-transporter, CNNM2: Cyclin 
M2, SLC41A3: Solute carrier family 41 member 3, FXYD2: FXYD-domain containing 2, HNF1β: Hepatocyte 
 Nuclear Factor 1β, PCBD1: Pterin-4 alpha-carbinolamine dehydratase, EGF: Epidermal Growth Factor, EGFR: 
 Epidermal Growth Factor Receptor, IR: Insulin Receptor, PI3K: Phosphoinositide 3-kinase, Rac1: Ras-related 
C3 botulinum toxin substrate 1, Cdk5: Cyclin-dependent kinase 5.
-
-
0 mV / -30 mV
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via ENaC results in simultaneous K+ secretion via Renal Outer Medullary K+ channels 
(ROMK)(125). Na+ transport in DCT is important for the development of a voltage gradient 
across the epithelium, which develops from 0 mV at the early DCT1 segment to -30 mV in 
DCT2 (Figure 1)(4, 144). 
DCT Cell Lines
Since the first attempts in the 1980s, the highly differentiated and polarized DCT cells have 
proven to be extremely difficult to culture in vitro. Initially, intact distal tubules from dogs 
and rats were, therefore, used to study electrolyte transport in DCT (22, 97). Given the 
limitations of using intact tubules to examine the cellular and molecular mechanisms of 
DCT electrolyte transport, several groups have pursued to establish a DCT cell line. In 1991, 
the group of Friedman reported the isolation and immortalization of murine DCT cells 
(mDCT) that were subsequently used frequently to study Na+, Ca2+ and Mg2+ influx (37, 
94). These cells have been shown to express NCC and to allow thiazide-sensitive 22Na+ 
uptake, but other DCT genes such as the mineralocorticoid receptor and TRPM6 are 
poorly expressed. Interestingly, the mDCT cells also express ENaC and can, therefore, be 
used as a model for DCT2. Although Mg2+ influx in these cells has been measured, this has 
been proven extremely difficult and sensitive to osmotic changes. Nevertheless, the 
mDCT cells have been instrumental in the identification of new Mg2+ transporters, 
including cyclin M2 (CNNM2), solute carrier family 41 member 1 (SLC41A1), nonimprinted 
in Prader-Willi/Angelman syndrome (NIPA) and membrane Mg2+ transporter (MMgT)(41, 
43, 98).  Functional evidence for the Mg2+ transport capacity of some of the new genes, 
such as NIPA and MMgT, is extremely scarce and their role in Mg2+ reabsorption should, 
therefore, be reconsidered (40, 44). Alternatively, Vandewalle and colleagues have 
established another DCT cell line from microdissected mouse DCT in 1999, named 
mpkDCT cells (29). By culturing these cells on collagen-coated permeable membrane 
filters, the mpkDCT cells will differentiate and form a confluent monolayer with a resistance 
comparable to primary DCT cultures (26, 29). Generally, the mpkDCT cells are considered 
to have higher thiazide-sensitive Na+ transport than mDCT cells, although a recent 
subclone, mDCT15, may provide similar transport rates (64). Just like the mDCT cells, the 
mpkDCT cells are of DCT2 origin, as shown by the expression of Transient receptor 
potential vanilloid type 5 (TRPV5), calbindin-D28k and the parathyroid hormone (PTH) 
receptor (26). Potentially due the DCT2 origin of both cell lines, they provide poor models 
to study transepithelial Mg2+ transport. Although Mg2+ transport has been measured in 
mDCT cells, many magnesiotropic DCT proteins are not expressed (unpublished data). 
Thus, the need for a DCT1 cell line to study transepithelial Mg2+ transport is high.
Primary DCT Cells
Over the last 50 years, microdissection using forceps has been the leading technique to 
obtain primary DCT cells (145). In contrast to the TAL and collecting duct (CD) cells that 
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each make up about 20 % of total nephron length, less than 5 % of the nephron consists 
of DCT cells (147). Therefore, microdissection of DCT cells is highly labor-intensive and 
results in very little material. In Chapter 2 automated-sorting of primary DCT cells was 
established to study Mg2+-sensitive gene expression at the whole genome scale using 
microarrays. Mice expressing the enhanced green fluorescent protein (eGFP) behind a Pv 
promoter were sacrificed and the fluorescent DCT cells were isolated using the Complex 
Object Parametric Analyzer and Sorter (COPAS) system (82). In comparison to microdissection, 
COPAS significantly increases the yield and, therefore, allows large-scale expression studies 
with pure DCT cells. Previous expression studies only reported mRNA transcript levels of 
the combined DCT/CNT segments of the kidney (95). Recently, COPAS-sorted DCT cells 
were shown to exhibit thiazide-sensitive Na+ transport, evidencing NCC activity (82). In 
Chapter 2, the expression of all DCT-specific genes including Ncc, Trpm6 and Pv was 
highly enriched compared to non-DCT tubules of the same kidney. The subsequent 
expression profiling revealed that of all genes implicated in hypomagnesemia-related 
genetic diseases, only Trpm6, Cnnm2 and Epidermal growth factor (Egf) were regulated by 
the Mg2+ availability. These results demonstrate that COPAS-sorted DCT cells are the first 
highly abundant alternative for microdissection and subsequent established DCT cell 
lines.
· Distal convoluted tubule cells are highly specialized cells characterized by 
basolateral invaginations and high amounts of mitochondria
· The distal convoluted tubule determines the final urinary Mg2+ excretion
· COPAS sorting of distal convoluted tubule cells provides a high efficiency and 
high quality alternative for microdissection and distal convoluted tubule cell 
lines
Apical membrane: Regulation of TRPM6
Mg2+ reabsorption in DCT is mediated by the apical influx of Mg2+ via TRPM6 (Figure 1)
(138). TRPM6 is composed of 6 transmembrane domains with the predicted channel pore 
between the fifth and sixth membrane-spanning domain (Figure 2). In this reentrant loop 
two glutamate residues, p.Glu1024 and p.Glu1029, determine the pore selectivity for Mg2+ 
ions (74). Interestingly, the same two residues render the pH-sensitivity of TRPM6 channels. 
Hence, acidification increases TRPM6 activity (74). TRPM6 forms homotetramers or hetero-
tetramers with its closest homologue TRPM7 to become functionally active (75). A unique 
characteristic of TRPM6 and TRPM7 proteins is that they have an atypical kinase domain 
fused to their intracellular COOH-terminus (135). The kinase domain is involved in the 
channel’s autophosphorylation, but its exact function remains to be identified. Recently, 
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the kinase of TRPM7 was shown to be proteolytically cleaved from the channel (25). TRPM7 
kinase fragments could translocate to the nucleus to activate chromatin remodeling (69). 
It would be of major interest to examine whether the kinase of TRPM6 is also cleaved 
and to identify which genes are regulated by the kinase fragments in the cell nucleus. 
The necessity of TRPM7 for the functional activity of TRPM6 has been extensively discussed 
over the last decade (14, 75, 112). Recent data on the regulation of TRPM6 activity by 
Figure 2   Overview of Regulatory Pathways of TRPM6 Mediated Mg2+ Transport
TRPM6 consists of 6 membrane-spanning domains with its predicted channel pore between the 
fifth and sixth transmembrane domain. Two lysine residues (p.Lys1024 and p.Lys1029) determine 
the pH sensitivity and specificity of the pore for Mg2+ transport. TRPM6 has a kinase domain fused 
to its C-terminus, which can be bound by interacting proteins including MSRB1, PHB2 and GNB2L1. 
The p.Thr1831 residue is essential for autophosphorylation of the channel and p.Met1755 is sensitive 
to oxidative stress. The activity of TRPM6 can be inhibited by extracellular ATP by binding the P2X4 
receptor. Insulin and EGF stimulate TRPM6 activity by activation of an intracellular signaling pathway 
including PI3K, Akt and Rac1. The p.Val1393 and p.Lys1584 are essential for insulin stimulation.
MSRB1: methionine sulfoxide reductase B1, GNB2L1: guanine nucleotide-binding protein subunit beta-2-like 
1, PHB2: prohibitin 2, P2X4: Purinergic receptor X4, EGF: epidermal growth factor, IR: insulin receptor, EGFR: 
epidermal growth factor receptor, PI3K: Phosphoinositide 3-kinase, Rac1: Ras-related C3 botulinum toxin 
substrate 1, Cdk5: Cyclin-dependent kinase 5.
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intracellular Mg2+ provide new arguments for a significant role of TRPM7. Intracellular Mg2+ 
acts as a negative feedback mechanism for excessive Mg2+ uptake and, therefore, inhibits 
TRPM6 and TRPM7. Although initial reports indicated that the IC50 of Mg2+ inhibition on 
TRPM6 was in the range of 0.5 mmol/L (138), a recent study by Zhang and colleagues 
reports much lower concentrations of intracellular Mg2+ (IC50: 29 μmol/L)(149). Interestingly, 
TRPM6-TRPM7 heterotetramers are inhibited at higher concentrations of intracellular Mg2+ 
(IC50: 466 µmol/L). Since the intracellular Mg2+ concentrations are normally in the range of 
0.2-1.0 mmol/L, these results question the physiological activity of homotetrameric TRPM6 
channels. Thus, the exact composition of functional TRPM6 channels in the DCT should 
be examined in future studies. 
 Mutations in TRPM6 lead to hypomagnesemia with secondary hypocalcemia (HSH), 
caused by intestinal malabsorption and renal wasting of Mg2+ (111, 140). Since TRPM6 is 
the gatekeeper of Mg2+ reabsorption in DCT, it is the main target of regulation of renal 
Mg2+ reabsorption. Over the last decade, genetic and molecular studies have identified 
several regulators of TRPM6 activity and plasma membrane availability, including 
epidermal growth factor (EGF), insulin, pH and several interacting proteins (Table 1)(10-12, 
74, 86, 126). In this thesis, two new regulatory pathways of TRPM6 activity are described, 
underlining the central role of TRPM6 in Mg2+ homeostasis. In Chapter 8, the role of 
purinergic receptors in ATP-mediated inhibition of TRPM6 was explained. Chapter 9 
reports a new biological compound of the flavagline family that can activate TRPM6 
activity. 
Endocrine and Paracrine Regulation
After reports of hypomagnesemia in patients using EGF receptor (EGFR) inhibitors such as 
cetuximab and in patients with diabetes mellitus type 2 (114, 141), research has focused 
the last years on the effect of EGF and insulin on TRPM6 activity (86, 126). EGF activates 
upon binding to the EGFR an intracellular signaling cascade including phosphoinositide 
3-kinase  (PI3K), Akt and Ras-related C3 botulinum toxin substrate 1 (RAC1) leading to an 
increased insertion of TRPM6 in the plasma membrane (47, 126) (Figure 2). In patients using 
cetuximab, EGFR cannot be activated, resulting in lower TRPM6 plasma membrane 
expression and thus reduced Mg2+ reabsorption in DCT. In a similar fashion, insulin can 
activate TRPM6 activity and plasma membrane expression (86). Interestingly, patients with 
diabetes mellitus have an increased incidence of two single nucleotide polymorphisms 
(SNPs), p.Ile1393Val and p.Lys1584Glu in TRPM6, which impair the insulin-sensitivity of the 
Mg2+ channel. Although EGF has been shown to be produced locally and may have some 
paracrine action, EGF and insulin are mainly endocrine factors reaching the DCT cells via 
the blood.
 In Chapter 8, a new autocrine and paracrine mode of TRPM6 regulation has been 
identified. Initial studies to P2X receptors in DCT performed by Dai and colleagues in 
mDCT cells demonstrate that Mg2+ transport is sensitive to ATP (21). P2X receptors form 
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ATP-activated ion channels. Each channel consists of homo- or heterotrimers in which the 
large extra cellular loops provide the ATP-binding sites (15, 89). Upon ATP binding the 
channel opens, resulting in a non-selective cation entry into the cell. The expression 
Table 1   Regulation of TRPM6 in the Kidney
Regulatory Hormones
Factor Effects  
on activity
Effect  
on transcription
Residues Ref.
EGF   (55, 126)
Insulin   p.Val1393, p.Lys1584 (71, 86)
Estrogen   (12, 46)
ATP  - Chapter 8
Intracellular Factors
Factor Effects  
on activity
Effect  
on transcription
Residues Ref.
Mg2+  - (138, 149)
pH  - p.Glu1024, p.Glu1029 (74)
H2O2  - (10)
ATP  - (127)
Drugs and Compounds
Factor Effects  
on activity
Effect  
on transcription
Residues Ref.
2APB  - (75)
FL3/FL23  - Chapter 9
Thiazide -  (87)
CNIs -  (54)
PPIs   (70)
Rapamycin   (57)
EGFR blockers   (27)
Interacting proteins
Factor Effects  
on activity
Effect  
on transcription
Residues Ref.
MSRB1  - p.Met1755 (10)
PHB2  - (12)
GNB2L1  - p.Thr1851 (11)
This table lists all regulating factors of TRPM6 activity and TRPM6 transcription. Activity is measured 
by whole-cell patch clamp analysis and can therefore be defined as the total of open pore probability, 
channel conductance and plasma membrane expression.
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pattern of P2x1-7 in the DCT was determined using COPAS-sorted DCT cells. Within the 
DCT, P2x4 and P2x6 were the only P2X isoforms with high expression levels in DCT cells. 
However, co-localization of P2X4 and NCC was not detected when staining for P2X4 on 
mouse kidney sections. In contrast, P2X6 is exclusively expressed in DCT. By patch clamp 
analysis P2X4 was shown to inhibit TRPM6 activity when co-expressed in human 
embryonic kidney cells (HEK293). Since both channels are expressed in the colon, a role of 
P2X4 in the intestinal regulation of Mg2+ absorption was suggested. The secretion of ATP 
in the lumen of intestine and the kidney tubule is regulated by flow (16). This suggests that 
luminal ATP release could provide an important paracrine feedback mechanism to correct 
for variations in flow in the tubule (72). Interestingly, ENaC has also been shown to be 
inhibited by P2X4 receptors (142), suggesting that ATP-induced inhibition of ion channels 
provides a general regulatory mechanism in response to flow changes. 
 Given that in patch clamp analysis P2X4 activation reduced TRPM6 currents and P2X6 
had no effect on the channel activity, it would be interesting to further clarify the role of 
P2X6 in the kidney. The unique expression pattern of P2X6, only being present in the DCT 
suggests a role of P2X6 in the regulation of Na+ and Mg2+ transport mechanisms. However, 
in our and previous studies it has been reported that P2X6 is not functional on its own but 
requires P2X2 or P2X4 channels to reach the plasma membrane (73, 131). This kind of 
mechanism is difficult to study in vitro, since it is challenging to influence and measure the 
exact composition of heterotrimeric channels. Moreover, overexpression studies are not 
conclusive since the endogenously expressed P2X receptors will also influence the 
heteromeric complexes of the overexpressed proteins. Recently, a large consortium 
developed a P2x6 knockout (KO) mouse (143) and it would be interesting to measure 
blood and urinary Na+, K+ and Mg2+ values in this strain to determine the physiological 
role of P2X6. 
Interacting Proteins
By pull down experiments using the atypical kinase domain of TRPM6, several interacting 
proteins have been identified (10-12). First, methionine sulfoxide reductase B1 (MSRB1) 
binds the TRPM6 kinase to protect the channel from reactive oxygen species (10). DCT 
cells are among the cell types with the highest mitochondria content in the body and are, 
therefore, sensitive to oxidative stress. Notably, free methionine residues are prone to 
oxidation, which inhibits TRPM6 channel activity (10). MSRB1 is a methionine reductase 
(62), which by binding TRPM6 can reduce Met1755 after oxidative stress and thus rescue 
TRPM6 inhibition (10). Second, guanine nucleotide-binding protein subunit beta-2-like 1 
(GNB2L1) / receptor for activated C-kinase (RACK1) was identified to bind TRPM6 at 
positions 1857-1885 and inhibit the channel activity (11). Autophosphorylation of TRPM6 at 
p.Thr1851 is necessary for this inhibitory effect, although it does not affect GNB2L1 binding 
(11). Interestingly, this autophosphorylation site is important for the regulation of TRPM6 
activity by intracellular Mg2+, which provides a negative feedback mechanism. GNB2L1 
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binding may thus regulate the Mg2+ sensitivity of TRPM6. Third, prohibitin 2 (PHB2)  / 
repressor of estrogen receptor activity (REA) binds to the TRPM6 kinase domain at the 
exact same location as RACK1 (12). PHB2 inhibits TRPM6 activity in kinase activity 
dependent manner. Interestingly, estrogen prevents the binding of PHB2 to TRPM6 and, 
thereby, stimulates channel activity.
 In Chapter 9, a subgroup of flavaglines was shown to bind PHB2 and, therefore, their 
functional effects on TRPM6 activity were tested. Flavaglines are cyclopental[b]benzofuran 
structures that were originally used in traditional Chinese medicine and extracted from 
the aglaia (Meliaceae) plant (103). Flavagline 23 (FL23) activated TRPM6 in the nanomolar 
range, making FL23 a potent molecule to increase Mg2+ transport. Patch clamp analysis 
demonstrated a similar effect of FL23 on mock currents, suggesting that TRPM7 was 
activated in an analogous manner. If the mechanism of action of FL23 depends on PHB2 
binding, this would suggest that PHB2 also binds TRPM7. PHB1 and PHB2 are central 
players in cell cycle control (128). Several studies have demonstrated the role of TRPM7 in 
cell growth and differentiation (91). PHB binding to TRPM7 could provide a new regulatory 
mechanism for TRPM7 activity in cell growth. For future research, it would be interesting 
to develop and test new flavagline compounds with higher specificity for TRPM6. TRP 
channels are highly homologous and, therefore, compounds targeting TRP channels 
show often relatively low specificity (88). For application of flavaglines in vivo or in clinic, 
the specificity of flavagalines should be improved.
· TRPM6 mediates apical Mg2+ entry in the distal convoluted tubule cell and is 
regulated by EGF, insulin and pH
· Extracellular ATP inhibits TRPM6 activity by binding P2X4 purinergic receptors
· Flavagline compounds provide a new class of TRPM6 activating agents
Nucleus: Transcriptional regulation
In Chapter 2 and in previous studies comparing mice fed with Mg2+-deficient and 
Mg2+-enriched diets, gene expression in the kidney was shown to be very sensitive to 
alterations in Mg2+ homeostasis (46, 133). Notably, Trpm6, Cnnm2 and Egf were among the 
genes that exhibit an increased expression in the low Mg2+ diet fed mice. However, the 
molecular players involved in transcriptional regulation of these magnesiotropic genes 
are largely unknown. Pioneering studies by Ikari and colleagues reported that the 
expression of TRPM6 is increased by EGF stimulation (55, 56). Their findings propose a 
mechanism in which the extracellular signal-regulated kinases (ERK) signaling pathway is 
activated upon EGFR binding, eventually resulting in activation of cFos/cJun binding to an 
Activator Protein-1 (AP-1) binding site in the TRPM6 promoter (56) (Figure 3). An additional 
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activators of TRPM6 transcription is estrogen, however the transcriptional mechanism of 
estrogen is still unknown (46). In Chapter 2 the microarray screening of Mg2+-sensitive 
mRNA transcription identified two new transcriptional regulators in DCT.
 First, Sex determining region Y-box 9 (Sox9) was upregulated 5-fold in low Mg2+ diet fed 
mice compared to littermates given the high Mg2+ diet. SOX9 is a key transcription factor 
in tissue development. Kidney-specific Sox9 KO mice show impaired kidney development 
en the formation of ectopic nephrons (99). Although the effect of SOX9 on nephron 
segmentation is unknown, Sox9 expression is considered very low in adult nephron tissue. 
Interestingly, in other epithelial cells such as colonic crypts and duodenal cells, SOX9 is 
used as a marker for proliferation of progenitor cells that are involved in the renewal of the 
Figure 3   Overview of Transcriptional Regulation of Mg2+ transport in the DCT
In the DCT cell nucleus, TRPM6 expression is regulated via an EGF signaling pathway resulting in 
activation of cFos/cJun proteins binding to an AP1 site in the TRPM6 promoter. FXYD2 transcription 
can be activated by binding of HNF1B and its transcriptional coactivator PCBD1. Sox9 expression in 
DCT has been shown to be extremely sensitive to dietary Mg2+ availability, but its molecular targets 
remain to be identified.
TRPM6: Transient receptor potential melastatin type 6, FXYD2: FXYD-domain containing 2, HNF1β: Hepato-
cyte Nuclear Factor 1β, PCBD1: Pterin-4 alpha-carbinolamine dehydratase, EGF: Epidermal Growth Factor, 
AP1: Activator Protein 1, SOX9: SRY (sex determining region Y)-box 9.
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epithelial cells (5, 137). Translating these findings to renal epithelia, this suggests that 
increased SOX9 expression in DCT can be associated with cell regeneration (96). One 
could speculate that high expression of SOX9 in response to stimuli like a low Mg2+ diet, 
could result in activation of renal progenitor cells potentially with the purpose to extend 
the DCT region to increase Mg2+ reabsorption capacity. SOX9 expression is regulated by 
the magnesiotropic hormone EGF in urothelial cells (77). It would be interesting to identify 
the gene targets of SOX9 in the kidney by ChIP-Seq analysis. This would allow distinguishing 
whether SOX9 directly regulates magnesiotropic genes or may be involved in DCT cell 
regeneration. 
 Second, Pterin-4-alpha-carbinolamine dehydratase (Pcbd1) transcription was identified 
to be highly Mg2+-sensitive in Chapter 2. PCBD1 encodes the transcriptional co-activator 
of hepatocyte nuclear factor 1 homeobox A and B (HNF1A/HNF1B) (Figure 3). In Chapter 
3, the effect of PCBD1 on HNF1B-induced FXYD domain containing ion transport regulator 2 
(FXYD2) transcription was examined with luciferase promoter assays, showing that PCBD1 
increased FXYD2 transcription with 50 %. Interestingly, Hnf1B transcription was not altered 
in response to a low Mg2+ diet, suggesting that PCBD1 is the regulating factor in the 
transcription of FXYD2. Patients with mutations in PCBD1 suffered from hypomagnesemia, 
renal Mg2+ wasting and maturity onset diabetes of the young (MODY). This phenotype 
closely resembled the phenotype of renal cysts and diabetes syndrome (RCAD), which is 
caused by HNF1B mutation. However, in contrast with RCAD patients, PCBD1 mutations do 
not cause renal cysts (32). This can be explained by the absence of PCBD1 in the CD, where 
HNF1B regulates PKHD1 transcription. In RCAD patients PKHD1 expression is disturbed, 
resulting in renal malformation and cysts (51). The fact that PCBD1 mutations result in a 
RCAD-like syndrome, suggests that mutations in other interaction partners may also cause 
hypomagnesemia, MODY or renal malformations. Over the last decade, several interacting 
proteins of HNF1B have been identified including E4F1 and ZFP36L1 (28). It would be 
interesting to screen for mutations in the genes encoding for these interacting proteins in 
patients with RCAD-like phenotypes, which test negative for HNF1B and PCBD1 mutations.
· Low dietary Mg2+ intake regulates renal Mg2+ reabsorption by increasing 
TRPM6, CNNM2 and EGF gene expression
· PCBD1 was identified to cause hypomagnesemia and MODY-like diabetes in 
patients with neonatal transient primapterinuria
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Basolateral Membrane: A Quest for Extrusion
During the last years, the mechanisms of apical Mg2+ entry in the DCT have been relatively 
well explained and many regulatory factors were characterized (23). In contrast, Mg2+ 
extrusion at the basolateral membrane from the DCT cell remains unexplained, despite 
the identification of several basolateral magnesiotropic proteins (7, 84, 113, 124). Early 
studies in the 80’s by Gunther and Vormann already suggested that Na+ as a counter ion 
can drive the Mg2+ extrusion from the cell (48). Since then, a large body of evidence was 
gathered by several groups in many different cell types confirming these original findings 
(106). This mechanism was shown to be electroneutral (2 Na+in : 1 Mg2+out), amiloride- 
sensitive and activated by agents increasing intracellular cAMP levels including, prostaglandin 
E2 (PGE2), forskolin and norepinephrine (106). The molecular identity of this alleged 
epithelial Na+/Mg2+ exchanger remains to be identified, although several candidates have 
been proposed (66, 124). In Chapter 5, 6 and 7, two of these candidates, Solute Carrier 
Family 41 Member 3 (SLC41A3) and CNNM2 were examined in detail. 
SLC41 Family of Mg2+ Carriers 
SLC41A3 is part of the family of SLC41 carriers, which are related to the bacterial Mg2+ 
transporter MgtE (81, 108, 139). SLC41A1 is the most investigated isoform of this transporter 
family and was initially studied in Xenopus laevis oocytes by voltage clamp analysis (41). 
In these experiments, SLC41A1 mediated Mg2+ currents, but also transported Fe2+, Cu2+, 
Zn2+ and Cd2+, suggesting a channel function or electrogenic exchanger (41). However, in 
patch clamp experiments using mammalian HEK293 cells overexpressing SLC41A1 Mg2+ 
currents were not observed (unpublished results). Publications by Kolisek and colleagues 
strongly advocate that SLC41A1 functions as a Na+/Mg2+ exchanger as they showed 
Na+-dependent Mg2+ extrusion using the cytosolic Mg2+-indicator MagFura (66). This 
finding was further substantiated in a recent study that identified mutations in SLC41A1 to 
be causative for a nephronophthisis-like phenotype (53). However, given the affinity of 
MagFura for other cations including Ca2+ and the sensitivity to osmotic changes due to 
saturation of the probe (unpublished results), these results should be interpreted with 
caution. Independent techniques such as 22Na+ uptake or 25Mg2+ extrusion assays should 
confirm these findings. To study SLC41A1 and other Mg2+ transporters in the future, a 
more specific and reliable Mg2+ probe to measure intracellular Mg2+ concentrations is 
essential. Although over recent years many new Mg2+ probes have been described based 
on RNA, protein or chemical structures, none of these have resulted in a specific and 
dynamic Mg2+ probe sensitive within the physiological range (0.2-1.0 mmol/L) and low 
affinity for Ca2+ (19, 35, 109). Future initiatives should be directed to develop such a probe, 
for instance based on the Förster resonance energy transfer (FRET) technique (76).
 In addition to SLC41A1, both SLC41A2 and SLC41A3 were tested in the Xenopus laevis 
oocyte voltage-clamp system and mediated similar Mg2+ currents as SLC41A1 (41, 42, 98). 
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SLC41A2 is mainly located in the intracellular compartments such as the Golgi-system and 
has been poorly characterized (107, 108). SLC41A3 has never been examined in detail. In mice 
fed with Mg2+-deficient diets, Slc41a3 expression was significantly upregulated in the DCT 
(Chapter 2). Therefore, SLC41A3 function was examined in vivo using Slc41a3 knockout 
(KO) mice in Chapter 5. Interestingly, Slc41a3 KO mice displayed hypomagnesemia due to 
renal Mg2+ wasting, further establishing the role of SLC41A3 in Mg2+ homeostasis. Slc41a3 
KO mice exhibited the same intestinal Mg2+ absorption rate as wild type (WT) littermates. 
The expression of Slc41a1 was increased in the duodenum of Slc41a3 KO mice, suggesting 
that Slc41a1 can compensate for the loss of SLC41A3 function and that both proteins are 
functionally redundant. In contrast, Slc41a1 expression was not increased in the kidney, 
which may be explained by the fact that SLC41A1 and SLC41A3 are not expressed in the 
same segments. RT-PCR analysis on COPAS-sorted DCT material showed that Slc41a3 is 
10-fold enriched, whereas Slc41a1 is not enriched. Unexpectedly, hydronephrosis was 
detected in 10% of Slc41a3 KO mice fed with Mg2+-deficient diets. Since a patient with 
nephronophthisis was reported to carry a SLC41A1 splice site mutation (53), this suggests 
that SLC41 proteins may play role in renal cyst formation and hydronephrosis. It would be 
of interest to screen more cystic patients for mutations in SLC41 genes. Moreover, further 
characterization of hydronephrosis formation in Slc41a3 KO mice is necessary to understand 
the etiology of hydronephrosis in these mice and to examine the role of Mg2+ in this 
process. 
CNNM Family of Mg2+-binding Proteins
In 2011, CNNM2 mutations were identified to be causative for hypomagnesemia in two 
patients suffering from epilepsy, tremor and muscle weakness (124). In Chapter 7, the 
phenotypical spectrum was further extended by the identification of 5 additional families 
with CNNM2 mutations. Interestingly, for the first time CNNM2 mutations were associated 
with mental retardation. Moreover, in the family with the most severe mental disability 
and brain malformations a recessive mode inheritance was observed. This is in contrast 
with all other mutations, which were detected in heterozygous state. Importantly, the 
parents of the patient with the homozygous (recessive) mutation were not affected; 
suggesting that this mutation does not completely impairs CNNM2 function. 
 CNNM2 is within the kidney expressed in the cortical TAL, DCT and CNT region (124). 
Given its basolateral localization at the plasma membrane, it has been proposed to be the 
long-sought Mg2+ extrusion mechanism (124). In Xenopus laevis oocyte voltage clamp 
experiments, CNNM2-mediated Mg2+ currents were within the physiological range of 
intracellular Mg2+ concentrations (43). Moreover, CNNM2 expression rescues cell growth in 
Mg2+-deficient Salmonella enterica (123). However, Mg2+ transport could not be measured 
in mammalian cells (124). In Chapter 6, the protein structure of CNNM2 was further 
examined to predict protein function. CNNM2 contains a N-terminal signal peptide, three 
membrane-spanning domains and potential reentrant region between the second and 
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third domain. By homology modeling based on the bacterial CorC protein (148), a protein 
3D structure of the cystathionine beta synthase (CBS) domains of CNNM2 was constructed. 
Interestingly, this model suggested that the CBS domains harbor a Mg-ATP binding site 
and that this site is disrupted by the p.Thr568Ile mutation identified in the first patient 
family. Based on these findings, it was proposed that CNNM2 functions as a Mg2+-sensing 
mechanism rather than as a Mg2+ transporter. In a recent study by Hirata and colleagues, 
the homology model was confirmed and the binding of Mg-ATP was demonstrated by 
filter binding assays (52). However, Mg-ATP binds the CNNM2 CBS domains with an 
apparent affinity of 158 µmol/L, which is far below the physiological range (52). Of note: 
intracellular Mg-ATP concentrations are considered to range between 2-10 mmol/L. Based 
on these findings an Mg2+-sensing mechanism should be excluded. However, it would be 
interesting to repeat the Mg-ATP binding experiments within a more physiological cell 
system, since other proteins and factors may influence the Mg-ATP binding.
 In Chapter 7, the effect of CNNM2 on Mg2+ transport was examined using the stable 
25Mg2+ isotope. CNNM2-expressing cells showed a higher 25Mg2+ uptake than mock-trans-
fected cells. The CNNM2 mutants identified in the patients exhibited a lower 25Mg2+ 
uptake than wild type CNNM2.  Importantly, the CNNM2-induced 25Mg2+ uptake was 
inhibited by 2-Aminoethoxydiphenyl borate (2-APB), a non-selective inhibitor of TRPM7 
Mg2+ channels (75), which are endogenously expressed in HEK293 cells. These findings 
support the hypothesis that CNNM2 regulates other Mg2+ channels instead of transporting 
Mg2+ itself. Brain development was impaired and Mg2+ homeostasis was disturbed after 
knocking down cnnm2 expression in zebrafish using the morpholino approach. Cnnm2 
morphants had impaired touch-response behavior, which has been reported before in 
trpm7 mutant zebrafish (31, 79). Interestingly, in the same zebrafish model it was shown 
that TRPM7 is essential for the development of dopaminergic neurons (24). CNNM2 has 
been associated with Parkinson’s disease and schizophrenia (104, 110, 122); both diseases 
are known to exhibit an abnormal dopamine balance (8, 90). Although it cannot be 
excluded that CNNM2 plays a role in neurodevelopment intrinsically, the combined in vitro 
and in vivo findings may lead to the hypothesis that CNNM2 regulates TRPM7 in brain. 
Therefore, it would be interesting to study the dopamine levels and development of 
dopaminergic neurons in cnnm2 morphants and compare these to the results obtained in 
trpm7 mutants. 
 TRPM7 may be expressed at low levels in the DCT, however, it is considered to 
contribute only to basal cellular Mg2+ homeostasis, not to transcellular Mg2+ transport. 
Thus, CNNM2-dependent activity of TRPM7 would not explain the renal Mg2+ wasting 
observed in the patients. Future studies should therefore be directed towards the 
identification of the interaction partners of CNNM2 in DCT. One could consider examining 
the effects of CNNM2 on TRPM6 activity by patch clamp analysis. In addition, the SLC41 
proteins are also interesting interaction candidates, given that both SLC41 and CNNM2 
share homology to the bacterial Mg2+ transporter MgtE (43, 49, 108). The CBS domains of 
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CNNM2 are highly homologous to the MgtE CBS domains, but the plasma membrane 
regions do not share any homology (Chapter 6). In contrast, the pore region including all 
essential residues for Mg2+ transport of SLC41A1, SLC41A2 and SLC41A3 are highly 
conserved from MgtE Mg2+ channels (81). In evolution, the functional domains of MgtE 
may have been divided between the CNNM and SLC41 proteins. Given that both CNNM 
and SLC41 proteins were evidenced to function in complexes (Chapter 6), it would be 
interesting to examine whether these proteins interact (65). This hypothesis would also 
explain the difficulties to measure the activity of the proteins individually. 
Other Mg2+-related Proteins at the Basolateral Membrane
In 2000, linkage analysis identified a heterozygous p.Gly41Arg mutation in FXYD2 causing 
dominant hypomagnesemia and renal Mg2+ wasting (83, 84). In Chapter 4, two new 
families were identified with familial dominant hypomagnesemia. The patients suffer from 
hypermagnesiuria, hypocalciuria, decline in renal function and epilepsy. Since these are 
the first patients reported since 2000 and they all origin from the Netherlands and 
Belgium, genealogy studies and marker analysis were performed. Indeed, marker analysis 
revealed a common allele suggesting one founder mutation. However, genealogy analysis 
until 1700 did not find a link between the families, although ancestors of two families 
could be traced to the same area near Liège, Belgium. FXYD2 encodes for the γ-subunit of 
the Na+-K+-ATPase that generates an electrochemical gradient across the basolateral 
membrane driving electrolyte transport. In total seven FXYD proteins have been described 
to date, each with its own expression pattern and effects on Na+-K+-ATPase function (36). 
Thus, by changing the expression of FXYD proteins, the Na+-K+-ATPase activity can be 
altered according to the needs of each tissue or cell. FXYD2 has been implicated in the 
stabilization of the α-subunit of the Na+-K+-ATPase, it decreases the affinity for Na+ and K+ 
and increases the affinity for ATP (3, 85). How the γ-subunit of the Na+-K+-ATPase influences 
the plasma Mg2+ concentrations is not understood. Over the years several hypothesis 
have been formed: i) the absence of γ-subunit binding to the α- and β-subunit of the 
Na+-K+-ATPase may reduce its function and thus affects the driving force for Mg2+ uptake 
via TRPM6 (33); ii) the γ-subunit of the Na+-K+-ATPase may form a functional channel on its 
own mediating Mg2+ extrusion to the blood (115); iii) FXYD2 may act as a subunit for the 
still unidentified Na+-Mg2+-exchanger, directly affecting Mg2+ extrusion to the blood. To 
date, none of the given hypothesis has been convincingly substantiated and the role of 
FXYD2 remains, therefore, to be determined. Interestingly, FXYD5 was recently shown to 
increase the paracellular permeability and reduce plasma membrane resistance (80). It has 
been shown previously that the β-subunit of the Na+-K+-ATPase is important for cell-cell 
adhesion (116). Therefore, it has been proposed that FXYD5 binding to the β-subunit of 
the Na+-K+-ATPase affects paracellular permeability (80). Knowing that FXYD2 expression 
is not restricted to DCT but is also present in TAL, a similar mechanism could be proposed 
(3). In this hypothesis, FXYD2 increases paracellular permeability in TAL. As a result, 
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mutations in FXYD2 would decrease Mg2+ reabsorption in TAL eventually resulting in renal 
Mg2+ wasting. 
 Patients with mutations in KCNJ10, encoding Kir4.1, present with epilepsy, ataxia, 
sensorial deafness and a tubulopathy phenotype (EAST/SeSAME syndrome) closely 
resembling Gitelman’s syndrome (7, 113). In these patients blood analysis showed 
hypokalemia, hypomagnesemia and metabolic alkalosis. Often these patients have 
polyuria and hypocalciuria. As in Gitelman’s syndrome the origin of the hypomagnesemia 
is not completely understood (38, 58). The most common explanation is that K+ efflux at 
the basolateral membrane is necessary to maintain Na+-K+-ATPase serving as a K+-recycling 
mechanism (Figure 4). Nonfunctional Kir4.1 would then result in decreased Na+-K+-ATPase 
activity and thus, reduced driving force for Mg2+ reabsorption. However, an underappre-
ciated symptom in patients with Gitelman’s syndrome and EAST/SeSAME syndrome is the 
presence of metabolic alkalosis (63). Given that Mg2+ reabsorption via TRPM6 is pH 
dependent and this channel has decreased activity in basic conditions (74), it could be 
hypothesized that the alkalosis results in reduced TRPM6-mediated Mg2+ transport. It is 
unclear how the blood pH status is reflected in the local pH of the DCT lumen. Nevertheless, 
it would be interesting to test whether treatment of the alkalosis can restore the Mg2+ 
balance in patients with EAST/SeSAME syndrome. 
· SLC41A3 is involved in Mg2+ homeostasis and may function as the basolateral 
Na+/Mg2+-exchanger
· CNNM2 binds Mg2+ in its CBS domains and may regulate other Mg2+ channels, 
including TRPM7
· The molecular mechanism of basolateral Mg2+ extrusion remains elusive
Clinical Perspectives: Mg2+ Disorders 
Hypomagnesemia is a relatively common phenomenon that is sparsely diagnosed in the 
clinic. Estimations of the incidence of hypomagnesemia range between 3 % and 10 % of 
the normal population and may rise up to 65 % in patients at the intensive care unit (129). 
The symptoms of hypomagnesemia are multifold; ranging from muscle cramps to epilepsy 
and cardiac arrhythmias in severely hypomagnesemic patients. However, patients with only 
minor deficiencies may experience only general signs of hypomagnesemia such as fatigue, 
lethargy or depression. Based on these symptoms it is difficult to diagnose hypomagnesemia 
in a clinical situation, especially because Mg2+ is not routinely determined in blood. 
 Given the impressive advancements that have been made in Mg2+ research during 
the last decade, the importance of Mg2+ is more frequently appreciated. Firm evidence is 
now available that the use of certain types of drugs, including proton pump inhibitors, 
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EGFR antagonists and diuretics may cause hypomagnesemia (45, 50, 92). As a result, 
clinicians prescribing these drugs are more aware of hypomagnesemia and test patients 
using these types of drugs more often for Mg2+ disturbances. Still the role of Mg2+ in 
health and disease needs more attention. Many patient groups, including diabetics or 
patients with chronic kidney disease, show a worse disease outcome when they suffer 
from low plasma Mg2+ levels (20). Recently, it was demonstrated in women with gestational 
diabetes that single nucleotide polymorphisms in TRPM6 are associated with diabetes 
and hypomagnesemia (86). Nevertheless, Mg2+ levels are still not routinely measured in 
diabetes patients. A clear example of how patient care can be improved by early detection is 
presented in Chapter 3 of this thesis. Three babies with neonatal transient primapterinuria 
were diagnosed at birth after the Guthrie test and were treated with BH4 supplements. 
Figure 4   Overview of the Regulation of Basolateral Mg2+ Extrusion in the DCT
At the basolateral membrane of the DCT, Mg2+ is extruded from the cell via a Na+-dependent 
 mechanism, which may be SLC41A3. Mg2+ extrusion relies, therefore, on Na+-K+-ATPase activity, 
which is in turn dependent on K+ transport via Kir4.1. CNNM2 regulates Mg2+ transport via an unknown 
mechanism. 
ClC-Kb: Chloride channel Kb, Kir4.1: K+ channel Ki4.1, SLC41A3: Solute carrier family 41 member 3, CNNM2: 
Cyclin M2.
0 mV / -30 mV
140 mM 15 mM 0.8 mM
5 mM 145 mM 0.8 mM
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However, at this time the fact that PCBD1 mutations cause renal Mg2+ wasting and MODY 
diabetes was not known. Based on the findings presented in Chapter 3, patients with 
PCBD1 mutations can now be supplemented with Mg2+ from birth and disease progression 
may be decreased. Earlier detection of this kind of disorders by including Mg2+ measurements 
in standard blood electrolyte screens, can significantly improve patient care.
Identification of Genetic Mg2+ Disorders
In a small group of hypomagnesemia patients, the disturbed blood Mg2+ levels could be 
attributed to a genetic defect. In 1999, CLDN16 mutations were identified to cause Familial 
Hypomagnesemia with Hypercalciuria and Nephrocalcinosis (FHHNC Type 1)(120) and 
since then the molecular causes for 15 other hypomagnesemia-related diseases were 
found. All genetic causes of hypomagnesemia are listed in Table 2. Next to FHHNC Type 1, 
the most common ones include Familial Hypomagnesemia with Hypercalciuria and 
Nephrocalcinosis with ocular involvement (FHHNC type 2, CLDN19 mutations)(68), Gitelman 
syndrome (SLC12A3 mutations)(121), Hypomagnesemia with secondary hypocalcemia 
(HSH, TRPM6 mutations)(111, 140) and Renal Cysts and Diabetes Syndrome (RCAD, HNF1B 
mutations)(1). 
 To identify the genetic cause of hypomagnesemia careful phenotyping of the patient 
is of major importance. A simple blood measurement including Na+, K+, Ca2+, Mg2+ and 
glucose is already sufficient to distinguish between the most common genetic Mg2+ 
syndromes. Additional phenotyping is necessary to identify the more rare diseases. The 
flow chart that is presented in Figure 5 may aid to find the causal gene in patients with a 
suspected genetic origin of hypomagnesemia. However, it should be noted that patients 
suffering form hereditary hypomagnesemia are heterogeneous and not every patient will 
present with all characteristics of a particular syndrome. Therefore, the differential 
diagnosis should always be confirmed by genetic testing. 
 Given the heterogeneity of hypomagnesemia patients, it is important to extend the 
knowledge on the known Mg2+ syndromes by extensive phenotyping of newly identified 
patients. An illustrative example is given in Chapter 6, where 5 new families with CNNM2 
mutations are reported and characterized. All patients presented with mental retardation, 
which was previously not described in CNNM2 patients. Moreover, for the first time a 
recessive mode of inheritance of CNNM2 patients was observed. In the future, patients 
with severe hypomagnesemia and mental retardation without Ca2+ and K+ disturbances 
should be immediately screened for CNNM2 mutations. To improve patient care, it is 
crucial to continue reporting new patients with mutations in known genes. The treatment 
regimes of such patients should be further emphasized in these reports, since genetic 
forms of hypomagnesemia are rare diseases that will never be suitable for clinical trials. 
In this perspective, the recent widely executed N=1 trials should be initiated for 
hypomagnesemia patients. An N=1 trial is a crossover study performed within a single 
patient (59). This allows testing the optimal treatment regimen in an objective manner, 
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but also provides a basis for the treatment of future patients. N=1 trials could, therefore, be 
a tool in providing personalized health care for hypomagnesemia patients.
 Although the cause of hypomagnesemia has been identified in many patients over 
the last decade, there are still numerous hypomagnesemia patients without known cause, 
but are suspected to have a genetic origin. Currently, next generation sequencing 
Figure 5   Schematic Representation of Clinical Symptoms of Hypomagnesemia to 
 Phenotypically Distinguish Genetic Forms of Hypomagnesemia
Careful phenotyping of the patient is essential to determine the origin of hypomagnesemia in 
 patients. Simple blood Na+, K+, Ca2+, Mg2+ and glucose measurement allow to distinguish the main 
genetic forms of hypomagnesemia. This flow chart may aid to find the causal gene in patients with 
a suspected genetic origin of hypomagnesemia. However, it should be noted that patients suffering 
form hereditary hypomagnesemia are heterogeneous and not every patient will present with all 
characteristics of a particular syndrome. Therefore, the differential diagnosis should always be  confirmed 
by genetic testing.
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technology is applied to identify new genes that may be involved in Mg2+ homeostasis 
(101). Identification of new genes will aid the understanding of the molecular mechanism 
of Mg2+ reabsorption in the DCT. These insights are important to design new treatment 
options for patients with renal Mg2+ wasting. 
Treatment of Mg2+ Disorders
Hypomagnesemia is treated by oral Mg2+ supplementation (± 360 mg/day)(2). Generally, 
organic Mg2+ salts are considered to be more soluble and bioavailable than inorganic 
Mg2+ salts (18). Oral Mg2+ supplementation is not tolerated well in some patients because 
it can cause diarrhea (34). Alternatively, intravenous Mg2+ administration may be more 
effective, but is invasive and requires regular hospital visits. The treatment regimen of 
intravenous Mg2+ supplementation normally consists of ±10 g of MgSO4 in the first 24 hrs 
followed by ±5 g per day for several days (130). When serum Mg2+ levels are extremely low 
or accompanied by hypokalemia, Mg2+ supplementation may not be sufficient to restore 
normal plasma Mg2+ levels. In the latter case, patients are often co-supplemented with K+ 
or receive K+-sparing diuretics like amiloride.
 In many patients, oral Mg2+ supplementation is not sufficient to restore normal 
plasma Mg2+ levels. Therefore, alternative approaches to increase serum Mg2+ levels 
should be developed. It has been proposed that dietary fibers may increase intestinal 
Mg2+ absorption (17). Therefore, it would be interesting to treat patients with 
hypomagnesemia with these oligo- or polysaccharides. In Chapter 9, flavaglines were 
shown to stimulate TRPM6 activity. If these compounds would be suitable for clinical 
applications, elevated TRPM6 activation may result in improved intestinal and renal (re)
absorption of Mg2+. Currently, flavaglines are subscribed for anticancer treatments in 
clinical trials and their application is marked by toxic effects (102). In the future, it would be 
interesting to develop more TRPM6-activating compounds to increase Mg2+ reabsorption 
in hypomagnesemia patients.
Although the recent advances in Mg2+ research have been mainly achieved in the relative 
small group of patients with genetic hypomagnesemia, the results can be often translated 
to more general diseases. Hypomagnesemia has been associated with diabetes mellitus 
type 2, chronic kidney disease and parkinson’s disease (93, 136, 146), and these diseases 
have been linked to activity of Mg2+ channels and transporters TRPM6, TRPM7 and 
SLC41A1, respectively (67, 78, 86). The findings on TRPM6 and SLC41A3 in this thesis may 
therefore be applicable to much larger population groups. Therefore, future research 
should be dedicated to further understand the molecular mechanisms by which Mg2+ 
can contribute to the etiology and progression of aforementioned general diseases. 
Especially because the first results with Mg2+ supplementation as treatment for diabetes 
and chronic kidney disease confirm that Mg2+ is potentially a powerful treatment option 
for these patients (105, 132).
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 The work presented in this thesis is the result of stimulating collaborations between 
clinicians, geneticists, physiologists and molecular biologists that have increased our 
understanding of Mg2+ reabsorption in the DCT. Nevertheless, many questions remain to 
be answered and ample patients with hypomagnesemia are still awaiting diagnosis. 
Aided by the many technological advances of recent years, integration of all different 
research disciplines will provide the first step towards true personalized medicine for 
hypomagnesemia patients. Combined efforts of clinicians, geneticists, and researchers are 
continuously necessary to improve patient care of hypomagnesemia patients and increase 
our understanding of Mg2+ homeostasis. 
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Magnesium Homeostasis
Magnesium (Mg2+) is an essential cofactor for more than 600 enzymes, a potent Ca2+ 
antagonist and anti-inflammatory agent. Therefore, Mg2+ plays an important role in virtually 
every cell in the human body. In brain, Mg2+ regulates the activity of the NMDA receptor. As a 
consequence, reduced serum Mg2+ levels cause hyperexcitability of the neurons and are 
associated with epilepsy, migraine, depression and traumatic brain injury. In heart, Mg2+ 
determines cardiac contractibility by antagonizing Ca2+ and as a result Mg2+ disturbances 
may result in cardiac arrhythmias. In muscle, low plasma Mg2+ levels result in hypercontract-
ibility of the muscles and therefore cause muscle cramps or spasms. Blood Mg2+ levels are 
maintained between 0.7 and 1.1 mmol/L by the tightly controlled balance between intestinal 
uptake, storage in bone and renal excretion. In the intestine, Mg2+ is passively paracellularly 
reabsorbed in the small intestine. Fine-tuning takes place by active transcellular reabsorption 
in the colon, where Mg2+ is absorbed apically via TRPM6 and TRPM7 Mg2+ channels and 
extruded via the CNNM4 Na+-Mg2+-exchanger. In the kidney, Mg2+ is filtered in the 
glomerulus and reabsorbed along the kidney tubule in a similar fashion. First, bulk Mg2+ is 
reabsorbed paracellularly in the proximal tubule and thick ascending limb of Henle’s loop. 
Second, fine-tuning is achieved in the distal convoluted tubule (DCT) where Mg2+ is 
reabsorbed transcellularly. Here, apical uptake from the pro-urine is facilitated by TRPM6 
Mg2+ channels. The molecular identity of the basolateral extrusion mechanism is still 
unknown. Over the last decade, genetic diseases have helped to identify the molecular 
players in DCT Mg2+ transport. Disturbances in Mg2+ reabsorption in the DCT inevitably 
result in renal Mg2+ wasting, since no reabsorption of Mg2+ takes place beyond the DCT. 
However, several players in Mg2+ transport, including the basolateral extrusion mechanism, 
remain to be identified. Therefore, this thesis aimed to identify and characterize new proteins 
in epithelial Mg2+ transport to extend our understanding of Mg2+ reabsorption in the DCT.
Identification of New Magnesiotropic Genes in the DCT
To identify novel genes that are involved in DCT, mice expressing GFP only in DCT were 
fed with low or high Mg2+ diets. The GFP expression allowed isolation of DCT cells by 
COPAS sorting. The gene expression of low vs. high Mg2+ diet fed mice was compared 
using microarrays. In chapter 2, four new candidate genes were identified to be involved 
in DCT Mg2+ transport. SLC41A3, PCBD1, TBC1D4 and uromodulin expression were 
increased in the low Mg2+ diet fed mice. Mutations in PCBD1 were previously linked 
transient neonatal primapterinuria. In chapter 3, we describe that these patients also 
suffer from hypomagnesemia due to renal Mg2+ wasting and MODY5-like diabetes. These 
clinical findings could be explained at the molecular level by the role of PCBD1 as tran-
scriptional co-activator of HNF1B. Interestingly, the symptoms of HNF1B patients also 
include hypomagnesemia and MODY5. By luciferase assays, it was shown that PCBD1 
increased HNF1B-induced FXYD2 transcription with 50 %. Indeed, mutant PCBD1 proteins 
were not capable to increase FXYD2 transcription. 
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 Although the exact role of FXYD2 in Mg2+ transport remains elusive, it is known that 
FXYD2 regulates the Na+-K+-ATPase activity. The Na+-K+-ATPase is essential for Mg2+ 
transport in the DCT, since it sets the membrane potential that provides the driving force 
for apical Mg2+ uptake. In chapter 4, two new families with mutations in the FXYD2 gene 
were reported. This is the first account of FXYD2 mutations since the initial identification 
of FXYD2 mutations more than 10 years ago, unequivocally confirming the importance of 
FXYD2 in renal Mg2+ homeostasis. Interestingly, the new patients carry the same p.Gly41Arg 
mutation that was described in the original study. Haplotype analysis revealed an 
overlapping haplotype in all families, suggesting a founder effect. However, genealogy 
studies did not identify a common ancestor until 1700. Given that no other FXYD2 
mutations have been reported to date, this may suggest that other FXYD2 mutations are 
embryonic lethal. The exact role of FXYD2 at the basolateral membrane of the DCT cell 
needs further investigation. 
 In chapter 5, SLC41A3, which was also identified in the microarray study (chapter 2), 
was further characterized. Recent studies with SLC41A1, a close homologue of SLC41A3, 
showed that SLC41A1 functions as a Na+/Mg2+ exchanger. Therefore, SLC41A3 may 
function as the Mg2+ extrusion mechanism at the basolateral membrane of the DCT cell. 
To understand its role in Mg2+ homeostasis, SLC41A3 knockout mice were examined for 
blood en urine electrolyte concentrations. Interestingly, SLC41A3 knockout mice had 
lower serum Mg2+ levels than wild type littermates, but showed similar urinary Mg2+ 
excretion levels suggesting a renal Mg2+ leak. Using the stable 25Mg2+ isotope, it was 
shown that intestinal Mg2+ absorption is not altered in SLC41A3 knockout mice. Strikingly, 
hydronephrosis was detected in 10 % of the SLC41A3 knockout mice fed with a 
Mg2+-deficient diet. Taken together, our data suggest that SLC41A3 is essential for DCT 
Mg2+ reabsorption.
Characterization of the Structure and Function of CNNM2
Recently, mutations in CNNM2 were shown to cause hypomagnesemia and seizures in 
two families with a dominant inheritance pattern. As SLC41A3 and FXYD2, CNNM2 is 
expressed at the basolateral membrane of the DCT cells. However, the exact function of 
CNNM2 remains to be identified. Although initial studies in Xenopus laevis oocytes 
suggested that CNNM2 operates as a Mg2+ transporter, these results could not be 
reproduced in mammalian cells. In chapter 6, the structure and regulation of CNNM2 was 
examined in detail. By immunocytochemistry, CNNM2 was shown to contain three 
 membrane-spanning domains with an extracellular NH2-terminus and intracellular COOH- 
terminus. The NH2-terminus is glycosylated at position p.Asn112. Cell surface biotinylation 
studies showed that this residue is essential for normal plasma membrane expression of 
the CNNM2 protein. A homology model of the CBS domains in the COOH-terminus of 
CNNM2, identified a Mg-ATP binding site. Importantly, the model predicted that Mg-ATP 
binding is lost by the p.Thr568Ile mutation that was identified in the patient families. 
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These findings resulted in the hypothesis that CNNM2 may function as a Mg2+-sensing 
mechanism rather than a Mg2+ transporter.
 In chapter 7, this hypothesis was tested using the stable 25Mg2+ isotope. HEK293 cells 
overexpressing CNNM2 exhibited higher 25Mg2+ uptake than mock-transfected cells. 
Interestingly, cells expressing mutated CNNM2 proteins did not display this stimulatory 
effect. The 25Mg2+ uptake was completely inhibited by the TRPM7 inhibitor 2APB, 
suggesting that CNNM2 may regulate TRPM7 activity. These findings were further 
examined in the zebrafish knockdown model. Using translation-blocking morpholinos, 
cnnm2 knockdown larvae were generated showing a decreased total Mg2+ content. 
Additionally, cnnm2 knockdown zebrafish suffered from a severely impaired brain 
development, increased embryonic spontaneous contractions and weak touch-evoked 
escape behaviour. Indeed, the weak touch-evoked escape behaviour is a characteristic of 
the trpm7 mutant zebrafish, further establishing the link between CNNM2 and TRPM7 
function. Importantly, five new families were identified with CNNM2 mutations. All the 
affected family members reported hypomagnesemia, seizures, but for the first time also 
mental retardation. Thus, CNNM2 is an essential gene for Mg2+ homeostasis and normal 
brain development. Future studies should be aimed to elucidate the role of CNNM2 in the 
regulation of TRPM7 and other Mg2+ transporters.
New Regulatory Pathways of TRPM6 Function
The last part of this thesis was dedicated to new pathways involved in the regulation of 
TRPM6 activity. TRPM6 subunits form tetrameric structures comprising six transmembrane 
segments, with a central divalent-selective pore and a Ser/Thr-kinase fused to its 
COOH-terminus. The epithelial Mg2+ channels TRPM6 provide the apical uptake of Mg2+ 
from the pro-urine into the DCT cell. Mutations in TRPM6 cause hypomagnesemia with 
secondary hypocalcemia and two SNPs in TRPM6 were associated with increased risk for 
diabetes mellitus. Over the last decade, several important regulatory factors of TRPM6 
were identified. EGF increases TRPM6 activity and plasma membrane expression and 
therefore patients using EGFR inhibitors often suffer from hypomagnesemia. In a similar 
fashion, TRPM6 can be activated by insulin. In chapter 8, extracellular ATP was shown to 
inhibit TRPM6 activity via the action of P2X4 purinergic receptors. P2X receptors form 
ATP-activated ion channels that transport cations into the cell. By RT-PCR, it was shown 
that P2X4 and P2X6 were specifically expressed in DCT and colon. Using whole-cell patch 
clamp, an inhibitory role of P2X4, but not of P2X6, on TRPM6 activity was demonstrated. 
The inhibition was dependent on the activity of P2X4, since a P2X4 mutant with reduced 
function did not inhibit TRPM6 activity. The inhibition was highly specific for TRPM6, since 
P2X4 was unable to inhibit TRPM7. The mechanism by which increased Na+ or Ca2+ influx 
via P2X4 can inhibit TRPM6 remains to be identified. The PKA, PKC and PI3K kinases were 
not involved in this process. 
274 | Chapter 11
 In chapter 9, flavaglines were studied as a new class of compounds activating TRPM6. 
Flavaglines belong to a family of natural compounds characterized by a cyclopenta[b]
benzofuran structure that binds to prohibitins. Previous studies have shown that 
prohibitin2 is capable to bind TRPM6 and can inhibit its activity. By whole-cell patch 
clamp, a stimulating role of FL3 and FL23, two flavaglines characterized by a bromine 
group at position 4’, on TRPM6 function was determined. Activation of TRPM6 is not 
dependent on its kinase activity, but requires the presence of the kinase domain. Moreover, 
HEK293 cells expressing the insulin-insensitive SNPs of TRPM6 do not respond to 
flavaglines. Given that flavagline-induced stimulation of TRPM6 activity provides great 
therapeutic potential for hypomagnesemia patients, in vivo effects were tested by the 
injection of flavaglines in mice.  However, low doses of FL3 did not lead to significant 
changes in ion homeostasis over the time course of the 7 days trial. Further optimization 
of the quantity and bioavailability of flavaglines in the DCT may be necessary to observe 
significant effects in vivo.
The Art of Magnesium Transport: A Clinical Perspective
This thesis extended our knowledge on DCT Mg2+ transport. DCT cells are highly 
specialized cells that are characterized by basolateral invaginations and high amounts of 
mitochondria. They determine the final urinary Mg2+ excretion. By COPAS sorting of distal 
convoluted tubule cells, a new high efficiency and high quality alternative for micro-
dissection was established that can be used for future DCT studies. TRPM6 mediates 
apical Mg2+ entry in the DCT and is regulated by EGF, insulin and pH. The identification of 
P2X4 purinergic receptors and flavagline compounds as new regulators of TRPM6 activity, 
provides novel pathways to target in the development of therapeutics to rescue Mg2+ 
disturbances. SOX9 and PCBD1 were identified as new transcriptional regulators of Mg2+ 
transport in the DCT. As a result, patients with PCBD1 can now be treated with Mg2+ 
supplements and sulfonylureas to improve their hypomagnesemia and MODY5-like 
diabetes, respectively. The molecular mechanism of basolateral Mg2+ extrusion remains 
elusive. The studies presented in this thesis, suggest that SLC41A3 may act as Mg2+ 
extrusion mechanism. CNNM2 may provide an Mg2+-sensing mechanism that regulates 
DCT Mg2+ transport. However, further studies are necessary to understand and connect 
all the molecular entities at the basolateral membrane.
 In a small but well-studied group of hypomagnesemia patients the disturbed blood 
Mg2+ levels could be attributed to a genetic defect. In the last years many causative genes 
have been identified, but there are still patients awaiting a molecular diagnosis. Recent 
technical advances in DNA sequencing techniques allow screening for mutations at a 
genome-wide scale. Although this will provide important insight in genetic orders of 
Mg2+ homeostasis, further development of bioinformatical techniques are necessary to 
deal with the enormous amount of data that are currently generated. 
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 In addition to the role of Mg2+ in the small group of genetic patients, there is 
increasing awareness for the important effects of Mg2+ in common diseases. Strong 
evidence is now available that the use of certain types of drugs, including proton pump 
inhibitors, EGFR antagonists and diuretics may cause hypomagnesemia. Nevertheless, 
Mg2+ measurements are still not standard in the clinic. Future studies should be directed 
to understand the function of Mg2+ in common diseases such as diabetes mellitus and 
chronic kidney diseases. Previous studies have evidenced a worse outcome of patients 
with these diseases when additionally suffering from hypomagnesemia. Only by further 
establishing the importance of Mg2+ in health and disease, the clinical attention for Mg2+ 
deficits will rise. Combined efforts of clinicians, geneticists, and researchers are continuously 
necessary to improve patient care of hypomagnesemia patients and increase our 
understanding of Mg2+ homeostasis.
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Magnesium in het Menselijke Lichaam
Magnesium (Mg2+) speelt een belangrijke rol in vrijwel iedere cel in het menselijk lichaam. 
Op celniveau is Mg2+ essentieel voor de goede werking van enzymen en als ontstekings-
remmer. Bovendien vervult Mg2+ vaak tegengestelde functies aan calcium (Ca2+), daarom 
moet de balans tussen Ca2+ en Mg2+ in  de cel goed moet worden geregeld. In de hersenen 
beïnvloedt Mg2+ de werking van de NMDA receptor. Daardoor ontstaat bij een Mg2+ tekort 
een overactiviteit van neuronen die kan leiden tot epilepsie, migraine, depressie en 
hersentrauma’s. In het hart functioneert Mg2+ als Ca2+ antagonist en is daarmee erg 
essentieel voor een goede samentrekking van de hartspier. Mg2+ tekorten leiden om deze 
reden tot hartritmestoornissen. Lage Mg2+ waarden in de spieren kunnen zorgen voor 
spierkrampen of spasmes. 
 De gebalanceerde samenwerking tussen de darmen, die Mg2+ opnemen, de botten, 
die Mg2+ opslaan, en de nieren, die Mg2+ uitscheiden, zorgt ervoor dat de Mg2+ 
bloedwaarden constant blijven tussen 0.7 en 1.1 mmol/L. In de dunne darm wordt Mg2+ 
opgenomen tussen de cellen door (paracellulair). De optimale afstemming van Mg2+ 
opname vindt vervolgens plaats in de dikke darm door Mg2+ door de cellen heen te 
transporteren (transcellulair). In de dikke darm wordt Mg2+ vanuit de darmholte (apicaal) 
opgenomen in de cel via TRPM6 en TRPM7 Mg2+ kanalen, en aan de bloedzijde 
(basolateraal) weer uitgescheiden via de CNNM4 Na+-Mg2+-uitwisselaar. In de nier wordt 
het bloed gefiltreerd in de glomerulus en hierdoor komt Mg2+ terecht in de pro-urine in 
de nierbuis. Op eenzelfde wijze als in de darm wordt Mg2+ vervolgens in twee stappen 
weer opgenomen uit de pro-urine. Eerst wordt de overgrote meerderheid van het Mg2+ 
paracellulair geresorbeerd in de proximale tubulus en het stijgende deel van de lis van 
Henle. Vervolgens vindt de afstemming van de definitieve Mg2+ uitscheiding plaats in het 
distaal convoluut (DCT) waar Mg2+ transcellulair wordt opgenomen. In het DCT neemt 
het TRPM6 Mg2+ kanaal Mg2+ apicaal op vanuit de pro-urine. De wijze waarop Mg2+ 
basolateraal wordt uitgescheiden naar het bloed moet nog geïdentificeerd worden. Het 
afgelopen decennium is door onderzoek naar patiënten met genetische vormen van 
Mg2+ tekorten (hypomagnesemie) de identiteit van de belangrijkste transporteiwitten in 
het DCT bekend geworden. Verstoringen van Mg2+ opname in het DCT leiden 
onvermijdelijk tot het verlies van Mg2+ via de urine, omdat er na dit segment geen Mg2+ 
meer kan worden geresorbeerd vanuit de nierbuis naar het bloed. Ondanks de recente 
vooruitgang zijn nog steeds niet alle Mg2+ transporterende eiwitten in het DCT, zoals het 
bovengenoemde basolaterale efflux mechanisme, bekend. Het doel van dit proefschrift 
was derhalve het identificeren en karakteriseren van nieuwe moleculaire spelers die 
deelnemen aan het Mg2+ transport in het DCT.
Identificatie van Nieuwe Genen die de Mg2+ Balans Beïnvloeden in het DCT
Allereerst was het zaak om nieuwe genen te identificeren die betrokken zijn bij het Mg2+ 
transport in het DCT. Hiertoe werden muizen die een groen fluorescent eiwit (GFP) tot 
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expressie brengen in het DCT op een Mg2+ dieet geplaatst. De GFP expressie maakte het 
mogelijk om specifiek DCT cellen te isoleren en met behulp van microarrays konden 
genen worden aangetoond die ten gevolge van het Mg2+ dieet werden gereguleerd. In 
hoofdstuk 2 wordt aangetoond dat de mRNA expressie van Mg2+ transporter SLC41A3, 
transcriptieregulator PCBD1, insuline-signaaleiwit TBC1D4, en urine eiwit uromoduline 
was verhoogd in de DCT cellen van muizen die het laag Mg2+ dieet werd gevoerd. 
Mutaties in PCBD1 veroorzaken transiënte neonatale primapeterinurie. In hoofdstuk 3 
wordt beschreven dat de patiënten met PCBD1 mutaties ook lijden aan een 
hypomagnesemie en MODY5-achtige diabetes. Deze symptomen leken erg op het 
ziektebeeld van patiënten met HNF1B mutaties, want ook zij presenteren zich met 
hypomagnesemie en een MODY5-type diabetes. HNF1B reguleert de mRNA expressie van 
FXYD2, een eiwit dat hypomagnesemie kan veroorzaken. Met behulp van bepalingen van 
de promotoractiviteit werd aangetoond dat PCBD1 de FXYD2 transcriptie verhoogt met 
50 %, als HNF1B ook aanwezig is. Gemuteerde PCBD1 eiwitten hadden geen stimulerend 
effect op de FXYD2 transcriptie.
 Hoewel de exacte rol van FXYD2 bij Mg2+ transport in het DCT nog niet is opgehelderd, 
is het bekend dat FXYD2 de activiteit van het Na+-K+-ATPase reguleert. Het Na+-K+-ATPase 
is essentieel voor het Mg2+ transport in het DCT, omdat het een gunstige membraanpo-
tentiaal opbouwt die de drijvende kracht levert voor de apicale Mg2+ opname. In 
hoofdstuk 4 worden twee nieuwe families met mutaties in het FXYD2 gen beschreven. 
Deze personen lijden aan hypomagnesemie en de gevolgen hiervan, die bestaan uit 
epilepsie en kraakbeenverkalking (chondrocalcinose). Dit is de eerste beschrijving van 
patiënten met FXYD2 mutaties sinds de identificatie van de hypomagnesemie patiënten 
met deze mutaties in 2000. Hierdoor wordt het belang van FXYD2 voor de Mg2+ 
huishouding ontegenzeggelijk vergroot en bevestigd. De nieuwe patiënten hebben 
dezelfde p.Gly41Arg mutatie als de patiënten die werd beschreven in 2000. Erfelijkheid-
sonderzoek bevestigde hetzelfde haplotype in deze patiënten, waardoor het mogelijk is 
dat ze een gemeenschappelijke voorouder hebben. Genealogiestudies die teruggaan tot 
het jaar 1700 konden deze gemeenschappelijke voorouder echter niet identificeren. 
Omdat er buiten de p.Gly41Arg mutatie geen andere FXYD2 mutaties zijn gemeld, zou 
gesuggereerd kunnen worden dat andere FXYD2 mutaties in een vroeg embryonaal 
stadium lethaal zijn. Ondanks de nieuwe bevindingen zijn er aanvullende studies vereist 
om de exacte functie van het FXYD2 eiwit op de basolaterale membraan te begrijpen.
 In hoofdstuk 5 wordt het eerdergenoemde SLC41A3 gen, dat verhoogd tot expressie 
kwam in muizen op een laag Mg2+ dieet, verder gekarakteriseerd. Recente studies gericht 
op SLC41A1, een homoloog eiwit aan SLC41A3, tonen aan dat SLC41A1 functioneert als een 
Na+-Mg2+-uitwisselaar. In tegenstelling tot SLC41A1 komt SLC41A3 sterk verhoogd tot 
expressie in het DCT. Als het eiwit daar dezelfde functie heeft als SLC41A1, zou SLC41A3 
een onderdeel kunnen zijn van het efflux mechanisme op de basolaterale membraan van 
de DCT cel. Om de rol van SLC41A3 in de Mg2+ huishouding te onderzoeken, werden 
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SLC41A3 knock-outmuizen onderzocht op de Mg2+ concentraties in het bloed en in de 
urine. Hieruit bleek dat de SLC41A3 knock-outmuizen een lagere bloed Mg2+ waarde 
hadden dan controle muizen uit hetzelfde nest. De SLC41A3 controle en knock-outmui-
zen hadden wel een vergelijkbare Mg2+ uitscheiding in de urine. Dit duidt op een 
verstoring van het Mg2+ transport in de nier.  Door gebruik te maken van het stabiele 
25Mg2+ isotoop werd vervolgens vastgesteld hoeveel 25Mg2+ in het bloed terecht kwam 
na toediening in de maag. Hierdoor kon worden aangetoond dat de Mg2+ absorptie in de 
darm niet verlaagd was in de SLC41A3 knock-outmuizen. Een interessante bevinding was 
de aanwezigheid van een waternier (hydronefrose) in de linkernier van enkele SLC41A3 
knock-outmuizen die een laag Mg2+ dieet werd gevoerd. Tezamen suggereren deze 
resultaten dat SLC41A3 essentieel is voor Mg2+ reabsorptie in het DCT.
Bepaling van de Structuur en de Functie van CNNM2
Recent werd aangetoond dat mutaties in het CNNM2 gen hypomagnesemie en epilepsie 
veroorzaken, zoals vastgesteld in twee families met een dominante overerving. Net als 
FXYD2 en SLC41A3 komt CNNM2 tot expressie op de basolaterale membraan van de DCT 
cel. De precieze functie van CNNM2 is nog niet bekend. Hoewel initiële studies met 
Xenopus laevis oocyten aantonen dat CNNM2 functioneert als een Mg2+ transporteur, 
konden deze resultaten niet worden gereproduceerd in zoogdiercellen. In hoofdstuk 6 
wordt de structuur en de regulatie van CNNM2 uitgebreid onderzocht. Door CNNM2 aan 
te kleuren op de plasmamembraan konden we laten zien dat CNNM2 drie transmembraan 
domeinen bezit met daarbij een extracellulaire NH2-terminus en een intracellulaire 
COOH-terminus. De NH2-terminus bevat een suikergroep op de positie p.Asn112. Door de 
CNNM2 van een label te voorzien op de plasmamembraan werd bewezen dat deze 
suikergroep essentieel is voor een correct transport van CNNM2 naar de plasmamembraan. 
Met behulp van een computer homologiemodel gebaseerd op de structuur van de 
bacteriële Mg2+ transporteur CorC, die veel verwantschap heeft met CNNM2, werd een 
Mg-ATP bindingsplek in de CBS domeinen van de COOH-terminus aangetoond. Volgens 
dit model zou de p.Thr568Ile mutatie, die werd gevonden in de patiënten, de binding van 
Mg-ATP op deze specifieke positie onmogelijk maken. Deze resultaten suggereren dat 
CNNM2 waarschijnlijk fungeert als een Mg2+-sensing mechanisme in plaats van als een 
Mg2+ transporteur.
 In hoofdstuk 7 wordt deze hypothese verder getest met behulp van het stabiele 
25Mg2+ isotoop. De HEK293 cellen waarin CNNM2 tot overexpressie werd gebracht, 
hadden een verhoogde 25Mg2+ opname in vergelijking met controlecellen. De cellen die 
gemuteerde CNNM2 eiwitten tot expressie brachten, lieten geen verhoging van de 
25Mg2+ opname zien. De 25Mg2+ opname werd volledig geremd door de TRPM7-remmer 
2APB te gebruiken. Hieruit zou men kunnen opmaken dat CNNM2 de activiteit van TRPM7 
reguleert. Met behulp van morpholino’s, die de eiwitproductie van CNNM2 blokkeerden, 
konden CNNM2 knock-down zebravislarven worden gegenereerd. Zebravissen waarin de 
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CNNM2 expressie werd onderdrukt, toonden een verlaagd Mg2+ gehalte. Bovendien 
leden de CNNM2 knock-down zebravissen aan een ernstig verstoorde hersenontwikkeling, een 
verhoogd aantal embryonische spontane contracties en een verminderd vluchtgedrag 
na aanraking. Juist dit verminderde vluchtgedrag werd eerder waargenomen in TRPM7 
zebravismutanten. In hoofdstuk 7 werden vijf nieuwe families met CNNM2 mutaties 
geïdentificeerd. Opnieuw hadden de patiënten last van hypomagnesemie en epilepsie, 
maar nu werd ook een mentale retardatie aangetoond in alle patiënten. Hieruit werd 
opgemaakt dat CNNM2 essentieel is voor de Mg2+ huishouding en de hersenontwikkeling. 
Toekomstige studies zijn noodzakelijk om de rol van CNNM2 in de regulatie van TRPM7 en 
van andere Mg2+ transporteurs te begrijpen.
Nieuwe Regulatiemechanismen van TRPM6 Activiteit
Het laatste deel van dit proefschrift wordt gewijd aan de beschrijving van twee nieuwe 
regulatiemechanismen voor de functie van het Mg2+ kanaal TRPM6. Mutaties in TRPM6 
veroorzaken hypomagnesemie met secundaire hypocalcemie. Daarnaast zijn twee amino-
zuurvariaties in TRPM6 geassocieerd met een verhoogd risico op diabetes mellitus. TRPM6 
kanalen zijn opgebouwd uit vier subunits die elk bestaan uit zes transmembraan segmenten 
en een Ser/Thr-kinase in de COOH-terminus. In de DCT cel zorgen TRPM6 Mg2+ kanalen 
ervoor dat Mg2+ wordt opgenomen vanuit de pro-urine in de DCT cel. De afgelopen jaren 
zijn enkele belangrijke regulatiefactoren voor de functie van TRPM6 geïdentificeerd. Zo 
verhoogt de epidermale groeifactor EGF de activiteit van TRPM6 en stimuleert het de 
hoeveelheid van TRPM6 kanalen op de plasmamembraan. Dit is ook de reden dat veel 
patiënten die remmers gebruiken van de EGF receptor vaak last hebben van hypo-
magnesemie. Op eenzelfde wijze kan TRPM6 geactiveerd worden door insuline. In 
hoofdstuk 8 werd aangetoond dat ATP een remmende werking heeft op TRPM6 activiteit 
via een activering van de P2X4 receptoren. P2X receptoren zijn ATP-geactiveerde ionkanalen 
die positiefgeladen ionen de cel in transporteren. Met RT-PCR werd bewezen dat P2X4 en 
P2X6 verhoogd tot expressie komen in het DCT en in de dikke darm waar Mg2+ resorptie 
plaatsvindt. Activering van de P2X4 receptor leidde tot een verminderde activiteit van 
TRPM6, zo bleek uit patch clamp analyse. P2X6 activering had geen remmende werking op 
TRPM6 activiteit. Deze remming was afhankelijk van P2X4 activiteit, want een P2X4 eiwit 
met een verminderde functie had geen effect op TRPM6 activiteit. De effecten waren 
zeer specifiek voor TRPM6, want TRPM7 werd niet geremd door P2X4. Het mechanisme 
waarmee een verhoogde Na+ of Ca2+ opname via P2X4 de activiteit van TRPM6 reduceert 
is nog onbekend. De kinases PKA, PKC en PI3K waren niet betrokken bij dit proces.
 In hoofdstuk 9 werden flavaglines beschreven als een nieuwe groep van stoffen die 
de TRPM6 activiteit kan stimuleren. Flavaglines behoren tot een familie van natuurlijke 
stoffen die zijn opgebouwd uit een chemische cyclopento[b]benzofuraan structuur die 
bindt aan prohibitines. Eerdere studies hebben aangetoond dat prohibitine2 een interactie 
aangaat met TRPM6 waardoor de activiteit is verminderd. Met behulp van patch clamp 
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analyse werd een stimulerende werking van FL3 en FL23, twee flavaglines met een bromide 
groep op positie 4’, gemeten op TRPM6 activiteit. De activering was niet afhankelijk van de 
kinasefunctie van TRPM6, maar wel van de aanwezigheid van het kinase domein. 
Bovendien reageerden HEK293 cellen die de insuline-ongevoelige TRPM6 varianten tot 
expressie brachten, niet op de flavagline activatie. Aangezien de flavaglines de Mg2+ 
opname verhogen, zouden ze kunnen dienen als een manier om hypomagnesemie 
patiënten te behandelen. Daarom werden de effecten van de flavaglines vervolgens 
getest in muizen. Injectie van een lage dosis FL3 zorgde echter niet voor significante 
veranderingen in de Mg2+ huishouding binnen 7 dagen. Verdere optimalisatie van de 
hoeveelheid en de beschikbaarheid van de flavaglines in het DCT zijn mogelijk nodig om 
effecten te kunnen waarnemen in muizen.
De Kunst van het Magnesiumtransport: Een Klinisch Perspectief
Concluderend kan gesteld worden dat dit proefschrift een bijdrage levert aan onze kennis 
over het Mg2+ transport in het DCT. DCT cellen zijn zeer gespecialiseerde cellen die grote 
basolaterale inhammen hebben. De DCT cellen bepalen de uiteindelijke excretie van 
Mg2+ in de urine, omdat er na het DCT geen Mg2+ meer wordt opgenomen. Door met 
behulp van GFP expressie in DCT cellen te isoleren,  wordt het mogelijk om met hoge 
efficiëntie en kwaliteit DCT cellen te gebruiken voor onderzoek. In het DCT is TRPM6 het 
eiwit dat Mg2+ opname verzorgt. Het is al jaren bekend dat TRPM6 wordt gereguleerd 
door EGF, insuline en de pH waarde. In dit proefschrift werden ook flavaglines en ATP 
gevonden als twee nieuwe regulatiemechanismen, die kunnen worden gebruikt voor de 
ontwikkeling van gerichte medicijnen om verstoringen in de Mg2+ balans te verbeteren. 
SOX9 en PCBD1 werden geïdentificeerd als nieuwe transcriptieregulatoren in de celkernen 
van het DCT. Hierdoor worden patiënten met mutaties in het PCBD1 gen nu behandeld 
met Mg2+ supplementen en sulfonylureumderivaten voor hun hypomagnesemie en 
diabetes. Hoewel het moleculaire Mg2+ uitscheidingsmechanisme aan de basolaterale 
membraan van het DCT nog altijd niet definitief is opgehelderd, suggereren de studies in 
dit proefschrift dat SLC41A3 hierbij een rol speelt. CNNM2 lijkt zelf niet direct onderdeel 
van het Mg2+ effluxmechanisme te zijn, maar kan mogelijk DCT Mg2+ transport reguleren 
via zijn functie als Mg2+-sensor. Verdere studies zijn vereist om de functies en de interacties 
van alle basolaterale eiwitten die betrokken zijn bij Mg2+ transport te begrijpen.
 In een kleine, maar uitgebreid bestudeerde, groep patiënten kunnen Mg2+ tekorten 
in het bloed worden toegeschreven aan een genetisch defect. Ondanks dat er de 
afgelopen jaren veel van deze defecten zijn opgehelderd, zijn er nog steeds patiënten die 
wachten op een diagnose. De recente technische vooruitgang in genetische onderzoeks-
technieken maakt het mogelijk te screenen voor mutaties op genoomschaal. Hoewel dit 
verder inzicht zal verschaffen in de genetische Mg2+ afwijkingen, zijn verdere bioinformatische 
ontwikkelingen nodig om te kunnen omgaan met de significante hoeveelheid data die 
deze technieken genereren. 
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 Naast de rol van Mg2+ in de kleine groep patiënten met een genetisch defect, komt 
er steeds meer aandacht voor de belangrijke effecten van Mg2+ in algemene en veelvoor-
komende ziektebeelden. Er is sterk bewijs beschikbaar dat het gebruik van bepaalde 
medicijnen zoals protonpompremmers (PPI’s), EGFR antagonisten en diuretica hypo-
magnesemie kunnen veroorzaken. Niettemin worden Mg2+ bepalingen nog altijd niet 
standaard uitgevoerd bij bloedtesten in de kliniek. Toekomstige studies zouden meer 
aandacht moeten besteden aan de rol van Mg2+ in veelvoorkomende ziektes als diabetes 
mellitus en chronisch nierfalen. Eerdere studies hebben reeds aangetoond dat hypo-
magnesemie de progressie van deze ziekten negatief kan beïnvloeden. Alleen door de 
belangrijke rol van Mg2+ in ziekte en gezondheid verder te benadrukken, zal de klinische 
aandacht voor het probleem toenemen. Verdergaande samenwerking tussen artsen, 
genetici en onderzoekers is vereist om de patiëntenzorg van hypomagnesemie te verbeteren 
en onze kennis van de Mg2+ huishouding te verbeteren.
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List of Abbreviations 
1,25(OH)2D3 1,25 hydroxy-vitamin D3
17βE  17β-estradiol
28K Calbindin-D28K
2APB 2-amino-ethoxydiphenyl borate
A Average signal value
ACDP2 Ancient conserved domain protein 2 or CNNM2 
ADH  Autosomal dominant hypomagnesemia
ALP  Alkaline phosphatase
ALT  Alanine transaminase
ANOVA  Analysis of variance
AP1  Activator protein 1
AQP1  Aquaporin1
AQP2  Aquaporin2
AS160 Akt substrate of 160 kD or TBC1D4
AST  Aspartate transaminase
ATP  Adenosine 5’-triphosphate
ATPase  Adenosine 5’-triphosphatase
BCRP  Breast cancer resistance protein
BH4 Tetrahydrobiopterin
BIODEF International database of tetrahydrobiopterin deficiencies
BSA  Bovine serum albumin
BSND  Gene encoding barttin
C3  Complement component 3
C4  Complement component 4
C57Bl/6 C57 black 6 mouse strain
Ca2+  Calcium ion
CaC2O4  Calcium oxalate
Ca(H2PO4)2  Calcium phosphate 
CaSR  Calcium-sensing receptor
CBS  Cystathionine beta synthase
CC  Chelerythrine chloride
CD  Collecting duct
CDH5  Cadherin 5, type 2
CDK5  Cyclin-dependent kinase 5
CGH Comparative genomic hybridization
Cl-  Chlorine ion 
ClC-Kb  Voltage-sensitive chloride channel Kb
CLCNKB  Gene encoding ClC-Kb
CLDN14  Gene encoding claudin-14
CLDN16  Gene encoding claudin 16
CLDN19  Gene encoding claudin 19
CNI  Calcineurin inhibitor 
CNNM1  Cyclin M1
CNNM2  Cyclin M2
CNNM3  Cyclin M3
CNNM4  Cyclin M4
CNS Central nervous system
CNT  Connecting tubule
COPAS Complex object parametric analyzer and sorter
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COPD  Chronic obstructive pulmonary disorder 
CorC Magnesium and cobalt efflux protein CorC
cRaf Raf-1 proto-oncogene, serine/threonine kinase
D  Dimerization domain
DAPI  4’,6-diamidino-2-phenylindole
DCOH  Dimerization cofactor of hepatocyte nuclear factor 1 alpha
DCT  Distal convoluted tubule
DNA  Desoxy ribonucleic acid
Dpf Days post fertilization
EAST  Epilesy, ataxia, sensorineuronal deafness and renal tubulopathy 
EC50  Half maximal effective concentration
EDTA Ethylenediaminetetraacetic acid
EEG Electroencephalography
EGF  Epidermal growth factor
eGFP Enhanced green fluorescent protein
EGFR  Epidermal growth factor receptor
ENaC  Epithelial sodium channel
ER Endoplasmic reticulum
ERK  Extracellular signal-regulated kinase
FE  Fractional excretion
FHHNC1  Familial hypomagnesemia with hypercalciuria and nephrocalcinosis type 1
FHHNC2  Familial hypomagnesemia with hypercalciuria and nephrocalcinosis type 2
FL Flavagline
FLAG FLAG octapeptide 
FRET  Förster resonance energy transfer
FXYD2  FXYD domain containing ion transport regulator 2 
FXYD2  FXYD domain containing ion transport regulator 5
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase
GCK Glucokinase
GEO Gene expression omnibus
GFR Glomerular filtration rate
GluR Glutamate receptor
GNB2L1  Guanine nucleotide-binding protein subunit beta-2-like 1
GO Gene ontology 
GSEA  Gene set enrichment analysis
h Slope
H-89  N-[2-[[3-(4-Bromophenyl)-2-propenyl]amino]ethyl]-5-isoquinolinesulfonamide
HA Human influenza hemagglutinin 
HbA1c  Glycosylated haemoglobin
HCO3-  Bicarbonate ion
H&E  Hematoxylin and eosin
HEK293  Human embryonic kidney clone 293
HNF1B  Hepatocyte nuclear factor 1 beta
HNF4A Hepatocyte nuclear factor 4 alpha
HPABH4D Transient neonatal hyperphenylalaninemia and primapterinuria
Hpf Hours post fertilization
hs-CRP High-sensitivity C reactive protein
HSH  Hypomagnesemia with secondary hypocalcemia
HSMR  Hypomagnesemia, seizures and mental retardation
IB  Immunoblot
IC50 Half maximal inhibitory concentration
IDH  Isolated dominant hypomagnesemia
IgA  Immunoglobulin A
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IgG  Immunoglobulin G 
IgM  Immunoglobulin M
IL1β  Interleukin 1 beta
IP Immunoprecipitation
IR  Insulin receptor 
IRES  Interinal ribosome entry site
IRH  Isolated recessive hypomagnesemia 
IV  Current voltage
K+  Potassium ion
KCNA1  Gene encoding Kv1.1
KCNJ1  Gene encoding ROMK
KCNJ10  Gene encoding Kir4.1
KD Knockdown
kDa  Kilo dalton
Kir4.1  Potassium channel 4.1
Km Michaelis Menten Constant
KO  Knock out
Kv1.1  Voltage-gated potassium channel 1.1
LacZ  β-galactosidase cassette
MAPK  Mitogen-activated protein kinase
Mb Megabases 
MC  Metabolic cages
MCM2  Minichromosome maintenance complex component 2
MDCK  Madin-Darby canine kidney
mDCT  Murine distal convoluted tubule 
MG-132 N-(benzyloxycarbonyl)leucinylleucinylleucinal
Mg2+  Magnesium ion
MGI  Mouse genome informatics database
MgSO4 Magnesium sulfate
MgtE  Bacterial Mg2+ transporter E
MHB Midbrain hindbrain boundary
MMgT Membrane magnesium transporter
MO Morpholino
MODY  Maturity-onset diabetes of the young
mpkDCT  Mouse microdissected distal convoluted tubule
MRI Magnetic resonance imaging
MRS2 Magnesium homeostasis factor
MSRB1  Methionine-R-sulfoxide reductase B1
MT  Mutant 
MW Molecular weight
n Number of replicates
N  Reference value
Na+  Sodium ion
NCC  Thiazide-sensitive sodium chloride co-transporter 
Neo  Neomycin resistance gene
NIPA Nonimprinted in Prader-Willi/Angelman syndrome
NKCC2  Sodium potassium chloride co-transporter
NLS  Nuclear localization signal
NMDA  N-methyl-D-aspartic acid
NMDG N-methyl-D-glucamine 
NPHP  Nephronophthisis
NSAID Non-steroidal anti-inflammatory drugs
OMIM  Online Mendelian inheritance in man
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P  Probability value 
P2X4  P2X purinoceptor 4
P2X6  P2X purinoceptor 6 
pA  Poly adenine
PAH  Phenylalanine hydroxylase
PBS  Phosphate buffered saline
PCBD1  Pterin-4 alpha-carbinolamine dehydratase 
PCR Polymerase chain reaction
PDB Protein data bank 
PGE2  Prostaglandin E2
PHB Prohibitin 
Pi  Phosphate ion
PI3K  Phosphoinositide 3-kinase 
PIP2  Phosphatidylinositol 4,5-bisphosphate
PKA  Protein kinase A
PKC  Protein kinase C
PKHD1 Polycystic kidney and hepatic disease 1
PNGase F Peptide N-glycosidase F
POUH  Atypical POU homeodomain 
POUS  POU-specific domain
PPI  Proton pump inhibitor
PT  Proximal tubule
PTH  Parathyroid hormone 
PV Parvalbumin
RAC1  Ras-related C3 botulinum toxin substrate 1
RACK1  Receptor for activated C-kinase 1
RCAD  Renal cysts and diabetes syndrome
REA  Repressor of estrogen receptor activity
RNA   Ribonucleic acid
ROMK  Renal outer medullary potassium channel
RT-PCR  Real time polymerase chain reaction
SA  Splice acceptor 
SeSAME  Seizures, sensorineural deafness, ataxia, mental retardation and electrolyte
  Imbalance
SEM Standard error of mean
SLC12A1  Solute carrier family 12 type 1, Gene encoding NKCC2
SLC12A3  Solute carrier family 12 type 3, Gene encoding NCC
SLC41A1  Solute carrier family 41 type 1
SLC41A2  Solute carrier family 41 type 2
SLC41A3  Solute carrier family 41 type 3 
SOX9  SRY (sex determining region Y)-box 9
SPC Signal peptidase complex 
SPFH  Stomatin/prohibitin/flotillin and HflK/C
SRP Signal recognition particle
t1/2 Time of half-maximal activation
TAL  Thick ascending limb of Henle’s loop
TBC1D4  TBC1 domain family, member 4
TH  Tamm-Horsfall protein
TM Transmembrane domain
TNFα  Tumor necrosis factor alpha
TRPM6  Transient receptor potential melastatin type 6
TRPM7  Transient receptor potential melastatin type 7
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TRPV5 Transient receptor potential vanilloid type 5
TUSC3 Tumor suppressor candidate 3
UMOD Gene encoding uromodulin
WB Western blot 
WNT4  Wingless-type MMTV integration site family, member 4
WT Wild type
ZDHHC Putative ZDHHC-type palmitoyltransferase 6-like
In this thesis protein and gene names are abbreviated and formatted according to the 
guidelines of the HUGO Gene Nomenclature Committee (HGNC), the International Committee 
on Standardized Genetic Nomenclature for Mice and the Zebrafish Nomenclature Committee:
Human (Homo sapiens) GENE PROTEIN 
Mouse (Mus musculus) Gene PROTEIN 
Zebrafish (Danio rero) gene Protein 
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De anatomische tekeningen die dit proefschrift sieren, tonen dat de kennis van de 
nieranatomie van 1500 tot nu steeds gedetailleerder is geworden. Iedere kunstenaar en 
wetenschapper leerde van zijn leermeesters, en voegde daarna zijn eigen inzichten toe. 
Ik hoop dat ik met dit proefschrift mijn steentje heb kunnen bijdragen aan de kennis van 
magnesiumtransport in de nier. Maar ook ik had dit nooit kunnen doen zonder de expertise, 
de inspiratie en de motivatie van mijn promotoren, collega’s, vrienden en familie. 
Natuurlijk wil ik ten eerste mijn promotoren Prof. dr. Joost Hoenderop en Prof. dr. René 
Bindels bedanken voor alle kansen en mogelijkheden die ze mij de afgelopen jaren 
hebben geboden. Joost, jouw enthousiasme en energie zijn onuitputtelijk en motiveren 
mij om dat stapje extra te zetten, ook als de resultaten tegen zitten. Het vertrouwen dat je 
de afgelopen jaren hebt laten blijken en in mij hebt uitgesproken ervaar ik als iets heel 
bijzonders. Hopelijk kunnen we de komende jaren samen nog veel wetenschappelijke 
successen vieren. René, ik bewonder de georganiseerde en efficiente manier waarop jij 
het onderzoek binnen de iontransport groep, de afdeling Fysiologie en het RIMLS richting 
geeft. Je leert mij altijd het einddoel voor ogen te houden. Mede dankzij deze focus heb 
ik binnen 4 jaar mijn proefschrift kunnen afronden.
To achieve great science, I am convinced that collaborations are essential to continuously 
exchange knowledge, ideas and expertise. During my PhD project I have had the privilege 
of enjoying many fruitful collaborations, for all of which I am extremely grateful.
Thanks to the joint-effort with Prof. dr. Dominik Müller, Dr. Iwan Meij and Dr. Marchel 
Stuiver, publication of the molecular characterization of CNNM2 went extremely 
smoothly. 
I would like to thank Prof. dr. Martin Konrad and Dr. Karl Peter Schlingmann for the 
stimulating and open discussions on the CNNM2 protein. Because of your detailed clinical 
characterization of CNNM2 patients, we could further understand its physiological 
function. 
I have experienced the extensive collaboration with Prof. dr. Olivier Devuyst as highly 
motivating. You have challenged me to develop new scientific hypotheses and goals. 
Although only a few of our collaborative efforts are currently at the stage of publication, I 
am confident that more papers will follow soon.  
The expertise of Prof. dr. Jens Leipziger has been an important starting point, when we 
embarked on a journey to characterize the purinergic regulation of TRPM6. I remember 
our regular discussions to be of great scientific benefit, but also as a lot of fun! 
I want to thank Dr. Laurent Désaubry for the collaboration on the flavaglines project. 
Because of the unique properties of the compounds that you synthesize we have new 
important tools to study TRPM6.
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Prof. dr. Frank Holstege and Marian Groot Koerkamp, met jullie hulp konden we de 
microarray analyse uitvoeren die de basis vormt van drie hoofdstukken in dit proefschrift. 
Dr. Hanka Venselaar, bedankt voor de eiwittenstructuren van CNNM2 en PCBD1.
De langlopende samenwerking met de genetica afdelingen van het Radboudumc en het 
UMC Utrecht zijn een continue bron van vooruitgang binnen het magnesiumonderzoek. 
In het bijzonder wil ik hierbij Dr. Erik-Jan Kamsteeg bedanken. Erik-Jan, geweldig dat je 
altijd tijd hebt willen maken om mijn vele vragen te beantwoorden en mij verder te 
helpen als ik eens niet verder kwam. Daarnaast dank aan Dr. Kornelia Neveling voor de 
exoomanalyse en alle anderen binnen de afdeling genetica die hebben bijgedragen aan 
dit proefschrift.
Een speciaal woord van dank voor Prof. dr. Nine Knoers. Nine, jij wees mij erop dat de 
afdeling Fysiologie misschien wel iets voor mij was. Wat heb je gelijk gehad! Ik heb het 
altijd als leuk en bijzonder ervaren dat ik met je mag samenwerken. Ik hoop dat we de 
familie niet teveel hebben verveeld met kleine discussies tijdens verjaardagen. Hopelijk is 
hoofdstuk 4 van dit boekje pas het begin van veel mooiere resultaten. Ik kijk uit naar de 
verdediging waar ik je tegenover me tref. 
Daarnaast ben ik alle artsen dankbaar die direct of indirect betrokken waren bij de studies 
die hebben geleid tot dit proefschrift. Hun opmerkzaamheid en zorg in de dagelijkse 
klinische praktijk vormen de basis voor veel van het werk dat ik heb kunnen verrichten.
In het bijzonder wil ik hierbij noemen Eiske Dorresteijn, Pattrick Ferreira, Roger 
Germann en Johannis de Klerk vanwege de prettige samenwerking. 
Aansluitend hierop ben ik ook dank verschuldigd aan de vele patiënten en hun familieleden die 
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enthousiasmé à l’idée de poursuivre dans la recherche. Durant mes stages dans les 
laboratoires de Prof. dr. Isabelle Limon et Dr. Philippe LeRouzic, j’ai appris les techniques 
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raisonnement scientifique, former des hypothèses et intégrer des résultats moléculaires 
dans un contexte physiologique. Chers Philippe et Isabelle, grâce a vous, j’ai vraiment 
aimé mes études à Paris et me suis retrouvé « accro » a la science ! (me suis retrouvé 
passionné de science) J’ai, en particulier, des souvenirs de diner chez Philippe et de mes 
visites chez Isabelle. J’espère vous revoir souvent dans l’avenir, la prochaine fois sera, je 
l’espère, à Nimègue pour la soutenance de ma thèse. 
Daarnaast waren er de afgelopen jaren gelukkig heel veel mensen die mijn leven in en om 
het lab heel plezierig hebben gemaakt!
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zijn! Bedankt voor de leuke tijd die we samen hebben gehad en heel veel succes in je 
nieuw baan.
Anke, mijn ‘lab-vriendinnetje’, jouw betrokkenheid en zorgzaamheid voor alles wat er in 
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doorheen zat, maar vooral voor het vele plezier dat we samen hebben gehad! Het is maar 
goed dat we nooit in elkaars buurt hebben gezeten, anders was er door het geplaag 
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Paco, Pacote, Pacito, it’s a small world! When I got to know all your friends in Cádiz during 
my studies, you were in Holland. Luckily you joined the Physiology department during my 
PhD and I could meet you too! You brought the zebrafish expertise to the fishiology 
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I have great memories to our trips to Cadiz, eating kebab after work and seeing you play 
against Jonkerboys. Thank you for your help and friendship!
Sjoerd, sjulz, short, helaas heb ik niet zoveel bijnamen voor jou als jij voor mij. Jouw 
enthousiasme en vele ideeën zijn een continue bron van inspiratie, je propjes en vliegen 
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blik op mijn schrijfsels en het vele plezier dat we hebben gehad in de kluizenaar, in Spanje 
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EvL, Ellen, het is fantastisch om te zien hoe jij bent gegroeid van twijfel over een PhD tot 
een harde werker die tig projecten tegelijk doet. Bovendien ben je met je vrolijke humeur, 
je grapjes en je oprechte interesse in al je collega’s, de sociale lijm van de afdeling 
Fysiologie. Bedankt voor je enthousiasme en betrokkenheid. Daar kan ik veel van leren, 
om te beginnen zal ik zorgen dat ik eens bij je presentaties zal zijn. ;)
Two chapters in thesis would not have been possible without Maxime. Maxime, I’ve 
enjoyed working with you a lot! Your impressive patch clamp expertise, calm attitude and 
great sense of humor moved our projects forward. I’ve learned a lot from your great 
writing skills.
Jenny en Mark H. jullie completeren het magnesium-team. Bedankt voor het vele plezier 
dat we samen hebben en de wetenschappelijke discussies die onze projecten sterker maken.
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om mee samen te werken. Andreas, ik herinner me het gesprek tijdens onze eerste 
onmoeting als enorm leuk en al snel hielp je me met het SLC41A3 project. Met jouw 
humor en geduld houd je me scherp en weet je ieder probleem te relativeren. Wat ben ik 
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Caro, ik heb veel bewondering voor hoe jij jezelf onmisbaar hebt gemaakt op onze afdeling 
tijdens een enorme hectische periode! Helaas heb je nu als chief CDL niet zoveel tijd meer 
voor mijn projectjes, maar ik ben blij dat je nog zolang aan ons lab verbonden bent!
Daarnaast ben ik ongelooflijk veel dank verschuldigd aan alle analisten op onze afdeling 
zonder wiens hulp mijn projecten nooit allemaal hadden kunnen worden uitgevoerd. 
Marla, telkens als ik weer aankwam met een nieuw idee voor een kleuring of een 
dierexperiment, zag ik je denken: ‘Hoe gaan we dit dan weer doen?’. En toch maakte je 
altijd weer ruimte in je planning en bedacht je een nieuwe technische oplossing. Bedankt 
voor je hulp, je humor en het enorme plezier dat we ook buiten het lab hebben gehad, in 
de kluizenaar en bij de Backstreet Boys. Femke L., bij welk project was jij niet betrokken? 
Jij bent degene die mij wegwijs hebt gemaakt op het lab toen ik net begon. Bedankt voor 
al je hulp, inzet en Hek cellen! ;) AnneMiete, Hans, Judy, zonder jullie had ik nooit alle 
dierexperimenten kunnen uitvoeren, bedankt! Lonneke, Mark d. G., Marleen, jullie inzet 
en hulp bij de vele moleculaire experiment zijn van grote waarde.
Irene, jouw bijdrage aan de afdeling Fysiologie is onschatbaar groot. Bedankt voor alle 
hulp, je begrip als ik weer eens ongeduldig was en je hart onder de riem als NEC weer 
eens verloor. Femke K., bedankt voor het vele regelwerk als ik weer eens een onmogelijk 
afspraak wilde inplannen. Nu nog de avondjes aeculaaf goed inplannen zonder afspraken 
met honden en goudvissen! ;)
Daarnaast wil ik alle collega’s bedanken die ieder op hun eigen wijze hebben bijgedragen 
aan een geweldige tijd op het lab: Liz, Lauriane, Marcel, Erik, Silvia, Kukiat, Jitske, 
Ramon, Rick, Steef, Sabina, Theun, Anil, Sergio, Pedro, Wilco, Sandor, Miyuki, Marco, 
Sami, Omar, Mohammad, Annelies, Ganesh, Joanna, Fareeba, Milène, Joris, Melissa, 
Claudia, Seng, Christiane, Genoveva, Tomasz, Anne, Dennis, Sjoeli, Peter, Michiel, 
Femke v.d. H., de collega’s van integratieve fysiologie en iedereen die ik hier nog vergeet!
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gelukkig dat ik iedere week een avond bij je kan aanschuiven, de tennis nemen we dan 
maar op de koop toe! Bedankt voor alle keren dat je mij hebt losgetrokken van het werk, 
door concerten, sportwedstrijden, tennis of de vele reisjes die we hebben gemaakt. Ik ben 
blij dat je bij mijn verdediging naast me staat als paranimf.
Yvo, Jonathan, Birgitta en alle andere vrienden en vriendinnen die mij de afgelopen 
jaren hebben afgeleid van mijn werk. Bedankt, ga zo door! ;)
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Linde, Mieke, Tijmen, Anne, Antal, Myrthe, Wouter, Silke, Janneke, Marc mijn lijstje 
van broertjes en zusjes is de afgelopen jaren steeds langer geworden. Er is altijd wat te 
doen in de huizen De Baaij-Wijgerde, Knoers-Princen! Maar wat is het fijn om zoveel lieve 
mensen om me heen te hebben. Bedankt voor al het plezier en de zorgzaamheid. 
Lieve Opa Fons en Oma Riet, helaas zijn jullie er niet meer bij om mijn promotie te vieren. 
Bedankt voor jullie aanmoedigingen, interesse en trots die zelfs in jullie laatste dagen 
bleek. Ik mis de bezoekjes aan de Beunigerbeemd. Opa, het is bijzonder om mijn 
proefschrift te verdedigen aan de universiteit waar jij mij voorging. 
Lieve Papa, in jouw grote tuin is het heerlijk bijkomen van het drukke leven. Samen met 
Jeanne zorg je dat deur in Stevensbeek altijd open staat. Het is bijzonder hoe julie samen 
een veilig thuis creëren waar iedereen zichzelf kan zijn. Bedankt voor je hulp, zorg en 
betrokkenheid, ook in de voorbereiding van dit proefschrift. 
Lieve Mama, we kijken terug op een jaar dat niet makkelijk was. Maar juist op dat soort 
momenten besef je wat we samen hebben. Zonder jouw liefde, zorg en aandacht had ik 
nooit gestaan waar ik nu ben. Ik ben dankbaar voor de bijzondere momenten in Spanje, 
in Parijs en in Nijmegen en ben blij dat je er samen met Thijs altijd voor me bent.
“Principles for the Development of a Complete Mind: Study the science of art. 
Study the art of science. Develop your senses- especially learn how to see. 
Realize that everything connects to everything else.” 
Leonardo da Vinci (1452-1519)
In this thesis our senses were stimulated by artistic scientific drawings that show the development of renal 
anatomy and renal physiology. The anatomical drawings that are presented in thesis are adapted from:
Chapter 1  Leonardo da Vinci, A Kidney with Notes (1509). 
Chapter 2  Andreas Vesalius, De Humani Corporis Fabrica (1543). 
Chapter 3  Bartholomeus Eustachius, Opuscola Anatomica (1564). 
Chapter 4  Frederik Ruysch, Thesaurus Anatomicus (1709).
Chapter 5  Govard Bidloo, Anatomia Humani Corporis (1685).
Chapter 6  Alexander Schumlansky, De Structura Renum (1782).
Chapter 7  Friedrich Gustav Jacob Henle, Zur Anatomie der Niere (1862).
Chapter 8   Camillo Golgi, Annotazioni Intorno all’Istologia dei Reni dell’Uomo e di Altri Mammiferi e 
Sull’Istogenesi dei Canalicoli Oriniferi (1889).
Chapter 9   William Bowman, The Physiological Anatomy and Physiology of Man (1857).
Chapter 10   Homer W. Smith, The Kidney: Structure and Function in Health and Disease (1951).
Chapter 11  Andreas Vesalius, De Humani Corporis Fabrica (1543).
Chapter 12  William Cheselden, Anatomy of the Human Body (1750).
Chapter 13   Richard Quain, The Anatomy of the Arteries of the Human Body, with its Applications to Pathology 
and Operative Surgery (1844).
Chapter 14  Koen Ketelaars (2014).

